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1.  
Liliana Moyers Ruiz 
Chemo Brain and Prospective Memory in Breast Cancer Patients: A Mixed Methods 
Study 
 
Some breast cancer patients report memory deficits after undergoing cancer treatment. 
This deficit has been given the term chemo brain. Patients who report such deficits 
usually complain about attention and concentration problems, such as forgetting to take 
their medication, or taking it twice, forgetting doctor’s appointments, reduced ability to 
multitask, and difficulties with driving, among others. These difficulties can 
significantly affect their quality of life. Most of the research to date has focused on 
examining a global neuropsychological aspect of chemo brain, and in the last decade, 
attention has been directed to the use of neuroimaging techniques. The major question 
addressed in this study is whether chemo brain in breast cancer patients specifically a 
prospective memory deficit, and whether neuropsychological assessment lacks 
ecological validity to measure chemo brain. It is also suggested that biological factors 
such as sleep and sleepiness are altered during the course of cancer treatment, and those 
factors may also be playing a role in the cognitive impairment of cancer patients. The 
method used to examine these questions included a mixed methods design in which a 
quantitative study was conducted using a neuropsychological battery and physiological 
measures as well as a qualitative study, which involved thematic analyses and case 
studies, aided by semi-structured interviews and questionnaires. 
Overall, the results of this study confirmed that breast cancer patients have poorer 
prospective memory than controls, and that patients’ self-reports are inconsistent with 
results derived from the objective neuropsychological battery. This implies that more 
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sensitive measures for the assessment of chemo brain should be developed, and that 
more emphasis needs to be placed on the study of prospective memory and chemo brain 
to provide patients with the most efficient care and psychological treatment in order to 
improve their quality of life.  
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“Now to Him who is able to do exceedingly abundantly above all that we ask or think, 
according to the power that works in us, to Him be glory in the church by Christ Jesus 
to all generations, forever and ever. Amen.” 
Ephesians 3:20–21 
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CHAPTER ONE 
1 INTRODUCTION 
 
1.1. Explanation of the phenomenon under study 
 
Breast cancer is by far the most common form of cancer in women in the UK, 
accounting for 31% of all cases. The probability of developing breast cancer in women 
is one in nine over the course of a lifetime. Most of the women diagnosed with breast 
cancer are in the 50–69 age group and, while 99% of diagnoses are found in women, 
breast cancer can also occur in men (less than 1%) (Statistical Information Team, 
Cancer Research UK, 2009). 
 
In recent years, the application of chemotherapy treatment has increased the rate of 
cancer-free survival in women with breast cancer. However, this treatment, or 
combinations of treatments, such as hormonal treatment, chemotherapy and radiation, 
can lead to a whole host of side effects, among which is mild cognitive impairment 
(MCI) (27–35%) (Vardy et al., 2008). This can result in a significant and prolonged 
deterioration of their quality of life, even when they become cancer free. This MCI has 
been given the term chemo brain or chemo fog, since patients report a mental cloudiness 
(Ahles & Saykin, 2001; Vardy et al., 2008; Jansen et al., 2007; Jansen et al., 2008; 
Shilling & Jenkins, 2007; Stewart et al., 2006; Collins et al., 2009; Tager et al., 2009; 
Bender et al., 2006; Weis et al., 2009; Wieneke & Dienst, 1995). 
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The existence of chemo brain has already been very well documented (Ahles & Saykin, 
2001; Vardy et al., 2008; Jansen et al., 2007; Jansen et al., 2008; Shilling & Jenkins, 
2007). However, methodological issues in some of these studies have been controversial 
(Raffa, 2011). Some of the controversy arises from issues such as small sample size, 
lack of baseline assessment, different statistical approaches, different testing measures 
among studies and lack of ecological validity of the measures, and to date, no causal 
relationship has been established between chemo brain and chemotherapy. 
 
The exact nature of the memory difficulties women experience as a result of 
chemotherapy is under-reported in the literature. Anecdotal evidence reports suggest 
that complaints range from forgetting to pay bills to difficulty retrieving familiar words 
or an inability to remember names and faces. Furthermore, an inability to multitask is 
common, which profoundly affects their daily activities. They also present difficulties 
learning simple things, such as a new version of a computer program they were already 
familiar with. All these problems have a major impact on patients’ lives and self-
esteem, making them feel that they are not the same people as before and that they have 
some sort of handicap. Due to these combinations of symptoms, some cannot perform 
the same activities they used to prior to their chemotherapy and either lose their jobs or 
are forced to resign (Mulrooney, 2007; Silverman & Davidson, 2009). 
 
When breast cancer survivors realise that their cognitive deficits are due to an actual 
brain dysfunction, probably caused by chemotherapy treatment, they feel relieved, since 
feelings of guilt are also a part of the process, as they feel responsible for the cognitive 
25 
 
failures, thinking that they are doing something wrong or not coping as they are 
supposed to (Silverman & Davidson, 2009). 
These reports suggest that the phenomena associated with chemo brain needs to be 
examined more closely, particularly to help clinicians and nurses provide adequate 
information and interventions that will result in a better quality of life for breast cancer 
survivors. 
 
1.2. Purpose of this study 
 
More frequent than not, clinicians fail to recognise the phenomenon of chemo brain. 
Patients’ anecdotal reports show that when they come to the clinic complaining about 
memory failures, they are usually ignored by their physician and nurses, attributing such 
failures to fatigue or other factors, ignoring the challenges patients face in their 
everyday lives. This research was designed with the purpose to help clinicians 
understand that it is a reality that some patients experience cognitive failures during or 
after cancer treatment, and that such failures can seriously affect patients’ quality of life.  
 
The author believes that, due to similarities between the cognitive failures reported by 
chemo brain patients – with literature reporting deficits in memory for planned 
intentions or prospective memory (PM) – chemo brain is a PM failure. The author 
decided to assess chemo brain objectively, using a tool for the exclusive assessment of 
PM. Further, as it is a part of the executive function (EF) system, working memory 
(WM) was also assessed. Measures of objective and subjective sleep, anxiety and 
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depression were included to explore the influence of these variables on chemo brain and 
PM. 
Consistent with the literature, the studied sample showed no significant cognitive 
decline in neuropsychological measures, but participants began to report memory 
difficulties. Due to the fact that there is no in depth study of PM and chemo brain in the 
literature, a qualitative study was included in order to assess the phenomenon. The 
author wanted to explore the discrepancy between neuropsychological assessment and 
patients’ reports from the perspective of PM. 
 
Since very little attention has been placed in the study of chemo brain as a PM deficit, 
one of the purposes of this study was to explore this relationship by considering 
quantitative and qualitative tools in order to motivate further investigation by the 
research community and the development of more reliable tools for the assessment of 
chemo brain in the future. A possible benefit of this kind of study would be that staff 
within the healthcare system would be able to provide adequate care and intervention to 
help patients cope with these problems. 
 
It was proposed that in order to gain a deeper understanding of the cause and effect 
relationship underlying chemo brain, researchers should begin to dissect and study each 
and every cognitive domain separately. The aim of this study was to focus on memory, 
specifically WM and PM, which might be considered a part of the WM model 
(Baddeley, 2003) and the multiprocess PM theory (McDaniel & Einstein, 2007), 
particularly the central executive system (Baddeley, 2003). Furthermore, sleep/wake 
activity patterns and day time sleepiness were analysed to observe their effect on WM 
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and PM and the possible relationship with cognitive decline in patients reporting chemo 
brain. 
According to Shilling and Jenkins (2007), only a minority of patients reported that these 
cognitive declines interfere with their everyday life; a vast majority of those patients 
reported experiencing more problems with attention and memory than those identified 
by objective cognitive measures. According to these authors, this should not undermine 
the personal experiences that patients report, which are mostly lapses and slips in their 
everyday lives.  
 
Patients who experience chemo brain report memory deficits that interfere with 
everyday living, ranging from minor disturbances to major problems that lead to a 
decrease in their quality of life, such as losing their jobs and social isolation. Depending 
on the social support patients have, they also feel misunderstood by people around 
them, because they attribute the memory declines to faulty thinking or poor 
performance rather than to chemo brain effects. They feel slow in their cognitive 
abilities, their self-esteem decreases, their ability to multitask declines and they face 
difficulty retrieving words (Mulrooney, 2007; Silverman & Davidson, 2009). 
 
According to the literature, one of the most affected cognitive domains in chemo brain 
patients is WM (Vardy et al., 2008; Jansen et al., 2007; Jansen et al., 2008; Shilling & 
Jenkins, 2007; Stewart et al., 2006; Collins et al., 2009; Tager et al., 2009; Bender et 
al., 2006; Weis et al., 2009). For this reason, one of the aims of this study was to focus 
on Baddeley’s WM model (Baddeley, 2003) as well as on the multiprocess prospective 
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theory proposed by McDaniel and Einstein (2007) as a theoretical framework, to 
systematically assess the memory deficits experienced by some chemotherapy patients. 
The WM model is a multimodal system in which short-term memory (STM) is 
implicated and considered as an active, rather than a passive, component of memory. 
WM may be defined as “a limited capacity system, which temporarily maintains and 
stores information, supports human thought processes by providing an interface 
between perception, long-term memory and action” (Baddeley, 2003). The components 
of the system are the central executive, the phonological loop and the visuospatial 
sketchpad (Baddeley, 2003). 
 
The central executive in the WM model is an attentional control mechanism responsible 
for coordinating all the activities among the other systems (slave systems). The 
phonological loop is a slave system made up by the articulatory control process and the 
phonological store. The articulatory control process controls subvocal rehearsal, and the 
phonological store is a memory store that can retain speech-based information for a 
short period of time (about two seconds). The visuospatial sketchpad processes and 
manipulates visual-spatial information, and the episodic buffer serves as a backup store 
that supports serial recall and other types of information. This last system is out of the 
scope of the study, due to the fact that no tests have been developed to assess it. Overall, 
WM deals with the ability to learn new information and retrieve stored information 
from LTM (Neath & Surprenant, 2002). 
 
Furthermore, according to Cohen and Conway (2008):  
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“planning, prospective memory and carrying out action sequences, depend on 
the ongoing operation of working memory and the allocation of attention”. 
 
The same authors explained that errors in PM are manifested in the form of slips of 
actions: repetition errors (forgetting that an action has already been performed and 
repeating it, e.g. placing two cheques in an envelope for the same bill); goal switches 
(forgetting the goal of a sequence of actions and switching to a different goal, e.g. 
intending to drive to one place and driving to another); omissions and reversals 
(omitting or wrongly ordering the component actions of a sequence, e.g. filling the 
kettle, but failing to switch it on); and confusion/blends (confusing objects involved in 
one action sequence with those involved in another sequence, e.g. taking a tin-opener 
instead of scissors into the garden to cut flowers (Cohen & Conway, 2008). 
 
PM is defined as “the ability to remember to perform some intended action at a 
particular point in the future” (McDaniel et al., 1999). It has been associated with daily 
and routinely performed activities such as paying bills, taking medications with certain 
schedules and requisites and remembering to pick up things. PM also involves 
performing familiar actions in novel contexts or at different times (Cohen & Conway, 
2008). 
 
The memory experiences that breast cancer patients report soon after chemotherapy are 
in accordance with the PM slips of action. As mentioned before, the sorts of complaints 
found in the literature are as follows: having a hard time remembering appointments, 
difficulty remembering words and names, problems with organizing their thoughts 
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together in a coherent sequence in a sentence, not learning new things because they are 
no longer fast enough to do so, difficulty with concentration, missing the exits while 
driving, not knowing how to get to familiar places, being unable to focus on work, 
difficulty following stories, losing train of thought, being unable to multitask or do two 
things at the same time and difficulty in keeping track of their workload (Mulrooney, 
2007; Silverman & Davidson, 2009). 
 
Therefore, it was suggested that chemo brain might be a problem of WM and PM and 
executive dysfunction. This work was aimed at analysing chemo brain in a mixed-study 
design to explore all the aspects involved in depth. In order to accomplish this, a series 
of psychology tests were used to observe whether this battery was sensitive enough to 
detect cognitive decline in breast cancer patients as a result of cancer treatment 
(chemotherapy, radiotherapy, adjuvant treatment) and to compare these test results with 
patients’ lived experiences through thematic analysis of online questionnaires and case 
studies. 
 
Furthermore, one of the most common complaints that chemo brain patients have is the 
difficulty in retrieving words. The author of this thesis suggests that this difficulty might 
be related to the tip-of-the-tongue (TOT) phenomenon, which is when a speaker cannot 
fully retrieve a word from memory that he or she knows will eventually be recalled; one 
common example is that when the speaker is unable to produce the name of a person 
from an individual, like the name of a teacher, but the name is “stuck” on the tip of the 
individual’s tongue (Gianico-Reyea et al., 2012). Our thematic analysis led us to believe 
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that chemo brain patients suffer from a persistent TOT experience, and further analysis 
should be recommended. 
 
 
1.3. Mixed methods design 
 
The research approach where we combine both qualitative and quantitative 
methodologies in the same study is known as “mixed methods”. It is suggested that 
more mixed methods studies are necessary, because in recent years, the UK’s health 
system has shown an increased demand of the investigation of complex health services, 
which need to be addressed by different methodologies to assess multifaceted 
interventions (O’Cathain, 2006; Bradley et al., 1999) to better understand the impact of 
an illness from every perspective. 
 
O’Cathain (2006) and Creswell (2003) explain that “quantitative components include 
experimental designs such as randomised control trials and surveys, while qualitative 
components include ethnography, case studies, in-depth interviews, focus groups and 
observation”. There are different mixed methods approaches, those considered within 
the context of a single study and those within the context of a programme, where 
different methods are used in separate parts of a programme of research and later 
integrated in some way (O’Cathain, 2006). 
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After extensive discussions and analysis, it was decided that this study would take a 
mixed methods approach in order to combine quantitative and qualitative data and gain 
a deeper understanding by looking at all aspects of chemo brain, considering 
quantitative and qualitative reports. Quantitative data collected from neuropsychological 
assessment provided us with information about the appropriateness of our measures to 
assess PM within the context of chemo brain in various time points and the significance 
of our results when compared with the general population. On the other hand, the 
qualitative studies provided more meaningful and specific information about how 
patients everyday experience cognitive difficulties in their own environment and to 
understand in specific detail how these failures relate to PM, with the proposal that in 
future research, more sensitive objective measures should be developed. This was 
followed by a deductive reasoning or “top-down” approach in which we analysed 
chemo brain and PM beginning from a broad spectrum of information, i.e. qualitative 
results, working down to specific cases. 
 
The use of mixed methods in a study is particularly useful because every method has its 
own limitations that can be overcome by the use of other methods (Cresswell, 2009). By 
combining qualitative and quantitative methodologies, each with its own strengths, it 
was hoped that the overall value of the study would be increased. The use of qualitative 
studies allowed more flexibility through interaction with the participants with the 
possibility of obtaining more detailed and in-depth exploration (Balbotin, 2012); it gave 
us a more comprehensive understanding of chemo brain and PM on breast cancer 
patients. Our study was strengthened with the use of mixed methodology, because we 
could explore how patients experience chemo brain difficulties in depth, and we were 
able to compare their experiences with their own neuropsychological tests, which at 
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times were inconsistent with patients’ reports. This provided useful information 
regarding the lack of sensitivity of objective tools to detect chemo brain cognitive 
failures.  
 
The use of quantitative methodologies allowed the testing of hypotheses derived from 
previous theories. The mixed methods approach enabled the combination of both 
methodologies in the same study in order to improve the quality and validity of the 
study. 
 
Balbotin (2012) reported that there are different designs for organising data for mixed 
methods studies. Parallel or concurrent mixed designs are used when the quantitative 
and qualitative phases are carried out in parallel either at the same time or with a time 
lapse in between. For sequential mixed designs, the different phases are carried out in a 
chronological order, with one component evolving as a consequence of the other 
(Balbotin, 2012). 
 
In this study, a sequential design was used in which the qualitative phase emerged from 
the quantitative phase. The qualitative study was designed to explain why the test results 
were inconsistent with patients’ reports and to test the hypothesis that chemo brain is a 
PM failure and further, to document the research hypotheses in a more comprehensive 
and reliable manner. Data collection began by testing some participants at two time 
points and others at four time points during the course of their treatment. After 
completion of that phase, the qualitative data was collected, beginning with an online 
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questionnaire to develop a thematic analysis, followed by face-to-face interviews to 
build case studies that gave rise to emerging theories.  
 
Equal weight was decided to be given to both the phases of the study. It was proposed 
that each phase depends on the other in order to achieve maximum credibility, validity 
and reliability. The quantitative approach provided the tools to begin to understand the 
cognitive decline as a PM deficit after cancer treatment and to better understand the 
discrepancy between neuropsychological tests and chemo brain complaints. The 
qualitative study led to gaining deeper knowledge and understanding of how the 
problem with words is a problem of the TOT associated with LTM. Without this 
knowledge, it might have been mistakenly believed that when patients reported having 
problems retrieving words and names, it was a problem similar to aphasia in patients 
who cannot pronounce words, or a problem of LTM, not related to metamemory, which 
refers to the feeling of “knowing that we know”. By comparing patient’s reports with 
what has been reported in the PM literature, it was also possible to corroborate the 
hypothesis that chemo brain is a PM problem. 
 
From a methodological standpoint, this study was based on “paradigmatic pluralism” by 
acknowledging that a variety of paradigms can be used as the underlying philosophy 
when conducting mixed methods (Balbotin, 2012; Tashakkori et al., 2010). The main 
objective of this study was to make sense of the data in a comprehensive and coherent 
manner; it did not adhere to any particular paradigm, rather used the most suitable 
approaches to help explain and understand the research questions based on the literature 
surrounding these topics. 
35 
 
 
1.4. Research design 
 
For our quantitative study, 56 participants took a neuropsychological battery and 
questionnaire. Twenty-eight participants underwent cancer treatment, and twenty-eight 
were healthy controls. Statistical analyses were conducted using SPSS V.21 Mixed 
ANOVA to explore mean scores across, between and within groups. Our qualitative 
research design combined multiple cases; the first part of the study consisted of three 
online questionnaires in which participants responded to eight open-ended questions and 
to PM self-reports. A thematic analysis was conducted, which comprised six different 
case studies in which quantitative and qualitative data were integrated. 
 
The focus of this work falls within the context of a single study undertaken sequentially, 
i.e. the qualitative study followed by the quantitative arm and two different methods, 
which produced two sets of data (Bryman, 1988; O’Cathain, 2006). The integration of 
qualitative and quantitative data was necessary, because it is not uncommon that a 
cancer patient’s memory decline reports are inconsistent with those shown in 
neuropsychological tests. In this work, the use of multiple methodologies allows a 
deeper understanding of such a phenomenon compared with the use of a single 
methodology alone, in which the study of chemo brain within the context of PM and the 
TOT phenomenon would be incomplete. 
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Because of the nature of chemo brain and PM failures, which are associated with 
everyday memory lapses, we consider the patient’s personal reports to be very 
important. Chemo brain studies that have used neuropsychological batteries have 
sometimes failed to explain the cause and effect relationship between cancer treatment 
and cognitive impairment, to the point that some researchers deny the existence of the 
problem or attribute it to factors such as personality or fatigue. Other studies 
successfully explain that chemo brain might be the consequence of structural damage in 
certain regions of the brain, but fail to recognise the meaning of chemo brain on 
patients’ experiences in their daily lives. By using multiple methods, it was possible to 
gain a deeper understanding of the TOT phenomenon experienced by participants. 
Problems with words are often reported in the literature, but have not been linked to this 
phenomenon before. TOT is a phenomenon in which a speaker cannot fully retrieve a 
word from memory that he or she knows will eventually be recalled; one common 
example is that when the speaker is unable to produce the name of a person from an 
individual, like the name of a teacher, but the name is “stuck” on the tip of the 
individual’s tongue (Gianico-Reyea et al., 2012). It is believed that chemo brain patients 
suffer from a persistent TOT experience, and further analysis should be recommended. 
As in every quantitative methodology, this study aimed to test the hypotheses that breast 
cancer patients would have lower scores than healthy controls; that they would present 
cognitive impairment after undergoing cancer treatment; and that such impairment is 
due to PM failure. To accomplish this, a series of neuropsychological tests and 
questionnaires were used along with a sleep monitor. In contrast, our qualitative arm 
aimed to generate new theories through an exploratory analysis by combining different 
methods to gain a deeper understanding and to obtain more consistent results. It is the 
37 
 
opinion of the author that the study was enhanced by the use of mixed methods, because 
a more complete picture of the phenomenon under study was achieved. 
 
1.5. Philosophical assumptions of mixed methods design 
 
According to O’Cathain (2006), qualitative and quantitative researchers are committed 
to different epistemological and ontological positions, in that qualitative researchers 
base their assumptions on constructivists or interpretivist paradigm, and quantitative 
researchers are inclined to positivism or post-positivist paradigm. The author explains 
that  
“the paradigms are contrasted on subjectivity-objectivity, induction-deduction, 
relativism-realism, holism-reductionism…” 
 
and argues that there is controversy amongst researchers, because they consider that the 
two paradigms represent incompatible assumptions (O’Cathain, 2006). Some authors 
propose that mixing methods is both unacceptable and impossible (O’Cathain, 2006; 
Ryman, 1988). Other researchers favour a more “pragmatic” or “instrumental” 
approach, claiming that the choice of which method to use depends on practical 
demands and on what would be the best approach to answer the research question. The 
researcher can then adopt the paradigm or philosophical stance that they consider the 
most appropriate for mixed methods research (O’Cathain, 2006).  
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For this study, a pragmatic stance was adopted (O’Cathain, 2006; Tashakkori & 
Teddlie, 1998) due to the fact that the research question was considered more important 
than the paradigm underlying the method. 
 
1.6. Rationale of the methodology 
 
Due to the fact that the majority of the existing research on chemo brain and PM is 
quantitative in nature, with few qualitative studies, it was decided that combining 
methodologies in a longitudinal study on chemo brain would be the most valuable 
approach to better understand the phenomenon of chemo brain as a PM failure and to 
understand how this impacts patients’ lives. Furthermore, to the author’s knowledge, no 
previous study has investigated the TOT phenomenon as a problem of chemo brain, 
although it has been widely recognised that chemo brain patients have trouble with 
words. 
 
To better understand the reality of patient’s experiences after receiving cancer 
treatment, a patient-focused approach was considered to be particularly useful for 
explaining the phenomenon in more depth and to explain contradictions in the current 
literature, such as neuropsychological batteries not showing impairment while patients 
reporting distressing memory complaints. In particular, the author considered that 
quantitative and qualitative findings would complement each other to explain the 
phenomenon in a broader manner through patients’ lived experiences as well as how 
and why there are discrepancies between test results and the patients’ self-reports. 
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1.7. Quantitative methodology 
 
A longitudinal approach was conducted for the quantitative study. Psychological scales 
and neuropsychological measures along with objective and subjective measures of sleep 
and sleepiness were administered at two point times to a group of breast cancer patients 
before and in the middle of patients’ treatment and to the healthy volunteers control 
group. Demographic information was collected at the beginning of the study. 
 
The memory problems reported by cancer patients known as chemo brain might be a 
problem of WM (ongoing STM) and PM (memory for the intended actions) on breast 
cancer patients undergoing chemotherapy treatment. Both WM and PM were assessed 
by scores resulting from neuropsychological batteries and questionnaires. 
Neuropsychological battery raw scores were the primary outcome measure. 
Neuropsychological Battery: 
1. CAMPROMPT (Cambridge Prospective Memory Test) 
2. BVRT (Benton Visual retention Test) 
3. DIGITS FORWARDS 
4. DIGITS BACKWARDS 
5. DIGITS SYMBOL 
6. COWAT (Controlled Oral Word Association Test) 
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Other Screening measures: 
7. NART (National Adult Reading test) 
8. HADS (Hospital Anxiety and depression Scale) 
9. Demographic information 
 
Sleep time was also considered, and participants were required to use a sleep monitor 
over a four-day period. 
 
1.8 Qualitative methodologies 
 
Two different qualitative approaches were considered in this study to gain deeper 
insight into the lived experiences of chemo brain. The first approach was to conduct a 
thematic analysis of the data collected through online asynchronous open-ended 
questionnaires, and the second approach was to build six case studies for the 
development of new theories explaining chemo brain with PM and the TOT 
phenomenon. This was accomplished through face-to-face interviews. 
 
1.8.1 Thematic analysis 
 
Cancer patients who took part in the quantitative assessment were invited to take part in 
an online questionnaire. This method of interviewing participants was selected because 
it was recognised that at this stage, cancer patients would be feeling tired or would be 
41 
 
still recovering emotionally and physically from their treatments. One of the advantages 
of the online questionnaire was that participants could respond to the questions at their 
own pace and had more time to think about their responses. Furthermore, they could ask 
their family members to help them provide answers, particularly about memory lapses 
they themselves might not have noticed. However, one major disadvantage was that if 
they provided an answer that was too short, or the answer was not very clear, there was 
no way for the author to gain further explanation or clarification. This issue was 
overcome by conducting additional face-to-face interviews conducted at a later date 
after they had recovered from their treatment. The questionnaires comprised eight open-
ended questions related to their memory difficulties and two PM questionnaires. 
 
To look for a major insight into the phenomenon of chemo brain and to interpret, 
organise and describe its observations, a thematic analysis was conducted, which was a 
process of encoding qualitative information through a list of themes that emerge as 
patterns derived from the information obtained from participants (Boyatzis, 1998). 
Boyatzis (1998) defined thematic analysis as follows: 
“a translator of those speaking the language of qualitative analysis and those 
speaking the language of quantitative analysis”, which allows the incorporation 
of operant and open-ended measures of information. 
 
1.8.2 Case studies 
 
Balbontín (2012) explained that a case study is an event taking place in a natural way 
where the researcher aims to gain deep insight into a phenomenon and to enquire how 
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and why the phenomenon occurs. Yin (2009) described a case study as an empirical 
enquiry investigating a phenomenon in depth within its real life context. In this study, 
case studies were analysed to explore the phenomenon of chemo brain as a whole, 
considering the patient’s perspective, test results and experiences, along with statistical 
analysis. The aim was to present individual cases with the objective of developing a 
theory of chemo brain and PM and the TOT phenomenon. 
 
Following the online questionnaire, cancer patients from the sample were invited to 
participate in individual face-to-face interviews to further analyse their responses and 
integrate their test results to explore the discrepancies between anecdotal reports and 
neuropsychological tests results. 
 
1.9 Integration/triangulation 
 
This study focussed on data triangulation described by Patton (2002), in which 
information of the same phenomenon is collected from multiple sources, i.e. 
neuropsychological battery, online questionnaires and face-to-face interviews, to build 
case studies in order to present the information from different perspectives and 
approaches to explain and make sense of a phenomenon under study. 
According to Yin (2009), the strength of case studies relies on the fact that data 
collection comes from different sources of evidence, which are more likely to be 
relevant because they allow the researcher to address a broader range of behaviours or 
observations of the same phenomenon. Yin (2009) emphasized that  
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“the most important advantage presented by using multiple sources of evidence 
is the development of converging lines of enquiry, a process of triangulation and 
corroboration”, resulting in more accurate and conclusive findings. 
 
1.10 Thesis outline 
 
Chapter one of this thesis is dedicated to an introduction of the research topic, 
explaining the phenomenon under study and the rationale of the methodology selected 
to conduct the study. Chapter two focuses on the explanation of breast cancer and the 
psychological impact it has on patients since being diagnosed with a potentially life 
threatening disease. Chapters three and four present a systematic review of the literature 
on chemo brain (Chapter three) and on PM (Chapter four). The following chapters 
present the quantitative methods and results (Chapters five and six) and qualitative 
methods and results (Chapters seven, eight and nine). The final chapter is the focus of 
the final discussion (Chapter ten). 
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CHAPTER TWO 
2 UNDERSTANDING BREAST CANCER: PSYCHOLOGICAL FACTORS, 
DIAGNOSIS AND TREATMENT 
 
2.1 Introduction 
This section will try to explain the psychological implications and challenges in 
women’s lives when they are diagnosed with breast cancer. It is important to understand 
the process that they have to go through for a better understanding of the cognitive 
deficits experienced even before treatment. The author will also explain potential 
biological markers that affect cancer patients, which may be playing a role in chemo 
brain, such as sleep and sleepiness. 
 
Breast cancer is the most common cancer in the UK. Of the 55,000 people diagnosed 
with breast cancer each year, only 350 are men. Eighty percent of women being 
diagnosed with breast cancer are over the age of 50. Breast cancer patients may be 
diagnosed with early or primary breast cancer or secondary (metastatic) breast cancer, 
which is when the cancer has spread to other parts of the body. Primary breast cancer is 
the cancer that has not spread beyond the breast or the lymph nodes (glands) under the 
arm. Different types of breast cancer include ductal carcinoma (non-invasive) and 
invasive breast cancer, which has the potential to spread to other parts of the body 
(Breast Cancer Care, March 2016, BCC4Ed. 10). All the participants in this study had 
been diagnosed with primary breast cancer. 
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Since breast cancer survival rates have increased over the years as a result of more 
effective treatments, it is important to understand how treatment and illness affect 
patients’ psychological well-being. When a woman is diagnosed with breast cancer, she 
faces a very traumatic event. Many experience anxiety, depression, sexual problems and 
sometimes cognitive impairment. Patients’ approach to life is changed permanently, and 
their expectancies of the future have to be revised. Even when they complete treatment 
successfully, many regard themselves as not fully cured, because of the fear of relapse 
and therefore experience a permanent feeling of uncertainty (Ray et al., 1985). 
 
Most women being diagnosed with breast cancer have a mastectomy, which is an 
operation to remove the breast. There are several types of mastectomies. It can be 
segmental mastectomy in which the tumour and a large area of normal breast tissue 
around it is removed, and some lymph nodes under the arm may also be removed. In 
simple or total mastectomy, the whole breast is removed, but not the lymph nodes. In a 
modified radical mastectomy, the whole breast and surrounding lymph nodes, muscles, 
fatty tissue and skin are removed. After surgery, most women experience soreness that 
lasts for two to three days, and many women experience what is called “phantom 
breast” sensations, which include itching, pain, pins and needles, pressure or throbbing, 
which may be a result of damage to the nerves. Many women may choose to have a 
breast reconstruction, and after choosing the appropriate procedure with a plastic 
surgeon, they must look at factors such as infections, implant movement or contracture. 
Women may also decide to wear an artificial breast instead of breast reconstruction, for 
whom a prosthesis is designed (Turkington, 2005). 
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The impact on women’s quality of life after losing a breast is very damaging. It affects 
their self-esteem, body image, feminine identity and sexual relations, added to the stress 
of having to decide whether they would have a reconstructive surgery (Eiser, 1985). 
After being diagnosed, most women are advised to take a combination of therapies that 
include surgery, radiotherapy, chemotherapy, hormone therapy and targeted therapies, 
which can be given in different orders. Guided by their oncologist, they have to decide 
the course of treatment they will receive. Sometimes, they can have the choice as to 
undergo chemotherapy or local treatments, and this itself is a very difficult decision 
making time for them, because they need to think about the implications about both the 
courses of treatment, and how these decisions will impact their lives and their health. As 
a result, worry, anxiety and low mood are present since the moment of being diagnosed, 
throughout the treatment, and many times these psychological factors increase even 
after post treatment because of the fear of the cancer coming back. 
 
When women are diagnosed with breast cancer, they also face the challenge of telling 
other people and family about it. They usually struggle talking about their diagnosis and 
how they feel. It is particularly difficult to tell their children or their employers about it. 
They also may need to take some time off work, but this is not always the case. Some 
patients feel upset and angry and worry about the side-effects of treatment, such as 
nausea, fatigue, lymphedema and menopausal symptoms and the changes in their 
appearance due to hair loss and nail and skin damage. 
 
Breast cancer is graded depending on its rate of growth into grade one or low grade, 
grade two or moderate or intermediate grade and grade three or high grade. It is also 
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classified by stages through a staging system called TNM staging, and depending on the 
tumour size (T), spread to lymph nodes involvement (N) or metastasis (M), the type of 
treatment is recommended (Macmillan Cancer Support, October 2013. MAC11616, 
10th Ed.): 
 
Stage 0: In situ (non-invasive treatment) breast cancer. 
Stages I and II are often called early breast cancer. 
Stage I: Tumour is less than 2 cm and has not spread to the lymph nodes in the armpit. 
Stage II: Tumour is greater than 2 cm, but less than 5 cm; axillary nodal involvement. 
Stage II is divided into two stages:  
 
1. Stage IIA – The tumour is not bigger than 2 cm and has spread to the lymph nodes 
in the armpit OR is bigger than 2 cm and has not spread to the lymph nodes OR it 
can’t be found in the breast, but is present in the lymph nodes.  
2. Stage IIB – The cancer is smaller than 5 cm and has spread to the lymph nodes in 
the armpit OR is bigger than 5 cm but has not spread to the lymph nodes.  
3. Stage III: Tumours greater than 5 cm; axillary nodal involvement; called locally 
advanced breast cancer. 
 
Stage III is divided into three stages:  
1. Stage IIIA – The cancer can’t be found in the breast OR it is under 5 cm and has 
spread to the lymph nodes in the armpit (which are clumped together) OR it is 
bigger than 5 cm and has spread to the lymph nodes.  
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2. Stage IIIB – The cancer has spread to tissue near the breast and may be attached to 
skin or muscle. There are usually cancer cells in the lymph nodes in the armpit.  
3. Stage IIIC – The cancer has spread to 10 or more lymph nodes in the armpit or to 
lymph nodes below the breastbone, near the neck or under the collarbone.  
 
Stage IV: The cancer has spread to other parts of the body, and it is called secondary or 
metastatic breast cancer. 
 
2.1.1 Understanding adjuvant chemotherapy and its toxic effects 
 
The role of chemotherapy as a cancer treatment is to interfere with the ability of cancer 
cells to divide and grow. Different chemotherapy treatments work in different ways 
affecting the cancer cells at different phases of growth. For primary invasive breast 
cancer, adjuvant chemotherapy (given in addition to other treatment) is recommended 
usually after surgery and radiotherapy after the chemotherapy treatment is completed.  
 
Primary or early breast cancer patients usually undergo a series of treatment every two 
to four weeks over a period of four to six months, depending on the stage of the tumour 
and the combination of drugs. These drugs may include hormone therapy usually 
prescribed to primary invasive breast cancer patients to reduce the risk of relapse. This 
therapy usually begins after surgery, but it can also begin post chemotherapy treatment. 
In some cases, it may even begin before surgery to reduce the size of the tumour, which 
is known as neoadjuvant treatment (Breast Cancer Care, March 2016, BCC4, 10th Ed.). 
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Chemotherapy drugs are often administered in combination. Some commonly used 
combinations include the following:  
1. FEC – fluorouracil (5FU), epirubicin and cyclophosphamide  
2. FEC-T – FEC followed by docetaxel (Taxotere®)  
3. AC or EC – doxorubicin (Adriamycin®) and cyclophosphamide or epirubicin and 
cyclophosphamide  
4. CMF – cyclophosphamide, methotrexate and 5FU  
5. E-CMF – epirubicin and CMF 
 
Adjuvant chemotherapy for breast cancer usually includes an anthracycline drug, such 
as epirubicin or doxorubicin. If the risk of the cancer coming back is higher, docetaxel 
is also usually included. The patient’s doctor may offer the patient a choice of the 
chemotherapy treatments.  
 
If the patient has HER2 breast cancer, they may be given trastuzumab (Herceptin) along 
with chemotherapy.Chemotherapy drugs can cause side effects. Many of these can be 
controlled well with medicines and are usually overcome post treatment. The patient’s 
doctor or nurse tells the patient more about what to expect. 
 
2.1.1.1 Chemotherapy side effects and necessary precautions 
 
Some of the most common side effects of chemotherapy treatment are listed as follows: 
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1. Reduction in number of white blood cells: Increased risk of infection due to 
chemotherapy can reduce the number of white blood cells, which help fight 
infections (neutropenia). 
2. Bruising and bleeding: Chemotherapy can reduce the number of platelets in blood, 
which aid in blood clotting. This increases the risk of bleeding. 
3. Anaemia: It is caused by a low number of red blood cells and can make the patient 
feel very tired and lethargic. The patient may also become breathless.  
4. Feeling sick: Some chemotherapy drugs can make the patient feel sick (nauseated), 
leading to vomit.  
5. Tiredness (fatigue): The patient is likely to become tired and have to take things 
more slowly.  
6. Hair loss: This includes loss in body hair, eyelashes and eyebrows.  
7. Loss of appetite. 
8. Sore or dry mouth: Patients’ may notice small ulcers during treatment.  
9. Diarrhoea. 
10. Effects on the nerves in the patient’s hands or feet: This can cause tingling or 
numbness, a sensation of pins and needles or muscle weakness (peripheral 
neuropathy).  
11. Early menopause. 
12. Infertility. 
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To better understand chemo brain, it is useful to get an understanding about the 
neurotoxic agents of chemotherapy, because they may pose as a very significant 
confounding variable.  
 
At the biological level, chemotherapy drugs affect cellular enzymes that are involved in 
DNA synthesis and/or function, which takes place during the cell cycle. Chemotherapy 
drugs interfere with the cell activities during one or more phases. Cell cycle specific 
(CCS) drugs affect cellular activity during specific phases, and cell cycle nonspecific 
(CCNS) drugs affect the cell during any phase. Actively diving cells are more sensitive 
to chemotherapy. Chemotherapy drugs can also be classified according to their 
functions and structures during cell cycle (Table 2.1). 
Drug Cell cycle Function 
ALKYLATING AGENTS CCNS Damage completed DNA 
molecule 
ANTIMETABOLITES CCS  Make cellular reproduction 
impossible 
NITROSOUREAS CCNS Cross the blood brain barrier 
ANTITUMOR 
ANTIBIOTICS 
CCNS  Interfere with cell division 
and transcription of RNS 
MITOTIC INHIBITORS CCS  Interfere with mitotic spindle 
formation 
Table Error! No text of specified style in document..1. Chemotherapy drugs 
classification on their function and structure during cell cycle (Preston et al., 1997). 
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Combining two or more agents has an advantage depending on the composition of 
malignant cells, which do not have a uniform composition within a given tumour. These 
combinations can have a greater chance of destroying a larger number of cancer cells, 
while at the same time increasing the toxicity of healthy cells. 
 
It is also important to understand the way chemotherapy is administered, because 
dosages can be greatly influenced by the routes of administration. Drugs that can 
potentially cause cellular damage when they infiltrate the subcutaneous tissue are called 
vesicants. Even a minute amount can cause damage. Breast cancer can be treated with 
vesicants (Doxorubicin). The routes are oral, subcutaneous, intramuscular, intravenous, 
intra-arterial, intrathecal and intracavitary (Preston et al., 1997). 
 
A list of the most common chemotherapeutic agents used for breast cancer and their 
side effects is presented in Table 2.2. As mentioned before, some of the side effects may 
alter cognition and have a psychological impact on the patient. 
 
Agent Dosage Administration Side effects 
Aminoglutethimid
e (Cytradren) 
CCNS 
 
Varies Oral. Always 
administered with a 
steroid (hydrocortisone 
40–100 mg PO daily in 
4 divided doses; 
Anorexia, dermatologic 
reaction (rash with or 
without fever), fatigue, 
gastrointestinal alterations 
(nausea, vomiting), 
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Florinef 0.1 mg PO 
every other day) 
 
hepatic toxicity, 
metabolic alteration, 
neurotoxicity (ataxia, 
head ache, nystagmus, 
somnolence) 
Cyclophospahmid
e (Cytoxan, 
Neosar) 
Alkylating Agent 
CCNS 
 
Varies IV, PO, intraplenural, or 
intraperitoneal 
 
Alopecia, anaemia, 
anorexia, cardiac toxicity, 
haemorrhagic cystitis, 
hepatic toxicity, 
leucopoenia, 
gastrointestinal alterations 
(nausea, vomiting), 
metabolic alterations 
(hyponatremia), renal 
toxicity, reproductive 
dysfunction, 
thrombocytopenia 
Chlorambucil 
(Leukeran) 
Alkylatin agent 
CCNS 
 
Varies 
 
Oral Anaemia, cystitis, 
dermatologic reaction, 
gastrointestinal alteration 
(nausea, vomiting, 
diarrhoea), hepatoxicity, 
leucopoenia, 
neurotoxicity (seizures, 
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peripheral neuropathies), 
pulmonary toxicities 
(fibrosis, alveolar 
dysplasia), renal toxicity 
(hyperuricemia), 
reproductive dysfunction 
(amenorrhea, 
ologospermia, 
azoospermia), secondary 
malignancies (acute 
myelogenous leukaemia), 
stomatitis, 
thrombocytopenia 
Agent Dosage Administration Side effects 
Doxorubicin 
(Adriamycin-
RDF) 
Antibiotic 
CCNS 
 
Varies IV Alopecia, anaemia, 
anorexia, cardio 
toxicities, diarrhoea, flu-
like syndrome, nausea, 
vomiting, dermatologic 
reactions, leucopoenia, 
stomatitis, 
thrombocytopenia 
Fluorouracil/5FU 
(Adrucil) 
Varies IV, intra-arterial, intra-
peritoneal, topical, oral 
Alopecia, anaemia, 
anorexia, cardiotoxicity, 
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Antimetabolite 
CCS 
 
dermatological reactions, 
diarrhoea, nausea, 
vomiting, increased 
lacrimation, leukopenia, 
neurotoxicity 
(photophobia, cerebral 
ataxia, stomatitis, 
thrombocytopenia) 
Agent Dosage Administration Side effects 
Lomustine/ CCNU 
(CEENU) 
Nitrosourea 
CCNS 
 
Varies Oral Alopecia, anorexia, 
anaemia, nausea, 
vomiting, 
hepatotoxicities, 
leucopoenia, 
neurotoxicities 
(disorientation, lethargy, 
ataxia, dysarthria), 
pulmonary toxicities, 
renal toxicities, 
stomatitis, 
thrombocytopenia 
Megestrol Acetate 
(Megace, Pallace) 
Varies Oral 
 
Alopecia, breast 
tenderness, dermatologic 
reaction, nausea, 
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Hormone 
Progestine 
Appetite Stimulant 
vomiting, stomach 
cramps, hepatic toxicity, 
neurotoxicity (headache), 
reproductive dysfunction, 
venous phlebitis, weight 
gain 
Mechlorethamine/
Nitrogen 
Mustard/HN2 
(Mustargen) 
Alkylating agent 
CCNS 
 
Varies Intracavitary infusion 
 
Alopecia, anaemia, 
anorexia, burning 
sensation along vein, 
dermatologic reaction, 
fever, diarrhoea, nausea, 
vomiting, peptic ulcer, 
leukopenia, 
neurotoxicities 
(weakness, headache, 
drowsiness, vertigo, 
convulsions, progressive 
muscle paralysis, 
paraesthesia, cerebral 
degeneration, coma), 
hepatic toxicity, 
ototoxicity, reproductive 
toxicity, renal toxicity, 
thrombocytopenia 
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Agent Dosage Administration Side effects 
Melphalan/L-
Phenylalinine 
Mustard/L-Pam/L-
Sarcolysin 
(Alkeran) 
Alkylatin agent 
CCNS 
Varies Oral Alopecia, anaemia, 
dermatologic reactions, 
diarrhoea, nausea, 
vomiting, leukopenia, 
pulmonary toxicity, 
reproductive dysfunction, 
secondary malignancies, 
stomatitis, 
thrombocytopenia 
Medroxyprogester
one (Depo-
Provera, Provera) 
Hormone 
Progestin 
Varies 
 
IM, oral Alopecia, fluid retention, 
nausea, vomiting, gluteal 
abscess, hepatoxicity, 
hypersensivity, metabolic 
alteration (increased 
calcium), weight gain 
Agent Dosage Administration Side effects 
Methotrexate/ A-
Methopterin/MTX 
(Mexate, Folex) 
Antimetabolite 
CCS 
 
Varies PO, IM, IV, intrathecal, 
or intra-arterial 
Alopecia, anaphylaxis, 
anaemia, dermatologic 
reactions, abdominal 
distress, nausea, 
diarrhoea, vomiting, 
hepatic toxicities, 
leukopenia, 
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neurotoxicities (dizziness, 
fatigue, headache), renal 
toxicity, stomatitis, 
thrombocytopenia, 
pulmonary toxicity 
Table Error! No text of specified style in document..2. Chemotherapeutic agents to 
treat breast cancer. 
 
The most common side effects that can cause cognitive impairment are as follows:  
1. Hepatic toxicity (impaired mental status, lethargy, confusion, disorientation, altered 
thought processes) 
2. Metabolic alterations (disorientation, confusion, alteration in thought processes) 
3. Hyponatremia (change in mental status, lethargy, seizure activity) 
4. Neurotoxicity (change in mental status, seizure activity, depression, altered thought 
processes) 
 
Other potential biological markers affected in breast cancer patients that might be 
interfering with cognitive decline are fatigue, sleep and sleepiness, which will be 
examined in the following section. We will also examine the role of breast cancer in 
health anxiety and depression. 
 
2.1.2 Relationship between cognition and sleep, anxiety and depression  
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There is a strong relationship between memory processes and sleep. Depressive 
symptoms, fatigue and poor sleep are frequently reported in breast cancer patients and 
frequently occur at the same time. They have a negative effect on the quality of life and 
are presented as a cluster of symptoms, which can be related to disease or treatment and 
could be mediated by relatively stable individual differences such as anxiety tendency to 
react when experiencing life threatening situations (trait anxiety). High trait anxiety 
leads to the development of depressive symptoms when experiencing stress and adverse 
events. Anxiety has also been identified as a risk factor in developing fatigue and sleep 
disruptions (Lockefeer et al., 2012). It is due to this cluster of factors that the current 
study aimed to explore the effects of sleep, sleepiness and affective disorders (anxiety 
and depression) in the context of PM and chemo brain. 
 
The discovery of rapid eye movement (REM) and non-REM (NREM) sleep has led 
researchers to gain insight into the hypothesis that sleep and specific sleep stages 
actively influence memory development. Today, this relationship is known as sleep-
dependent memory (Walker & Stickgold, 2006).  
 
According to Ancoli-Israel et al. (2001), fatigue is one of the most common complaints 
in cancer patients, which interferes with their daily lives and affects their quality of life. 
It is also one of the most common reasons why patients withdraw treatment. It is 
believed that fatigue can be originated by physical as well as psychological factors. 
Research has demonstrated that there is a relationship between self-reported fatigue and 
self-reports of sleep quality (Ancoli-Israel et al., 2001). 
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Ancoli-Israel et al. (2001) also made the point that breast cancer patients are among 
those who most often experience fatigue during, and several months after, treatment. 
Sleep disruption in cancer patients may be caused by multiple factors, such as insomnia 
or/and hypersomnia, whose causes may be pain, depression or anxiety. Chemotherapy 
and radiotherapy are also known to cause sleep disturbance. 
 
On the other hand, two major memory systems are identified by Schatcter and Tulving 
(1994) that consist of five memory systems. The  most general of all are procedural and 
declarative memory. PM is involved in behavioural and cognitive skills related to 
“knowing how” to do things (how to ride a bicycle, how to type, how to solve puzzles), 
whereas declarative memory involves “knowing that” (e.g. knowing that 2+2=4). PM 
includes learning motor skills, simple conditioning, simple associative learning and 
learning about patterns and regularities in the environment. STM (WM), episodic and 
semantic memory are encompassed into what is known as declarative memory. 
Semantic memory processes factual information, and episodic memory includes 
autobiographical memory, which includes involvement of personal experience (Neath & 
Suprenant, 2003). 
Chemo brain patients often complain about forgetting factual information such as 
important events, names, appointments, dates, etc., which can be categorised as a 
problem with their declarative memory. It has also been very well established that breast 
cancer patients suffer from disturbed sleep patterns, especially in the active phase of 
chemotherapy (Savard et al. 2009). Evidence in literature demonstrates that there is a 
relationship between memory and sleep, and that declarative memory is enhanced 
during sleep; therefore, the disruption of sleep patterns may cause a disruption in 
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declarative memory, which is consistent with chemo brain patient’s reports (Rasch & 
Born, 2008). 
 
According to Rasch and Born (2008), there is evidence that sleep promotes the 
consolidation of declarative memories for events and facts. It is during sleep that 
consolidation takes place and memories stabilise against future interference. Neuronal 
reactivation of recently acquired memories redistributes and integrates these memories 
into the network of pre-existing memories during sleep consolidation of memories, 
which takes place during the slow-wave cycle of sleep. According to these authors, 
sleep specifically enhances declarative aspects of memory. 
 
Circadian rhythms and sleep disruption are becoming an issue of interest among 
researches. Ancoli-Israel et al. (2001) concluded that disruptions in circadian rhythms 
can affect sleep quality and alterations in rhythms and at the same time, they can disrupt 
a variety of physiological mechanisms pertaining to fatigue. Other disruptions in 
circadian rhythms, such as a lack of entrainment to day–night cycle and sleep, can lead 
to feelings of grogginess akin to those of jet lag (Ancoli-Israel et al., 2001). 
Savard et al. (2009) analysed how breast cancer patients have progressively impaired 
sleep-wake activity rhythms during chemotherapy. They conducted a study with a 
sample of 95 women scheduled to receive neo-adjuvant or adjuvant anthracycline-based 
chemotherapy for a stage I–III breast cancer. 
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The purpose of their study was to assess longitudinally to what extent circadian rhythm 
impairments evolve over the course of chemotherapy, as previous research suggested 
that sleep and circadian rhythms may be altered even prior to the initiation of 
chemotherapy. Their findings showed that compared to baseline, all circadian rhythm 
variables were significantly impaired during the first week of both chemotherapy cycles, 
suggesting that more enduring impairments in sleep-wake activity rhythms worsen with 
repeated administration of chemotherapy. They also found out that patients with 
disrupted sleep-wake cycles showed increased fatigue levels and decreased quality of 
life. Women with breast cancer demonstrated more phase-delayed rhythms, 
experiencing more daily dysfunctions. 
 
In a study conducted by Kuo et al. (2006), the quality of sleep and related factors using 
actigraphy and sleep subjective and objective assessments of 16 women during 
chemotherapy in patients with stage I/II breast cancer were analysed. They found that 
sleep quality was negatively affected during the active phase of chemotherapy. Patients 
experienced better sleep quality during the recovery phase than during the active phase, 
meaning that chemotherapy alters sleep/wake activity.  
 
Banks and Dinges (2007) stated that as a consequence of several days of chronic 
restriction of sleep below <7 hrs per night significantly affects day time cognitive 
function, similar to the cognitive dysfunction found after severe acute total sleep 
deprivation. Restricted sleep can cause neurobehavioral deficits on attention, mood, 
WM, cognition and preservation of thought. These deficits that accumulate after days of 
partial sleep loss are equivalent to 1–3 nights of total sleep loss. They also suggested 
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that there is a possibility of a genetic effect with regard to responses to sleep restriction 
and vulnerability in cognition. 
 
Cognitive function is also associated with sleep disturbance by Meerlo et al. (2009). 
They stated that a short-term sleep restriction interferes with learning processes, and 
that prolonged sleep loss may endanger hippocampal integrity, leading to cognitive 
dysfunction and the development of mood disorders. 
 
It is now clear that cognition and sleep loss are inter-related. Davidson et al. (2002) 
suggested that sleepiness in cancer patients is prevalent and causes distress and 
disturbance in the patient’s quality of life. Therefore, its effects on cognition deserve 
further investigation. 
 
In the current literature, there is a gap in the experimental assessment of memory and its 
relationship with chemo brain. Most of the studies have focused on neuropsychological 
assessment and general cognitive performance in those assessments. A specific study on 
memory and its diverse stages and categories along with their relationship with various 
sleep stages in cancer patients who experience chemo brain is proposed to help better 
understand what happens with memory processes in patients’ daily lives. 
 
Breast cancer patients undergo a very stressful process from the moment they are 
diagnosed with cancer. Some authors have suggested that even before treatment, they 
begin to experience cognitive deficits (Mehlsen et al., 2009). Some of the possible 
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causes of these cognitive deficits may be fatigue as a consequence of sleep loss 
triggered by anxiety and treatment.  
 
2.1.2.1 Sleepiness 
 
There is a difference between the definitions of sleepiness and fatigue. For the purpose 
of this study, it is important to distinguish between them, since both the terms are often 
used interchangeably. This study does not focus on fatigue because of the lack of 
objective measures to assess it and to avoid confusion between the overlapping 
characteristics of both the constructs. Instead, special attention is given to the study of 
sleep and sleepiness and the related cognitive deficits. 
 
In the literature, several different definitions of sleepiness include a subjective state of 
sleep need; a physiological drive derived from sleep deprivation; and a strong sleep 
propensity (Cursio et al., 2001). According to Pigeon et al. (2003), sleepiness during the 
day refers to sleep propensity, dismissed alertness and drowsiness, whereas fatigue 
should be accounted as exhaustion, worn-out energy and weakness. Shen et al. (2006) 
distinguished sleepiness from fatigue as an impairment of arousal mechanism. These 
authors also made it clear that sleepiness is a phenomenon that can be a symptom of 
some psychiatric and sleep disorders and a normal physiological state. In addition, it can 
be considered as being pathological and abnormal when it occurs at inappropriate times 
or when desired, as is the case with narcolepsy and insomnia (Shen et al., 2006). 
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On the other hand, Shen et al. (2006) stated that sleep propensity or the act of falling 
asleep (objective sleepiness) – the transitional state between wakefulness and sleep – 
should be distinguished from subjective feelings of drowsiness or somnolence 
(subjective sleepiness) – a greater tendency to fall asleep, with decreased cognitive 
performance, mood, motivation, autonomic and physiological responses. 
 
Another distinction of sleepiness is the one explained by the four-process model of 
sleep and wakefulness. In this model, the interaction between sleep and wake drives 
consists of independent but mutually inhibitory interactions between primary (sleep-
wake drives influenced by circadian rhythms) and secondary components 
(environmental and behavioural factors). Therefore, sleepiness (sleep propensity) results 
as a function of the interaction between total sleep drive (primary and secondary) and 
total wake drive (primary and secondary) (Johns 1993, 2002, 2003; Shen et al., 2006). 
Sleep propensity has also been considered as a trait (long term, personality related) and 
as a state (short-term, situational related). Sleepiness is caused by disruptions of 
sleep/wake mechanisms, which may not be necessarily involved in fatigue (Shen et al., 
2006). 
 
A lack of sleep may lead to patients feeling fatigued, but sleepiness is usually 
underestimated by them. People usually state that they are not sleepy, when in fact they 
are. For that reason, objective measures are being used to collect physiological measures 
of sleepiness, such as galvanic skin response and sleep latency, along with a subjective 
scale. It is hypothesized that deficient sleep patterns lead to sleepiness during the day, 
which in turn leads to attention deficits and ultimately to problems with PM. 
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Sleep disturbance in cancer patients was analysed in a cross-sectional study conducted 
by Davidson et al. (2002). They found that sleepiness is one of the most prevalent 
problems, affecting 28% of cancer patients. A significantly higher prevalence of 
excessive sleepiness and fatigue was found in those who had undergone recent cancer 
treatment (37%). Despite the fact that sleepiness is prevalent in cancer patients, the 
issue has not been widely studied in the cancer population, particularly in the context of 
chemo brain (Davidson et al., 2001). 
 
It was hypothesized that cancer patients participating in this study would show higher 
rates of sleepiness and sleep/wake pattern alterations, leading to a decline in PM and 
WM. Women who are diagnosed with breast cancer experience several challenges 
ranging from physical challenges imposed by treatment and surgery, and their mental 
health is also at risk. During and after treatment, they learn to cope with the physical 
changes that their bodies experience, and patients have to learn to accept their new 
identity as breast cancer survivors as well as their new body image. This in itself poses a 
very distressing challenge, and factors such an anxiety and depression are usually 
present before, during and after treatment, being the most commonly reported 
psychological problems by breast cancer patients (Burgess, 2005). 
 
The excessive worry or fear about becoming ill or being ill receives the term of health 
anxiety. This excessive fear or worry is due to a preoccupation with the incorrect belief 
of being in danger of developing a serious disease or medical condition 
(Hadjistavropoulos et al., 2012). It has been very well established that women receiving 
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breast cancer diagnosis develop acute anxiety and depressive disorders (Kissane et al., 
2004), and according to Grassi et al. (2004), 38% of women diagnosed with breast 
cancer report elevated health anxiety, with 20% in early breast cancer patients (Wade et 
al., 2005). Furthermore, even after successfully completing the treatment, anxiety may 
persist for a long period of time, affecting patients’ quality of life (Feng et al., 2014).  
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CHAPTER THREE 
3 CHEMO BRAIN EXPLAINED 
 
3.1 Chapter overview 
 
Despite the fact that cancer treatment significantly improves patients’ survival rate, it 
also has adverse side effects that can be manifested immediately or delayed, depending 
on the type of treatment received or each individual patient’s response. Some of these 
side effects may be transient, whilst others may last for longer periods of time. The most 
common and well-known effects are fatigue, alopecia, anaemia, anorexia, cardio 
toxicity, dermatological reactions, diarrhoea, nausea, vomiting, increased lacrimation, 
leukopenia, neurotoxicity (photophobia, cerebral ataxia, stomatitis and 
thrombocytopenia) and hormonal changes. 
 
A lesser known and arguably not so uncommon symptom is MCI. Many patients report 
difficulties during and after treatment. This impairment has been termed as chemo brain 
and chemo fog (Raffa et al., 2006; Raffa & Tallarida, 2010). When neuropsychological 
assessment is conducted, the most affected cognitive domains are attention, 
concentration, WM, verbal and visual memory and multitasking (Raffa, 2011). 
 
Patients who report cognitive deficits also report having difficulties with multitasking, 
remembering appointments or planned intentions, problems retrieving words and 
names, repetition or omissions of actions, problems following instructions and difficulty 
with learning new information. They also report feeling fuzzy, hence the term chemo 
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fog. In the literature, it has been very well established that patients experience cognitive 
failure during and after treatment (Ahles & Saykin, 2001; Vardy et al., 2008). However, 
establishing a causal relationship between cancer treatment and chemo brain has been 
questionable. 
 
Most of the research on chemo brain has been conducted using diverse 
neuropsychological batteries to detect cognitive impairment, and the results are 
controversial. Some authors found significant impairment (Paquet et al., 2013), while 
others found non-significant impairment. Some have concluded that the phenomenon 
does not even exist (Mehlsen, 2007). The problem with this type of research has been 
the lack of consistency of the use of neuropsychological batteries, the type of sample 
and control groups, diverse statistical analysis and the lack of qualitative reports. 
 
On the other hand, common difficulties found in the study of chemo brain are several 
confounding factors such as anxiety, depression, fatigue, hormonal status, education, 
age and IQ to mention a few. Factors such as anxiety and depression may have an effect 
on neuropsychological assessment, and it can be argued that cognitive impairment may 
occur due to such factors, rather than as an effect of chemotherapy treatment (Hodgson 
et al., 2013; Bender, 2006; Paquet, 2013). However, some authors found no effect on 
cognition (Ahles, 2007). 
 
In order to establish a causal relationship, the latest research has been focused on 
neuroimaging techniques, which is shedding some light on which areas of brain get 
affected after cancer patients undergo chemotherapy treatment, with promising results 
(Deprez et al., 2011; de Ruiter, 2012). 
 
70 
 
Below systematic review of the literature will help better understand this little known 
phenomenon, which emerges after patients have undergone cancer treatment. 
The analysis begins with a brief review of the historical background of the study of 
chemo brain on breast cancer patients, current neuropsychological studies and 
neuroimaging as well as qualitative reports of patients who have experienced chemo 
brain as a side effect of their treatment. 
 
3.2 Historical background of the neuropsychological assessment of chemo brain  
 
Cognitive changes in patients undergoing chemotherapy was first reported by Silberfarb 
et al. (1980). Patients with different cancer types were included in their study. The 
authors reported that overall significant worse results were found in cancer patients on 
various tests of cognition and recall (Alusie et al., 2011). A study by Gregg et al. (1991) 
of 44 pre-bone marrow transplant recipients with a prior history of chemotherapy found 
that cognitive dysfunction was present in memory, attention, motor and higher 
processing and that such impairments were associated with previous courses of 
chemotherapy (Wieneke et al., 1995). 
 
Wieneke and Dienst (1995) conducted the first study that used neuropsychological tests 
with early breast cancer patients undergoing conventional (not high dose) adjuvant 
chemotherapy and Tamoxifen treatment (Wieneke et al., 1995). Their findings 
suggested that breast cancer patients present cognitive dysfunction several months after 
treatment cessation, which were unrelated to co-morbidity, depression and length of 
treatment. 
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An increased interest in the study of cognitive decline after chemotherapy rose after 
studies by Silberfab (1980), Gregg (1991) and Wieneke et al. (1995). Although these 
preliminary studies lacked baseline assessment, recruited small sample sizes and lacked 
control groups, they were important, because it became evident that not only does 
cranial radiation cause cognitive impairment, but also chemotherapy treatment, which 
does not target the brain. 
 
A study conducted by van Dam et al. (1998) examining cognitive impairment in 
patients undergoing adjuvant chemotherapy for breast cancer was the first to include a 
control group consisting of 39 breast cancer patients treated with adjuvant 
chemotherapy and 34 negative breast carcinoma not treated with adjuvant chemotherapy 
two years after treatment. Their findings suggested that breast cancer patients were at a 
higher risk of cognitive decline than patients not treated with chemotherapy. They 
reported that 31% vs. 6% (p = 0.007) presented problems with concentration, and 21% 
vs. 3% exhibited problems with memory. 
 
It was not until the early 2000s that the research community increased interest in the 
study of chemo brain. Larger samples were recruited, and the first studies were mainly 
cross-sectional. However, later longitudinal studies emerged, and control groups 
became more diverse. For example, in a cross-sectional study, Brezden et al. (2000) 
found that cognitive differences were present in breast cancer patients receiving 
adjuvant chemotherapy when compared with healthy controls. A total of 107 women 
took part in their study, and it was found that memory and language were significantly 
different between cancer patients and healthy controls (p = 0.024 and p = 0.33, 
respectively). 
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Pioneers in the study of neural correlates of cognitive impairment and chemotherapy, 
Meyers et al. (2000) reported abnormal results for conventional electroencephalography 
(EEG) in chemotherapy cancer patients for non-CNS disease, and Schagen et al. (2001) 
conducted a study to gain understanding of the physiological correlates of treatment 
related to cognitive impairment on breast cancer patients. They found a significant 
difference between their three groups of breast cancer patients with respect to the 
asymmetry of the alpha rhythm of 0.5 Hz, which indicates certain cortical or subcortical 
dysfunction. Their results suggested that there is neuropsychological support for 
cognitive dysfunction as a complication of high-dose systemic chemotherapy in breast 
cancer patients. 
 
In the last few years, there has been an increased interest in the study of chemo brain 
and neural correlates, bringing new insights into the phenomenon. 
 
The existence of chemo brain has been very well documented since the early 1990s 
(Ahles & Saykin, 2001; Vardy et al., 2008; Jansen et al., 2007; Jansen et al., 2008; 
Shilling & Jenkins, 2007). However, methodological issues in some of these studies led 
to the results being considered as controversial (Raffa, 2011). Some of these problems 
were small sample size, lack of baseline assessment, different statistical approaches, 
different testing measures between studies and lack of ecological validity of the 
measures. These methodological problems might be caused as a result of over-reliance 
on retrospective and cross-sectional designs and a lack of qualitative and mixed 
methods methodologies, which would provide a wider understanding of the spectrum. 
However, although subtle, a causal relationship has been established between chemo 
brain and chemotherapy by some authors, which is discussed further below. 
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3.3 Aetiology: The nature of memory impairments in chemo brain 
 
The fact that some patients who survive cancer present with memory deficits after 
undergoing chemotherapy has already been established in the literature (Ahles & 
Saykin, 2001; Vardy et al., 2008; Jansen et al., 2007; Jansen et al., 2008; Shilling, & 
Jenkins, 2007; Stewart et al., 2006; Collins et al., 2009; Tager et al., 2009; Bender et 
al., 2006; Weis et al., 2009; Wieneke & Dienst, 1995). However, the aetiology of this 
phenomenon remains unknown, as does the question as to whether this phenomenon is 
physiological, psychological or ecological, or a combination of all the three. It is also 
well known that mood, anxiety, stress, neuro-chemical toxicity and hormone therapies 
play a role in poor cognitive performance in cancer patients who have undergone 
chemotherapy treatment and may represent a threat to the validity of the study of chemo 
brain. For that reason, chemo brain should be considered as a multifactor phenomenon, 
since no single factor fully accounts for the cause-effect relationship on the memory 
deficits reported by patients who undergo chemotherapy. All these should be considered 
as confounding factors for the study of chemo brain. 
 
Objective, reliable and robust neuropsychological measures have shown inconsistencies 
with patients’ self-report indicators, i.e. patients report cognitive declines that are not 
identified by neuropsychological measures (Mehlsen et al., 2009). The reason for such a 
discrepancy might be that neuropsychological batteries relate more to laboratory 
conditions rather than everyday life activities experienced by cancer patients, lacking 
ecological validity, or that the current neuropsychological batteries are not sensitive 
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enough to detect the MCIs implicated in chemo brain (Jansen et al., 2007). For that 
reason, it has become necessary to assess the memory deficits that patients face in their 
daily living activities with more sensitive measures to further analyse the phenomenon 
of chemo brain. 
When breast cancer survivors realise that their cognitive deficits are due to an actual 
brain dysfunction probably caused by chemotherapy treatment, they feel relieved, since 
feelings of guilt are also a part of the process, as they feel responsible for the cognitive 
failures, thinking that they are doing something wrong or not coping as they are 
supposed to (Silverman & Davidson, 2009). 
 
On the other hand, most of the literature has been focused on analysing the whole 
spectrum of what is called the cognitive domain, i.e. memory (short-term, long-term, 
WM), attention, concentration, information processing speed, EF, visuospatial skills, 
verbal and visual memory, motor function, language and learning abilities (Vardy et al., 
2008; Jansen et al., 2007; Jansen et al., 2008; Shilling & Jenkins, 2007; Stewart et al., 
2006; Collins et al., 2009; Tager et al., 2009; Bender et al., 2006). 
 
It is proposed that in order to gain a deeper understanding of the cause-effect 
relationship underlying chemo brain, researchers should begin to dissect and study each 
and every domain separately. The aim of this study was to focus on memory, 
specifically, WM and PM, which might be considered as a part of the WM model 
(Baddeley, 2003) and the multiprocess PM theory (McDaniel & Einstein, 2007) and in 
particular, the central executive system (Baddeley, 2003). Furthermore, sleep/wake 
activity patterns and day time sleepiness were analysed to observe their effect on 
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working and PM and the possible relationship with cognitive decline in patients 
reporting chemo brain. 
 
According to Shilling and Jenkins (2007), only a minority of patients report that these 
cognitive declines interfere with their everyday life, and a vast majority of those patients 
reported experiencing more problems with attention and memory than those identified 
by objective cognitive measures. According to these authors, this should not undermine 
the personal experiences, which patients report are mostly lapses and slips in their 
everyday lives. 
 
Patients who experience chemo brain-related memory deficits report symptoms ranging 
from minor disturbances to major problems that lead to a decrease in their quality of 
life, including losing their jobs and social isolation. Depending on the social support 
patients have, they also feel misunderstood by people around them, because they 
attribute the memory declines to faulty thinking or poor performance, rather than to 
chemo brain effects. They face difficulty retrieving words, feel slow in their cognitive 
abilities, their self-esteem decreases and their ability to multitask declines (Mulrooney, 
2007; Silverman & Davidson, 2009). 
 
To gain further understanding of the underlying mechanisms of chemo brain, some 
authors have proposed that factors such as chemotherapy-induced menopause, genetics 
similar to those predisposed to Alzheimer’s disease, aging and neurotoxic effect of 
chemotherapy on brain structures are responsible.  
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3.4 Risk factors 
 
One potential risk factor for cognitive decline is aging (Ahles, 2012). It has been 
speculated by some researchers that older patients’ cognition may be more affected by 
chemotherapy, and that older patients with lower pre-treatment scores showed poorer 
performance in post-treatment assessment, particularly processing speed (Ahles, 2010). 
This theory is confirmed by the analysis of older breast cancer patients in which 
Tamoxifen had a larger effect on more cognitive domains than in patients younger than 
65 years of age (Schilder et al., 2010). However, these conclusions contradict other 
findings in which women experiencing chemotherapy-induced menopause were the 
most affected in their cognitive abilities (Tannock et al., 2004; Phillips et al., 2003; 
Jenkins et al.; 2006). 
 
The role of genetics has also been discussed in the literature. Cognitive decline in 
adults, including Alzheimer’s disease, stroke and traumatic brain injury (TBI), has been 
associated with Apolipoprotein E (APOE), a glycolipoprotein that plays a role in 
plasticity and neuronal repair. Ahles et al. (2003) compared the neuropsychological 
performance of one group of long-term survivors of breast cancer and lymphoma who 
carried the E allele 4 (e4) to another group carrying other APOE alleles, both of which 
had undergone standard dose chemotherapy treatment. After controlling for age, gender, 
education, diagnosis and IQ, they found that survivors with e4 scored significantly 
lower in visual memory (p < 0.03) and spatial ability (p < 0.05). Their findings suggest 
that the presence of e4 may increase vulnerability to chemotherapy-induced cognitive 
dysfunction. 
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The neurotoxic effects of chemotherapy have also been analysed. Although it is 
believed that chemotherapy does not cross the blood-brain barrier, some neuroimaging 
studies using positron emission tomography (PET) have shown that some chemotherapy 
agents were found in the brain after intravenous administration. This might be 
associated with genetic variability (Ahles, 2007). Furthermore, DNA damage through 
oxidative stress occurs as a result of exposure to toxins that alter normal cellular 
metabolism. Chemotherapy agents, such as alkylating agents used for cancer treatment, 
cause DNA damage in normal cells as well as tumour cells. A link between DNA 
damage and chemo brain has not been determined, but cognitive changes linked to DNA 
damage in Alzheimer’s patients have been reported (von Zglinicki, 2005). This suggests 
that studies of the association of cognitive decline with chemotherapy and genetics 
deserve more attention. 
 
Normal cognitive function depends on cytokines for the regulation of inflammation and 
the modulation of neuronal and glial cell functioning, normal CNS function in general 
and regulation of dopamine and serotonin neurotransmitters. Alterations in cytokine 
activity has been linked with neurotoxicity and Alzheimer’s disease, multiple sclerosis 
and Parkinson’s disease (Wilson et al., 2002) as well as with cognitive failure, 
depression and fatigue (Cleeland et al., 2003).  
 
In a preliminary study that assessed the effects of two different chemotherapy agents on 
cytokine levels and its implications for cognitive impairment in breast cancer patients, 
Janelsins et al. (2012) examined 54 breast cancer patients undergoing either 
doxorubicin-based chemotherapy with cyclophosphamide or cyclophosphamide plus 
fluorouracil (AC/CAF), or cyclophosphamide, methotrexate and fluorouracil (CMF). In 
their study, they evaluated whether cytokines (IL-6, IL-8, MCP-1) that are markers for 
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cognitive difficulties in MCI and Alzheimer’s disease, which have been associated with 
inflammation, were differentially expressed depending on chemotherapy regimen. They 
found that levels of IL-6, IL-8 and MCP-1 increased in the AC/CAF group and 
decreased in the CMF group, suggesting that AC/CAF chemotherapy is more cytokine 
inducing than CMF. This result suggests that inflammatory responses following the use 
of these chemotherapy agents contribute to brain oxidation, which may lead to cognitive 
impairment. 
 
Hormonal changes can also account for memory loss. Many breast cancer treatments 
involve hormone therapies, which might have an effect on cognitive function. Collin et 
al. (2009) suggested that further research should be conducted to analyse whether 
adjuvant hormonal therapy affects cognition in breast cancer patients. According to their 
findings, subtle cognitive changes occur in breast cancer patients after experiencing 
chemotherapy, which remain for one year after the treatment, but they advised that their 
results should be considered tentative, because hormone therapy exerts a negative 
impact on cognition by itself. They suggested that studies on the effects of these 
therapies on mood and cognition should also be addressed to better understand their 
impact on quality of life in patients who have survived breast cancer. 
 
Many cancer patients experience chemotherapy-induced menopause, and research has 
shown that these hormonal changes are associated to cognitive decline (Jansen, 2005). 
Links between verbal memory and levels of oestrogen have been established in which 
high levels of oestrogen are associated with improved verbal memory, while low levels 
are linked to poorer verbal memory (Anderson-Hanley et al., 2003). 
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In a study aiming to analyse the effects of oestrogen in cancer patients, Shilling et al. 
(2003) found significant impairment on measures of verbal memory (p = 0.026) and 
processing speed (p = 0.032). Similar results were found by Schilder et al. (2009) where 
although no statistically significant differences were found between cancer groups, 
memory complaints were reported by 28% of Tamoxifen users, 24% of Exemestane and 
6% of healthy controls, where both the cancer groups were undergoing chemotherapy. 
Tamoxifen users reported lower scores in verbal memory, whereas Exemestane users 
reported slower manual motor speed. Both the cancer groups scored significantly lower 
than healthy controls for verbal fluency and processing speed. 
 
The role of oestrogens and anti-oestrogens should also be considered when studying the 
effects of cancer treatment on cognition, because they have been associated with the 
modulation of cognitive function (Shilling et al., 2001). Since they are widely used in 
cancer treatment, it would be useful to know whether or not they contribute to 
chemotherapy-related cognitive decline. 
 
 
3.5 Neuroimaging studies: Chemo brain neural correlates 
 
An alternative proposal to study potential risk factors, which provides a more objective 
assessment of cognitive failures associated with chemo brain, has been aided by the 
advancement of neuroimaging techniques. Due to variations as a result of 
methodological inconsistencies and to better understand the aetiology of chemo brain, 
new techniques have been implemented in order to obtain more reliable and consistent 
findings. 
80 
 
 
Despite the fact that few studies using neuroimaging have been carried out so far, the 
increased interest in the study of chemo brain using neuroimaging techniques has 
provided further empirical evidence of the phenomenon (Shagen et al., 2001; Deprez et 
al., 2013; Koppelmans et al., 2011). Several neuroimaging techniques have been used to 
find abnormalities in brain structure in cancer patients, which might explain cognitive 
deficits (Deprez, 2011). Such techniques are conventional EEG, which analyses the 
timing and organisation of brain processes while performing a task (Mayers et al., 
2000), PET, which provides a measure of neural metabolism (Ahles, 2007) and 
magnetic resonance imaging (MRI), which produces high resolution images of atrophy 
and visible pathology that allows the researchers to segment or classify structural 
images, including grey and white matter (Koppelmans et al., 2011). Diffusion weighted 
MRI (DWI) assists the assessment of changes in grey matter and loss of integrity of 
white matter (Deprez et al., 2013). Functional magnetic resonance imaging (fMRI) 
assesses functional activation of cortical and subcortical regions while the patient 
performs cognitive or sensory motor tasks through blood-oxygen-level contrast (Zunini 
et al., 2012). 
 
Results from these studies have shown that the regions of the brain that are most 
affected in breast cancer include the frontal cortex, cerebellum and basal ganglia 
(Silverman, 2006), white matter (Inagaki et al., 2007; Abraham et al., 2008; Deprez et 
al., 2011; Ruiter et al., 2012), grey matter reductions (McDonald et al., 2010), 
prefrontal cortex (PFC) (Kesler, 2009) and bilateral, frontal and hippocampal cerebral 
regions (McDonald et al., 2010). The cognitive domains most commonly assessed in 
neuroimaging studies are WM (Cimprich et al., 2010; McDonald et al., 2012; Scherling 
et al., 2011; Ferguson et al., 2007), response inhibition (Sherling et al., 2012), selective 
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attention (Cimprich et al., 2010), memory recall (Silverman et al., 2007), declarative 
memory (Kesler et al., 2009), EF (de Ruiter et al., 2011; Kesler et al., 2011) and 
episodic memory (de Ruiter et al., 2011). The brain regions implicated in chemo brain 
are shown in Table 3.1. 
 
Cognitive domain Brain region 
Working memory Bilateral prefrontal and parietal regions 
Episodic Memory Temporal lobes and prefrontal cortex 
Verbal Memory Left hemisphere 
Attention/Concentration Left hemisphere 
Reaction time Frontal subcortical network 
Visual-spatial ability Right parietal and bilateral frontal lobes 
Visual memory Right hemisphere 
Motor speed  Bilateral, frontal lobes and pyramidal tracts 
Processing speed Frontal subcortical network 
Executive function Bilateral prefrontal cortex 
Table Error! No text of specified style in document..3. Cognitive domain and brain 
regions implicated in chemo brain (Argyio et al., 2011). 
 
A selection of the seminal studies using neuroimaging techniques are discussed below. 
Although neuropsychological assessment conclusions from these studies have not been 
free from the same controversies as in previous studies, imaging results appear to be 
more promising for understanding chemo brain. 
 
82 
 
In a cross-sectional study, breast cancer patients (n = 16) treated with chemotherapy 
were recruited 5–10 years after treatment. Participants were required to undergo 
neuropsychological testing and a PET scan and were compared with control subjects (n 
= 8) who had never received chemotherapy (Silverman et al., 2006). It was found that 
during a performance of a short-term recall, modulation of cerebral blood flow in 
specific regions of frontal cortex and cerebellum was significantly altered in the study 
group. Alterations were mostly found in frontal cortex, cerebellum and basal ganglia 
activity, particularly in participants using Tamoxifen. 
 
In an attempt to explain the neural circuitry of chemo brain, de Ruiter et al. (2011) 
conducted a fMRI study with a group of breast cancer survivors 10 years after high-dose 
chemotherapy treatment (n = 19) compared to breast cancer survivors who never 
received chemotherapy (n = 15). It was found that during the assessment of EF in the 
whole brain analyses, a hypo-responsiveness was present in the whole brain in regions 
of bilateral posterior parietal cortex in the chemotherapy group. 
 
Both the studies confirmed that the differences in brain alteration in cancer patients 5–
10 years after treatment indicates a long-term effect after chemotherapy. However, 
although they provided reliable information, the aetiology of the phenomenon remains 
unknown because of its cross-sectional nature and small sample size. These studies 
showed differences in the condition of the brain compared to controls, but no pre-
chemotherapy assessment was provided, and the status of the brain structure before or 
immediately after treatment is unknown. 
 
One of the first longitudinal studies aiming to isolate the effects of chemotherapy 
treatment was conducted by Deprez et al. (2012). Thirty-four premenopausal women 
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with early breast cancer were tested with a neuropsychological battery together with 
diffusor tensor imaging (DTI) MRI immediately after surgery, but before commencing 
chemotherapy, and again at 3–4 months after treatment. Results were compared with 16 
patients not exposed to chemotherapy and 19 healthy controls. 
 
The aim was to study white matter integrity before and after chemotherapy treatment. It 
was found that the chemotherapy-treated group scored significantly lower after 
treatment (p < 0.05) in tests of attention, memory and psychomotor speed, and there was 
a significant decrease in frontal, parietal and occipital white matter tracks after 
treatment, suggesting that white matter is compromised by chemotherapy treatment. 
 
In another study of white matter and grey matter alterations, Scherling et al. (2012) 
recruited 23 early stage breast cancer patients who underwent MRI scanning before 
chemotherapy and after surgery, matched with non-cancer controls. They found 
significant neuroanatomical differences between patients and controls depending on the 
type of analysis and covariates used. Their conclusions highlighted the importance of 
including baseline assessment and rigorous methodological designs in future studies, 
challenging previous studies, which argue that chemotherapy treatment affects 
structures of the brain. 
 
Stewart et al. (2006) observed that after exposure to chemotherapy and radiation 
treatments, computerised brain scans and MRI demonstrated brain damage, which 
affected white matter. It has been suggested that possible mechanisms implicated in 
cognitive dysfunction generated by adjuvant chemotherapy treatments (supplementary 
therapy implemented after surgery in which all noticeable illness has been removed, but 
where there might be a danger of setback due to hidden illness) could be 
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“direct or indirect chemical toxicity to neurons or other non-neuronal elements 
in the central nervous system, oxidative damage, inflammation and destructive 
autoimmune responses” (Barton & Loprinzi, 2002). 
 
Major organ toxicity and endocrine systems can ultimately have an effect on brain 
function, as in the case of oestrogens, which play an important role in normal memory 
function. Other side-effects of chemotherapy treatment such as anaemia and fatigue can 
also hold back brain function (Stewart et al., 2006). 
 
Studies that focus on the neuroimaging analysis of chemo brain offer a promising 
perspective on the objective basis of the phenomenon, but caution should be taken in the 
methodology and attention should be paid when considering the whole of brain rather 
than specific areas. The fact that chemo brain is a multifactor phenomenon should also 
be considered, and cognitive changes should not only be attributed to a single factor, but 
to a combination of factors (Scherling et al., 2012). 
 
3.6 Systematic review of the literature 
 
As mentioned above, Silberfarb et al. (1980) were the first to report cognitive 
impairment in cancer patients. Since then, an increased interest has emerged, but there 
has been a lot of controversy surrounding the topic. Some studies report significant 
impairment, whereas others even deny the existence of the phenomenon. On the other 
hand, a great deal of interest has been placed in the aetiology of the phenomenon. Some 
have associated it with APOE allele 4, menopause status and hormonal treatment, but 
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the results are inconclusive. In recent years, an increased interest in neuroimaging has 
emerged to explain the aetiology of chemo brain, which has shown promising results. 
 
One of the main problems in this area of study is that a large number of methodologies 
are involved, which in turn produce different results and make it difficult to predict the 
incidence of chemo brain in the cancer population. Most of the publications use 
different methods of neuropsychological assessment, different statistical analyses, 
diverse control groups or lack control groups and baseline assessment, which would 
provide a better understanding of the cognitive status before treatment. 
 
As a result of these inconsistencies, there is a lack of agreement on whether the 
phenomenon is significantly affecting cancer patients and physicians are failing to 
provide proper care, because the patients are not given information about this possible 
side effect, or by not referring patients to adequate psychological therapies for further 
support, leaving patients feeling helpless and distressed about their memory difficulties. 
 
The review below discusses issues related to chemo brain and current research 
directions. An explanation of cognitive functioning is followed by a synopsis of the 
literature. The review is divided in three sections: common neuropsychological 
assessment, neuroimaging and neuropsychological assessment and qualitative studies. 
The common neuropsychological assessment analysis is divided into retrospective, 
cross-sectional and prospective studies and candidate mechanisms for chemo brain. 
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3.7 Cognitive functioning 
 
Cognitive functioning is a process in which the primary sensory areas located in both 
central hemispheres of the brain (temporal, parietal and occipital lobes) register the 
sensory input from the external environment. For this process to take place, a degree of 
alertness, concentration and attention is required. Verbal information is processed in the 
left hemisphere of the brain and visuospatial information in the right hemisphere. All 
new information is screened in relation to previous experience already stored in the 
subject’s memory and proceeds to the highest level of central processing, involving 
reasoning, abstraction, logical analysis and concept formation. Processing implies an 
appropriate response to the initial stimulus, and thus, impairment at this level affects an 
individual’s ability to function in a logical and meaningful way. The most common 
factors that affect cognitive function are age, education, intelligence, fatigue, anxiety 
and depression (Vardy et al., 2007). 
 
The assessment of cognitive function is carried out through neuropsychological tests. 
Most of the studies include these domains; however, there is wide inconsistency 
because each study includes different domains with very diverse tools, providing very 
different results, and making it difficult to make accurate or reliable inferences. 
 
The cognitive domains most studied in chemo brain are WM, episodic memory, verbal 
memory, visual memory, EF, processing speed, visuospatial ability, attention, 
concentration, reaction time and motor speed.  
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3.8 Studies using neuropsychological assessment 
 
Some of the most influential works that have used neuropsychological assessment for 
the study of chemo brain are described below, including a discussion of how the topic 
has evolved over time, the major findings and assumptions to date. They are divided 
into cross-sectional and prospective studies. 
 
3.8.1 Cross-sectional studies 
 
The first attempts to investigate the phenomenon of chemo brain were mostly 
retrospective in nature and relied on neuropsychological assessment and self-reports. 
The cognitive status of the patients before treatment was unknown. 
 
The first study to include three groups to assess cognitive function and mood in breast 
cancer patients was by Brezden et al. (2000), which also controlled for age, education 
level and menopausal status, factors that are of high importance to control, as they may 
represent significant confounding variables. In a cross-sectional study, they assessed if 
there was a difference between breast cancer patients treated with adjuvant 
chemotherapy compared with healthy controls. Their three groups consisted of 31 breast 
cancer patients undergoing adjuvant chemotherapy (A), 40 patients who had completed 
adjuvant chemotherapy treatment approximately two years earlier (B) and 36 healthy 
controls (C). A univariate analysis showed statistically significant difference (p = 0.009) 
in overall cognitive function between groups A and C on the High Sensitive Cognitive 
Screen and the Profile of Mood States (POMS). Both the patient groups showed a 
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moderate to severe cognitive impairment compared with controls (p < 0.002). They did 
not find significant differences in POMS, suggesting that mood does not influence the 
results. 
 
To analyse the long-term impact of chemotherapy regimens on cognition, Ahles et al. 
(2002) conducted a cross-sectional retrospective study of breast cancer and lymphoma 
survivors five years after diagnosis. The two groups were divided into 35 breast cancer 
survivors plus 36 lymphoma patients not presently receiving treatment and 35 breast 
cancer plus 22 lymphoma patients treated with local therapy only (radiation or surgery). 
Some of the patients were receiving Tamoxifen. They completed a series of 
neuropsychological and psychological tests, controlling for affective measures and 
fatigue. A significant, but low correlation was found between the number of cycles and 
test results (p < 0.02, r = −0.31), indicating that the more the cycles of chemotherapy 
undertaken, the lower the test results. No significant differences were found between 
patients taking Tamoxifen and those who were not. These results suggest that systemic 
chemotherapy can have a detrimental effect on cognition, although not all cancer 
survivors are prone to experience them. Depression, anxiety and fatigue did not affect 
the results. 
 
To further assess long-term effects of cancer treatment, Schagen et al. (2002) conducted 
a follow-up from a previous study, in which patients showed elevated risk of cognitive 
impairment two years after treatment (van Dam et al., 1998). Seventy-six cancer 
patients treated with chemotherapy and 39 controls consisting of ancillary lymph node-
negative breast cancer patients not receiving chemotherapy were re-examined using 
neuropsychological tests four years after treatment. In this case, the cancer patients 
showed an improvement in performance. These findings suggest that the detrimental 
89 
 
effects of cancer treatment may improve with time. However, the control group showed 
a subtle decline, though this might be due to age differences and menopausal status. 
Patients who performed worse were premenopausal, raising the question of the 
influence of hormone status on cognition. 
 
One of the first studies to consider the use of anti-oestrogen drug Tamoxifen as a factor 
influencing cognitive decline in breast cancer patients was by Castellon et al. (2004). 
Tamoxifen is widely used in hormone therapy for breast cancer both during and after 
treatment. Since some patients begin using Tamoxifen immediately after surgery and 
before commencing chemotherapy, it would be useful to know its impact on cognition. 
A sample of 53 cancer survivors were tested 2–5 years after diagnosis, with 19 healthy 
controls. Along with a comprehensive neuropsychological battery, they measured mood, 
energy level and self-reported cognitive function. 
 
Among the cancer groups, breast cancer patients who received adjuvant therapy scored 
significantly lower than those who did not receive adjuvant therapy (p = 0.01). Neither 
group differed significantly from the healthy controls, but their finding suggests that 
those who received adjuvant treatment and Tamoxifen showed more cognitive decline. 
The domains most affected by adjuvant therapy were visual memory, visuospatial 
function and verbal learning. The results from self-reports did not show a relationship 
between cognitive complaints and objective measures, instead cognitive complaints 
were associated with anxiety, depression and fatigue. 
 
Another study reporting inconsistent results between self-reports and 
neuropsychological impairment was conducted by Mehnert et al. (2006). In a cross-
sectional design, breast cancer survivors were compared five years after chemotherapy. 
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They were divided into three study groups: 23 standard adjuvant, 24 high-dose and 29 
early-stage following radiation therapy. Participants were assessed using a 
neuropsychological assessment, together with the questionnaire for self-perceived 
deficits in attention (FEDA), the Multidimensional Fatigue Inventory (MFI-20) and the 
EORTC-QLQ-C30. Forty-six percent of the patients reported self-perceived cognitive 
deficits and 82% reported cancer related fatigue. However, there was no significant 
finding on objective measures. They did not find an association between self-perceived 
cognitive decline and neuropsychological measures, despite the fact that cognitive 
impairment was present in 13% of the standard dose patients versus 8% of high-dose, 
compared to 3% of the comparison group. 
 
In spite of the importance of these publications, one of the major limitations of all these 
studies is the lack of baseline assessment, meaning the status of cognition before 
treatment, cognitive function immediately after treatment when cognitive problems 
begin to develop, and whether cognitive decline is improving or worsening is unknown. 
All these factors are important because it is not known if participants’ cognition is 
affected by chemotherapy or simply because of being diagnosed with cancer. 
 
In summary, cross-sectional studies help to raise more awareness that some cancer 
patients experience cognitive difficulties after chemotherapy treatment. However, these 
are limited to the long-term impact of chemotherapy on cognition, and there is no 
information on when patients begin to experience symptoms, once treatment has begun. 
In general, most of the studies assessed cognitive functioning 2–5 years after 
chemotherapy and although no significant differences were reported, impairment was 
found in some patients (Mehnert et al., 2006; Ahles et al., 2002), and that the use of 
hormonal treatment has a major impact on cognition (Castellon et al., 2004), as opposed 
91 
 
to mood and fatigue, which were found to have no influence on test scores (Ahles et al., 
2002). 
 
Despite the finding that neuropsychological test results are not influenced by mood and 
fatigue (Ahles et al., 2002), the opposite was found for patients’ self-reports (Mehnert et 
al., 2006; Castellon et al., 2004), which might be biased by patients presenting higher 
levels of anxiety, depression and fatigue. 
 
An interesting finding was reported by Schagen et al. (2002), where an improvement 
was found in cancer patients and a decline in healthy controls over time. These findings, 
along with Castellon et al.’s (2004), show the importance of studying hormonal 
treatment as covariates of chemotherapy-induced cognitive decline. 
 
The use of control groups helped to realise that despite patients reporting memory 
difficulties, with objective decline present in some, the differences were not statistically 
significant and fall within normal limits, therefore classifying chemo brain as a MCI 
phenomenon. To address this issue of normality, authors analysed an index of individual 
impairment, which helped to provide evidence of cognitive decline. 
 
3.8.2 Longitudinal studies 
 
Because of not being able to compare results with the patients’ previous cognitive 
abilities and the research design drawbacks mentioned above, researchers began to 
consider longitudinal assessments with a baseline, which included testing before and 
after treatment, and larger sample sizes were recruited. Initially, most of the studies 
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considered neuropsychological assessments, self-reports and interviews only. However, 
controversy surrounding the phenomenon emerged due to the fact that some studies 
found no significant changes in cognition, which contradicted patients’ complaints. To 
further analyse this phenomenon and to try to explain such controversy, increased 
attention has been paid to neuroimaging techniques combined with neuropsychological 
assessment. 
 
One of the first longitudinal studies was conducted by Wefel et al. (2004). In their 
study, they evaluated 18 breast cancer patients before treatment (baseline), three weeks 
after treatment and six months after baseline. Although the sample size of 18 was 
relatively small, they found that while 33% of the women presented cognitive 
impairment at baseline, 61% presented a decline after baseline. Six months after 
baseline, 50% of participants who showed decline in the previous test exhibited an 
improvement and the other 50% remained at the same level. 
 
The importance of this publication was that it was the first longitudinal study assessing 
cognitive decline as a result of chemotherapy treatment. Although their results were not 
statistically significant, they showed some indication of how cognition can be affected 
even before treatment, that it can deteriorate after treatment and that some improvement 
could be seen six months later. 
 
Shillings et al. (2005) reported the neuropsychological test results of 50 women with 
early breast cancer prior to the start of chemotherapy and 43 healthy controls, before 
and after treatment, using a neuropsychological battery and self-report measures of 
quality of life and cognitive failures. The testing schedules were conducted at baseline 
and six months and 18 months after treatment. Their findings suggested that 
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chemotherapy patients were significantly more likely to show cognitive impairments 
than the comparison group. At testing session two, participants took part in a semi-
structured interview to determine whether they had experienced memory changes. 
Seventy-eight percent of the patients reported experiencing memory difficulties, 
although significant cognitive decline was not indicated by the objective measures. 
 
To address cognitive function in older women receiving adjuvant chemotherapy for 
breast cancer, Hurria et al. (2006) conducted a longitudinal pilot study, which included 
28 breast cancer patients with Stage I, II or III. Participants were tested prior to 
treatment and 6 months after treatment. No significant differences were found from 
baseline to second testing. Fifty percent of the subjects remained stable, 39% showed 
decline and 11% showed improvement. Limitations of this study are that there was no 
control group and a lack of statistical power due to the small sample size. However, 
baseline assessment was included. 
 
Cognitive function, fatigue and menopausal symptoms in women after adjuvant 
chemotherapy for breast cancer from a follow-up prospective study were assessed by 
Mar Fan et al. (2005). Matched pairs of patients were recruited (n = 104 patients and 
102 healthy controls). Baseline assessment took place towards the end of chemotherapy 
and at least three cycles of chemotherapy were completed. At this stage, participants 
completed self-reports for fatigue, quality of life and menopausal symptoms. Cognitive 
performance was measured using a neuropsychological battery. Blood samples were 
collected for measuring hormone status. Participants were classified as pre-menopausal 
or post-menopausal. Follow-up assessment was conducted one and two years after 
baseline. Patients who received chemotherapy showed substantial levels of fatigue 
compared to controls (p < 0.0001) and showed improvement over time. They found a 
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significant association between menopausal symptoms at follow-up sessions (p < 
0.0001), but no other significant association was found. Patients undergoing 
chemotherapy showed more menopausal symptoms due to chemotherapy-induced 
menopause, but hormonal therapy had no effect on patients’ menopausal symptoms. 
Cognitive function results showed that near the end of chemotherapy, patients showed 
more cognitive dysfunction than controls (p = 0.02). These results improved over time 
for both the groups. Hormonal treatment did not have an effect on test scores. 
 
One of the strengths of this study was that it included the analysis of biological factors 
in a longitudinal study, highlighting the importance of comorbidity, and because it 
shows how symptoms of fatigue and menopause affect cancer patients, which in turn 
might be one of the underlying factors inducing cognitive impairment. This might be 
confirmed by the fact that fatigue and menopausal symptoms as well as cognitive 
impairment improved over time, but this may also be a result of practice effects. 
Another important aspect of Mar Fan et al.’s (2005) study is that it followed a large 
group of patients over a two-year period. However, a weakness of the study is that it 
does not provide the cognitive status of patients before chemotherapy treatment, and it 
is unknown whether cognitive deficits were present. 
 
In a three-year longitudinal study conducted by Jenkins et al. (2006), 85 women with 
early stage breast cancer who were scheduled for chemotherapy were tested. The study 
was divided into three groups: 83 women were scheduled for chemotherapy and/or 
radiotherapy, 43 were scheduled for endocrine therapy and/or radiotherapy and 49 were 
healthy controls. Testing was carried out at baseline or before treatment, post-treatment 
or six months later and 18 months after baseline. Controls for variables such as 
menopause status, age and education were used. Their results reported that 20% of 
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chemotherapy recipients presented cognitive impairment in one or two measures. For 
the control groups, 26% of cancer patients not receiving chemotherapy showed a 
decline and 18% of the healthy control group presented a decline. Improvement was 
observed in 22% of chemotherapy patients, 16% of patients undergoing other cancer 
treatments and 16% of the healthy controls.  
 
Their findings suggested that only a few women experienced cognitive impairment, 
those who experienced chemotherapy-induced menopause, although no significant 
changes were found. Improvement of performance after baseline in test scores was also 
found in some patients, which was attributed to practice effects. It is interesting to 
observe that women experiencing chemotherapy-induced menopause are the most 
affected, which is consistent with the findings of Mar Fan et al. (2005). The results of 
these studies may be interpreted as showing that accelerating menopause in women has 
a detrimental effect on cognition. 
  
To further evaluate cognitive function prior to chemotherapy treatment and assess 
changes in cognition over time and the potential relationship between this and anxiety, 
depression, fatigue, haemoglobin levels, menopause and self-perception of cognitive 
function, Jansen et al. (2008) evaluated 30 women with breast cancer before 
chemotherapy and after four cycles of treatment. Contrary to previous studies, they 
found significant changes in some cognitive abilities. They reported a significant 
decrease in visuospatial skills (p = 0.001) and total cognitive scores (p = 0.001) 
following chemotherapy, confirming the hypothesis that chemotherapy may have a 
negative impact on cognition. However, these results should be treated with care due to 
the small sample size and the lack of a control group. Of interest for the current study is 
that the work by Jansen et al. (2008) used the Repeatable Battery of Adult 
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Neuropsychological Screening (RBANS), which includes some aspects of PM (attention 
and delayed memory). The authors concluded that RBANS is more sensitive than other 
neuropsychological tests for detecting subtle changes in cognition. However, their 
results are consistent with other studies with other measures of psychological 
assessment, in that no significant changes were detected. 
 
In an attempt to address the controversy regarding cancer patients’ cognitive status at 
baseline, Ahles et al. (2007) compared test results of breast cancer patients with 
invasive cancer (n = 110) and non-invasive cancer (n = 22) prior to adjuvant treatment. 
Participants completed a battery of neuropsychological tests after surgery, prior to 
commencing chemotherapy, radiation or hormonal therapy. They also included a control 
group comprising 45 healthy women. Their results showed no statistical significance in 
abnormal test results, but patients with invasive cancer showed significantly lower 
scores than healthy controls in the reaction time domain (p = 0.005) and were more 
likely to be classified as having lower than expected cognitive performance compared 
with non-invasive counterparts and healthy controls. 
 
The authors concluded that patients with early breast cancer do not exhibit cognitive 
decline before treatment, whereas invasive carcinoma patients presented some decline, 
but the differences are minor or non-existent when compared to controls. Factors such 
as depression, surgery, anaesthesia and biological markers were not associated with 
lower than expected cognitive performance. This may indicate that the severity of the 
illness may affect cognition and the more threatening the condition, the more the 
cognitive abilities might be affected. It is interesting to mention that invasive carcinoma 
patients’ self-reports did not indicate more cognitive impairment than the non-invasive 
patients, meaning that they are not aware of their deficits. 
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The studies discussed above show a common characteristic, which is a general 
agreement that MCI exists in a subsample of cancer patients, despite such results being 
statistically insignificant, that anxiety and depression are not at the core of these results 
and that patient’s self-reports are inconsistent with the findings, in which patients seem 
to overstate their cognitive complaints. However, in a study conducted by Mehlsen et al. 
(2009), the findings showed disagreement with previous studies. 
 
Mehlsen et al. (2009) conducted a study in which 34 cancer patients receiving 
chemotherapy were examined and compared with 12 cardiac patients and 12 healthy 
controls in a 3–4 month interval. The rationale for using a cardiac patients group was to 
control for the fact that both the groups of patients were facing a life threatening 
condition, which by itself may cause cognitive problems. They argue that the symptoms 
reported by patients are merely a subjective experience as a result of the psychological 
distress caused by the disease and treatment-induced stress and fatigue, because they did 
not find statistical significance on test results. They supported their rationale by the 
discrepancy between results of self-reports and validated batteries. Their results showed 
no differences in cognitive abilities between the three groups, with no significant 
deterioration in performance exhibited by cancer patients compared to cardiac patients 
and healthy controls. Twenty-nine percent of cancer patients showed a decline in more 
than two cognitive measures versus 25% of cardiac patients and 25% of healthy 
controls. They attributed this to normal variation over time, rather than illness or 
treatment. The testing intervals were different between the groups. Cancer patients were 
tested 0–7 days before treatment and 4–6 weeks after the last cycle of chemotherapy. 
Cardiac patients were tested four days after hospitalization, before being discharged and 
retested three months later. Healthy controls were tested at 12–16 weeks. The results 
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should be treated with care, because the control groups had shorter testing intervals, 
which might have influenced the test results. Similar results were reported by Jenkins et 
al. (2006) and Hermelink et al. (2007). It is possible that the observed improvements 
might be due to practice effects, rather than improvement in cognition over time. 
 
Another study not supporting the hypothesis of cognitive decline after chemotherapy 
treatment is that of Tager et al. (2009) for a group of post-menopausal women. Thirty 
patients received chemotherapy, while 31 received no chemotherapy and were used as 
controls. Their testing schedules were post-surgery but before commencing 
chemotherapy treatment, followed by a second testing session within a month of 
completing treatment and a third testing session six months after the second testing 
session. In a sample of 61 post-menopausal women with non-metastatic breast cancer, 
patients treated with chemotherapy performed worse at baseline than in the following 
assessment. 
 
However, Stewart et al. (2009) found the opposite results in a similar population. They 
found that post-menopausal breast cancer patients scheduled to receive adjuvant 
chemotherapy (n = 61) showed a subtle negative influence of chemotherapy when 
compared to breast cancer patients scheduled to receive adjuvant hormonal treatment (n 
= 51). The mean scores for both the groups were within the normal range in both testing 
sessions, remaining stable from baseline to time two. However, chemotherapy patients 
were 33% more likely to show cognitive decline than controls. 
 
These findings suggest that there is no causal effect of adjuvant chemotherapy on 
general cognitive dysfunction, with a poor correlation between subjective and objective 
measures. These two studies controlled for menopausal changes by including only post-
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menopausal participants, but they differed in the neuropsychological batteries applied, 
statistical analysis, sample size and number of testing sessions. 
 
More recent studies have focused on domain-specific analyses rather than on global 
cognitive domain. In a study conducted by Ganz (2013), where 189 early-stage post-
treatment breast cancer patients were assessed with a neuropsychological battery and 
self-report questionnaires prior to endocrine therapy, 23.3% showed higher memory 
complaints and 19.0% higher EF complaints. Regression modelling showed statistically 
significant association of higher memory complaints with combined chemotherapy and 
radiation treatments (p = 0.01), inferior verbal memory performance (p = 0.02) and 
greater depressive symptoms (p = 0.001). For executive functioning complaints, they 
found a statistically significant relationship with superior visual memory performance (p 
= 0.03) and higher depressive symptoms (p = 0.001) using multivariable modelling. On 
the other hand, combined chemotherapy and radiation treatment showed being 
statistically significant (p = 0.05). These results provide evidence that breast cancer 
patients present significant levels of memory and EF difficulties associated with 
domain-specific neuropsychological performance, but it is unclear if breast cancer 
patients were compared to healthy controls and they were subject to the limitations of 
cross-sectional studies. However, their sample size was very large, providing 
confidence in their results. 
 
Collins et al. (2013) found a dose-response relationship, which provided “the most 
compelling clinical evidence to date that cognitive decline is caused by chemotherapy 
exposure”. They enrolled 60 women with early breast cancer, matched with a poll of 60 
healthy women, who underwent neuropsychological assessment after surgery and prior 
to chemotherapy treatment and after each cycle. 
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They included paper-based assessment and a computerised cognitive test that measured 
attention, WM, EF and visual and episodic memory. To assess change over time and 
domain-specific cognitive scores, they used multilevel modelling, which accounted for 
individual or group baseline status depending on the variable under investigation. The 
model also controlled other variables that may affect change such as age, education and 
depression. 
 
These results showed that the chemotherapy group showed a significant decline after 
each testing session compared to controls, although raw data fell within normal ranges. 
However, they argued that when corrected for practice effects, the magnitude of the 
decline was large. This argument is worth noting, because it might be that despite the 
lack of sensitivity of common neuropsychological tools, the selection of statistical 
analysis makes a big difference to the results and when drawing conclusions (Shilling et 
al., 2005), and common statistical methods might be becoming obsolete, and therefore, 
more attention should be paid to newer and more effective statistical analyses. 
 
According to Shilling et al. (2005), the extent of impairment found in chemo brain 
patients is influenced by the type of statistical analysis chosen. To confirm this 
statement, they analysed data from 92 breast cancer patients at four weeks post-
chemotherapy and from 42 healthy controls, using seven different methods previously 
used in publications related to the topic. They reported that impairment ranged from 
12% to 68.5% in the chemotherapy group and from 4.8% to 64.3% in the healthy 
control group, demonstrating that different methods of analyses yield very different 
results, obscuring the understanding of chemo brain. 
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It is due to these contradictions found in the literature that one of the aims of the current 
study was to include qualitative measures as well as in-depth interviews and domain-
specific qualitative analysis. It is evident that some decline is observed in 
neuropsychological batteries, but results indicate only moderate impairment and no 
significant difference when compared with controls. Due to statistical methodology 
bias, it is not possible to rely on quantifying symptoms, because despite all the studies 
that do not find a link between chemotherapy treatment and cognitive impairment, 
patients continue to report these problems and the effect they have on their lives. 
 
Neuropsychological studies assessing global cognitive domain have failed to provide 
standard and sensitive measures to assess chemo brain accurately. Mehlsen et al. (2009) 
suggested that the more cognitive tests that are included, the greater the probability of 
finding evidence of cognitive decline, whereas in the literature, most studies only 
include tests from a single session. A greater awareness of what patients are 
experiencing is needed, and therefore more sensitive and reliable measures should be 
developed. 
 
3.8.3 Summary of longitudinal studies 
 
To resolve the lack of baseline assessment, researchers began to address the limitations 
of cross-sectional studies by including baseline assessment before treatment (Wefel et 
al., 2004; Shillings et al., 2005; Jenkins et al., 2006; Jansen et al., 2008). This has been 
of paramount importance because since then, emphasis has been placed on having 
patients’ previous mental status. 
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Another significant advancement in the study of chemo brain was considering other 
biological factors and covariates such as haemoglobin (Jansen et al., 2008) and blood 
samples (Mar Fan et al., 2005) in order to consider comorbidity with other biological 
factors. 
 
Menopause-induced cognitive dysfunction and menopause status have been considered 
as potential underlying factors of chemo brain in at least two of the studies (Jenkins et 
al., 2006; Mar Fan et al., 2005). These studies influenced subsequent studies, which 
began to include hormone treatment as control groups in order to further analyse the 
effects of hormone therapies on cognition (Stewart et al., 2008; Schilder et al., 2009; 
Jim et al., 2009; Collins et al., 2009). 
 
Attention was also paid to whether patients’ cognitive abilities were affected by 
chemotherapy alone or as a result of the illness, surgery, anaesthetics or psychological 
distress due to facing a life-threatening illness. To control for these issues, studies of the 
potential impact of surgery were undertaken (Ahles et al., 2007); cardiac patients were 
included in some studies (Mehlsen et al., 2009) and menopausal status began to be 
considered. Biological factors were also considered by analysing patients’ blood 
samples (Shillings et al., 2005; Jansen et al., 2008). 
 
Studies not supporting the hypothesis of cognitive decline started to emerge where no 
causal effect of adjuvant chemotherapy on general cognitive dysfunction was found 
(Tager et al., 2009; Shillings et al., 2006; Mehlsen et al., 2009). Self-reports had been 
included in the majority of the studies. However, there is poor correlation between them 
and objective measures of cognition (Tager et al., 2009). Interestingly, while objective 
measures are not affected in the most part by mood or anxiety (Ahles et al., 2007), self-
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reports are influenced by them, according to some authors (Tager et al., 2009). To 
determine change over time, some researchers started to use the Reliable Control Index 
(RCI) (Wefel et al., 2004; Shillings, 2005), although this method yields high error rates 
(Temkin et al., 1999).  
 
Arriving at the conclusion that chemotherapy alters cognition remains controversial, but 
the majority of studies differ greatly in their designs, tests used, control groups, disease 
stage, therapy regimens and sample size, which makes the results difficult to interpret 
(Jansen et al., 2008; Shilling et al., 2005). 
 
3.9 Prospective memory, attention and chemo brain in the literature 
 
It is hypothesized that PM, the memory for planned intentions, is implicated in chemo 
brain. The author suggests that cognitive decline after chemotherapy is associated with 
memory difficulties presented in day-to-day life and with planned intentions, which are 
related to attention difficulties and EF impairment. 
 
This new line of research on chemotherapy-related cognitive impairment was pioneered 
by Paquet et al. (2013). Their findings suggest that breast cancer survivors exhibit a PM 
deficit, with fatigue as a major contributing factor. They examined failures of PM in the 
everyday lives of breast cancer patients. In a cross-sectional study, they assessed 80 
patients diagnosed with early breast cancer within one year of having completed 
adjuvant chemotherapy, with or without hormonal treatment, and 80 matched healthy 
controls. The PM assessment was carried out using the Memory for Intention Screening 
Test (MIST), which includes event-based and time-based activities. It is important that 
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the activities are relevant for an effective study of PM (McDaniel, 2007). A statistically 
significant difference (p = 0.001) was found between groups on the MIST scores, with 
post-menopausal patients showing significantly lower scores (p = 0.05) than matched 
controls. These findings suggest that PM might be one of the cognitive domains most 
affected by chemotherapy treatment. In contrast to Ahles et al. (2007), who suggested 
that factors such as depression and fatigue are not intervening factors in chemo brain, 
Paquet et al. (2013) found that patients had significantly higher levels of fatigue and 
depression (p = 0.0001) than controls. This contradiction might be explained, because 
MIST is a more reliable measure of daily living. On the other hand, Ahles et al. (2007) 
used a more laboratory-like battery, which may mask the effects of such factors. 
 
However, this finding should be taken with caution due to the fact that the Canadian 
study (Paquet et al., 2013) was cross-sectional in nature. A baseline assessment of PM 
should be considered. Nevertheless, the results were promising due to the fact that other 
domains of cognition have been well studied, using very diverse statistical measures, 
and very few have found statistically significant difference, although cognitive decline 
has been found consistently. The study of PM, and evidence from Paquet et al. (2013), 
should start gaining more attention, due to the fact that patients reports widely 
associated with those of PM failures. 
 
Factors such as selective and divided attention, EF and attentional function have been 
associated with the study of PM. However, very few studies in these areas have been 
related to the area of chemo brain.  
 
Weis et al. (2009) examined the effect of cognitive impairment in cancer patients in 
their everyday lives. They evaluated the correlation between subjective self-appraisal 
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and neuropsychological test results in a population of 90 breast cancer patients, nine 
months after receiving adjuvant chemotherapy. Participants were assessed on measures 
of attention, using the Test Battery for Assessment of Attention (TAP), a computer-
based test that examines alertness, reaction change, divided attention, sustained 
attention and WM at three time points: at the start of in-hospital rehabilitation, the end 
of in-hospital rehabilitation and 6 months later. They also included measures of quality 
of life, fatigue, anxiety, depression and self-perceived measures of attention. 
 
Participants were divided in three groups: the neuropsychological training group (n = 
33), an individual personal computer-supported training group (n = 34) and a no special 
training group (n = 29). Their findings showed that an improvement in cognition took 
place after some time had elapsed. Time three parameters were normal, confirming the 
hypothesis that adjuvant systemic therapy does not play a long-term role in cognition, 
and only 21% of the study group showed significant clinical impairment. A low 
correlation between self-perceived deficits and objective measures was obtained, but an 
association with depressive mood was found, supporting the hypothesis of Shilling et al. 
(2007) that depressive symptoms impair performance. 
 
However, the authors found that 87.5% of patients showed a decline at Time one in at 
least one of the neurological test results (1.5 SD below the mean of age-adjusted norm 
data) and 56.2% showed a decline in more than two or three tests and hence were 
classified as having relevant impairment. Most deficits were found in measures of 
sustained attention (TAP, omissions, 49%) and semantic memory (delayed 
reproduction, 34%). Patients who were objectively shown to be severely affected 
reported their everyday living subjectively as being extremely poor.  
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The important aspect of this study is that a very different approach was used, focusing 
on the study of specific aspects of attention. Although there was an improvement over 
time, this might have been due to their training sessions, which shows promising results 
to develop patients’ interventions after experiencing cognitive decline after 
chemotherapy. However, this is not the scope of the current study. What is noteworthy 
is the fact that patients were assessed for the first time nine months after treatment, at 
which point they exhibited attentional deficits such as omission errors. This is important 
because this confirms that PM plays a role in chemo brain. 
 
To further assess everyday functioning in chemo brain patients, Adams-Price et al. 
(2009) recruited 38 breast cancer survivors (3–45 months after chemotherapy 
treatment), who were compared with 55 age-matched healthy controls. They used 
Useful Field of View (UFOV), a computerised test of visual information processing; 
this test is used to predict driving performance in older adults and has been associated 
with information processing speed, ability to divide attention and the ability to ignore 
distractors or selective attention (Ball et al., 1990). They found significant interactions 
between treatment and age on processing speed (p = 0.002) and marginal significance 
for selective attention (p = 0.074) measures. Older participants performed less well than 
younger controls on speed of processing, but not in the other measures.  
 
Care should be taken when considering results from this study due to several 
methodological issues. Although it has a healthy control group, the sample size was 
relatively small and no baseline was assessed before treatment. Of greater concern is the 
fact that the differences between the post-chemotherapy groups with respect to end of 
treatment were very wide and participants were at very different stages. This group 
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could have been divided into short-term effects and long-term effects to better 
understand the effects of time on these measures. 
 
3.10 Qualitative studies 
 
In the chemo brain literature, very few studies have focused on the study of the 
phenomenon through qualitative analysis. Although many studies include self-reports 
and quality of life questionnaires, few have conducted semi-structured interviews, face-
to-face interviews and case studies to analyse patients’ daily-lived experiences. 
 
Due to contradictory findings in qualitative results and particularly because of the 
contradiction between patients’ reports of daily living and neuropsychological 
assessment, the author believes it is of greater relevance to pay more attention to the 
study of the patients’ experiences so that better assessment tools can be developed and 
to focus attention on PM cognitive failures in these areas of study. 
 
In the following section, some of the most relevant qualitative studies of chemo brain 
are discussed, in order to better appreciate what sufferers of chemo brain report, how 
they experience their cognitive failures and how this relates to PM complaints. 
 
The first study to analyse self-reported cognitive complaints and report what patients 
were saying was by Downie et al. (2006). They tested 21 breast cancer patients while 
undergoing chemotherapy using a neuropsychological test, followed by a semi-
structured interview. Unsurprisingly, they found no correlation between self-reports and 
objective assessment, with patients’ self-perceptions of cognitive changes greater than 
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scores in the objective assessment. They suggested that the neuropsychological 
assessment used in their sample was not sensitive enough to detect MCI, and they 
attributed this discrepancy to factors such as lifestyle, mood, fatigue and resilience, 
which may have an impact on the experience of symptoms. 
 
They followed up their assessment with a semi-structured interview, where questions 
about patients’ memory, concentration, attention, spatial orientation, ability to organise, 
menopausal symptoms and coping strategies were asked. The results indicated that 
patients suffered from changes in STM, concentration, verbal fluency and word finding 
abilities, mental fluency, processing speed and, to a lesser extent, planning and 
visuospatial abilities. They also reported that patients experienced increased 
forgetfulness of names, words, places and appointments. 
 
These cognitive problems affected all aspects of life (work, home and social), with 
problems related to reading and concentration, processing information more and mental 
sharpness decline. Decreased ability to multitask and problems with their ability to drive 
were also reported. 
 
Limitations of this study are the relatively small sample size, a lack of baseline 
assessment before chemotherapy and that no comparison group was included, which is 
understandable because of the qualitative nature of the study, which aims to report what 
patients were experiencing. 
 
Another study analysing self-reports was conducted by Shilling et al. (2007). They 
reported interview data from a large sample of 142 breast cancer patients receiving 
adjuvant chemotherapy and the associated cognitive impairment to quality of life and 
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psychological distress. Baseline assessment was included as well as assessment of six 
months and 18 months after treatment. They divided their participants into two groups, 
those scheduled to receive chemotherapy (n = 100) and those receiving radiotherapy 
and/or endocrine treatment (n = 53). All the participants took part in a semi-structured 
interview and a neuropsychological battery. 
 
They found that 71% of the participants reported problems with memory and 
concentration at six months after treatment and 60% after 18 months. As with Downie 
et al. (2006), these reports were unrelated to objective assessment. The majority of 
failures were associated with everyday slips and lapses and were associated with 
psychological distress and quality of life. Reports from family and friends were also 
included, with 53% of the cases reported having noticed memory and concentration 
problems in the patient. 
 
To capture the experiences and perceptions of cognitive decline, two studies conducted 
in-depth analysis of the phenomenon. Mitchell et al. (2011) explored how this decline is 
interpreted and made meaningful to the individual, providing a reference of how 
patients perceive chemo brain. The authors reported that patients and healthcare 
providers were usually unaware that the phenomenon exists. Memory decline was 
attributed by the patient to other factors such as fatigue illness, bereavement and in 
some cases, even dementia. One patient also believed that she was unable to remember 
words because of her menopause status. The authors argue that the use of 
neuropsychological batteries merely provides external evidence that is not related to the 
reality of patients’ experiences. 
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Reports of more in-depth studies indicate that patients perceive chemo brain as the most 
troublesome side effect of chemotherapy treatment. In one study, patients reported a 
diminished quality of life and daily functioning, which led them to develop coping 
strategies to be able to continue with their daily routines and social life (Boykoff et al., 
2009). Fitch et al. (2008) reported that patients indicated that they would have preferred 
to be warned about chemo brain as a side effect and its implications on their lives after 
chemotherapy. This last finding contradicts Schagen et al.’s finding (2012), who 
concluded that patients informed about cognitive changes may induce a stereotype 
threat, which may contribute to the incidence of cognitive problems. 
 
The suggestion that factors such as personality, stereotyping, mood and fatigue may 
interfere with the accuracy of self-reports is of concern if reliable results are to be 
obtained. However, relatives and friends of the patients usually notice these changes and 
can help to validate the responses. On the other hand, experiences in daily life are also 
important and for that reason, case studies and interviews were decided to be included 
in the current research. Things such as misplacing things, missing appointments and not 
finding words are a fact of life for patients, regardless of their self-perceptions. 
 
Emerging themes from a phenomenological analysis conducted by Player et al. (2014) 
revealed that participants have varying experiences as a result of chemotherapy, with six 
themes being reported. Among these themes, the majority of patients expressed 
uncertainty about the origin of chemo brain and attributed their memory difficulties to 
diverse factors such as mental fatigue and shock of diagnosis. All the participants from 
their sample reported persistent but inconsistent impacts on cognitive function, and that 
simple functions turned complex, causing significant frustration and loss of identity. 
They also reported losing functional independence in family life due to reduced 
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concentration and motivation, and that they had to learn to depend on strategies to 
maintain function. Finally, participants reported the need for recognition of the 
subjective experience of the treatment. 
 
Reports from case studies also allow an understanding of how patients experience 
memory decline after chemotherapy. In an analysis of two case studies using 
neuropsychological test results and cognitive self-reports, along with blood samples to 
assess hormone status, Paraska et al. (2003) reported that both the participants 
experienced cognitive decline during and after treatment. Interestingly, both reported 
self-perceived cognitive decline before deterioration was detected in their tests scores at 
baseline testing, which might be due to the shock of the diagnosis, and both experienced 
chemotherapy-induced menopause. 
 
These studies corroborate the importance of drawing attention to qualitative reports. 
Although quantitative studies are of great importance and provide information about the 
general population, in the case of chemo brain, their results cannot be considered in 
isolation because of the risk if misinterpreting a diagnosis. Factors such as diverse 
statistical analyses or inconsistent methodologies may lead to a loss in the richness of 
patients’ experiences and a lack of understanding of reality of the phenomenon. Most 
importantly, patients may miss quality care and proper intervention to help them cope 
with this debilitating side effect of chemotherapy. 
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3.11 Animal research 
 
The focus of this research is not based on animal models, but it is very important to 
consider what is being done in the experimental area of psychology and biology with 
animal models to gain information about potential confounding variables, such as the 
effects of toxicity on the hippocampus and other brain regions. 
 
Chemo brain can be greatly influenced by chemotherapeutic agents. Studies in animal 
research have helped to understand factors that might affect brain structures related to 
memory and cognition, specifically in hippocampal regions. Many animal studies have 
been conducted to observe the effects of chemotherapy on cognition. 
 
El Beltagy et al. (2010) studied the chemotherapeutic agent 5FU. They found that it 
crosses the blood-brain barrier, having a direct impact on brain function. They also 
reported that Fluoxetine, an antidepressant of the selective serotonin reuptake inhibitor 
(SSRI) class, can improve cognition and memory. 
 
Within the same line of research, Yang et al. (2010) studied the effects of 
cyclophosphamide (CYP). They suggested that CYP may act as an underlying 
mechanism for memory impairment after a regimen of chemotherapy by inhibiting adult 
hippocampal neurogenesis involved in learning and memory processes. Their results 
showed significant memory deficits in mice trained at 12 hrs after CYP injection. They 
explained that cognitive impairment following chemotherapy might cause indirect 
chemical toxicity and oxidative damage, direct injury to neurons and inflammation. 
These toxic effects reduce cellular resistance to oxidative stress allowing entry of 
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possibly neurotoxic molecules to the brain as a result of damage to the blood-brain 
barrier, which probably incurs cognitive changes. The authors suggested that 
 
“the impairment of memory retention might be associated with the change in 
neural progenitor/stem cell marker proteins in the hippocampus in adult mice. In 
addition, this study shows that a single injection of CYP in adult ICR mice can 
interrupt the functioning of the hippocampus, including learning and memory, 
possibly through the inhibition of neurogenesis” (Yang et al., 2010). 
 
Animal models of research are needed to better control for potential co-occurring 
diseases or psychological factors. They have also provided knowledge about the 
potential locus of action on pharmacological agents, allowing researchers to make 
predictions, as in the case of the effects of chemotherapy on cognition, and to identify 
neurobiological effects of different agents. The studies discussed above provide insight 
into the sense that it has been discovered that chemotherapeutic agents can cross the 
brain-blood barrier, causing neurotoxicity on hippocampal structure and leading to 
cognitive deficits (MacLeod et al., 2007). 
 
3.12 Summary 
 
It is a fact that patients who have survived cancer present memory and language deficits 
after undergoing chemotherapy. However, the underlying causes remain unknown. 
Mood, depression and anxiety might be important factors that could be altering 
cognitive function due to psychological distress, because there might be a strong 
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relationship between depression and mood disturbances and cognitive deficits in cancer 
patients (Burgess et al., 2005). 
 
The most commonly affected domains in chemo brain are WM, processing speed, 
attention and learning. Despite these declines usually being subtle, patients have 
reported high incidences of functional loss, such as decreased ability to work, which 
seem to be associated with a central neurotoxicity. 
 
Hormonal changes can also account for memory loss. Many breast cancer therapies 
involve hormone treatment, which might be having an effect on cognitive function 
(Collins et al., 2009). Therefore, the effects on cognition of adjuvant hormonal therapy 
on breast cancer patients should be studied.  
In a meta-analysis study of neuropsychological batteries implemented to test the effects 
of chemotherapy on cancer survivors, Jansen et al. (2007) implied that the adequacy of 
the test being used for the assessment should be considered more carefully. Factors to 
consider when selecting a test should be the domain to be measured, reliability and 
validity, appropriateness of the test, the normative data, availability of parallel forms 
and the specificity and sensitivity of the test.  
 
3.12.1 Key points 
 
1. Neuropsychological measures have shown inconsistencies with patients’ self-report 
indicators. 
2. Mood might be an important factor that could be altering cognitive function, but 
evidence comes mostly from self-reports. 
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3. Chemical toxicity to neurons causes oxidative damage, inflammation and 
destructive autoimmune responses, such as anaemia and fatigue. 
4. Despite these declines usually being subtle, patients reported high incidences of 
functional loss, such as decreased ability to work. 
5. Hormonal changes can also account for memory loss. 
6. Changes remain for one year after treatment. 
7. There is a need to identify more reliable, valid and sensitive tests for short or long-
term effects. 
8. Subtle cognitive impairment is observed in some breast cancer patients. 
9. A vast majority of the research has been focused on global cognitive dysfunction. 
10. A more specific and detailed study is necessary to deeply analyse the specific 
memory processes affected. 
11. More sensitive and domain-specific memory measures are required. 
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CHAPTER FOUR 
4 PROSPECTIVE MEMORY THEORETICAL FRAMEWORK 
 
4.1 Chapter overview 
 
This chapter briefly explains the history of the study of memory in order to explain 
some of the concepts that are essential for the understanding of PM, and how it is 
associated with daily cognitive function. After a brief explanation of how the study of 
memory emerged, diverse models of memory, such as the modal model and the WM 
model are summarised. Since EF has been largely associated with WM (Repovs & 
Baddeley, 2006) and PM (McDaniel et al., 2007), this is also explained, along with the 
theory behind PM. 
 
4.1.1 Brief history of the study of memory 
 
Memory function is crucial for daily life for doing any kind of activity. Research has 
shown that memory is not a single system, but a complex system involving several 
regions of the brain, and different theories of memory have been developed to explain 
its complexity (Baddeley, 2009). To gain a better understanding of memory processes, 
particularly PM and EF, which are included in the scope of this investigation, a brief 
explanation of memory models and theories is presented. 
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The study of memory has been the subject of interest dating from Plato (427–347 BCE), 
who believed that the truth was stored in memory and that learning is the recollection of 
these truths, and Aristotle (384–322 BCE), who explained that memory was the power 
of retention and that recall was due to recollection, which is formed by associations 
(connection of two mental events) (Neath et al., 2003). It was Augustine (354–430 
BCE) who was the pioneer in identifying separate kinds of memory: sense and 
intellectual memory, the first one associated with reproduction of images, sound, odours 
and touch, and the latter related to knowledge, such as the study of literature, science 
and philosophy. Augustine’s view was that memory was not a passive or a simple 
process, but a complex series of actions (Neath et al., 2003). 
 
The Spanish humanist Luis Vives (1492–1540) began talking about forgetfulness and 
suggested writing things down to aid memory. A few years later, Rene Descartes 
(1596–1650) introduced his ideas of Cartesian Dualism, in which mind and body are 
separated into two distinct entities, whereby the essence of man was the mind, which 
can interact with the body, but can also act independently. The experimental approach 
for the study of the human memory emerged with David Hume (1711–1766), who based 
his assumptions on Aristotle’s ideas of association through similarity and continuity, but 
with emphasis on the principle of cause and effect (Neath et al., 2003). 
 
One of the first people to study memory under laboratory conditions was Herman 
Ebbinghaus (1850–1909) in an experiment in which he studied how learning interacted 
with what was already known. He studied associations between stimuli and responses 
by using lists of words and non-words (Baddeley, 2009). The importance of his research 
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was that although he was his only subject of study, the emphasis was placed on creating 
two conditions to assess his predictions; he conducted an experiment to analyse his 
hypothesis, thus becoming the first experimental psychologist (Neath et al., 2003).  
The modern history of the study of memory began in 1890 when William James 
distinguished primary memory from secondary memory, dividing memory into multiple 
stores. Primary memory refers to “the contents of consciousness or the information that 
is the focus of attention at any one time” (Neath et al., 2003). It has also been termed 
STM, WM and short-term store, because primary memory specifically holds on to 
information for a short period of time (Neath et al., 2003). Secondary memory, on the 
other hand, refers to “a long lasting, unlimited capacity store holding information that is 
no longer in the focus of consciousness” (Neath et al., 2003) and items that have been 
absent from consciousness for a period of time, which have to be retrieved (Neath et al., 
2003). 
 
The study of human memory has continually increased, and more recent studies on 
memory explain the different subsystems that have been identified, such as sensory 
memory (SM), STM, WM and PM, which will be explained later in the following 
section of this chapter. To expand the study of memory, researchers nowadays also rely 
on neuroimaging techniques to observe the biological basis of memory, in which 
participants are required to perform a task while diverse types of brain scans are 
conducted, so that researchers can identify the structures of the brain involved. 
 
Furthermore, the complexity of memory systems are better understood by comparing 
them with computer-based theoretical models, which are commonly used to explain 
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memory processes by comparing memory systems with computer systems. The 
computer metaphor has become a very useful model to explain memory processes 
(information processing approach). One example is the use of this metaphor by 
Baddeley (2009) to explain memory processes as comprising mere storage systems that 
require the same elements as computer systems, which are as follows: 
1. The capacity to encode or enter information into the system 
2. The capacity to store it 
3. The capacity to retrieve it 
 
4.2 Theoretical models of memory and executive function 
 
To better understand PM and EF, it is useful to understand some theoretical models of 
memory that attempt to explain its role in our daily lives. To date, the question of how 
many types of memory exist is still controversial, but this study will follow Baddeley’s 
(2000, 2009) assumptions to explain the structures and processes involved in WM and 
EF processes (Baddeley, 2009) due to the associations found in the literature with these 
processes and chemo brain. 
 
The discussion begins with an explanation of Atkinson and Shiffrin (1968) modal 
model, which describes sensory, short-term and LTM systems, divided into separate 
components in order to explain human memory. The Baddeley WM model (Baddeley, 
2000) is also discussed, in which the key components are the central executive system, 
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the phonological loop, the visuospatial sketchpad and the episodic buffer. EF and PM 
are discussed later in the chapter. 
 
4.2.1 The modal model 
 
The way information is stored determines what and how it is stored, and how it will be 
retrieved. Several theories of memory have emerged, with one of the most influential 
being the modal model presented by Atkinson and Shiffrin (1968). In the model, the 
general assumption was that sensory input that comes from the environment is first 
processed by a series of SM systems, to later be passed on a temporary STM system, 
where information is maintained for a short period of time (Figure 4.1). If this 
information is rehearsed, it will be encoded or registered in LTM to be retrieved at a 
later time. If not rehearsed, information will be lost (Baddeley, 2009).  
 
4.2.2 Sensory memory 
 
SM is described as a brief storage of information more related to perception than 
memory and can be subdivided into iconic (visual) SM and echoic (auditory) SM. These 
perceptual processes are summed to lead to temporary STM or WM and capable of 
temporary storage (Sperling, 1960; Neisser, 1967; Jones et al., 2007; Baddeley & 
Larsen, 2007). 
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Figure Error! No text of specified style in document..1. The Atkinson and Shiffrin 
Modal Model (1968). 
 
4.2.3 Short-term memory 
 
STM is a temporary storage of small amounts of material over periods of a few seconds. 
It is not only limited to verbal material and verbal rehearsal, but also involves visual and 
spatial information, smell and touch (Baddeley, 2009). Generally speaking, STM refers 
to remembering things over a brief period of time, but it is best to describe it as the 
performance of a particular task by retaining small amounts of information, tested either 
immediately or after a short delay, in contrast to WM, which not only temporarily stores 
information, but also manipulates it to perform complex activities such as learning, 
comprehension and reasoning. It serves as a mental workspace. 
 
STM is usually reflected by the digit span test, which is the maximum number of 
sequentially presented digits that can reliably be called in the correct order. Assessment 
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of WM span involves more complex tasks and is described as a range of complex 
memory tasks in which simultaneous storage and processing is required. 
 
The modal model (Atkinson & Shiffrin, 1968) identifies STM as WM, because they 
have common and similar models. It assumes that information perceived from the 
environment enters a brief temporary SM system (iconic + echoic), which is then 
transferred to short-term store, freeing it into LTM and acting as a WM by operating 
and selecting rehearsal strategies and serving as a global work space (Baddeley, 2009). 
 
 
4.2.4 Working memory model 
 
Badderley and Hitcht (1974) proposed a more complex model to analyse STM, which 
they called WM model. The term “working” was used to differentiate from STM, which 
was more focused on storage, whereas “working” refers more to a functional role, 
which involves complex cognitive activities that support mental work and coherent 
thought (Baddeley et al., 1974). WM can be described as a “combination of controlling 
attentional mechanisms (the central executive) and a number of subsidiary slave 
systems (phonological loop, and visuospatial sketchpad)” (Neath et al., 2003). 
 
4.2.4.1 Working memory: A multicomponent model 
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This model comprises three components: 
1. Phonological Loop: This component holds sequences of acoustic or speech-based 
items. 
2. Visuospatial Sketchpad: Its main function is to hold visual and/or spatial-encoded 
items and arrays. 
3. Central Executive: This controls the whole system. It is an attention limited system 
that selects and manipulates material in the subsystems. 
 
According to Baddeley (2000), the central executive, phonological loop, episodic buffer 
and visuospatial sketchpad are associated with fluid cognitive capacities, such as 
attention and temporary storage (Figure 4.2). On the other hand, visual semantics, 
episodic LTM and language are associated with crystallised abilities, such as language 
and semantic knowledge (Hadjiefthyvoulou, 2011).  
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Figure Error! No text of specified style in document..2. Baddeley’s Working Memory 
Model (Baddeley, 2000). 
 
The phonological loop consists of the slave system of the model, which is concerned 
with verbal STM and assumes a temporary store and a verbal rehearsal process. The 
loop is responsible for temporary storage of speech-like information. It is assumed to 
have two subcomponents, a short-term store and an articulatory rehearsal process. The 
store is of limited capacity and decays within a few seconds, but items can be refreshed 
by sub vocal rehearsal. 
 
Memory span deals with remembering items and the order in which the items are 
presented. Two terms usually studied in memory are interference and forgetting, as 
there is evidence that learning can be disrupted by subsequent activity. Interference 
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occurs when retrieval of a memory is disrupted by the presence of similar traces in 
memory. 
The visuospatial sketchpad is the second component of Baddeley’s model (Baddeley et 
al., 1974), which is responsible for temporary maintenance of visual and spatial 
information (to store visuospatial information and to solve problems) (DiVesta et al., 
1971; Baddeley et al., 2000; Finke et al.; 1988). The episodic buffer, the third 
component of the slave system, helps to understand how WM links, or interacts with 
LTM. It is assumed that the buffer is a storage system that can hold chunks of 
information in a multidimensional code and acts as a link between the various 
subsystems of WM, connecting them to LTM and forms of perception. Each of these 
information sources uses a different code, but these can be combined within the 
multidimensional buffer through what is called binding. 
 
WM is assumed to be directed by the central executive, which is an attention controller 
rather than a memory system. Norman et al. (1986) assumed two modes of functioning 
of the central executive, one automatic (habitual actions) and the other attention limited. 
It is possible to describe them with the example of driving a car, which is a skill based 
on habitual actions that require little attention, but when a novel situation occurs such as 
a road closed for repairs, the second system is called into action. This second system is 
known as the supervisor attention system (SAS) and is activated to seek other alternate 
solutions. This SAS is of major importance for the central executive (Baddeley, 2006). 
 
One of the major functions of the central executive is that of attentional focus, which is 
the capacity to direct attention to the task in hand and also the capacity of dividing 
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attention between two or more tasks (Henson et al., 1996; Baddeley et al., 1991a). This 
assumption is very relevant to this research work, because one of the major areas of the 
study of PM is focused and divided attention, which are discussed in the following 
sections of the chapter. 
 
In summary, the four main functions of the central executive according to Baddeley 
(1996, 2000) are selective attention, which is the ability to attend a piece of information 
while ignoring irrelevant information; executing two or more activities simultaneously, 
i.e. the ability to effectively multitask by coordinating the WM resources required for 
the tasks; switching attention and mental flexibility required to perform habitual 
behaviours; and retrieving information from LTM (Hadjiefthyvoulou, 2011).  
 
Failures of the central executive result in an inability to multitask, rigid behaviour and 
failure to identify target events in goal-oriented behaviour (Hadjiefthyvoulou, 2011), 
which are also relevant for PM performance. Norman and Shallice (1986) also 
investigated attentional control in patients with frontal lobe damage, usually reflected in 
perseveration, which is when the person repetitively performs the same action or makes 
the same mistake repeatedly, or fails to focus attention by simply responding to 
environmental cues present at that time, leading to bizarre behaviour. 
 
For a better understanding of WM in action, Baddeley (2009) explained how this system 
operates in a simple and clever way by inviting us to think of our current house and 
work out how many windows it has. To figure out how many windows there are, we 
would probably create a visual image of the house which relies on the sketchpad, or we 
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would probably count the windows verbally by using the phonological loop, and to do 
so, the central executive would select and run the strategy, and thus, these are the three 
components of WM in action. 
 
Examples in which SAS fails to operate are slips of action (a lapse of attention 
producing unforeseen consequences) such as planning to go to the grocery store at the 
weekend, but finding yourself driving to work or, more tragically, errors that pilots 
commit that lead to plane crashes (Norman & Shallice, 1986). Additionally, according 
to Gilbert and colleagues (2008), damage to the supervisory system can cause excessive 
rigidity, which involves failing to make the right decision or not being able to make 
alternative choices, and also when experiencing excessive distractibility, there is a 
reduction in supervisory involvement, failing to pay attention to cues in the environment 
that would otherwise lead to making the right choice (Gilbert et al., 2008). 
 
To summarise, WM is the temporary maintenance and manipulation of information, 
which helps in performing a number of complex tasks. It helps to “keep things in mind” 
when performing complex tasks and “works as a mental work space, providing the basis 
for thought” (Baddeley, 2009). It is assumed to be linked to attention and EF (Miyake & 
Shah, 1999, in Baddeley, 2009), which are central cognitive skills for PM and fall 
within the scope of this study.  
 
Additionally, the author believes that the study of WM is relevant for PM, because the 
central EFs are essential components of PM. These functions are task switching, divided 
attention and inhibition (Burgess et al., 2000). Furthermore, according to Cohen and 
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Conway (2008), “planning, prospective memory, and carrying out actions sequences 
depend on the ongoing operation of working memory and the allocation of attention”; 
thus, it is believed that PM is embedded or correlated with WM, as a part of EF system. 
 
4.3 Executive function (EF) 
 
4.3.1 Executive function explained 
 
Several definitions exist in the literature that attempt to explain cognitive function. This 
is mainly due to the overlap among related distinct abilities (Gioia et al., 2004). 
However, despite the fact that many authors may give many different definitions, most 
of them agree that cognitive function is a set of separate multiple processes, controlled 
mainly by the central executive. Since the main scope of this research is PM, attention 
was focused on definitions that help better understand the overlap of PM with the 
processes that we consider are interrelated. 
 
Friedman et al. (2008) described EF as the collection of control processes that regulate 
lower level cognitive abilities in order to shape complex performance. These functions 
are separable, but correlated by the same control processes. Gioia et al. (2004) 
summarised the list of cognitive domains that fall under the umbrella of EFs as a set of 
interrelated capacities rather than a unitary function. These abilities include the 
following: 
 
129 
 
1. Ability to initiate behaviour 
2. Inhibition of competing actions or stimuli 
3. Selection of relevant task goals 
4. Planning and organising means for problem solving 
5. Flexible strategies for shifting and problem solving 
6. Monitoring and evaluating one’s own behaviour 
7. WM capacity to hold information actively for problem solving 
8. Emotional control 
 
Within this context, EF’s role is that of a directive system that exerts regulatory control 
over basic functions such as language, memory, visuospatial functions and emotions in 
order to reach a goal by making intentional active decisions. For this reason, EF is a 
self-regulatory system that organises cognitive abilities and behaviours (Gioia et al., 
2004). 
 
According to Friedman et al. (2008), EF can be understood as the cognitive control 
process that regulates thought and action. EFs have also been described as 
“the high level cognitive processes that facilitate new ways of behaving, and 
optimise one’s approach to unfamiliar circumstances” (Gilbert et al., 2008). 
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Other mental processes can be organised and controlled because of these higher 
processes. Thanks to these processes, people are capable of living independent lives and 
are able to make plans for the future, switching from one activity to the other, or 
inhibiting certain behaviour in the face of temptation. The structures in the brain 
involved in these processes are those related to the frontal lobes, particularly the PFC 
(Gilbert et al., 2008). 
 
Although there is disagreement on what are the underlying components of EF, response 
inhibition (Inhibiting), updating WM representations (Updating) and set shifting 
(Shifting) have received most attention within EF research. Dual tasking and proactive 
interference have received less attention, but are also are also considered as functions of 
EF (Friedman et al., 2008; Della Salla et al., 2004). According to Friedman et al. 
(2008), response inhibition refers to the ability to inhibit either automatic or dominant 
responses. Updating WM representations can be explained when monitoring takes place 
while looking for incoming information relevant to the present task and then updating 
the no longer relevant information by replacing it with the new information. Set shifting 
is the ability to accurately switch back and forth between tasks (Friedman et al., 2008).  
 
In the literature, EFs are defined as the superior abilities that help with self-regulation 
and monitoring of the environment as well as to design plans and to anticipate and 
establish goals (Lezak, 1983). According to Gioia et al. (2001), EF is 
“a collection of interrelated processes that are responsible for goal-directed or 
future-orientated behaviour with the executive system acting as the ‘conductor’ 
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that controls, organises and directs cognitive abilities, emotional responses and 
behaviour” (Hadjiefthyvoulou, 2011). 
 
To better understand EF, it is necessary to understand that schemas (a set of actions or 
cognitions) become activated by events in the environment, such as a red light 
triggering the appropriate automatic behaviour when we are driving (use the brakes) 
(Sahllice et al., 1991; Gilbert et al., 2008). However, for non-automatic behaviours, 
where inhibition of a well-learned response has to take place, such as in a novel 
situation, and where environmental prompts are insufficient, a “supervisory system” 
goes into action, supported by the frontal lobes (Gilbert et al., 2008). 
 
For the purpose of the current study, it was hypothesized that a damage to the 
supervisory system explains the kind of distractibility reported when there is frontal 
lobe damage, which corresponds to PM failures and chemo brain cognitive decline. This 
has been observed in patients who misplace things, become unable to multitask or miss 
the exit on their way home when they find an unexpected detour. 
 
4.4 Prospective memory: Theory and terminology 
 
The following section aims to summarise the most prominent theories and concepts of 
PM, particularly those that the author of this thesis believed are more related to chemo 
brain. An examination of the models of PM, including time and event tasks will follow, 
which are associated with the PM measure selected for our current study. 
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PM refers to the realization of intended actions at the appropriate time. McDaniel et al. 
(2007) referred to it as “remembering to carry out intended actions at an appropriate 
point in the future”, and the main challenge is remembering to recall. An intended 
action is the willingness of a person to perform a certain activity or behaviour that has 
been previously and consciously organised or planned in the future. PM can also be 
described as the realisation of delayed intentions, which means that an intention is 
postponed until its execution at the appropriate time or when an appropriate event for its 
realization occurs (Kvavilashvili & Ellis, 1996). In daily life, people usually depend on 
prompts in the environment that remind them to perform PM tasks. 
 
To date, most of the literature on memory has focused on retrospective memory (RM), 
which relates to learning and reproduction. A technique associated with it is known as 
“cue remembering” (Gonen-Yaacovi et al., 2012), in which the experimenter presents 
cues to the participant that help them retrieve the information. On the other hand, PM 
requires a person to remember to perform intentions in the future without obvious cues 
triggered by the environment. These remembering of intentions has been termed as 
“self-cued” remembering (Gonen-Yaacovi et al., 2012). This means that to perform an 
intention, the process of remembering must be self-initiated, using strategies for 
monitoring for cues that reminds the person what they are supposed to remember. PM 
remembering differs from RM, in that RM is the memory for events that have occurred 
in the past, and PM is the memory for the future. 
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Intended actions or delayed intentions, either in laboratory tasks or in everyday 
activities, are formed of PM and RM, where remembering to recall an intention is the 
PM component (go to the grocery store to buy a loaf of bread on our way home) and 
remembering the content of the intention is the RM component (stop by the grocery 
shop and remember to buy the bread). An example of an unsuccessful attempt might be 
to forget to stop by the shop to by the loaf of bread (PM failure) or to stop by the shop 
and forget to buy it (RM failure). The key difference is that in RM, one needs to 
remember the content of the intention, whereas in PM, one needs to remember to recall 
the intentions or plans for the near future. This study focused on the PM component of 
memory.  
 
Research on PM involves tasks in which participants are usually required to perform an 
ongoing activity of behaviour that demands attention. They are usually kept busy or 
distracted by this ongoing activity. Then, at the moment of the target event (namely the 
event-based PM) or at the termination of a pre-determined time (namely time-based 
PM), they need to perform an action that is unrelated to the ongoing activity (McDaniel, 
2007; Costa et al., 2011). An example of a real life situation of PM paradigm is when a 
person holds a delayed intention (e.g. post a letter) while performing an ongoing task 
(e.g. driving to the post office while engaged in a conversation). On encountering the 
target (the post office), one may make the appropriate PM response (stop by the office 
to post the letter) or miss the target and continue the ongoing task (drive past the post 
office). 
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Since PM is the memory for intentions, goals and plans for the future, it is intimately 
related to our everyday life activities. Examples of successful PM range from going to 
the grocery shop to buying some food for today’s dinner, or remembering to take our 
medicines, or attending to a very important appointment with the doctor or a job 
interview. Daily routines such as driving from home to work, posting a letter or giving a 
message to a friend also depend on PM. Poor PM leads to failures in meeting such goals 
and plans, such as forgetting to give a message, missing appointments, failing to take 
one’s pills or taking them twice.  
 
More often than not, when someone refers to their own memory’s poor performance, 
they refer to PM (Baddeley, 1990). Lapses in attention are particularly important in PM. 
When a person’s attention is divided or they are distracted, it is still sometimes possible 
to successfully carry out the tasks in hand, but if PM is poor, they fail to execute them 
successfully, forgetting or missing the cues that would lead to the successful execution 
of the intention.  
 
Furthermore, PM relies on self-initiating retrieval of intentions, which get encoded 
when the intention is formed; therefore, in order to attend the target event or goal, it is 
necessary to pay attention or monitor the environment, for cues that prompt the 
execution of the planned action, i.e. in order to remember to execute the intentions, a 
person relies on cues in the environment to remind them what they had planned. 
Missing those cues leads to failure to execute plans successfully. However, in the 
literature on PM, there is controversy as to whether these processes are automatic (or 
spontaneous), or if there is a more conscious process that aids in monitoring these cues. 
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Theoretical models are reviewed later in this chapter. Firstly, the terminology and the 
parameters of PM are discussed to gain a clearer picture of PM and its function in 
everyday life, which in turn helps to understand the hypothesis that chemo brain patients 
experience PM failure when they report having memory difficulties. The PM theory has 
been related as much as possible to everyday PM failures to give a better picture of what 
the participants have experienced. 
 
Throughout the literature, diverse approaches or explanations have been found that try 
to explain cognitive processes involved in PM. For example, Ellis (1996) distinguished 
five phases for delayed intentions to take place; Einstein et al. (1992) analysed PM 
according to the complexity of the task; Harris (1980) stressed on the importance of 
analysing the frequency of the tasks; and McDaniel et al. (1990) explained how delayed 
inattentions are executed depending on time-based or event-based retrieval phases, and 
how delayed intentions are formed, maintained and executed (McDaniel et al., 2007).  
 
These approaches to PM will be the focus of the following section, paying particular 
attention to time-based and event-based PM, as our main analysis of PM was based on 
the analysis of such variables on breast cancer patients’ PM, as a result of cognitive 
impairment developed thought their course of cancer treatment. It was hypothesized that 
chemo brain affects time-based tasks the most, as a result of the tasks being more 
demanding, which requires more attentional resources. In the literature of chemo brain, 
findings suggest that problems with attention are found in breast cancer patients (Vardy 
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et al., 2008; Stewart et al., 2006; Collins et al., 2009; Tager et al., 2009; Bender et al., 
2006).  
 
Ellis (1996) explained that the realization of the intended actions or delayed intentions 
takes place in five phases: 
1. Formation and encoding of intention and action. This phase is mainly concerned 
with the content of an action and the form of the retention of an action (“what is 
what we want to do”), an intent (the decision to do something) and the retrieval 
context (associated with the conditions of recall). Einstein et al. (1990) suggested 
that this phase corresponds to the retrospective aspect of PM, and that the 
subsequent phases are the prospective components of PM; readiness and motivation 
play a role in the execution of the intended action. Factors such as the strength of the 
intention, personal importance, benefits and consequences are associated with this 
phase. 
2. Intention retention. This phase involves the delay between encoding (phase A) and 
the possible beginning of the performance interval (Phase B), and it is the period 
prior to the occasion to carry out the action (Gillian et al., 2008), in which the 
intention is retained in memory at the time the ongoing activity is taking place 
(Kliegel et al., 2008). This period or interval can vary significantly either in duration 
or in content. Here, the primary cognitive ability is storage. 
3. Performance interval or intention initiation. This is the phase when the intended 
action should be recognised and the intention should be initiated. 
4. Initiation and execution of intended action. This is the actual execution of the 
intended plan (Kliegel et al., 2008). 
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The previous two phases rely on monitoring, cognitive flexibility or inhibition. 
Retrospective remembering and executive functioning are believed to play a 
major role during PM performance, i.e. being aware of the appropriate moment 
to initiate and execute an intended action (the prospective component of PM) 
strongly depends on EF (Kliegel et al., 2008). Therefore, the retrospective aspect 
of PM relies mostly on RM abilities. 
 
5. Evaluation of the outcome. This phase is necessary to avoid repetition of a 
successful realization of an intended action. 
 
To better understand how delayed intentions or plans for the future are performed, 
McDaniel et al. (2007) explained that it is necessary to form an intention and maintain 
the intention in memory for a period of time while performing other activities (ongoing 
task, execute the plan at the appropriate time and evaluate the outcome). The following 
parameters have been identified:  
 
1. Execution of the intended action is not immediate. The delayed intention must be 
performed at some point in the near future. 
2. The PM task is embedded in the ongoing activity. In PM, task stimuli or cues appear 
as a part of another activity or situation, and performance of that activity must be 
interrupted to carry out the PM task. For example, when we intend to buy a loaf of 
bread at the store, we must stop driving our car to perform the activity. In everyday 
life, PM involves interrupting daily routines or activities to perform an intended 
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activity. During an ongoing activity, we need to remember that there is something 
else that has to be done. 
3. The window of response initiation is constrained. A PM intended action must be 
performed during a specific window of opportunity. It is because of this window 
that PM remembering or forgetting is defined. Remembering takes place when we 
perform the PM task within this window (e.g. it is when 20 minutes have elapsed 
that we need to take the cookies out of the oven). Failing to perform these activities 
will be considered as forgetting. 
4. The time frame for response execution is limited. Kavavilashvili and Ellis (1996) 
refer to PM tasks when they have to be executed in no more than a few hours. 
Reading a book or planning a trip are not PM actions despite the fact that they do 
arise from intentions and cannot be accomplished immediately, but the time frame 
required is much longer.  
5. There must be an intention. To distinguish PM from other behaviours, a conscious 
intention or plans must be formed. For instance, we plan to attend an important 
meeting at work, take our pills, pick up our children from school, buy our groceries, 
give a message or pay the bills. 
 
4.5 The role of context in PM 
 
For successful execution of an intended action, it is important to consider the role of 
how the environment or the circumstances in which events take place influence the 
retrieval of an intention. Considering the context in which the intention was encoded, 
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the context of the ongoing activity and when the target event is going to be executed has 
received attention in the research community, because it has been shown that context 
plays an important role in PM. 
For instance, Marsh et al. (2002) found that changing the context had a negative effect 
on participants’ ability to remember whether they had executed the target event or not, 
in a study where output monitoring (recalling that a task has already been performed) 
was under study. In a study conducted by McDaniel et al. (1998) using semantic 
manipulations, changing the context conditions between encoding and retrieval lead to 
poor PM performance. Other authors have also reported the influence of the context on 
PM performance (Craik, 1986; Henry et al., 2004). The influence of context familiarity 
has also been considered, suggesting that familiarity with the context improved planning 
in PM tasks (Titov & Knight, 2001). Other studies stressing the importance of the 
contexts on event-based and time-event tasks are those trying to replicate real life PM 
tasks while ongoing activities take place, keeping the participants busy (Einstein et al., 
1990; 1996). 
 
However, the findings of these studies were based on laboratory conditions and should 
be interpreted differently than naturally occurring events, because naturalistic situations 
vary greatly from laboratory conditions in the way they prompt automatic retrieval on 
PM (Henry et al., 2004). This observation is of great importance in this study, because 
chemo brain has usually been assessed under laboratory conditions, and so there is a 
need to consider developing more sensitive measures that resemble what patients 
experience in their everyday lives while they undergo treatment. It is assumed that their 
mental state, mood and sometimes their physical surroundings (e.g. at home or at 
hospital, during the time they received treatment) would be very different than at other 
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times where their lives seem more normal (e.g. between chemotherapy treatments 
and/or after finishing treatment). Factors such as this should be considered at the time of 
testing. For that reason, it was decided to include a qualitative analysis to the study, in 
order to obtain a broader spectrum of memory problems associated with everyday life 
PM dysfunction in breast cancer patients. 
 
4.6 Types of PM failures 
 
In the literature, there are differences of opinion on the difference between PM failure 
and absent-minded errors (or slip of action). Kvavilashvili et al. (1996) distinguished 
PM failures from absent-minded errors by defining slip of actions as failures occurring 
during the execution of an intended action and PM failures as consisting of failures to 
retrieve an intended action completely.  
 
An example of an absent-minded error or slip of action is the substitution error (e.g. 
taking one thing out of the fridge when the plan was to take another). Another type of 
absent-minded error that Kvavilashvili et al. (1996) deny to be a PM failure is when 
someone starts carrying out an intended action, but suddenly realises that they no longer 
remember what they had planned to accomplish (e.g. when someone goes into a room 
and forgets why they are there). These authors argue that this cannot be a PM problem, 
but rather a loss of contents of an immediate intention during an ongoing activity 
(Kvavilashvili et al., 1996). On the other hand, Einstein et al. (1996) explained that PM 
contains components of RM and that in order to execute a PM task successfully, the RM 
component must also be executed successfully, and that many PM failures occur as a 
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result of problems with remembering the RM component. For example, in the situation 
where a person forgets why they went into a room, it is because they have forgotten the 
RM component of PM. 
 
Slips of action has been classified by Cohen and Conway (2008) as follows: 
1. Repetition errors (commission errors). Forgetting that an action has already been 
performed and repeating it, e.g. placing two checks in an envelope for the same bill. 
Scullin et al. (2012) suggested that commission errors are of great importance in the 
study of PM. These types of errors occur when an individual fails to suppress 
executing an intention that has already been performed, when the completed 
intention is spontaneously retrieved (Scullin et al., 2012). 
2. Goal switches. Forgetting the goal of a sequence of actions and switching to a 
different goal, e.g. intending to drive to one place and driving to another. 
3. Omissions and reversals. Omitting or wrongly ordering the component actions of a 
sequence, e.g. filling the kettle, but failing to switch it on. 
4. Confusion/blends. Confusing objects involved in one action sequence with those 
involved in another sequence, e.g. taking a tin-opener instead of scissors into the 
garden to cut flowers. 
 
Breast cancer patients usually report things such as forgetting to turn the vacuum 
cleaner off (goal switches), frequently misplacing things (confusion blends), not 
remembering if they have already taken the medicine or not, paying bills twice, 
repeating the same story to the same person over again, reading the same article twice 
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and not noticing that they had read it before until the very end (commission errors). 
These common complaints fall into the category of PM lapses; therefore, it was 
hypothesized by the author of this thesis that poor PM plays an important role in chemo 
brain. 
 
4.7 Prospective memory models 
 
A review of different views on underlying mechanisms of PM is presented in this 
section. At the core of the debate among the presented models is the question as to 
whether the successful execution of an intended action is activated by automatic or 
strategic monitoring or both (two-process model). 
 
The monitoring model is discussed first, because it provides a clear explanation of what 
monitoring implies for PM and the costs of monitoring too late, followed by the key 
aspects of the two leading (opposing) models on the theory of PM, i.e. the preparatory 
attentional and memory processes (PAM) theory and the multiprocess theory of PM, 
which is the main focus of the current study, because it is the opinion of the author that 
some cancer patients complaints have to do with some automatic monitoring, such as 
routine activities like driving back home from hospital, whereas others are more self-
initiated and require a more conscious decision, such as beginning a new course of 
medication and keeping their appointments for treatment. 
 
4.7.1 Monitoring model 
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A successful PM requires that individuals monitor the environment, which means 
checking for cues or signals that will lead to the performance of the intended action at 
the appropriate time, and according to the monitoring model (Harris, 1984), monitoring 
the environment implies an attentional cost, i.e. attentional resources must be allocated 
to monitor for the cues in the environment and to check if the response is correct. 
This model suggests that people do not necessarily monitor continuously, but 
periodically, to observe if the conditions are suitable to perform a planned action, and 
that the cost of monitoring late can be high, which can lead to missing the target event 
(McDaniel et al., 2007) and subsequently causing problems for individuals, such as 
when they forget to take their medication, which puts their health at risk. Thus, late 
responses have been associated with poor monitoring behaviour. On the other hand, 
frequent monitoring, particularly when the target event approaches, helps to execute PM 
tasks effectively. However, engagement in the ongoing activity can disturb monitoring 
by keeping a person distracted and disturbing the maintenance of the intention 
awareness, which accounts for PM lapses (McDaniel et al., 2007). 
 
Miller et al. (1960), in a procedure called Test-Wait-Test-Exit (TWTE), found that 
people monitor periodically and begin to monitor early because if monitored late, the 
cost may be too high by forgetting to perform their target event. They found that early 
monitoring follows a waiting period where attention is maintained, and then another 
monitoring test takes place and so on, until the appropriate time to perform the target 
action occurs. Similar results were found by Harris and Wilkins (1982), Einstein, and 
McDaniel et al. (1995). These authors also reported a periodical checking rather than 
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occurrence of continuous monitoring, with frequency of monitoring increasing as the 
time to perform the targeted action approached, and that a possible executive system 
interfered in the participants’ decision to initiate the checking behaviour (McDaniel et 
al., 2007). 
 
4.7.2 The preparatory attentional model (PAM)  
 
Another view for the monitoring approach is the PAM theory, which maintains that 
monitoring is constant rather than periodical, and that attention is always implicated 
through a strategic preparatory attentional process that helps to monitor the 
environment, which should be present at all times for successful PM (Smith & Bayen, 
2004). According to PAM, the individual is always conscious of the plan in order to 
perform an intended action, and the intention is always the focus of attention when the 
plan is encoded (or formed) and at retrieval (when it is actually performed). Smith 
(2008) defined an intention as “a decision about an action that consciously references a 
prior plan” and distinguishes between immediate intentions (performed at the time the 
intention is formed) and delayed intention (action that is not in the focus of attention 
during the time interval between encoding and retrieval). The ongoing activity is what 
receives the focus of attention during that interval. Furthermore, when an event of the 
environment captures the attention for retrieval of the target event, a preparatory 
attentional process leads the individual to a conscious recollection of the delayed 
intention to execute the plan or intention (Smith, 2008). 
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Nevertheless, McDaniel et al. (2007) argued that continuous monitoring for retrieval of 
a target event would be too costly for the ongoing activity. If PM requires continuous 
monitoring from the moment the intention is formed and its execution in everyday life, 
it would be impossible that non-automatic monitoring of the environment would take 
place, especially because PM execution is sometimes hours or days from the formation 
of the intention, arguing that cognitive systems rely more on automatic processes. On 
the other hand, increasing attentional demands should reduce attentional resources 
available for monitoring. 
 
4.7.3 The multiprocess theory of prospective memory 
 
An opposing view to the PAM theory of conscious and constant monitoring is the 
multiprocess theory of PM. This theory takes into account that memory processes can 
be context dependent and that their effectiveness also depends on factors such as the 
importance of the task, the salience of the target item and the dispositions to remember. 
The multiprocess theory assumes that PM retrieval involves spontaneous processes 
triggered by cues in the environment and considers variables such as how busy the 
individual is during the ongoing activity, the length of the retention interval, the salience 
of the cue and the importance of the task (McDaniel et al., 2007). 
 
Three main assumptions comprise the multiprocess theory (McDaniel & Einstein, 
2000). The first one is that PM is supported by strategic monitoring of the environment 
and by spontaneous retrieval. The second assumption is that an individual’s personality, 
ongoing tasks demands and uniqueness of the PM tasks play an important role on 
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effective monitoring and retrieval. The less engagement in monitoring processes 
anticipates that spontaneous retrieval will be favoured by the context in which the PM 
retrieval is expected to take place (i.e. a very salient cue that will automatically remind 
the person of the target event). On the other hand, when it is perceived that spontaneous 
retrieval will be unlikely, the person tends to rely more on monitoring. The third 
assumption implies that spontaneous retrieval is more common than constant 
monitoring because of the cost implicated for the ongoing activities, which may 
negatively affect their performance during the retention interval, i.e. a few hours or days 
(McDaniel et al., 2007). 
 
McDaniel et al. (2007) claimed that monitoring can be identified as a self-regulatory 
behaviour with a limited capacity. According to Bargh and Chartrand (1999), this 
capacity is limited and quickly exhausted. As McDaniel et al. (2007) explained, 
exerting conscious self-regulatory behaviour for a task will affect people’s ability to 
expend conscious effort in a later stage, just as someone who runs a marathon on one 
day will not be able to run another one the following day, because their physical 
abilities are depleted. For that reason, it is believed that monitoring is not the preferred 
strategy, because it represents a cost for ongoing activities and it is difficult to maintain 
consistently over extended retention intervals (McDaniel et al., 2007). 
 
In the multiprocess theory,  
“the nature and demands of the ongoing task affect the degree of processing of 
the PM target event and thus determine the type of processes that support PM 
retrieval and the likelihood of PM success” (McDaniel et al., 2007). 
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Furthermore, when more effort is allocated to the ongoing task, PM is poorer, because it 
pulls resources away from processes needed to detect PM targets (McDaniel et al., 
2007).  
 
Another postulation essential to the multiprocess theory is that ongoing tasks that 
promote focal processing of the target event are more likely to lead to spontaneous 
retrieval. However, when this focal processing is absent, strategic monitoring of the 
environment for the target event takes place depending on the situation, and some tasks 
and activities are more demanding than others. Tasks and ongoing activities that are 
more demanding leave fewer resources available for strategic monitoring, which could 
be the cause of PM failures. The more someone engages in an ongoing activity, the less 
they think about PM tasks (McDaniel et al., 2007). 
 
More distinctive or salient target events produce better performance than less distinctive 
ones and cause spontaneous attention and automatic noticing. Salience of a target item 
can be the meaning of an activity, physical size of an item, how something is written, a 
geographic location, etc. Moreover, strong and weak associations between the target cue 
and the intended action play a role on PM performance. Target actions can be 
sometimes highly associated with the intended actions and sometimes not. When the 
association is strong, spontaneous retrieval takes place, and when it is weak, monitoring 
is the preferred behaviour (McDaniel et al., 2007). 
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4.7.3.1 Cues 
 
Good PM is necessary for efficient and effective everyday life functioning, such as 
carrying out social obligations (remembering to attend an engagement with a friend), 
managing household needs (paying bills) and accomplish work activities (remembering 
to finish your job) (Parker et al., 2011). It is more likely that PM failures take place 
when good cues are not available for spontaneous retrieval, and good PM takes place 
when the intended action depends on resource demanding monitoring processes (Parker 
et al., 2011; Einstein et al., 2005). According to Parker et al. (2011), successful PM 
retrieval depends on the relation between the ongoing task and the PM cues. 
Focal cues relate to those where ongoing task attention is directed to features of the cue 
or target event proceed at encoding. Presentation of the cue can trigger retrieval, even if 
monitoring is absent. An automatic spontaneous retrieval process can be initiated with 
the occurrence of the cue, bringing the intended action into awareness (Parker, 2011; 
Harrison et al., 2010; Scullin et al., 2010). Nonfocal cues are those in which attention of 
the ongoing task is directed away from the target. Remembering depends on monitoring 
processes, assumed by performance on the ongoing task. Monitoring is more likely to 
happen with nonfocal cues (Einstein et al., 2005; Parker et al., 2011). Nonfocal PM 
tasks are thought to require a larger effort. 
 
Current studies on PM have been trying to explain controversies between the different 
models of PM, particularly between those favouring strategic vs. automatic monitoring. 
Gilbert et al. (2012) developed a computational model in which PM reactions emerge 
from direct environmental triggering, meaning that some PM responses can be made in 
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the absence of strategic monitoring (Scullin et al., 2010). This view is consistent with 
the multiprocess framework proposed by McDaniel and Einstein (2000). 
 
On the other hand, more automatic responses can trigger PM cue recognition in the 
presence of the stimulus and in the absence of preparatory monitoring (Gilbert, 2012). 
In some circumstances, focal cues can lead to automatic PM, and nonfocal cues require 
monitoring (Gilbert, 2012; McDaniel & Einstein, 2013). Depending on the nature of the 
task, monitoring becomes more or less important according to the nature of the PM and 
ongoing task (Gilbert et al., 2012). 
For the propose of the current study, it is suggested that that chemo brain’s PM failures 
fall into the “multiprocess theory of prospective memory”, because this model considers 
the context, salience of the target, individual’s personalities, uniqueness of the tasks and 
spontaneous retrieval, as opposed to constant monitoring. It is important to consider that 
breast cancer patients face very particular circumstances. Their contexts become 
extremely transformed, even at the moment of diagnosis. Their physical bodies begin to 
change after surgery and during treatment. Each patient faces the illness in a very 
different manner according to their personalities and depending on the amount of their 
social support, and their focus and attention are directed towards survival, which 
becomes their main goal. In addition, their physical strengthen might prevent them from 
constant monitoring of the environment, because more effort has to be put on the 
ongoing tasks (treatment, survival), which might pull away the resources required for 
successful PM. 
 
4.7.3.2 Time-based and event-based PM tasks 
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It has also been suggested that PM is performed within two contexts: time-based and 
event-based PM. For time-based tasks, a certain period of time must elapse during the 
ongoing activity to perform the PM task, which relies on self-initiating monitoring 
behaviour, because no external cues in the environment are available to remind the 
subject of the intention and an action should be performed; therefore, the subject must 
self-monitor the environment to perform the intention in the absence of any cue in the 
environment. 
 
Event-based tasks are when a particular stimulus or event must occur while performing 
the ongoing activity to carry out the PM task, which relies on cue-dependent responses, 
depending more on spontaneous retrieval when the target event or intention is prompted 
by a cue found in the environment. For example, take the cookies out of the oven after 
20 minutes (time-based) or stop to buy the milk when you see the grocery shop (event-
based) (see McDaniel, 2007 for further reference). 
 
In the current study, these two last features of PM were analysed based on the 
CAMPROMPT test. It was hypothesized that time-based tasks would be more affected 
than event-based tasks as a result of cancer treatment. It was assumed that due to the 
demands of the cancer treatment itself and anxiety experienced by patients, self-
initiating monitoring would be more affected, and the absence of focal cues in the 
environment for time-based tasks would lead to missing the target events in breast 
cancer patients 
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4.7.3.3 Executive function, frontal lobes and PM 
 
Since it is believed that EF and PM are highly correlated (McDaniel et al., 2007; 
Kliegel et al., 2008), this section explains the role of EF in PM. Although this is only a 
small section within the chapter, it is important to stress that EF plays an important role 
in PM, because of the hypothesis that chemo brain is a PM failure, and therefore, it 
might also be considered as an EF dysfunction. If this hypothesis is correct, it would 
help with the diagnosis of chemo brain in the future and lead to the development of 
therapies that could help patients cope with the memory lapses that they might 
encounter.  
Some examples of why it is important to consider patients’ day-to-day lived experiences 
with quantitative research, followed by an explanation of WM and its relationship with 
PM and chemo brain, the main focus of this thesis, are discussed below. 
 
Memory lapses associated with PM in everyday life involve forgetting to realise an 
intended goal, plan or activity, such as forgetting to buy the milk on the way home, not 
passing on a message to a friend when meeting them or not attending an important 
medical appointment. Furthermore, lapses such as leaving the vacuum cleaner on, 
frequently misplacing things, forgetting to take medicine or, more dangerously, taking 
the medicine twice without even realising, losing track of a conversation and forgetting 
the usual route when driving are considered everyday life failures of PM associated with 
attention, some of which can have serious consequences for sufferers.  
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The rationale behind the assumption that EF is a part of PM performance relies on the 
evidence that the frontal lobes of the brain are involved in PM, particularly the PFC 
(Martin et al., 2003; Burgess et al., 2008), and that PM tasks depend on executive 
processes, including monitoring the environment, planning and attentional control 
(Kliegel et al., 2008). 
 
Some authors have found no association of PM failure and executive control and have 
attributed the PM impairment to automatic reflexive processes instead (Costa et al., 
2011). This discrepancy might be attributed to the fact that PM relies on the frontal 
lobes, but to various degrees, and depends on the PM task and/or the test being used. 
For instance, if the retrospective aspect of PM is being assessed, it is not expected to 
find frontal lobe involvement. Nonetheless, if complex self-initiating tasks are required, 
such as tasks demanding WM, planning, time tracking, inhibiting ongoing activities and 
when the environment has to be monitored to search for clues, frontal lobe involvement 
is required (Glisky, 1996). 
 
To successfully perform a planned intention in the future, multiple cognitive abilities 
are involved, such as organising how to execute that plan, remembering the plan for a 
period of time while other activities are taking place, monitoring when and how to 
execute the plan, followed by execution of the plan and remembering that the plan has 
already been carried out (van den Berg et al., 2012).  
 
An everyday example of PM in action is when someone is given a medical prescription 
that requires taking the medication every 12 hrs for the next three months. From the PM 
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literature point of view, the first thing they do is to organise the intention as to when to 
take the medication (e.g. every day, first thing in the morning and before going to bed). 
Every day they need to remember in the morning and at night that they must take the 
medication, and they must keep monitoring the time and/or cues that remind them to 
take the pill and inhibit any ongoing activity that may distract them and prevent the 
realisation of the action. They may look at the clock or look for cues in the environment 
that help them remember, such as at breakfast and dinner time. During the day, they will 
delay the intention and hold it in a higher activation state, so that they will not forget to 
take the pill. When they successfully execute the plan, they must also remember that 
they have already taken the medication, otherwise, they would be in the danger of 
taking the medication twice, putting their health and possibly life at risk (van den Berg 
et al., 2012). 
 
On the other hand, from the EF literature point of view, patients would have to initiate 
the behaviour. Firstly, by organising how they are going to execute the plan of taking 
the medication (problem-solving and organisation), they would have to select relevant 
goals to successfully execute the action (first thing in the morning and before going to 
bed, paired perhaps with breakfast and supper) and inhibit distractors that may prevent 
them from taking the medicine, such as leave the house in a hurry to go to the office. 
They would also have to keep monitoring for cues in the environment in order to 
remember to take the pills and evaluate their behaviour to remember that they took or 
have not yet taken the medicine. During the day, they would hold the information in 
mind, while performing daily activities, so as not to forget to execute the plan (Gioia et 
al., 2004). 
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In this simple example, it is possible to observe the active role that EF plays in PM by 
maintaining the activation level of mental representation of the intended plan. By 
holding the delayed intentions in a higher attentional state than other mental 
representations, they would more readily be retrieved for future intention, when the cue 
occurs (Goschle & Kuhl, 1993; Hadjiefthyvoulou, 2011). 
 
Further evidence that explains the association between PM and EF is that WM and 
inhibition take place when complex PM tasks are initiated and executed (Kiegel et al., 
2000; Hadjiefthyvoulou, 2011), for example, when attention is divided between an 
ongoing task and monitoring for cues in the environment that may lead to execution of 
the goal. 
 
Lapses of PM can also therefore be attributed to an EF deficit, and they can also help us 
understand the role of EF in PM. For instance, Mioni et al. (2012) reported that 
although healthy participants and TBI patients increased their monitoring frequency 
close to the target time, while performing a time-based PM task, TBI participants 
monitored more and were less accurate, confirming PM dysfunction. These authors 
explained that in time-based PM tasks, which are EFs, inhibition and updating are 
strongly involved (Mioni et al., 2012). 
 
4.7.3.4 Prospective memory in clinical populations  
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Studies from patients affected by brain injuries have shown that failure to execute 
intended actions are the most affected areas of cognitive deficits, and it is assumed that 
this is because TBI often involves PFC and/or medial temporal lobe damage, affecting 
both the prospective and retrospective components of PM (Kliegel et al., 2008), and 
although clinical research in the area of PM has been on the rise, it remains under 
examined. Despite the fact that at the beginning, most of the studies in the area focused 
on patients suffering from TBI, in recent years, the focus has shifted to other diseases. 
Additionally, it is essential to mention that this flourishing area of research is of extreme 
importance due to the fact that PM has been associated with treatment observance (Liu 
et al., 2004) and with taking medications (Woods et al., 2008; Scullin et al., 2013). 
 
In a study conducted by Costa et al. (2011), 24 participants with MCI and 24 healthy 
controls were recruited and tested with a lexical task and a neuropsychological battery 
to assess EFs in a 2x2 experimental design. They found that PM is severely impaired 
when compared to healthy controls; however, their findings suggested that reflexive 
automatic processes were taking place rather than executive control, and the authors 
argued that this finding might be because the task in question was a focal task, which is 
more reliant on reflexive-automatic mechanisms (McDaniel et al., 2004). 
 
Kant et al. (2014) investigated PM failure in stroke patients aiming to analyse the 
underlying processes of time-based or event-based PM within this population. In a study 
design using an experimental PM paradigm that resembled everyday functioning, a 
naturalist PM test and neuropsychological test battery that assess EF were used. They 
found that stroke patients (n = 39) performed significantly lower than their healthy 
156 
 
counterparts (n = 53), and that deficits in PM occurred as often as RM, more regularly 
than deficits in attention, and that diverse cognitive processes are involved in the 
different components of PM. They also found that monitoring was positively correlated 
with time-based PM (r = 0.64) (Kant et al., 2014). The importance of this study is that it 
was an attempt to systematically study a clinical population, and Kant et al. ( 2014)  
used a tool that claimed to be sensitive to detect PM failure (the Bourdon-Wiersma test, 
adapted to study PM) due to its naturalistic nature and deserves careful consideration. 
 
Anxiety has also been related to PM performance. Harris et al. (1999) explained that 
elevated state anxiety also affects PM, leading to a reduced PM performance, but not 
RM performance. These authors stated that “anxiety may interfere with capacity 
demanding cognitive tasks because of distracting thoughts (worry) associated with state 
anxiety competing for limited resources”. This suggests that the detrimental effects of 
anxiety on cognition would be higher in tasks with high demands for WM capacity. 
Where continuous monitoring is required, such as event-based PM tasks, concurrent 
WM overload takes place and WM resources are diverted to allow continuous and 
sustained monitoring. The conclusion of this work was that PM may be sensitive to 
anxiety. These findings suggest that elevated state anxiety was correlated with poorer 
performance in PM tasks, but not with RM, and that although anxiety affects PM 
performance, it is not related to WM capacity (Harris et al., 2003).  
 
Furthermore, PM impairment has also been associated with HIV (Doyle et al., 2013), 
schizophrenia (Ordermann et al., 2014), depression, Parkinson’s disease (Kliegel, 
2011), mild dementia (Costa et al., 2011), autism (Henry et al., 2014), hypertension 
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(Scullin et al., 2013), multiple sclerosis (Thelen et al., 2014), pulmonary diseases 
(Witkowska, 2011), cardiac disease (Habota et al., 2013) and breast cancer (Paquet et 
al., 2013). 
 
Another line of research that is receiving increasing attention in this area is sleep, which 
is relevant to this research because sleep has also been studied within the context of 
chemo brain. Therefore, a sleep analysis was conducted with the sample in this study to 
observe if poor sleep has a deleterious effect on breast cancer patients’ PM. 
 
4.7.4 Prospective memory in the context of chemo brain 
 
An area of study that has been neglected by PM researchers is related to cognitive 
impairment in the cancer population. To date, there are only a handful of publications 
that have directed attention to this subject. Paquet et al. (2013) reported that PM deficit 
and fatigue were seen as the major contributors to increased cognitive decline in breast 
cancer patients on the MIST when compared with healthy controls. In their study, they 
found that the breast cancer group showed significantly lower scores on PM than 
controls t (79) = −3.51, p = 0.001, Cohen d = −0.80, and that 23% of the patients had 
PM impairment as opposed to 5% in controls. Additionally, Mihuta et al. (2012) used a 
virtual reality assessment to test PM on breast cancer survivors. Their preliminary 
results showed that the breast cancer group exhibited significantly more cognitive 
deficits than controls, and that PM experimental tasks correlate with neuropsychological 
assessments and self-reports of PM. They confirmed that PM deficits were present in 
breast cancer patients after undergoing chemotherapy. 
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Cheng et al. (2013) have also recently investigated PM in breast cancer patients in a 
cross-sectional study, in a sample of 40 breast cancer patients and 40 matched controls, 
using a battery of neuropsychological tests that include assessment of verbal fluency, 
time-spatial orientation, STM and digit span, paired with event-based (word selection 
task) and time-based PM (number selection tasks) tasks. Their findings suggest that 
there are significant memory deficits in event-based PM but not in time-based PM on 
breast cancer patients who have recently finished treatment compared to controls. A 
limitation of this study is that it is cross-sectional in nature, and no baseline assessment 
was provided. 
 
A matter of concern is that studies on chemo brain have shown inconsistent reports with 
neuropsychological tests, which is evident from PM literature. Burgess (2001) stated 
that “a clinical mystery in neurology” (Mesulam’s frontal lobe mystery) within the 
context of PM is that some patients who had suffered frontal lobe damage could present 
no abnormality in behaviour in the clinic or in test performance on neuropsychological 
measures, yet suffered from some sort of severe disability in everyday life situations 
(Burgess et al., 2009, referenced in Shallice et al., 1991). Such discrepancies have led 
researchers to investigate the areas of the brain that are affected when patients suffer 
from frontal lobe damage while they take PM tasks. 
 
Interestingly, studies in the area of chemo brain have shown similar discrepancies, in 
which neuropsychological tests do not show impairment on the tests results despite 
patients reporting significant impairment in their daily routines (Burgess et al., 2009). 
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These sorts of discrepancies are not surprising. In the famous case of EVR reported by 
Eslinger and Damasio (1985), they found that despite the fact that EVR had undergone 
removal of a bilateral frontal meningioma, extensive neuropsychological assessment did 
not find deficits in cognition. On the contrary, EVR scores were superior or above 
average. However, his everyday life was completely disrupted, as EVR was unable to 
make simple decisions and his personality changed in a completely negative way. 
Elinger et al. (1985) identified EVR’s problems as failure of PM, because he lost the 
ability to encode delayed intentions and to act on those intentions at the appropriate time 
(Burgess et al., 2009). One of the most important findings of Elinger et al. (1985) was 
that they could empirically demonstrate the discrepancies in the everyday behavioural 
disorganization test, believed to be sensitive to detect deficits in frontal lobe EFs 
(Burgess, 2009).  
 
Shallice and Burgess (1991) continued with this line of study and reported the case of 
AP, who had an open head injury in a traffic accident, had the rostral prefrontal cortex 
(RPC) completely removed and also had a damage to the surrounding regions. 
However, despite this, AP did not show neuropsychological impairment in measures of 
intelligence, perception or EF, but performed in the above average range. However, AP 
did show impairment in experimental measures of PM and multitasking, such as 
tardiness and disorganisation, and performed below the 5% level compared with IQ 
matched controls. In real life situations, these results show that people with problems 
with PM find themselves having to go to the shop more than once to buy items that 
could have all been bought in one visit, and they also forget to carry out tasks that they 
needed to or to follow procedures or instructions (Burgess et al., 2009). This kind of 
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behavioural disorganisation was named by Shallice and Burgess (1991) as “Strategy 
Application Disorder” (Further examples following this line of research is presented in 
the qualitative part of this thesis).  
 
Burgess (2009) concluded that “traditional methods of assessing cognitive deficits 
following frontal lobe damage typically do not measure the full range of deficits that 
can occur, particularly those involving rostral prefrontal cortex” and that successful 
performance in well standardised neuropsychological tests cannot always be taken as 
evidence of unimpaired multitasking abilities, such as those found in PM failure (See 
Shallice & Burgess, 1991 for further examples). 
 
In this study, it is not suggested that chemo brain patients have the same magnitude of 
frontal lobe damage as the cases presented above, but it is hypothesized that their 
cognitive problems are related to those presented in frontal lobe damage or more 
specifically, of PM, because neuropsychological assessment fails to detect such 
impairments. It is for this reason that the author wants to emphasize the importance of 
considering the use of mixed methods studies in which patient’s day-to-day life 
experiences are taken into account, in order to provide suitable care and help while 
learning coping strategies related to chemo brain. 
 
The Shallice and Burgess (1991) studies presented above might explain why some 
authors report no cognitive decline in their samples. However, this does not mean that 
the problem does not exist or that it is driven by patient’s expectations or suggestions, 
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but that neuropsychological assessment measures do not include features that resemble 
everyday life situations (domestic or work related) (Burgess et al., 2009). 
 
Experimental tests presented to assess PM, such as those used by Shallice and Burgess, 
have made successful attempts to include situations presented in everyday life, such as 
doing errands in a shopping mall (Multiple Errands t-Test) and time-based situations 
(Six Element Test) (Shallice et al., 1991). The author believes that the 
neuropsychological battery CAMPROMPT includes features that make the assessment 
of PM similar to everyday life situations. 
 
This study aims to analyse if CAMPROMPT is a more sensitive measure of PM and to 
analyse case studies to compare neuropsychological assessment of EF vs. patients’ 
experiences with chemo brain through PM self-reports and interviews in a mixed design 
study. 
 
Considering the failure of neuropsychological tests to detect EF deficits in patients who 
have suffered extensive frontal lobe damage, even though they present severe PM 
impairment in everyday life situations, it is not surprising that the literature on the study 
of chemo brain has not always validated the deficits reported by patients. For this 
reason, the problem has sometimes failed to be recognised as such, leaving patients 
frustrated and with no confirmation of their impairment (Scherling et al., 2013). As a 
result, patients do not receive enough information and support when they receive cancer 
treatment and start reporting cognitive deficits. 
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According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition 
(DSM-5), diagnostic criteria, patients are diagnosed with mild neurocognitive disorder 
(MND) when there is evidence of modest cognitive decline from a previous level of 
performance in one or more cognitive domains, including EF, learning and memory, 
based on a concern of the individual, a knowledgeable informant or the clinician that 
there is a mild decline in cognitive function. A modest impairment in cognitive 
performance either by standardised tests or quantified clinical assessment; the cognitive 
deficits do not interfere with independence on daily activities, although there may be 
subtle interference with function or report that tasks require more effort or take more 
time than previously.  
 
Anecdotal reports from breast cancer patients show that few patients stop driving or quit 
their jobs as a result of the cognitive decline experienced after chemotherapy, and a lot 
more effort has to be put in tasks that were very easy to accomplish before treatment 
(Silverman et al., 2009), and despite some inconsistencies in the literature, there is 
scientific evidence that this mild neurocognitive impairment exists and that it is 
significantly affecting patient’s quality of life (Deprez et al., 2012; Sherling et al., 2013; 
Koppelmans et al., 2011). 
 
4.7.5 Neuropsychological assessments of PM 
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There are only a handful of tests that can be used to measure PM within clinical 
populations that have been specifically designed to assess PM or that include a PM 
aspect in them. Such tests are the Rivermead Behavioural Test (RBMT) (Wilson et al., 
1985), which includes two items of PM and has been used with MCI patients, “patients 
involved in substance abuse and neuropsychologically impaired patients. The drawback 
of this test is that it does not provide a standardised score and only offers a score of the 
overall memory impairment (Thone-Otto et al., 2008). 
 
Another measure designed for the specific assessment of PM is the MIST. This test 
consists of eight PM tasks divided into four time-based and four event-based tasks. 
However, the tasks are not evenly distributed in the type of responses and, 
consequently, there are three time-based tasks requiring a verbal response and only one 
requiring an action response. 
 
The other measure that has been developed to measure PM is the CAMPROMPT. This 
was the first standardised test that is ecologically valid, specifically designed to measure 
PM (Wilson et al., 2005). The CAMPROMPT will be discussed further later in this 
work, because it was the measure of choice for this research. 
 
Other tests that include a PM aspect are Test Everyday Attention (TEA) (Robertson et 
al., 1994) and the Behavioural Assessment of Dysexecutive Syndrome (BADS) 
(Wilson, 1996). Currently, an experimental paradigm is under way to assess everyday 
living PM, which has been used in clinical population, such as in breast cancer patients 
(Green et al., 2011). 
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4.7.6 The CAMPROMPT test battery 
 
According to Gioia et al. (2004), there is no single measure for the assessment of EF, 
and the assessment has largely relied on laboratory or clinical conditions, which, lacking 
ecological validity, do not reflect real life situations. The term ecologically valid refers 
to the ability to generalise results of controlled laboratory conditions to naturally 
occurring events in real life situations. Therefore, an ecologically valid measure is one 
that reflects situations similar to naturally occurring events and behaviours and are valid 
for predicting everyday behaviour. 
 
In the selection of tools for the assessment of PM in this study, the CAMPROMPT test 
was chosen because it attempts to overcome problems of ecological validity and 
contains a balance between time-based and event-based PM assessment that are in line 
with the theoretical model proposed by McDaniel et al. (2002). The authors of the test 
designed testing conditions that resemble demands in everyday life, such as giving a 
message when a certain event happens and remembering to give a set of keys to the 
researcher at a certain time, while they are working on distractor tasks. Another reason 
for deciding to use CAMPROMPT and a neuropsychological battery was because it was 
believed that it would be more convenient to use them with a clinical population, 
particularly with recently diagnosed breast cancer patients. Furthermore, although there 
is evidence of the validity of many PM paradigms, such tasks take too long and are too 
complicated to administer, and an important aspect of this work was to disturb patients 
as little as possible using less demanding tasks. The most viable possibilities for NHS 
165 
 
ethics approval were also taken into consideration, and therefore, a neuropsychological 
battery was considered more likely to receive approval. When making these decisions, 
the least intrusive strategy was chosen, particularly because it was difficult to reach the 
population and because of the difficult circumstances the patients were experiencing at 
that moment in their lives. 
 
To better understand what is happening with PM processes in chemo brain patients’ 
daily lives, the hypothesis was that CAMPROMPT was a more sensitive as well as a 
more valid measure to detect the MCI reported by some cancer patients. Therefore, it 
was expected that cognitive decline in attention would be detected using this battery and 
that the healthy controls would perform better than the cancer group, due to the fact that 
they were not under the influence of cancer treatment. A decline in attention was 
expected in patients receiving cancer treatment, but not in healthy participants.  
 
The CAMPROMPT was developed by Wilson and Watson (2005) as a result of an 
increased interest in PM (Shimamura et al., 1991; McDaniel, 1996) and from the 
realisation that there was very little transfer to the clinical setting; therefore, no clinical 
benefit was being obtained from experimental studies that studied PM (Wilson et al., 
2005). Wilson and Watson concluded that in the area of neuropsychology, no formal 
assessment measure existed for PM.; although the RBMT included three PM items, it 
only included event tasks, failing to provide a comprehensive assessment of PM 
(Wilson et al., 1985). 
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PM failure can occur due to several reasons such as attentional difficulties, EF deficits, 
such as planning and organisational problems (Wilson et al., 1996), which lead people 
to have problems with organising and initiating the appropriate behaviour at the 
appropriate time. The lack of standardised test led this team to develop a tool for the 
assessment of PM to suit the clinical need to identify PM failures. 
 
They defined PM deficits as a “failure to do things at the right time, or within a certain 
interval or when a particular event occurs” and tried to make the test items comparable 
to everyday life experiences (Wilson et al., 2005). 
 
4.7.7 Description of the test 
 
In this test, examinees were asked to work on several distractor tasks (paper and pencil). 
These tasks consisted of answering quizzes and puzzles during a period of 25 minutes. 
While they were working on the tasks, they were instructed to remember to do other 
tasks, such as reminding the examiner of something, or for them to remember to do 
something, either during or after the session. 
Examinees were required to perform three event-based tasks and three time-based tasks. 
The time interval between instructions and actions is balanced across conditions. There 
were two parallel versions of the test (A and B) with different materials for each 
version. A minimum of six weeks passed between each testing session. 
 
4.7.7.1 Time-based tasks 
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These three tasks were cued by a kitchen timer and a clock. One time-based task 
consisted of giving the instruction to remind the tester to ring the garage/reception. The 
task should be carried out 20 minutes after the instruction was given, at the end of the 
distractor period. The cue came from a clock. Another time-based task was to remind 
the examiner not to forget the keys/cup, with a time interval of 13 minutes. The last task 
consisted of changing the task/pen with a time interval of seven minutes. 
 
4.7.7.2 Event-based tasks 
 
One event-based task was to remind the tester about five objects that were hidden at the 
start of the session. The time interval was cued by the beeper going off and by a prompt, 
with 20 minutes between the instruction and the cue “we have finished this test”. The 
other event-based task consisted of giving a book/map to the examiner when they come 
to a quiz question about EastEnders/Coronation Street. The time interval was seven 
minutes. The last event-based interval was to give the tester a message in an envelope at 
an interval of 13 minutes. The cue was when the tester said “there are five minutes left”. 
Depending on whether the examinee performed the right action, the tester responded as 
follows: 
1. If the response occurred at the right time, the examiner informed the examinee that 
it was the correct response and timing. If it was the wrong action, the tester 
prompted the examinee that she had to do something, and if there is no correct 
168 
 
response, the tester informed the examinee that it was not the right action and 
reminded her which one was correct. 
 
2. When there was no response at the expected time, the tester waited for one minute 
following the question or for 15 seconds depending on the task, and then prompted 
the examinee by reminding her that she was going to do something when the 
specified time/event cue took place, followed by prompts or assurance, depending 
on the response. 
3. When there was no response at the correct time even after the prompts, the tester 
prompted again and said “good” if the correct action was performed or “don’t 
worry” if no correct action was performed. 
 
4.7.7.3 Classification 
 
The CAMPROMPT test classifies test score results into six categories: impaired, poor, 
borderline, good, above average and very good. In this study, the categories impaired, 
poor and borderline were classified as being Below Average, with good, above average 
and very good classified as Above Average. 
 
The distractor tasks or ongoing activities consisted of various quizzes and puzzles. They 
ranged from very difficult to easy, verbal and non-verbal. They involved puzzles, word 
search, shapes, scrambled words, word squares, general knowledge, famous people, 
sentence checking, spot the difference, mazes and join the dots. Participants were 
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advised to change to another task if they had difficulty with a particular task or if they 
were not enjoying it. These tasks were designed to keep participants distracted for 20 
minutes. Quiz questions were handed out on separate sheets 13 minutes into the testing 
session. 
 
The interrater reliability of the CAMPROMPT according to Wilson (2005) is r = 0.998 
(correlation coefficient). The test-retest reliability is 0.64 (Kendall’s Tau-b) between 
performances of the test (Wilson et al., 2005). Validity and reliability of the test have 
also been reported by Kliegel et al. (2008). 
 
The CAMPROMPT test has previously been used in studies related to substance and 
tobacco abuse (Hadjiefthyvoulou et al., 2011; Heffernan & O’Neill, 2012). None of 
these studies used the test more than once, but their findings confirm that it is a valid 
measure for PM.   
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CHAPTER FIVE 
5 QUANTITATIVE METHODS 
 
5.1 Aims and objectives 
 
The literature on chemo brain has demonstrated that there is subtle cognitive 
impairment in some breast cancer patients subjected to chemotherapy. It remains 
unknown which are the mechanisms underlying this phenomenon. More sensitive 
memory measures are needed to better understand the MCI as a by-product of 
chemotherapy, known as chemo brain. 
 
In this study, we aimed to identify whether PM and WM along with quality of sleep and 
sleepiness during the day are underlying factors of the so-called chemo brain experience 
reported by cancer survivors who received chemotherapy treatment and completed it 
successfully. It is hypothesized that cognitive deficits on breast cancer patients are due 
to PM and WM impairment, and PM being an attentional process, we hypothesized that 
chemo brain is an attentional deficit.  
 
To date, most of the studies have focused on neuropsychological assessment and in 
general, on cognitive performance in those assessments. A specific study on memory, 
particularly on PM and WM in cancer patients who experience chemo brain, is proposed 
in this study, in order to better understand what is happening with memory processes in 
the daily lives of patients.  
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For this purpose, MCI, decline in attention, impairment in retrieval of words, memory 
and visual memory, sleepiness and sleep efficiency were measured using the following 
criteria and hypotheses: 
 
1. A decline in attention on these two interrelated aspects of memory was expected in 
patients receiving cancer treatment and no decline in healthy participants. PM and 
WM were tested by using the CAMPROMPT, Digit Span (Forward and Backwards) 
tests (Wechsler, 1997, 2008) and digit symbol tests (Wechsler, 1997). It was 
hypothesized that CAMPROMPT (Wilson et al., 2005) was a more sensitive as well 
as a more valid measure to detect the MCI reported by some cancer patients. 
 
2. Anecdotal accounts showed that one of the most common complaints chemotherapy 
patients report is that they have difficulty retrieving common words; therefore, it 
was hypothesized that participants would show a decline in their test results from 
COWAT, which assesses verbal communication deficits and evaluates spontaneous 
production of words compared to a baseline, with more decline in the cancer group 
and no decline in the healthy group. 
 
 
3. The BVRT was used to analyse memory and visual memory. It was hypothesized 
that the chemotherapy group would have shown more decline in this test results than 
the non-chemotherapy group, and no decline was expected for the healthy group 
(Benton, 1996). 
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4. A possible cause of the cognitive deficits may be sleepiness, which alters attentional 
process as a consequence of sleep loss triggered by anxiety and treatment; therefore, 
we hypothesized that alteration of sleep patterns during the course of cancer 
treatment caused sleepiness, impairing PM and WM. Sleepiness was evaluated by 
the subjective measurement Epworth Sleepiness Scale (ESS) (Johns, 1991). It was 
hypothesized that participants undergoing cancer treatment would report more 
daytime sleepiness than the other group.  
 
5. Factors such as anxiety, depression, chemical toxicity, hormonal treatments for 
cancer and menopausal status of the patients represent confounding variables of the 
study, and it was aimed to control them by matching participants with the healthy 
groups. It was hypothesized that the chemotherapy group would show the highest 
rates of impairment on these measures than the healthy group. 
 
Sleep efficiency was observed to further analyse sleep impairment using a SenseWear® 
Armband (SWA) multi-sensor activity monitor. It was hypothesized that more 
impairment on sleep efficiency would be found on the chemotherapy group as a 
consequence of altered sleep patterns and no significant impairment in the healthy group. 
It was expected that self-reports from the Pittsburgh Sleep Quality Index (PSQI) 
(Buysse et al., 1989) would show a correlation with results obtained from the SWA in 
the two groups, with no sleep disturbances for the healthy group and more sleep 
disturbances for the cancer group. 
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To summarise, it was hypothesized that breast cancer patients would develop 
prospective and WM impairment as a consequence of sleepiness and attentional decline 
caused by altered sleep patterns. This impairment may last for many years after 
completing their treatment. For the healthy control group, a significant difference 
between PM and WM cognitive impairment was not expected. However, some decline 
would be found due to menopausal status or hormonal, non-chemotherapeutic treatment. 
To control for this potential risk factor, we would be matching patients according to 
their age and menopausal status. 
 
It is important to highlight that although this study observed sleep and sleepiness, it was 
not the aim of the researcher to make comprehensive analyses of such biological factors, 
but merely observe if changes in such factors may or may not have had an effect on 
memory process, specifically, WM and PM during and after the course of cancer 
treatment; therefore, only raw data obtained from those measures were considered for 
analysis in this study. 
 
In summary, the aims of this part of the project were to 
1. Analyse only one aspect of the cognitive domain (as opposed to the general 
cognitive domain), by analysing EF, including PM and WM. This would be 
achieved by using a neuropsychological battery targeted specifically to assess WM 
according to the Baddeley (2000) WM model and a specific battery that assessed 
PM. By doing so, it was hoped to be able to identify whether the CAMPROMPT 
was more sensitive to the mild cognitive changes presented in chemo brain patients. 
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2. Control for potential confounding variables (i.e. depression, anxiety, hormonal 
changes, variety of chemotherapy treatments, demographic information), by 
recruiting and matching a group of cancer patients not receiving chemotherapy and a 
group of healthy participants.  
 
3. Identify if changes that occur as a consequence of cancer treatment on biological 
factors such as sleep and sleepiness had an effect on memory processes, causing 
impairments in WM and PM. These were analysed by assessing sleep activity (SWA 
and sleep quality scale) and sleepiness during the day (ESS sleepiness scale). 
 
 
4. Control for practice effects that could happen as a consequence of taking the same 
tests several times. This was controlled by using alternate forms of the tests and the 
healthy group. 
 
5.2 Recruitment 
 
After receiving ethics approval from NHS REC Ethics Committee Southampton A 
(IRAS) and from research and development (R&D) from each NHS trust where 
recruitment and testing took place and from Bournemouth University ethics committee, 
an invitation to participate in the project was provided to patients and healthy controls 
who met the inclusion criteria. Cancer patients were identified by clinicians, oncology 
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support nurses, breast cancer care nurses and at oncology team meetings at 
Bournemouth and Poole hospitals and Dorset County and Weymouth Hospitals. 
 
5.2.1 Cancer patients (PT) 
 
As required by NHS ethics procedures, members of the staff at the hospital extended 
letters of invitation to patients to participate in a study to test their memory during 
cancer treatment. If patients were interested in the study, they were invited to talk to the 
principal investigator (PI) to receive further explanation about the project. They were 
provided with an Information Sheet for Participants, which expanded on the 
implications of the study. If they agreed to participate, PI took consent and provided the 
self-report questionnaires. 
 
Most of the cancer participants were tested the day of their pre-treatment assessment to 
avoid an extra visits to the hospital, and healthy controls were either tested at the 
hospital or at the university. 
 
Ninety-three patients were invited and 62 agreed to take part in the study. Two cancer 
participants cancelled on the day of testing and another six cancer participants withdrew 
after measuring the baseline and were excluded from the study. Most of the 28 cancer 
participants underwent both chemotherapy and radiotherapy (n = 19), while the others 
only received radiotherapy treatment (n = 9). 
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All cancer participants underwent surgery before chemotherapy or radiotherapy and 
received additional adjuvant hormonal treatment before and during testing. They were 
tested before commencing chemotherapy or radiotherapy (baseline). All chemotherapy 
participants received the standard treatment of six cycles over a period of four months. 
One of those participants discontinued her treatment in the middle of the cycles, but 
decided to continue with our testing sessions. Radiotherapy-only participants received 
three-week radiotherapy treatment. 
 
The patient group consisted of 19 participants undergoing chemotherapy and adjuvant 
treatment (n = 19) and nine participants undergoing radiotherapy and adjuvant treatment. 
 
5.2.2 Healthy control group (HC) 
 
A convenience sample of 28 women from Bournemouth University and from 
Bournemouth and Poole hospitals as well as from Dorset County NHS trusts was 
recruited to be a part of the healthy control (HC) group. The study was advertised 
around the hospitals and at the university. 
 
5.2.3 Inclusion criteria 
 
For cancer patients: being recently diagnosed with early breast cancer, scheduled to 
begin cancer treatment and no previous history of cancer treatment.  
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For the healthy controls: no previous history of cancer treatment. Due to the nature of 
the tests, English language proficiency was required for all the participants.  
 
5.2.4 Exclusion criteria 
 
Patients with previous history of cancer and/or chemotherapy could not be invited to 
take part in the study. Patients who had been previously diagnosed with some sort of 
cognitive impairment, mental problem, dementia, brain injury and mood or anxiety 
disorders were also excluded. 
 
Participants were 98% British, with one cancer patient from Portugal and one healthy 
control each from Slovakia and Peru. All participants were proficient in the English 
language and well-educated (98% went to secondary school or above). The Intelligence 
Coefficient (IQ) mean FIQ ( Full IQ) scores on the NART test for PT group was 118 
and 113 for HC. Eighty two percent of participants were in employment, while 64% 
were menopausal. Since alcohol or substance abuse affect cognition, participants were 
asked if they drank alcohol. None of the participants said they were heavy drinkers. 
 
5.2.5 Amendments to the recruitment process 
 
During this study, seven amendments had to be made to change recruitment strategies 
such as adding a research site, change typo errors in invitation letters and participant 
information sheet details, changes in advertisement strategies to improve recruitment, 
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add collaborators, change questions to background information and make changes in the 
protocol, such as requesting authorization for a qualitative study. Each process of 
amendment took between 35 and 60 days to complete and involved liaising with R&D 
departments from each NHS trust and with the National Research Ethics service (NRES) 
in the UK. Although necessary and efficient, the processes required by the ethics 
committee within the NHS represented a major drawback to the study, particularly 
because they are extremely time consuming and affected recruitment and testing 
schedules. 
 
5.2.6 Testing schedule  
 
Of the cancer group, 28 participants (100%) were tested two times: 
1. Baseline (start of treatment) (Test one). 
2. Eight weeks after baseline (before fourth cycle of chemotherapy), in the middle of 
their treatment (mid-treatment) (Test two). 
 
Twenty six patients were tested for the third time after their treatment was completed: 
during their post-chemo assessment (approximately three weeks after finishing their 
treatment (post-treatment) (Test three). Thirteen patients were tested six months after 
treatment for the fourth time (Test four). Test results for stage 3 and 4 were used for 
qualitative analyses. 
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The cancer patients who did not undergo chemotherapy treatment as well as the healthy 
controls were tested for the second time, six weeks after baseline. 
 
5.3 Procedure 
 
All the participants were screened for a history of any mental illness that may be 
altering cognition and may affect test results. The HADS was used at baseline and 
before every testing session. None of them showed abnormal levels of anxiety or 
depression, and no other significant history of mental illness was reported. 
 
Participants who agreed to participate and met the inclusion criteria were scheduled for 
testing sessions and were provided with the sleep monitor SWA multi-sensor activity 
monitor, the HADS questionnaire and subjective measures of sleep (PSQI and ESS) to 
complete at their convenience one week before the testing session. Testing sessions for 
cancer patients were often conducted the same day before their chemotherapy treatment, 
in order to avoid extra visits to the hospital. For the healthy controls, testing sessions 
were conducted at the hospital or at the university at their convenience.  
For each testing session, participants were asked about any change in their medical 
condition.  
 
The researcher was not provided a particular room to test participants, and therefore the 
testing rooms were usually different from session to session, and this study could not 
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account for controlling the environment at testing sessions, although all sessions were 
conducted in a quiet room specifically reserved for that purpose. 
 
5.4 Measures 
The order of the test was the same for each participant across conditions. The battery 
was composed of six standardised neuropsychological tests and three self-reports. Self-
reports to assess sleep, anxiety and depression were conducted at home, and the 
neuropsychological tests took place at the hospitals and at the university. The duration 
was about 45–50 minutes. Additionally, a SWA monitor was delivered to record 
measured sleep for four days and nights. 
 
To control for practice effects, different versions of the tests were used that provided 
alternate versions. For CAMPROMPT, versions A and B were used for the first and 
second time, respectively, only for a subset of participants to take part in the qualitative 
aspect of this study. For the Digit Span tests, Wechsler versions III and IV were used. 
For the BVRT, versions D, C and E were used, with version D repeated for the fourth 
test. The Digit Symbol and COWAT tests do not provide alternate versions; hence, the 
same version was used every time.  
 
CAMPROMPT Scoring 
Each response was recorded according to the values given in the record form. The 
responses were categorised using letters A to H and they translated into marks of 6, 4, 2, 
1 or 0 and were assigned to time tasks (CAMPROMPT TIME) or to event tasks 
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(CAMPROMPT EVENT). The sum of the scores gave the CAMPROMPT total score. 
The developers of the test classify tests takers into five categories according to their 
total score compared to a normative sample into Poor, Borderline, Average, Above 
Average and Very Good. In the current study, in order to simplify our analysis, we 
subcategorised Poor and Borderline as Below Average (BA), and Above Average and 
Very Good as Above Average (AA), using a cross tabulation analysis. 
 
The distractor tasks consisted of various quizzes and puzzles. They ranged from very 
difficult to easy, verbal and non-verbal. And they involved puzzles, word search, shapes, 
scrambled words, word squares, general knowledge, famous people, sentences checking, 
spot differences, maze, and join the dots. Participants were advised to change the task if 
they were finding it difficult or if they were not enjoying it. These tasks should have 
kept participants distracted for 20 minutes. Quiz questions were handed out on separate 
sheets, 13 minutes into the testing session.  
 
Version A and B of the tests presented equivalent but different distractor tasks, and the 
commands given by the instructions were slightly different for each version. For 
example, on version A of the tests, participants were instructed to give the researcher a 
book or a mug, depending on the test version, or give a response when they found a 
question about East Enders or Coronation Street. 
 
The interrater reliability of the CAMPROMPT according to the authors is 0.998 
(correlation coefficient). The test-retest reliability was 0.64 (Kendall’s Tau-b) between 
performances of the test (Wilson et al., 2005). 
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5.5.2 Digit symbol test 
 
This test is a subtest of the Wechsler test (WAIS-III), which consists of four rows 
containing 100 small pair of squares, one containing a number from 1 to 9 and the other 
one blank (Wechsler, 1997). Above these rows, there is a key that matches each number 
with a symbol. After a practice trial, the individuals are instructed to fill in the blank 
spaces with the symbol that corresponds to the number above the blank space as quickly 
as they can, without making any mistakes and without skipping any space. They are 
given 120 seconds to do this task. The score is the number of squares filled correctly 
(Lezak, 1983). 
 
The Digit Symbol test intends to determine which skills are deficient if the performance 
is poor; it assesses the ability to learn unfamiliar tasks, it involves speed and accuracy of 
visual motor coordination, speed of mental operation (processing speed), attentional 
skills, visual acuity, visual scanning and tracking, STM for new learning, cognitive 
flexibility (in shifting rapidly from one pair to another), handwriting speed and possibly 
motivation. This test is sensitive to visuo-perceptual difficulties (Sattler, 2001). 
 
The test also measures the ability to learn combinations of numbers and symbols and the 
ability to make associations quickly and accurately. Speed and accuracy are a measure 
of intellectual ability; therefore, this test is an information processing task. This involves 
discrimination and memorisation of visual pattern symbols. It is a reliable subtest (rxx = 
0.84) with reliability above 0.81 at all age groups. 
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It is useful for evaluating the attention of individuals, when attentional difficulties are 
suspected. If the examinee has an adequate speed and visual acuity, poor scores indicate 
attention deficits and not visual perceptive problems. A slow and deliberate approach 
may indicate depression. The distortion of forms may indicate perceptual difficulties. 
Low scores may indicate visual-motor coordination difficulties, distractibility, anxiety, 
visual defects, poor pencil control, poor motivation, excessive concern for detail, 
lethargy, boredom, impulsivity (Sattler, 2001). 
 
We consider that this test was relevant for the study of chemo brain, because it reports 
qualitatively the inability to learn new tasks (Silverman, 2009). Some other patients 
complain about visual problems, and PM may be related to missing cues in the 
environment, which may lead to attentional PM problem. 
 
5.5.3 Digit span test 
 
The Digit Span test is a measure of short-term sequential auditory memory and attention. 
This is a subtest of the WAIS–IV (Wechsler, 2008) test, and it is divided into two parts, 
digits forwards and digits backwards. To obtain the digit span score, the sum total of the 
points in each test is calculated.  
 
The Digits Forward subtest is formed of a series of numbers from two to nine digits and 
digits backwards from two to eight digits. The examinee listens to a series of digits 
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given orally by the tester and then repeats the digits. There are two sets of digits of each 
length. The test is discontinued after the examinee gets a score of 0 in the same set. 
Each series counts one point, and each set has two series. 
 
Each of the tests involves different mental activities, which are affected differently by 
brain damage. Both the tests consist of seven pairs of number sequences, and the 
examiner reads aloud at the rate of one digit per second. Both the tests involve auditory 
attention. 
 
This test is relevant for this study, since digits forwards is involved with planning ability, 
related to PM and WM, and it is a measure of attention affecting PM. It assesses the 
ability to retain several elements, which have no logical relationship with one another 
and sequencing skills. It can be negatively affected by anxiety. It involves rote learning 
and memory (Sattler, 2001). 
 
The digits backwards test involves transformation of the stimulus previous to 
responding, i.e. the sequence is mentally manipulated before restating it. High scores 
may indicate flexibility, good tolerance for stress and excellent concentration. It 
requires more complex processing than digits forwards and involves planning ability 
and sequential processing, providing some insight for WM, which was one of the areas 
of study of this research. It may involve abilities to make mental images and scan 
internal visual display formed from an auditory stimulus (Sattler, 2001). 
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According to Lezak (1983), the simplest of mental tracking is digit span, which tests 
how many bits of information a person can attend to at once and repeat in order. The 
role of visual scanning in conceptual tracking demonstrates the scanning eye 
movements presented while performing conceptual tracking tasks, such as digits 
backwards (Weinberg et al., 1972). Tracking tasks require to track two or more stimuli 
or associated ideas simultaneously, called double or multiple tracking behaviour (Lezak, 
1983). This is important because this multiple tracking most likely to fail when there is 
brain damage. Furthermore, Lezak (1983) explained that 
 
“the disturbance appears as difficulty in keeping two or more lines of thought in 
a cocktail party conversation, in solving two or three number addition or 
problem, or multiplication problems mentally, or in remembering one thing 
while doing another.” 
 
The reliability of the test is rxx = 0.90 with reliability coefficients at or above 0.84 for 
all age groups. Low scores on digits backwards may indicate anxiety, inattention, 
distractibility, a possible learning deficit, difficulty in auditory sequential processing, 
poor short-term auditory memory, boredom, difficulty in shifting, impaired hearing and 
negativism. 
 
5.5.4 Controlled oral word association test (COWAT) 
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Lezak (1983) stated that following brain injury, changes in speed and verbal production 
may be experienced, which does not necessarily mean the presence of aphasia. This 
verbal impairment fluency is also associated with frontal lobe damage, particularly the 
left frontal lobe anterior to Broca’s area. This fluency problem can be seen in speech, 
reading and writing (Lezak, 1983). 
 
This test is relevant to this study, since patients experiencing chemo brain complain of 
having difficulty in retrieving words; although they preserve the mental image of what 
they want to say, they do not have the word for what they want to describe or the name 
of the person they want to mention, similar to the TOT phenomenon. They also 
complain about not being able to follow or articulate sentences in a conversation or 
when reading a book. 
 
The COWAT (Benton, 1983) consists of three word naming trails (FAS), which were 
selected on the basis of the frequency of an English word beginning with these letters. 
The examiner instructs the subject to say as many words as she can think for one minute 
with a given letter of the alphabet, excluding proper names, numbers and the same word 
with different endings. A practice trail was provided in this study using the letter “C” to 
make sure the participant understood the instructions. The score is the sum of all the 
acceptable words and is adjusted by age, gender and education, which then are 
converted to percentiles. Word frequency has proven to be a good indicator of brain 
dysfunction. Frontal lesions tend to “depress” frequency scores (Lezak, 1983). 
 
5.5.5 New adult reading test (NART) 
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This is the best indicator of premorbid intellectual ability and comprises 50 phonetically 
irregular words (Nelson et al., 1978). It was used in this study to match participants for 
IQ level and as a necessity for CAMPROMPT assessment. Participants were required to 
read the list of words and the number of errors was scored and adjusted later and then 
converted to WAIS-R VI ( Wechsler Adult Intelligence Scale-Revised) , PIQ  
( Performance IQ) and FSIQ (Lezak, 1983). Accuracy of pronunciation is used to 
predict IQ. 
 
The NART test reliability estimates are above 0.90, and an alpha coefficient of 0.94 is 
correlated with years of education. 
 
5.5.6 Benton visual retention test (BVRT)  
 
This test is used to assess visual perception and visual memory (Benton, 1996). The test 
has shown to be a good measure to identify difficulties in memory, spatial orientation 
and motor behaviour as well as attentional difficulties. For that reason, it was selected in 
this study.  
 
The BVRT test consisted of a series of 10 images, which were shown for 10 seconds. 
After that time, the image was covered and the participants had to draw the image from 
memory on a sheet of paper. The tests provided three equivalent forms (C, D and E) of 
the task and four alternative methods of administration (A, B, C and D). In this study, 
method A was selected, which consisted of a 10 seconds presentation of the image, 
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because it was the most frequently used, and normative data for this test was most 
commonly based on administration A (Benton, 1996). 
 
To score the test, each of the images drawn by each participant were compared with 
those in the scoring manual with examples of correct and incorrect responses. Two 
scores were used to describe the performance of participants, which were number 
Correct Score and number Incorrect Score. The number Correct Score was based on all-
or-none basis. If the image had no errors, one point was awarded, but if it had any errors, 
0 points were received. The range of the possible scores is 0–10. The number Correct 
Score was used for this analysis. 
 
5.6 Testing sessions 
 
All testing sessions were conducted by the PI in a quiet room, where only the PI and 
participant were present. Comprehensive neuropsychological assessment of 28 cancer 
patients and 28 healthy controls was conducted. The duration of each testing session 
was 45 minutes. The order of the tests was presented as follows for all participants: 
CAMPROMPT, Digits Symbol (Digits Backwards, Digits Forwards), COWAT, 
BENTON (second testing session was presented in the same order, but using alternate 
forms of the tests). All participants were tested for IQ using NART only at baseline. 
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CHAPTER SIX 
 
6 QUANTITATIVE RESULTS 
 
6.1 Data preparation for analysis 
 
After missing values and data accuracy were examined, assumptions for mixed 
multifactorial ANOVA were addressed. Participants who did not complete the 
testing session were excluded to account for the missing values. 
 
6.2 Statistical considerations 
 
The primary form of statistical analysis was mixed between and within ANOVA 
models, with Group (cancer/healthy controls) as a between-subjects factor and 
Time of Testing (stage 1, stage 2) as within-subjects factor, with the WM and PM 
measures as dependent variables. 
 
Questionnaires and other screening measures that produced interval data were 
analyzed using mixed ANOVA. If the main effects or interactions proved 
significant, marginal means were analyzed, which examined these effects in more 
detail and explored which measures contributed to significance in the Group 
and/or Time of Testing effects. 
Participants were for the most part British, except from one cancer patient who 
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was from Portugal. All the participants were proficient in the English language, 
well educated (98% went to upper school or above), 64% were menopausal and 
75% admitted to having memory problems as a result of chemo treatment. 
 
6.3 Results 
A summary of independent variables used for these analyses along with mean 
differences and groups under consideration are presented in Tables 1 and 2. 
Shapiro-Wilk or Kolmogorov tests were considered to assess normality 
(according to sample size). Where normality was violated, Z-scores were used to 
identify outliers; however, no significant violations were found. Homogeneity of 
variance was addressed using Leven’s tabulation for between-groups 
comparisons. 
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Table 6.1 Patient and healthy controls means 
 Patient Group Healthy Control Group 
N (28) Stage 1 Stage 2 Time 1 Time 2 
TEST Mean 
Std. 
Error 
Mean 
Std. 
Error 
Mean 
Std. 
Error 
Mean 
Std. 
Error 
Camprompt 
Time 
12.04 0.65 13.46 0.89 13.79 0.80 16.39 0.43 
Camprompt 
Event 
12.96 0.76 13.93 0.59 13.96 0.60 14.54 0.46 
Camprompt 
Total 
25.00 1.07 27.39 1.27 27.71 1.13 30.93 0.67 
Digit 
Symbols 
68.14 3.11 72.54 2.89 73.64 2.84 78.14 3.18 
Digit Span 
Forward 
9.53 0.37 10.28 0.44 10.17 0.37 10.67 0.44 
Digit Span 
Backwards 
7.32 0.38 8.53 0.41 7.03 0.38 9.32 0.41 
Digit Span 
Total 
16.86 0.57 18.86 0.76 16.82 0.77 20.00 0.76 
COWAT 43.18 2.06 44.25 2.16 39.39 2.06 39.5 2.14 
BENTON 
Correct 
7.46 0.33 7.64 0.37 8.25 0.22 8.07 0.30 
Measured 
Sleep(4 days 
and nights) 
29.07 0.71 29.38 0.66 26.82 0.66 26.83 0.59 
PSQI 7.11 0.69 7.54 0.58 3.82 0.42 4.14 0.41 
ESS 4.96 0.75 5.79 0.70 6.39 0.87 6.68 0.81 
Anxiety 6.64 0.70 5.54 0.69 4.57 0.42 4.75 0.47 
Depression 2.21 0.42 4.04 0.55 1.68 0.40 1.82 0.42 
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6.3.1 Mixed ANOVA 
 
Table 6.2 Mixed ANOVA simple effects and interactions 
 Between Subjects Within Subjects Interactions 
 
Simple Effect (n 
= 54) 
Simple Effect (n 
= 54) 
 
TEST F P F P F P 
CAMPROMPT 
Time 7.959 .007 11.845 .001 1.010 .319 
Event 1.347 .251 .135 .715 .135 .715 
Total 5.905 .018 12.978 .001 .279 .600 
Executive function 
Digit Symbol 1.824 .182 15.979 .001 .002 .962 
Digit Span 
Forwards 
.982 .326 5.899 .019 .236 .629 
Backwards .240 .626 51.328 .001 4.810 .033 
Digits total .351 .556 36.327 .001 1.882 .176 
COWAT 2.255 .139 .403 .528 .206 .652 
BENTON 2.271 .138 .001 .000 .943 .336 
HADS 
Anxiety 3.413 .070 2.305 .135 4.419 .040 
Depression 5.880 .019 10.587 .002 7.731 .007 
SLEEP 
ME 7.768 .007 0.192 .663 .166 .685 
PSQI 23.459 .001 1.233 .272 .025 .875 
ESS 1.171 .284 3.070 .085 .719 .400 
 
6.3.2 CAMPROMPT 
 
When mixed 2x2 ANOVA analyses were conducted, a significant simple effect for 
between-groups (patient, healthy controls) difference was found for CAMPROMPT 
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Time-based tasks F(1,54) = 7.959, p = 0.007, η2 = .128, and for CAMPROMPT total 
score F(1,54) = 5.905, p = 0.018, η2 = .099, but not for CAMPROMPT Event F(1,54) 
= 1.347, p = 0.251. 
Within groups, simple effects (stage 1, stage 2) were significant for CAMPROMPT 
Time-based tasks for stage(Time points) F(1,54) = 11.845, p = 0.001, η2 = .180 and for 
CAMPROMPT Total score F(1,54) = 12.978, p = 0.001, η2 = .194. 
6.3 CAMPROMPT marginal means table 
 PATIENT HEALTHY MARGINAL 
MEANS 
CAMPROMPT 
TIME 
 
STAGE 1 12.03 13.78 12.91 
STAGE 2 13.46 16.39 14.92 
MARGINAL 
MEANS 
12.75 15.08 13.92 
CAMPROMPT 
EVENT 
 
STAGE 1 12.96 13.96 13.46 
STAGE 2 13.92 14.53 14.23 
MARGINAL 
MEANS 
13.44 14.25 13.84 
CAMPROMPT 
TOTAL 
 
STAGE 1 25.00 27.71 26.16 
STAGE 2 27.39 30.92 29.16 
MARGINAL 
MEANS 
26.19 29.32 27.75 
 
6.3.3 CAMPROMPT Time (CTIME)  
Estimated marginal means for time points (stage 1 and 2) indicated a trend for higher 
scores for the healthy control group. The marginal means for CTIME between-groups 
for patients’ scores were 12.75(SE = .087) and 15.08 (SE = .586) for healthy controls, 
a statistically significant mean difference of 2.339, 95% CI [.677, 4.002], p = .007. 
Additionally, marginal means for CTIME within-groups effects scores were 12.91 (SE 
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= .516) for stage 1 and 14.92 (SE = .499) for stage 2, a statistically mean difference of 
2.018, 95% CI [.842, 3.193], p = .001, indicating improvement over time for both the 
groups. 
 
6.3.4 CAMPROMPT Total (CTOTAL) 
Estimated marginal means for CTOTAL between-groups for patients’ group scores 
were 26.19 (SE = .909) and for healthy controls were 29.32 (SE = .909), a statistically 
significant mean difference of 3.125, 95% CI [.547, 5.703], p = .018, which indicates a 
trend for higher scores for the healthy control group. Within-groups simple effect 
marginal means for stage 1 were 26.35 (SE = .780) and 29.16 (SE = .722) for stage 2, 
statistically significant mean difference 2.804, 95% CI [1.243, 4.364], p = .001, 
indicating improvement over time for both the groups. 
 
Overall, our results confirmed the hypothesis that breast cancer patients have poorer 
PM, particularly on time-based tasks, than healthy controls, and that the effects are 
stronger in the middle of the treatment. The hypothesis that PM would be poorer for the 
patient group for the second time, in the middle of treatment, was not confirmed by 
these tests. This might be due to familiarity effects with the tests. 
 
6.3.5 Executive function measures 
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6.3.5.1 Digits Symbol 
 
6.4 Digits symbol marginal means table 
 PATIENT HEALTHY MARGINAL 
MEANS 
 DIGITS SYMBOL 
STAGE 1 68.14 73.64 70.89 
STAGE 2 72.53 78.14 75.33 
MARGINAL 
MEANS 
70.33 75.89 73.11 
 
The hypothesis that patients will obtain lower scores on Digit Symbol test was not 
confirmed; however, no statistically significant higher rates of improvement were 
observed to confirm the hypothesis that healthy controls will show better performance 
than patients. 
 
Significant within-groups simple effects were found for Digit Symbol F (1,54) = 
15.979, p = .001, η2 = .228. Estimated marginal means for between-groups for patient 
group were 70.33 (SE = 2.907) and 75.89 (SE = 2.907), and for healthy controls, a non-
statistically significant mean difference was found, 5.554, 95% CI [−2.690, 13.797], p = 
.182; however, a statistically significant mean difference was found for the within-group 
comparisons, which indicated an improvement over time for both the groups 4.446, 
95% CI [2.216, 6.677], p = .001. Marginal means were stage 1 70.89 (SE = 2.109) and 
stage 2 75.33 (SE = 2.150), indicating improvement over time for both the groups, with 
a higher increment for the healthy control group, confirming the hypothesis that healthy 
controls will show better performance than patients.  
 
6.3.5.1.2 Digit Span 
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6.5 Digit Span marginal means table 
 PATIENT HEALTHY MARGINAL 
MEANS 
DIGIT SPAN  
 DIGIT FORWARDS 
STAGE 1 9.53 10.17 9.85 
STAGE 2 10.28 10.67 10.48 
MARGINAL 
MEANS 
9.91 10.42 10.16 
 DIGIT BACKWARDS 
STAGE 1 7.32 7.03 7.17 
STAGE 2 8.53 9.32 8.92 
MARGINAL 
MEANS 
7.92 8.17 8.05 
 DIGIT SPAN TOTAL 
STAGE 1 16.85 16.82 16.83 
STAGE 2 18.85 20.00 19.42 
MARGINAL 
MEANS 
17.85 18.41 18.13 
 
Generally, our results indicate that our hypothesis that the patients group would 
experience cognitive decline after cancer treatment has not been confirmed; however, 
mean results confirm the hypothesis that the healthy group would perform better than 
the cancer group. 
 
Significant within-groups simple effects were found for Digits Span Forward F(1,54) 
= 5.899, p = .019, η2 = .098, Digits Backwards F(1,54) = 4.810, p = .033 η2 = .487, 
and Digit Span Total F(1,54) = 36.327, p = .001, η2 = .402. Marginal means for digits 
forwards indicated a statistically significant mean difference for within groups .625, 
95% CI [.109, 1.141], p = .019. Stage 1 mean was 9.85 (SE = .267), and stage 2 mean 
was 10.48 (SE = .314), indicating improvement over time for both the groups. Digits 
backwards for stage 1 and stage 2 indicated a significant mean difference 1.750, 95% 
197 
 
CI [1.260, 2.240], p = .001; stage 1 mean scores were 7.179 (SE = .272) and for stage 
2 were 8.929 (SE = .294). Digit Span total within-subjects marginal means for stage 1 
16.839 (SE = .484), stage 2 19.42 (SE = .542) showed a statistically significant mean 
difference 2.589, 95% CI [1.728, 3.451, p = .001. A significant interaction was found 
for Digits Backwards test F (1, 54) = 4.810, p = .033, η2 = .082 . Related t-tests 
showed significant improvement on cancer patients t (27) = −4.320, p = 0.001, d = 
0.816 and on healthy controls t (27) = −4.391, p = 0.001, d = 0.830 with a greater 
improvement for the healthy control group.  
 
Together, these results indicate that there was an improvement over time in the above 
measures, and that although the patient group scores improve overtime, there was 
greater improvement within healthy controls scores. Our hypothesis that scores after 
chemotherapy treatment would decline was rejected; however, the hypothesis that 
healthy controls will show a better performance was met. 
 
6.3.6 Sleep 
On measures of sleep, no interaction and within-subjects simple effect was found; 
however, measured sleep (ME) F (1, 54) = 7.768, p = .007, η2 = .126 and PSQI F (1, 
54) = 23.459, p = .001, η2 = .303 showed significant between-subjects simple effects. 
 
 
 
 
 
 
 
198 
 
6.6 Sleep marginal means table 
 PATIENT HEALTHY MARGINAL 
MEANS 
 MEASURED SLEEP 
STAGE 1 29.07 26.82 27.94 
STAGE 2 29.38 26.83 28.11 
MARGINAL 
MEANS 
29.22 26.83 28.02 
 PSQI 
STAGE 1 7.10 3.82 5.46 
STAGE 2 7.53 4.14 5.83 
MARGINAL 
MEANS 
7.32 3.98 5.65 
 
Measured sleep (ME)-4 days–24/7 
Between-groups simple effect marginal means for patient group 29.22 (SE = .607) and 
healthy control group 26.83 (SE = .607) showed a statistically significant mean 
difference of 2.393, 95% CI [.672, 4.144], p = .007, indicating that the patient group 
significantly slept for more hours than the healthy control group. Furthermore, 
independent t-tests were examined, and the results confirmed that the patient group 
slept significantly for more hours at both times when compared with healthy controls, 
stage 1 t(54) = 2.305, p = 0.0125, stage 2 t(54) = 2.847, p = 0.003. 
On the other hand, self-reports data analysis from PSQI showed that the patient group 
reported significantly higher scores on measures associated with poor sleep. PSQI 
marginal means for between-groups for patient group were 7.32 (SE = .488) and for 
healthy controls 3.98 (SE = .488), a significantly mean difference of 3.339, 95% CI 
[1.957, 4.722], p = .001, indicating that the patient group reported more sleep 
disturbances. Independent t-test reports revealed significantly poorer scores for the 
patient group than for the healthy control group for both time points stage 1 t(54) = 
4.045, p = 0.001; stage 2 t(54) = 4.709, p = 0.001. 
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The hypothesis that the patient group would show poorer sleep patterns, which in turn 
would affect PM, was not confirmed by measured sleep; however, PSQI results 
confirmed the hypothesis; the patient group showed impaired levels of sleep (>5 on 
PSQI scoring) when compared to controls. 
 
6.3.7 Anxiety and Depression 
 
6.7 HADS marginal means table 
 PATIENT HEALTHY MARGINAL 
MEANS 
HADS  
ANXIETY 
STAGE 1 6.64 4.57 5.60 
STAGE 2 5.53 4.75 5.14 
MARGINAL 
MEANS 
6.08 4.66 5.37 
 DEPRESSION 
STAGE 1 2.21 1.67 1.94 
STAGE 2 4.03 1.82 2.92 
MARGINAL 
MEANS 
3.12 1.75 2.43 
 
Increased levels of anxiety were revealed on the patient group at stage 1, but decreased 
for stage 2. The healthy controls revealed lower levels of anxiety when compared with 
the patient group at stage 1 and remained almost the same for stage 2. 
Estimated marginal means for depression for between-groups for the patient group 
mean 3.12 (SE = .401) and healthy control group 1.75 (SE = .401) showed a 
statistically significant mean difference of 1.375, 95% CI [.238, 2.512], p = .019, 
indicating higher levels of depression for the patient group. Within-groups marginal 
means indicated that depression scores were higher for the second testing session, 
where stage 1 mean scores were 1.94 (SE = .294) and for stage 2 2.92 (SE = .347), 
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with a statistically significant mean difference of .982, 95% CI [.377, 1.587], p = .002. 
Independent t-test revealed a significant difference on stage 2 t (54) = 3.195, p = 
0.001, but not at stage 1 t (54) = 0.912, p = 0.183. 
 
On measures of anxiety and depression, and interaction was found for anxiety F (1, 54) 
= 4.419, p = .040, η2 = .076, and for depression F (1, 54) = 7.731, p = .007 η2 = .125. 
Depression results showed significant between-groups F (1, 54) = 5.880, p = .019 and 
within-groups F (1, 54) = 10.587, p = .002 main effects, but not for anxiety. Paired 
samples t-test exposed a statistically significant difference for the patient group in both, 
anxiety t(27) = 2.480, p = 0.01, and depression t(27) = −3.445, p = 0.001, but no 
significant difference for the healthy controls for anxiety t(27) = −0.427, p = 0.462 and 
depression t(27) = −0.486, p = 0.31. 
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CHAPTER SEVEN 
7 QUALITATIVE METHODOLOGIES: THEMATIC ANALYSIS AND 
CASE STUDIES 
 
7.1 Thematic analysis 
 
7.1.1 Thematic qualitative analysis research question  
 
The aim of this part of the research was to analyse to what extent PM self-reports and 
interviews relate to the actual chemo brain experiences and PM lapses of patients, based 
on previous research conducted on chemo brain and PM.  
 
The approach taken was a “theoretical thematic analysis” (Boyatis (1998) which was 
analyst driven due to the fact that we were looking for a specific themes in order to 
answer the research question. The approach implied looking for patterns in 
questionnaires interviews and self-reports in order to identify emerging themes. 
 
The research question was that chemo brain is a PM deficit, since common complaints 
range from forgetting to pay bills to facing difficulty in retrieving familiar words or 
being unable to remember words and names. The inability to multitask is also common, 
which could profoundly affect daily activities. Patients also present difficulties learning 
new, but simple things, such as a new version of a computer program they were familiar 
with earlier. All these problems have a major impact on the lives and self-esteem of 
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patients, making them feel that they are not the same people as before and that they 
have some sort of handicap. Due to these combinations of symptoms, some patients 
cannot perform the same activities as well as they used to prior to chemotherapy and 
may even lose, or resign from, their jobs (Mulrooney, 2007; Silverman & Davidson, 
2009).  
 
Errors in PM, referred to as PM deficits, are manifested in the form of slips of actions: 
repetition errors—forgetting that an action has already been performed and repeating it 
(e.g. placing two cheques in an envelope for the same bill)—goal switches—forgetting 
the goal of a sequence of actions and switch to a different goal (e.g. intending to drive to 
one place and driving to another)—omissions and reversals—omitting or wrongly 
ordering the component actions of a sequence (e.g. filling the kettle, but failing to 
switch it on) and confusion/blends—confusing objects involved in one action sequence 
with those involved in another sequence (e.g. taking a tin-opener instead of scissors into 
the garden to cut flowers) (Cohen & Conway, 2008).  
 
Furthermore, PM failures have been associated with daily and routinely performed 
activities such as paying bills, taking medications with certain schedules and requisites 
and remembering to pick up things. It also involves performing familiar actions in novel 
contexts or at different times (Cohen & Conway, 2008). 
 
Based on these assumptions, the method of analysis of this study was based on the 
research findings in both areas of study. We aimed to identify the relationship between 
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both areas through the comparison of qualitative and quantitative data obtained from a 
population of breast cancer patients. 
 
 
The research question for the qualitative study was how the lived experience of chemo 
brain relates to PM failures. In order to understand the extent of this relationship, PM 
self-reports, descriptions from participants of their memory complaints and 
neuropsychological test results were analysed. Sample results were also compared with 
what other patients have reported on Internet blogs and in previous research. 
 
7.1.2 Advantages and disadvantages of conducting online research 
 
There are many advantages of collecting data through the Internet. According to Mann 
et al. (2000), researchers “can capitalise on the ability of the World Wide Web to cross 
barriers of time and space”. It is now possible to gather information from people who 
are geographically distant or otherwise difficult to reach because they are ill, busy, 
working or disabled (Mann et al., 2000). Internet data collection also solves issues 
related to cost and time. From the participants’ point of view, it is cheaper to respond to 
an Internet survey than attending a specific venue. They save on transportation, petrol, 
parking and time. From the point of view of the PI, costs are reduced, as no venue is to 
be rented, no transportation costs and no printing costs. Attrition can also be reduced, 
because participants do not have to cancel interviews because of illness or work/family 
commitments. The Internet gives participants the opportunity to take part in scientific 
research from the comfort of their home or at work. Once data has been gathered, there 
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is no need to transcribe the information, because the script is immediately available for 
analysis (Mann et al., 2000, Das, 2012, Bampton et al., 2002). 
 
Another advantage is the “online disinhibition effect” (Suler, 2004) which explains that 
sometimes people are shy, and they might feel more comfortable answering sensitive 
questions in private. If the participant feels at ease, they may give more honest and 
complete responses. Suler, J. (2004). The online disinhibition effect. Cyberpsychology 
& Behavior, 7(3), 321-6. 
 
On the other hand, some people might not be good at expressing their thoughts in 
writing, and this might present as a problem, particularly when looking for an in-depth 
exploration of the phenomenon. In this study, to overcome this issue, the online 
questionnaires were followed by face-to-face interviews. 
 
Misreading the questions or misunderstanding responses are also potential problems, 
because if the interview is asynchronous, immediate feedback cannot be received. A 
qualitative researcher relies on non-verbal communication to find out if the interviewee 
has understood the questions, which gives them the opportunity to clarify. To overcome 
potential problems, questions related to the experiences of patients were developed with 
the intention to be clear and simple to understand.  
 
By the time the qualitative part of the study began, cancer patients were already under 
treatment (chemotherapy and/or radiotherapy) and had already taken part in the 
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quantitative tests. They would have been exhausted, both physically and emotionally. 
Although they had shown a constant willingness to participate in the study, it was 
decided that the qualitative study would begin using the advantages that the Internet has 
to offer, and therefore, we would not be intrusive at such a highly sensitive time in the 
lives of the participants. This approach helped us get a good number of participants 
taking part in the online questionnaires and self-reports. 
 
These types of questionnaires allowed participants to respond at their own pace and 
carefully think what they wanted to express; it also allowed the PI to get a preliminary 
sense of what the participants were experiencing. Connections between the data for all 
participants through neuropsychological tests, PM self-reports, online questionnaires 
and face-to-face interviews over a period of time allowed the researcher to gain a sense 
of temporality. Participants had time to reflect on their experience with chemotherapy 
and how it affected their memory throughout the testing and interview sessions 
(Mitchell, 2011). 
 
Although the Internet is a relatively new phenomenon, it has helped social science 
researchers to develop a new combination of methods. The use of the Internet has 
allowed combining of approaches resulting from different methodological traditions, 
where qualitative and quantitative methods are used together with data collected from 
online and offline environments (Hine, 2015). 
 
There are several techniques that can be used when we use the Internet as a tool to do 
research. The most commonly used in mixed methods research design are presented 
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below. These techniques help researchers to interpret qualitative data, presenting most 
of the time a great advantage with regard to recruitment and cost-effective possibilities. 
 
Some of the Internet research methods are as follows: 
Online qualitative questionnaires. The use of questionnaires as a data collection tool 
in qualitative research is a useful way for gathering information about participants, such 
as attitudes, behaviour, opinions, attributes, beliefs and social interactions. There are a 
couple of techniques that can be used to gather data from online questionnaires. One 
could be “real time” using chats or messaging services (synchronous) and the other one 
is “off line” or asynchronous, using emails or other sources that allow the participants to 
respond at their own time. This gives the researcher time to analyse at a later time. 
Interview questions may be very structured or flexible and the data collected is recorded 
through the exchange of communication between researcher and participants. This 
method allows the researcher to exchange, in a private manner, sensitive information 
with participants and to focus on areas of specific concern. However, this technique 
limits the understanding of the offline, real lives of the participants, leaving little 
probability of validating participants’ responses (Hine, 2015, McGuirk et al., 2005). To 
overcome this limitation, the author of this thesis conducted face-to-face interviews as 
well as all the quantitative data collection processes, allowing greater interaction with 
the participants and avoiding a mere artificial communication that could undermine the 
richness of interviews’ results. 
 
When researchers develop qualitative questionnaires, they must take into consideration 
that the target population understand the questions and that participants are familiar with 
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the topic. There are two types of questions when we develop questionnaires: Closed and 
open questions. Closed questions may be looking for quantitative information, such as 
years in education, how many times a behaviour occurs, and may require participants to 
select categories, rank items, etc. In this type of questions, responses are easily coded 
and analysed. On the other hand, open questions help participants to provide greater in-
depth responses making these responses more meaningful. These type of questions are 
less structured and give the opportunity to participants to express understanding, and to 
explain experiences and opinions in their own terms (McGuirk et al., 2005). 
 
The focus of our study was to conduct online questionnaires (closed and open), to 
understand breast cancer patients’ PM difficulties and to obtain as much information as 
possible from participant’s live experiences and to help the researcher to guide the face-
to-face interviews. 
 
Online surveys. Data collection is conducted by asking structured questions presented 
on a website, such as Survey Monkey. These kinds of surveys allow the researcher to 
explore participants’ experiences that leads to quantitative analysis. If the population of 
the survey is unknown as a result of recruiting through online invitations or social 
media, there may be a problem of generalization which would limit online surveys, 
thereby complicating the analysis of response bias and how artificial the responses 
might be. (Hine 2015). However, for this study, our population was well known to the 
researcher from the beginning of the study.  
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Studies that have used online research methods are on the rise. They range from being 
large-scale and small-scale or a combination of both. They can depend on online or 
offline interactions and usually should complement each other with more traditional 
methods to gain deeper understanding and provide a more valid and reliable explanatory 
power, such as quantitative data and/or face-to-face interviews (Procter et al. 2013; De 
Mayer 2013, Hine, 2015). Due to the nature of the Internet and its role in the everyday 
lives of people, researchers tend to include it as a tool and use it by mixing both the 
Internet and qualitative and quantitative methods, in order to gain a deeper perspective 
of a phenomenon (Hine, 2015). 
 
As we can see, nowadays researchers who design mixed methods studies are beginning 
to incorporate the Internet more and more as a research tool. This is done through the 
vast range of communication technology, such as web and videoconferencing, social 
media, email and mapping tools, which can be conducted globally or at their own 
communities (Salmons, 2015). 
 
Examples where researchers use the advent of new communication technology are 
found in literature. Dowling (2012) studied breastfeeding support groups through face-
to-face interviews, but his study was complemented with the use of email-based online 
interviews when the women could not attend the face-to-face meetings. Dowling (2012) 
carefully designed her online questions based on clear expectations and a steady 
communication with the participants. In her study, she found that some participants 
understood the in-depth nature of the open-ended responses and wrote detailed accounts 
in log emails, but others responded as if they were responding to more structured 
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questions providing short responses. However, she found that online interviewees 
responded at their own pace when they could avoid distractions, as opposed to face-to-
face interviewees who were usually with their children and/or around other distracting 
factors during the interview (Salmons, 2015). 
 
Other forms of online tools is found on Castanos and Percy (2010). In a study 
conducted to analyse a model course content for family therapists, to better understand 
how relationships differ in consulting and in therapy,  the authors created a Wiki 
community (a virtual space created for data collection that promotes interactions with 
other participants through the internet), formed with the purpose of creating a research 
setting. The researchers collected data from online questionnaires, telephone interviews 
and online observations. Their data collection process began with semi-structured 
interviews to identify different perspectives, followed by online questionnaires in the 
form of Linkert-scales and narrative explanations in order to produce more in-depth 
details of the emerging themes from the initial interview (Castanos, 2010).The 
advantages of using the wiki community is that wikis are inexpensive, easy to use, and 
allows participants to exchange ideas, allowing the researcher to identify emergent 
ideas. However, some limitations occurred because wikis use specific browsers. On the 
other hand, reliability was also compromised because other participants can edit another 
person’s responses.  
In summary, the previous studies collected and triangulated their data derived from their 
multimethod, multistage qualitative approach, where data is obtained from different 
sources (QUAL+ QUAL+QUAL) (Salmon, 2015). Other studies focus on mixing 
quantitative and qualitative data, the same as our current study that obtained data from 
test scores, online interviews and face-to-face interviews (QUANT- QUAL+QUAL). 
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To explore the uses and influences of video content on political campaigns, Hussain 
(2012) designed a mixed methods study in which the qualitative stage comprised 
observations from blogs and videos that lead to formation of categories with codes that 
were later analysed through descriptive statistics (QUAL- QUAN) (Salmons 2015). 
Arsel and Bean (2013) conducted a study using a Quan-QUAL-QUAL approach to 
observe taste regimens and market-mediated practices, obtaining data from user-posted 
content and interviews and observation in person and online. McDermott and Roen 
(2012) also used online observations and user-posted content, online surveys and online 
interviews for a QUAL-quan-QUAL paradigm (Salmons, 2015). 
 
In our study data was collected and triangulated obtained from neurological assessment 
test scores, online questionnaires related to PM and chemo brain experiences, and face-
to-face interviews where participants provided more in-depth accounts of their memory 
difficulties after experiencing cancer treatment. (QUANT- QUAL+QUAL). 
 
On the other hand, the E-Interview Research Framework (Salmons 2012, 2015) 
suggests that studies that include data collected from online interviews or observations 
should address the following key points to ensure that the choice of methodology is 
appropriate and our research questions are well-served by our choices of methods of 
data collection: 
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Aligning purpose and design: Are research purpose, theories and epistemologies, 
methodologies and methods clearly aligned? Does the researcher offer a compelling 
rationale for using the designated methods to achieve the research purpose? Do the 
qualitative and quantitative aspects of the study fit in a complementary way? 
 
Choosing online or technology-enabled data collection: Are online or technology-
enabled methods chosen in order to investigate real-world phenomena or are online 
methods chosen in order to investigate online phenomena? 
 
Selecting the ICT and milieu: Does the study use text-based audio and/or visual 
communication data? 
 
Determining the research approach and collecting the data: How does the 
researcher ensure that the choices made with regard to technology are appropriate to the 
particular study? How does the researcher align ICT (Information and Communication 
Technologies) functions, features and/or limitations with the selected methods for 
collecting and analysing data? (Salmons 2015, Oxford. P. 539). 
 
In our current study the researcher intend aligning the different  methodologies used 
within the theoretical frameworks of chemo brain research and PM, and by triangulating 
data obtained from qualitative measures with qualitative data collection from 
questionnaires and interviews, to develop case studies. The use of online data collection 
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was chosen in order to investigate a real-world phenomenon using online open-ended 
questionnaires and surveys, in order to facilitate breast cancer patients’ participation. 
 
Salmons (2015) concluded that the choice of ICTs influences the entire research design, 
sampling and mode of data collection, such as what data to collect from and how to 
collect it, would it be synchronous or asynchronous and if it fits the purpose of our 
research. 
 
In our study, following the online questionnaires, a conversational-style face-to-face 
interview was conducted to obtain further insight into the experience of patients and to 
clarify information that was ambiguous or incomplete in the online interview. The 
interviews were recorded and transcribed verbatim. To check for accuracy, the 
interview recordings were compared with the interview transcripts. 
 
Continuity between participants was achieved since the beginning of the study. Prior to 
the interviews, all the participants met with the PI at least two times for a 
neuropsychological assessment. These sessions were useful to establish rapport and 
trustworthiness (Denzi & Lincoln, 2003; Mitchell, 2011). 
The time between the interviews and neuropsychological testing was eight months, due 
to the time it took to receive the approval of ethics committees, and because after 
analysing the online interview, it was decided that more in-depth information would be 
useful from some participants. Those interviews allowed us to assess whether their 
memories had improved or worsened after finishing the treatment.  
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Both, questionnaires and the interviews were read several times by the PI to find 
patterns and to provide categories and descriptions in order to help identify themes. The 
responses of participants to the face-to-face interviews were also used to validate 
themes.  
 
7.1.3 Recruitment criteria 
 
Only cancer patients who took part in the quantitative study were invited to take part in 
the qualitative part of the study. This sample bias was unavoidable, since healthy 
controls did not report memory difficulties and were not suffering from the effects of 
any treatment.  
After obtaining ethical approval from the NHS ethics committee and from Bournemouth 
University, 27 participants were invited to take part in the online questionnaires. Twelve 
participants agreed to take the online questionnaires. A convenience subsample of six 
participants who completed the online questionnaires was selected for the face-to-face 
interview. In order to explore the implications of PM failure in cancer patients, 
participants were chosen with a wide range of memory problems (mild-medium-severe).  
 
 
 
7.1.4 Methods and tools for data collection 
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The tools for data collection for qualitative research range from interviewing and 
observation to document analysis (Mann et al., 2000). Interviewing is the most widely 
used method for data collection. Interviews can be either standardised (structured) or 
non-standardised (unstructured) and can be classified as one-to-one (individual) or 
group interviews (focus groups).  
 
In structured interviews, participants are asked to respond to questions with a limited set 
of response categories. These are called surveys or self-completion (self-report) 
questionnaires. These surveys are usually analysed statistically, and the researcher 
controls the interview by providing standardised questions and constraining responses.  
 
Non-standardised interviews look for the meaning and interpretations of responses, 
rather than the pre-formulated ideas of the researcher (Mann et al., 2000). In this type of 
interview, participants are allowed to respond to questions in their own terms, and the 
choice of interview questions depend on the research question itself (May, 1993; Mann 
et al., 2000).  
 
According to Mann et al. (2000), a semi-structured interview is based on an interview 
protocol that is structured around specific thematic areas, which follows a 
conversational manner. Supplementary questions called probes are usually added into 
the conversation for further clarification and elaboration. In order to gain an in-depth, 
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subjective understanding of the experiences of patients, unstructured or in-depth 
interviews are usually chosen (Mann et al., 2000).  
 
The data collection to conduct the qualitative line of enquiry consisted of an online 
semi-structured, open-ended interview, aided by two validated structured PM self-report 
questionnaires, followed by a face-to-face interview. This method was chosen because 
the aim of the PI was to develop questions related to common cognitive problems in 
cancer patients with PM failure, in order to compare the two approaches with each other 
and with the neuropsychological test results of patients. 
 
In order to avoid potential researcher bias, reference was made to the chemo brain and 
PM literature when designing the open-ended, semi-structured questions (Kidd, 2007). 
Although the interviews allowed for a certain flexibility, the aim of the PI was to 
accurately interpret the data based on previous research, not her own assumptions, so 
that the findings would give a clear interpretation of the experiences of patients, relevant 
and transferable to other sufferers of the phenomenon (Kidd, 2007). 
 
Ethics approval was sought to conduct both the interviews. Invitation letters and 
information sheets were posted to the participants. They also were contacted by phone 
and email to confirm participation and to give them access to the online questionnaires. 
All information remained confidential and only the PI and her supervisory team had 
access to the interviews. Consent was sought for the interviews before commencing data 
collection. 
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For the online questionnaires, participants received an identification code to gain access 
to the PM questionnaires and the open-ended questions. They were allowed to leave the 
interview at any time and come back to it later, without losing previously input 
information. The identification code was unique to each participant, giving access only 
to their interview.  
 
Once participants accessed the questionnaires, they read a welcome letter and an 
explanation of the implications of the study and were requested to give their consent. 
They were instructed to provide demographic information and received specific 
directions on how to use the web page. The instructions were simple and consisted of 
clicking boxes to complete the self-reports and typing their responses in the box 
provided for the open-ended questions. Participants were informed that they could save 
and close the survey and come back at a later time, allowing them to work at their own 
pace. The instructions also explained that members of their family were allowed to help 
them remember their memory anecdotes. No problems with this online system were 
reported. 
 
The face-to-face interviews were conducted at Bournemouth University at the time that 
was most convenient for the participants. This interview helped gain further clarification 
of their experience in order to validate the information from the online questionnaires 
and gave them an opportunity to expand with examples and to confirm if their memory 
had improved or worsened. It also allowed the PI to gain more insight into the themes 
identified in the online questionnaires. 
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Semi-structured interviews were conducted on two occasions. The first time, 
participants were asked a series of online open-ended questions related to their memory 
difficulties and the impact on their social, family and work life. Before responding to 
the online questionnaires, they were requested to complete PM self-reports to help 
understand if their cognitive complaints were related to PM, which was the main 
concern of this mixed methods study. The questionnaires asked questions related to 
memory problems, such as misplacing things, forgetting appointments, missing the exit 
on their way home, etc. The second time they were invited to a face-to-face interview, 
and they were asked to elaborate on how they thought cancer treatment had affected 
their cognitive abilities and how that made them feel. They were also asked questions 
on the way they were coping, how people around them reacted to their memory 
complaints and if they could remember when they had started noticing their memory 
deficits (Refer to Appendix III). 
 
7.1.5 Prospective memory self-reports 
 
To determine if the participants were suffering from PM failure, two validated self-
reports were used: the Prospective and Retrospective Memory Questionnaire (PRMQ) 
(Smith et al., 2000) and the Comprehensive Assessment of Prospective Memory 
(CAPM) (Roche et al., 2007).  
The PRMQ is “a set of questions about minor memory mistakes that everyone makes 
from time to time” (Crawford et al., 2003). The participants were asked to rate the 
frequency of the type of memory failures on a 5-point scale (very often, quite often, 
sometimes, rarely, never). 
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The CAPM is a measure that assesses PM lapses using 39 items, with 10 items focusing 
on basic activities of daily living (e.g. “forgetting to eat a meal”) and 23 items focusing 
on instrumental activities of daily living (e.g. “not remembering to pay bills”). 
Participants were required to rate the frequency of memory lapses as never, rarely, 
occasionally, often and very often. A “not applicable” response was also possible.  
All online questionnaires were conducted approximately one year after treatment, 
followed by the face-to-face interview, which took place two years after treatment. They 
were recorded and transcribed verbatim by the researcher. 
 
The advantage of conducting this research from before the treatment, until a few years 
after, was that the patients could discuss the whole experience with the PI, which gave a 
more complete picture of the effects of their treatment. 
 
Our sample also included cancer patients who did not receive chemotherapy, but 
received radiotherapy and adjuvant treatment. They were also invited to take part in the 
qualitative part of the study, but none of them reported memory difficulties. Therefore, 
the qualitative study is solely based on breast cancer patients who underwent 
chemotherapy. 
 
7.1.6 Thematic analysis  
 
All the participants in this study took part in the quantitative part of this research and 
agreed to participate in the second one to analyse their cognitive deficits in depth. 
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Recruitment of this convenience sample took place at Bournemouth, Poole, Weymouth 
and Dorset County hospitals. The sample comprised 14 women who were treated with 
chemotherapy and reported having memory difficulties, despite the fact that the 
neuropsychological tests showed no impairment. Despite the fact that no impairment 
was found in the quantitative study for the cancer group, significant differences were 
found in performance when compared with the healthy control group. 
 
After taking part in the neuropsychological assessment and receiving ethics approval, 
participants were invited to an online asynchronous questionnaire, which consisted of 
answering two PM self-reports for screening and eight open-ended questions (see 
Questionnaires Appendix). The responses of each participant were paraphrased, patterns 
were categorised and coded, and six emerging themes were identified. 
 
Chemo brain has been defined as follows: 
“A term used by cancer survivors to describe a change in cognitive function, 
particularly in the domains of memory, concentration/attention, verbal abilities 
and multitasking that occurs after chemotherapy. The presence and intensity of 
chemo brain can be impacted by demographics, disease, specific and individual 
characteristics. Chemo brain has been reported to occur with other symptoms 
such as depression, anaemia or fatigue and these symptoms may identify the 
experience. Both objective evidence and subjective perception are important 
components of chemo brain. Consequences can include a change in functional 
status and psychological well-being. This in turn can affect work and 
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educational goals, quality of life, role function and self-esteem” (Mulrooney, 
2007). 
 
7.2 Thematic analysis procedure 
 
To look for a major insight into the phenomenon of chemo brain, a thematic analysis 
was conducted. This implies a process of encoding qualitative information through a list 
of themes that emerge as patterns derived from the information obtained from 
participants. This helps to interpret, organise and describe observations of the 
phenomenon (Boyatzis, 1998). Themes were generated deductively based on previous 
research findings on the topic. A code book was created, which included the 
compilation of codes that emerged from the identified themes. 
 
Participants were asked to complete an open-ended, asynchronous online questionnaire 
after having participated in a series of neuropsychological tests for the quantitative 
analysis. The interview questions were related to their experience of cancer treatment, 
specifically how their treatment affected their memory and how this in turn impacted 
their social life, work and relationships. After completing the online questionnaire, six 
participants were invited to attend a face-to-face interview to gain a deeper 
understanding of their experience. 
 
Following thematic analysis procedures, the interviews were paraphrased twice for later 
building the responses of the participants into a paragraph, which was paraphrased 
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again. This analysis drew on previous research in the areas of chemo brain and PM, but 
focused on the question of whether the memory complaints of participants were 
associated with PM problems.  
  
 
7.2.1 Methodology 
 
There were three stages in the analysis of interviews, following the recommendations on 
conducting thematic analysis by Boyatis (1998):  
3. Recruitment  
4. Development of themes and codes 
5. Code validation 
 
7.2.2 Recruitment (Stage one) 
 
Participants who had previously participated in the quantitative study were invited to 
take part in the online questionnaires and complete PM self-reports. Only those 
participants who reported memory decline in the online questionnaires were invited to 
participate in the face-to-face interviews. 
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7.2.3 Development of themes and codes (Stage two) 
 
Thematic analysis was conducted following Boyatzis’s (1999) suggestions for analysis. 
Boyatzis (1998) defined thematic analysis as “a translator of those speaking the 
language of qualitative analysis and those speaking the language of quantitative 
analysis”.  
 
 Categories and themes development was conducted as follow:  
 
Raw data from participants’ responses was analysed. Key words were identified 
according to frequency of usage, and a colour code was assigned to similar words or 
phrases. After the key words were identified, participants’ responses were paraphrased 
twice with the objective to create a summary from each participant’s responses to later 
develop a paragraph that makes sense to the researcher. Each paragraph was compared 
with other participants’ paragraphs to identify emergent themes (see Appendix IV for an 
example). 
 
Participants’ responses were analysed using Survey Monkey’s word analysis as an 
initial stage to identify the percentage of usage of similar words (see Appendix IV for 
an example). This step was followed in order to identify the frequency of usage of 
keywords, such as “memory loss”, “forgetfulness” etc., which contributed to create the 
study categories. A colour code for each question’s category was assigned to identify 
the key words to aid the development of clusters that comprise similar keywords. 
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The method of clustering was used in order to identify clusters on the basis of similar 
characteristics between underlying constructs. For example, key words involving words, 
names or any other semantic difficulty were identified in the metamemory construct and 
coded as the  Tip-of-the Tongue (TOT) theme. 
 
Each paragraph was then compared with other participants’ paragraph to identify the 
emerging themes. 
 
In order to identify themes and codes, the following steps for thematic analysis were 
taken: 
6. Identify categories from raw data (responses of participants).  
7. Paraphrase. Create a summary and a paragraph. 
8. Re-read and re-write.  
9. Identify key words and cluster them into similar topics for data reduction. Go back 
to survey to redefine categories and have more accurate categories in order to 
develop a code. 
10. Identify themes. Compare summaries, determine similarities and find patterns. 
11. Compare themes. Reduce into small packets. 
12. Create a code (simplified themes). 
13. Create paragraphs with the responses of participants and make sense of the themes 
(see Appendix IV for an example of steps followed). 
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7.2.4 Code validation (Stage three) 
 
For code and themes validation, a face-to-face interview was conducted to corroborate 
if the identified themes accurately described the experience of participants. The 
percentage of the codes reoccurrence within the sample was recorded. The themes 
identified in this study were compared with those in the literature related to chemo brain 
and PM. 
 
7.3 Data management and analysis 
 
Data were analysed according to the guidelines provided by Boyatzis (1998) for 
transforming qualitative information. Each participant was assigned an ID, and no data 
about their identity was recorded. The online questionnaires and recordings helped the 
PI to better understand the answers to the interviews. Categorization was carefully 
selected derived from observed patterns; descriptions were assigned for each category, 
and emerging themes were identified. 
 
7.3.1 Online questionnaires and face-to-face interviews 
 
Qualitative researchers have adopted the Internet and email communication as a 
research tool for open-ended semi-structured interviews, diary recordings and virtual 
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focus groups, in areas such as education (Salmon, 2000), sociology (Mann, 1998), 
health (Stewart et al., 2005) and psychology (Williams et al., 2011). For this study, it 
was decided to design an asynchronous, open-ended, semi-structured online 
questionnaire and to include two PM self-reports.  
 
The use of computers for communication has become widely accepted and is accessible 
to people from all backgrounds. The Internet has been described as a “worldwide 
interconnected academic, business, military and scientific communication network” and 
is becoming a very powerful method of communication between individuals (Mann and 
Stuart, 2000). Qualitative researchers can take advantage of the possibilities that this 
communication medium has to offer (Mann et al., 2000). 
Based on the demographic information of participants, it was assumed that most of them 
would have access to the Internet, but it was also suggested that they could use their 
community library if they did not have access to computer or Internet at home. The 
assumption that the majority of participants were computer literate and had access to 
Internet was confirmed when the researcher contacted the participants and found out 
that all of them could provide an email address. 
 
This type of questionnaire allowed participants to respond at their own pace and 
carefully think what they wanted to express; it also allowed the PI to get a preliminary 
sense of what participants were experiencing. Connections between the data for all 
participants through neuropsychological tests, PM self-report, online questionnaires and 
face-to-face interviews over time allowed the researcher to gain a sense of temporality 
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(Mitchell, 2011). Participants had time to reflect on their experience with chemotherapy 
and how this affected their memory through the testing and interview sessions.  
 
Following the online questionnaires, a conversational-style face-to-face interview was 
conducted to obtain further insight into the experience of patients and to clarify 
information that was ambiguous or incomplete in the online questionnaires. The 
interviews were recorded and transcribed verbatim. To check for accuracy, the 
interview recordings were compared with the interview transcripts. 
 
Continuity between participants was achieved from the beginning of the study. All the 
participants met with the PI at least twice for neuropsychological assessment before the 
interviews. This was useful to establish a rapport and trust (Denzi & Lincoln, 2003; 
Mitchell, 2011). 
 
The time between the first and second interviews was eight months. This was due to 
several factors, including the time it took to receive ethics approval, and because after 
analysing the online interview, it was decided that more in-depth information from 
some participants would be useful. This had the advantage that it provided an 
opportunity to establish whether their memories had improved or worsened with time 
after finishing the treatment.  
 
Both the interviews were read several times by the PI to find accurate patterns in order 
to provide categories and descriptions and to help identify themes. In addition, the PI 
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asked the participants if the themes were accurate in order to validate the themes after 
the face-to-face interviews were completed. It was expected that both the interview 
responses will correlate with each other.  
Participants were all British, except for one cancer patient who was from Portugal. 
 
All the participants were proficient in the English language and well educated (98% 
went to secondary school or above). Sixty-four percent of the participants were 
menopausal. The mean age was 20.27 for HC and 36.73 for the PT group.  
 
Since alcohol or substance abuse affect cognition, participants were asked about their 
alcohol intake. All the participants said that they only drank alcohol occasionally. 
Seventy-five percent of the participants said that they had memory problems, which 
they attributed to their chemotherapy treatment. When asked to explain how they 
noticed their memory changes and if it had continued changing after treatment, 50% of 
participants could not recall exactly when their memory problems started, while 40% 
said it was during treatment and 10% after the treatment finished. When asked to rate 
their memory before treatment, 67% said their memories were good, 25% said it was the 
same and 8% said it was poor. Seventy percent of the participants felt anxious about 
their memory difficulties, while 55% reported an acceptance attitude. 
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7.4 Case studies research methodology 
 
According to Balbontín (2012), a case study is an event taking place in a natural way 
where the researcher aims to gain deep insight into a phenomenon and to inquire how 
and why the phenomenon occurs. Yin (2009) describes a case study as an empirical 
enquiry investigating a phenomenon in depth within its real life context. 
 
7.4.1 Aims 
 
The aims of the case studies were 
14. to explore the relationship or similarities among PM lapses and chemo brain, and 
15. to compare test results of participants with their self-reports and interviews to 
explore the discrepancies between them, since quantitative test results showed no 
memory impairment, whereas interviews showed that participants experienced 
memory difficulties in everyday life related to PM and the TOT phenomenon 
(LTM). 
 
Due to the nature of the study, participant bias could not be avoided. For the case 
studies, breast cancer patients who reported memory difficulties were selected from the 
sample, covering the full spectrum of impairment, ranging from the least affected to the 
most affected. This selection was based on self-reports and interviews. The overall 
impact of memory impairment on their everyday life considering their social relations, 
work and daily activities was examined. 
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According to Yin (1994), generalizing from case studies to theory multiple case studies 
can lead to theory development, rather than individual cases. Multiple cases are to be 
considered as multiple experiments, and the methods of generalization are called 
“analytic generalization”, in which previous theories are used as a template to compare 
empirical results of the case study (Ying, 1994). The author of this thesis suggests that a 
complete research design requires the development of a theoretical framework 
irrespective of whether it is explanatory, descriptive or exploratory, because the use of a 
theory when we analyse case studies becomes the main vehicle for generalising results. 
If two or more cases support the same theory, replication may be claimed.  
 
For case studies, as in all other types of research, factors such as construct validity, 
internal and external validity and reliability are of extreme importance. Construct 
validity is achieved by using multiple sources of evidence to establish appropriate 
operational measures to explain the concepts under analysis. In our sample, we used 
neuropsychological tests, self-reports and interviews to establish a chain of evidence 
related to PM and chemo brain based in the literature of both the areas.  
 
External validity has to do with how our findings generalise beyond the case studies by 
relying on “analytical generalization”, rather than on “statistical generalization”, in 
order to generalise a particular set of results to a broader theory. In our case, we aimed 
to analytically generalise to PM and chemo brain theories.  
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Replication was achieved in our sample by analysing six case studies. Internal validity 
was used to explain in detail the causal relationship between chemo brain and PM, by 
trying to identify neural correlates between both the aspects of the study. A brief 
explanation of these neural correlates can be found in the Prospective Memory chapter 
of this thesis.  
 
The aim of reliability was to produce the same results following exactly the same 
procedures to minimise error bias. All efforts were made to establish guidelines, so that 
the current study could be easily replicated, following the themes that emerged from the 
thematic analysis. In the current sample, six case studies where presented; all of them 
reported PM failures as well as problems with words and names.  
 
7.4.2 Case study design 
 
To address the research questions of this study, we used a multiple case study design by 
presenting evidence from tests and interviews of six participants who also took part in 
our quantitative study, with the aim to add robustness to it (Herriot & Firestone, 1983; 
Yin, 1994). We based our assumptions of reliability on the replication logic used in 
multiple experiments (Hersen & Barlow, 1976; Yin, 1994). That is, we had access to six 
cases to analyse the effects of cancer treatment on the PM of breast cancer patients.  
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We analysed the six cases by using tests and data from interviews. We found that the six 
cases reported PM difficulties that had also been associated with chemo brain; therefore, 
replication was achieved.  
 
Each case was carefully selected to explore the relation between chemo brain and PM 
failure, with the logic of literal replication and in order to develop a theoretical 
framework for generalization. We chose participants ranging from those who reported 
not having been severely affected to those who admitted being profoundly affected. 
 
We aimed to explain that the phenomenon of chemo brain exists despite 
neuropsychological tests results, that there is a relationship between chemo brain and 
PM failures, and that the TOT phenomenon is also a problem, if not the most common 
problem in this population. 
To follow the replication approach suggested by Yin (1994), our initial step consisted of 
the theory development of chemo brain as a PM failure and the association of the TOT 
phenomenon in chemo brain. After the theory development was established, six cases 
where selected from our sample to present data obtained from each participant. Each 
individual case consisted of a whole study, and convergent evidence was sought. The 
conclusions of each case were considered for replication by other individual cases, and 
the summary report was composed of both, individual and multiple case results (Yin, 
1994).  
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Efforts were made to indicate why and how a particular position was demonstrated, i.e. 
we tried to explain why we believe chemo brain is a PM failure by associating examples 
and theoretical accounts from each area, reporting on how participants describe their 
experiences, and how test results differ from participants’ reports. We also tried to 
explain why we believe the TOT phenomenon is involved by presenting reports of 
patients and looking at how it was manifested. We also presented the contrasting results 
from neuropsychological tests.  
 
This approach was relevant because by investigating how the experiences of patients 
with chemo brain relate to PM lapses and attentional difficulties (such as how patients 
struggle with words and names and fail to remember certain places they have visited), it 
was possible to observe how neuropsychological batteries might lack sensitivity to 
detect MCI, which despite being considered mild may have an impact on everyday life 
that is far from mild. 
 
Despite the fact that neuropsychological tests are extremely useful tools for diagnostic 
and research purposes, they may misrepresent everyday situations. On the other hand, 
the use of surveys and self-reports alone to investigate memory deficits are very limited 
because of the subjective nature of self-reporting. In order to conduct a further in-depth 
analysis of chemo brain, the research team decided to investigate the contemporary 
phenomenon within its real context by using interviews for the thematic analysis as well 
as analysing case studies. Moreover, as the relationship between neuropsychological 
measures and chemo brain has previously shown inconsistent findings, up to the point 
233 
 
that some authors have concluded that the problem does not exist, the research team 
decided to present this contradiction within the sample. 
 
The case studies were used to further explore the research question that chemo brain is a 
PM problem based on the current literature in both the areas of research, by combining 
qualitative and quantitative data. The advantage of using case studies for this research 
was seen as the ability to explore the phenomenon of chemo brain within the context of 
PM from the point of view of patients (adding to the analysis of test results those of 
self-reports and interviews). It also helped to observe the paradoxical situation where 
the information provided by the quantitative tests did not reflect the problems reported 
by patients in their everyday lives. 
 
The questions used in the case studies were related to how cancer treatment had had an 
impact on the memories of patients, and why it had been suggested as a PM problem. 
They were designed to explore the difference between what the quantitative test results 
had shown and what the interviews and self-reports suggested.  
Case studies of this sample were drawn from individuals who reported memory deficits 
as a result of cancer treatment and who had previously participated in the quantitative 
and qualitative studies. 
 
The approach used to present the case studies was “pattern matching” (Yin, 1994), in 
which several pieces of information from the same case may be related to the same 
phenomenon and theoretical findings. Two opposing arguments were presented, e.g. test 
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results indicating no significant memory problem vs. anecdotal accounts of memory 
difficulties in everyday life as well as how PM matches with chemo brain complaints. 
The data on PM deficits and the TOT phenomenon were also presented. 
 
Before each interview, the surveys were carefully analysed to choose the questions for 
the interview that were relevant to PM and TOT phenomena. This was important 
because sometimes interviewees deviated from the topic by talking about their physical 
symptoms and other side effects of chemotherapy, which were not related to memory 
and were out of the scope of this study. 
 
Data collection was performed using focused interviews (Merton et al., 1990; Yin, 
1994). Each patient in the sample was interviewed for about 40 minutes using semi-
structured, open-ended questions conducted in a conversational manner (allowing for 
the possibility to adapt the questions as the conversation progressed), following on from 
the PM questionnaires and online interviews. The aim of the interview was to 
corroborate our research question and to validate responses from online interviews as 
well as to validate themes that emerged from the thematic analysis. 
 
7.5 Case study analysis 
 
As indicated by Yin (1994), in order to conduct this analysis, it was necessary to rely on 
theoretical proposals for chemo brain, PM and TOT phenomenon to develop the 
research questions, direct the literature reviews and develop new theories.  
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According to Yin (1994), there are four analytical techniques that should be used to 
report case studies: pattern matching, explanation building, time-series analysis and 
program logic models. Pattern matching was chosen for this study. 
 
The case studies investigated the experiences of patients who had undergone cancer 
treatment and experienced memory difficulties, regardless of their neuropsychological 
test results, with PM as one of cognitive domains affected and the TOT phenomenon, 
associated with LTM, also present. 
 
This statement presents the basis for the theory that chemo brain is a PM deficit. It also 
gives insight to explore a new theory in the context of chemo brain, the TOT 
phenomenon, which has not been addressed as such in the chemo brain literature. 
 
7.5.1 Pattern matching 
 
To achieve internal validity in case studies, Trochim (1989) explained that the logic of 
pattern matching is to compare an empirically based pattern with a predicted one (Yin, 
1994). When PM failures were compared with cognitive decline after chemotherapy, 
both the patterns coincided. The participants reported problems in accordance to PM 
failures despite the fact that the psychological measures failed to report this, confirming 
Mesulam’s frontal lobe mystery around neuropsychological batteries (Burgess et al., 
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2009). The TOT phenomenon was also observed through reports of participants having 
problems with words and names. 
 
Although case studies cannot be generalised to the entire population, this study is 
relevant because of the emphasis placed on PM. From these studies, we could infer how 
chemo brain was in accordance to PM lapses and attentional difficulties, and we could 
clearly observe how neuropsychological batteries lacked sensitivity to detect MCI, 
which despite being considered mild, could have an impact on everyday life which 
might have been far from mild. 
 
7.5.1.1 Explanation building 
 
The aim of explanation building, as the name suggests, is to build an explanation about 
the case (Yin, 1994). The theories behind the current study’s research question together 
with data collected from neuropsychological tests and surveys served as elements of 
explanation to observe the casual links between the theory and the results and to explain 
the rival assumptions behind the current study (Yin, 1994). That is, this exploratory 
study aimed to explain why test results reflect opposite results to the interviews, and 
why such a discrepancy exists. Another aim was to explore the relationship between PM 
decline and chemo brain. 
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7.5.1.2 Time-series analysis 
 
A third analytical approach for case studies is when data is collected over time (time-
series analysis). The neuropsychological tests were administered at two, three and four 
time points: at baseline, mid-treatment, end of treatment and six months later. The 
qualitative interviews took place one year and two years after the treatment. The design 
was based on the research question that PM performance would decrease during and 
after the treatment. 
 
7.5.1.3 Program logic models 
 
The fourth strategy for analysis suggested by Yin (1994) is a complex chain of events 
which combines pattern-matching and time-series analysis. 
 
7.6 Research questions for case studies 
 
The questions to be analysed for each case study were how cancer treatment had 
impacted the memories of participants and why the problems could be suggested as a 
PM problem. The differences between the quantitative test results and what the 
responses to the interviews and self-reports implied were explored. 
 
 
238 
 
7.7 Triangulation 
 
When data collection is based on multiple sources of evidence, the principle of data 
collection called triangulation takes place, which gives the researchers an opportunity to 
explore the issue under observation in a much more complete and broader manner, 
increasing the accuracy of the research (Yin, 2009). This study was based on data 
triangulation, i.e. multiple sources of information were used for the exploration of the 
phenomenon of chemo brain. One of the advantages of triangulation is that construct 
validity can be established, because evidence of multiple measures of the same 
phenomenon can be provided (Yin, 2009). 
 
Another principle of data collection when conducting case studies is to create a database 
(Yin, 2009). The database for the current study consisted of the demographic 
information of the participants, interpretation of data collected from neuropsychological 
test at various time points and the narratives of six case studies derived from online and 
face-to-face interviews. 
 
7.8 Significance of the case studies 
 
Among the strengths of the current study were the use of multiple sources of data 
collection by examining test results, questionnaires and interviews as well as analysing 
the literature in several areas of study (PM, chemo brain, TOT, sleep), which allowed to 
study chemo brain in a broader manner by presenting objective and subjective evidence. 
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Data triangulation was achieved by using multiple sources, helping to corroborate firstly 
that PM failures and chemo brain present the same cognitive disadvantages to sufferers, 
that chemo brain patients show the TOT phenomenon and that neuropsychological tests 
might not be sensitive enough to detect MCI (Patton, 1987; Yin, 1994; Burgess et al., 
2004). Issues regarding construct validity were also addressed with data triangulation, 
because the multiple sources of evidence provided multiple measures of the same 
phenomenon, enhancing the quality of the case studies presentation (Yin, 2004).  
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CHAPTER EIGHT 
8 THEMATIC ANALYSIS: RESULTS AND DISCUSSION 
 
This study explored the memory difficulties experienced by breast cancer patients after 
receiving chemotherapy treatment. All the participants in this study had taken part in the 
quantitative part of this research and agreed to participate in the second one to analyse 
their cognitive deficits in depth. Recruitment of this convenience sample took place in 
Bournemouth, Poole, Weymouth and Dorset County hospitals and comprised 14 women 
who were treated with chemotherapy and reported having memory difficulties, despite 
the fact that the neuropsychological tests showed no impairment. 
 
After taking part in the neuropsychological assessment, participants were invited to an 
online asynchronous questionnaire, which consisted of completing two PM self-reports 
and answering eight open-ended questions (see Questionnaires Appendix). Each 
participant’s response was paraphrased and patterns were categorised and coded from 
which six themes emerged. 
 
To better understand chemo brain experience in the context of PM, six women who 
received treatment for breast cancer responded to an invitation to a face-to-face 
interview. All the participants in this sample also took part in the neuropsychological 
assessment and online questionnaires. The objective of the case studies was to discuss 
the potential role of PM in chemo brain patients and to further analyse the discrepancy 
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between neuropsychological assessment and the experiences lived by patients, 
following on from the quantitative study and the thematic analysis. 
Sleep was assessed by measuring the number of hours (ME) of sleep during a period of 
four days wearing the SWA. In each table, percentile ranks are included to understand 
overall percentile rank of each individual patient within the sample and to observe how 
scores fall within the normal range. 
 
8.1 Research question 
 
Based on previous research conducted on chemo brain and PM, the author wanted to 
analyse to what extent PM self-reports and interviews relate to participant’s chemo 
brain experiences and PM lapses. The theoretical thematic analysis approach selected to 
conduct our analysis was analyst driven, because we aimed to look for a quite specific 
research question. We will look for patterns on interviews and self-reports to later 
identify emerging themes. 
 
The method of analysis of this study was based on the research findings in both the 
areas of study. The aim was to identify the relationship between chemo brain and PM 
through the comparison of qualitative and quantitative data obtained from a population 
of breast cancer patients. 
 
The research question for this study is essentially how the symptoms of chemo brain 
experienced by cancer patients relate to PM failures. In order to understand the extent of 
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this relationship, PM self-reports, descriptions from participants of their memory 
complaints and neuropsychological test results were analysed. Sample results were also 
compared with what other patients have reported and accounts on Internet blogs as well 
as the results of previous research.  
 
8.2 Online questionnaire results  
 
Three themes related to EF emerged from data analyses: words and names, attention and 
multitasking. The titles of the themes came from the patterns found in the responses of 
patients and are explained below. Three additional themes were identified related to 
patients’ mood and the ability to cope; more emphasis was given to those related to EF, 
which is the scope of this research, with those related to emotions analysed later.  
 
Participants were for the most part British, except from one cancer patient who was 
from Portugal. All participants were proficient in the English language and well 
educated (98% went to upper school or above), 64% were menopausal and 75% 
admitted to having memory problems as a result of chemo treatment.  
 
When we asked them to explain how they had noticed their memory changes, and if 
they had continued changing after the treatment, 50% could not recall when exactly they 
started, 40% thought that it was during treatment and 10% thought they had started after 
the treatment was completed. Sixty-seven percent said their memories were good before 
treatment, 25% said they were the same and 8% said they were poor. Seventy percent 
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felt anxious about their memory difficulties, while 55% reported an attitude of 
acceptance. 
 
8.2.1 Words and names: Tip-of-the-tongue phenomenon (Theme one) 
 
Phrases such as difficulty following conversations and completing sentences and 
problems with words and names were clustered in the category “problems following 
conversations and remembering names”. This theme incorporates how participants had 
difficulty remembering the names of people, even if they had known them for years, 
even the names of their children. Another problem within this theme was that chemo 
brain patients struggled with following conversations. They could not follow their train 
of thought or simply could not remember the word they wanted to use, and instead, they 
tried to describe the word that they intended to say. This made patients feel stupid and 
embarrassed; they felt frustrated and did not like to offend the people whose name they 
had forgotten. Some patients felt like a “lesser person” than they were before, because 
their verbal abilities had diminished and they had to use simpler words or needed to ask 
other people for helping them remember the word they were trying to say.  
 
Cancer patients usually reported that they had difficulty retrieving names, normally very 
familiar words, even when they could remember the face and the other information 
about the person. They may have felt confident that they knew the person well, but at 
that precise moment, they could not recall the name. Pires et al. (2012) suggested that 
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“forgetting names of family members or friends plays an important role in 
subjective memory complaints in the clinical setting. This symptom is possibly 
perceived as particularly worrisome and likely drives people to seek for clinical 
help.” 
 
Unfortunately, the vast majority of chemo brain patients complained about forgetting 
names and words, as can be seen from the anecdotal reports in this work. Many of the 
participants in this study expressed their feelings of frustration as a result of not 
remembering words and names: 
“I still have difficulty remembering words, and I have to describe the meaning 
so that someone reminds me the word… Although it is frustrating, I am coping 
perfectly well. It has been a matter of making adjustments”. Participant 8 
“I feel frustrated and confused at times, especially because I can’t remember 
simple words, but I am getting on with it. It is my only choice”. Participant 8 
 
8.2.1.1 Examples 
“It was very apparent that my memory problems began during treatment. 
Making sentences became a very difficult thing to do, as well as remembering 
names.” Participant 1. 
 
“My memory before treatment was average, but better than it is after treatment. I 
used to remember processes more easily. I had better recall of words, 
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particularly difficult ones. My memory was good for remembering appointments 
and names.” Participant 8 
 
“I frequently forgot where I put things down, and I even forget my children’s 
names. During a conversation, I had to stop in the middle of it because I forgot 
what I wanted to say, or I cannot find the word to complete my sentence. As a 
driving instructor, I feel worried about causing an accident, because I need to be 
quick giving verbal instructions, but sometimes I can’t remember what I have to 
say. I feel frustrated and confused at times, especially because I can’t remember 
simple words, but I am getting on with it. It is my only choice.” Participant 9 
 
“After treatment commenced I have problems remembering people’s names. I 
noticed the forgetfulness after the first cycle when I started having problems 
with names, and although it has not gotten any worse, it has not improved either. 
Before treatment, I did not have memory difficulties. I was very good at 
remembering people and tasks.” Participant 10 
 
“My memory has been affected by treatment, but I have not seen significant 
deterioration, other than confusing words.” Participant 13 
 
“I cannot recall when my memory start changing, but it was during treatment 
that I noticed lack of concentration and forgetting people’s names. I feel stupid 
and that I insult people by calling them with a different name.” Participant 14 
246 
 
 
8.2.2 Attention (Theme two) 
 
Words and phrases such as forgetfulness, lack of attention, unable to concentrate were 
clustered in the category “problems with attention, concentration and forgetfulness”.  
 
Some cancer patients complained about attention difficulties. They also mentioned that 
they found it harder to read, because they could not focus their attention on what they 
were reading. The same thing happened when they could not follow conversations and 
lost their train of thought through a lack of attention or forgetfulness, because they did 
not pay attention to cues in the environment which later could serve as reminders. They 
may also have frequently misplaced things, forgotten to take medication and missed 
appointments with doctors or social engagements. 
 
Attention is the ability to focus or concentrate on specific stimuli and comprises 
selective (focusing on relevant information and filtering out irrelevant information), 
sustained (maintaining attention on a task over a prolonged period of time), divided 
(focusing on multiple tasks at the same time) and alternating attention (switching 
attention between two or more sources of information), which play an important role in 
WM and PM (Neath et al., 2002; Rich et al., 2007). This section of our study is focused 
on divided attention, which is the type of attention the author believed affects chemo 
brain patients and that is most involved in PM. 
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PM permeates daily life activities such as remembering to take medication, passing on a 
message, remembering to pay the bills, remembering to attend appointments, etc. 
People are particularly prone to forgetting to carry out these tasks when they are busy, 
because increasing the attentional demands of an ongoing task interferes with PM. For 
example, patients might forget to pick up their children if they are thinking about their 
next chemotherapy treatment or forget to attend their appointment when they are 
engaged in a conversation with a friend (McDaniel et al., 2007; Harrison et al., 2013). 
 
Monitoring processes are needed to accomplish PM tasks, and people spend attentional 
resources on searching the environment for PM cues or to maintain the intention 
activated at the same time the ongoing activities take place (Harrison et al., 2013; 
Burgess et al., 2001; Smith, 2003). According to Harrison et al. (2013), monitoring 
must take place before the occurrence of the target event is to be recognised as a signal 
for an action to occur. Vigilance tasks can be impaired as a result of divided attention. 
Driving a car provides a good example of this, because a driver might pay attention to 
the travelling signs while searching for an upcoming turn. To do these monitoring 
processes, it is necessary to allocate WM and attentional resources, but attentionally 
demanding divided attention tasks may interfere with monitoring (Harrison et al., 2013; 
Burgess et al., 2001). This example is relevant to this study because participants 
complained about having trouble with driving and paying attention and giving 
instructions while driving. The author’s research question is that such troubles are due 
to the divided attention that might be interfering with monitoring.  
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Harrison et al. (2013) suggested that when a person’s attention is divided, superficial 
analyses of the environment are conducted, leading to poor processing, which in turn 
prevents retrieval of the intention, and that PM intention enters conscious awareness, as 
one of the participants explained:  
“I have been unable to concentrate for a long time. This lack of attention does 
not allow that my memory register things, therefore I cannot remember later.” 
Participant 3 
 
8.2.2.1 Examples 
“My memory has been affected by treatment, but I have not seen significant 
deterioration, other than confusing words and keep forgetting things, misplacing 
things, etc.” Participant 13 
“After treatment, I have been unable to concentrate for a long time. This lack of 
attention does not allow that my memory register things, therefore I cannot 
remember later.” Participant 3 
 
“At work, I have to write everything down, so I do not forget what I have to do. 
Before treatment I was able to follow map directions by seeing the map once, 
now I have to refer to the map constantly to get to my destination.” Participant 3 
 
“My life at work became difficult because I couldn’t remember what I had 
previously done the day before, or had difficulty following procedures that I was 
familiar with, and were easy to follow before. My memory before treatment was 
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average, but better than it is after treatment. I used to remember processes more 
easily. I had better recall of words, particularly difficult ones. My memory was 
good for remembering appointments and people. When talking to my friends, I 
feel embarrassed because I am unable to remember stories they had told me, and 
I keep asking questions about things they have already told me about.” 
Participant 8 
 
“I began having really bad and noticeable memory problems during and since 
treatment. I frequently forgot where I put things down, and I even forget my 
children’s names. During a conversation, I had to stop in the middle of it 
because I forgot what I wanted to say, or I cannot find the word to complete my 
sentence.” Participant 9 
 
“After treatment commenced I have problems remembering people’s names and 
what household jobs I am doing. I have trouble remembering names, and if I 
deviate my attention from a task I am working on, I completely forget to finish it, 
until I see it again later (e.g. putting the washing away).” Participant 10 
 
“Now my mind is having complete blank lapses, and I do not have recollection 
of certain things at all, for example, when we discuss a holiday or places I have 
been, I simply cannot remember. I used to have good memory about these sort of 
things, and at work I had good memory as well. I have always been bad 
remembering actors/actresses names, and now that is impossible. Once I forgot 
to turn up for a class (I am the teacher), something that has never happened 
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before, but I did not attribute this to my current condition. With all these, I feel 
anxious, but now I avoid making plans in advance as I used to do, because I fear 
I will forget and I do not want to disappoint people, because that makes me feel 
very bad. I need to ask them to remind me about our appointments.” Participant 
7 
 
“I need to write everything down and then remember to look at it. Recently I 
forgot when we need to leave the hotel and I was checking out a day earlier and 
moving to a different town a day before.” Participant 11 
 
“I have never had a great memory, but since treatment I feel that I cannot 
remember certain things from the past. The most noticeable thing is the lack of 
concentration and feeling of fuzziness. I have poor concentration and it is 
difficult for me to prepare a lesson for work. Also I avoid to work too far away, 
because I have trouble driving because of the lack of concentration. The lack of 
concentration has prevented me to drive and I feel very limited because of that.” 
Participant 14 
 
8.2.3 Multitasking (Theme three) 
 
Phrases like inability to multitask, more difficult to do my job, harder to do my job, 
slowness, were clustered in the category “inability to multitask”. Examples include, “It 
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now takes more effort to do simple tasks than before treatment” and “It is more difficult 
to follow familiar procedures and instructions.” 
 
Cancer patients experiencing memory difficulties frequently complained about losing 
their multitasking abilities. They usually explained that they were unable to do several 
things at a time as they used to do before treatment. They also complained about being 
slower or struggled to follow instructions or procedures, even those they were familiar 
with and used to master before treatment. They often reported being unable to complete 
a shopping list, or that they very often had to go to the grocery shop several times, 
because they could only buy one thing at a time. 
 
Performing two or more things concurrently is referred to as the ability to multitask. In 
real life situations, we face the extra challenge to remember to carry out our intentions 
at a later time while we are multitasking. This ability to multitask and to remember to 
do other things requires an effective distribution and coordination of attentional 
resources, but it can become impaired (Deprez et al., 2013). Cancer patients usually 
complain about impaired multitasking abilities, despite performing well in the 
neuropsychological tests. This might be due to increased WM demands and divided 
attention (Deprez et al., 2013; Santangelo et al., 2013). 
 
Volle et al. (2011) reported that multitasking involves RPC and that patients with 
lesions in this area frequently present problems with multitasking. These authors also 
stated that an essential component to multitasking is PM, and that patients with rostral 
prefrontal lesions present difficulties when there are several ways to behave, when the 
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behaviour is not fully guided by the environment and when two or more task are 
required to be performed concurrently. Examples of these situations in everyday life are 
preparing a meal, shopping, completing a job assignment, etc. (Volle et al., 2011). In an 
experiment with 60 rostral patients, Burgess et al. (2000) concluded that these patients 
showed impairment in the intentional component of multitasking (Volle et al., 2011). 
Other necessary components of PM are the ability to remember multiple instructions 
and the ability to switch between them (Volle et al., 2011). Therefore, the inability to 
follow instructions and slowness at work because of this deficiency are in the same 
category of multitasking. 
 
8.2.3.1 Examples 
“Since my memory problems began, after chemo, it takes me longer to work. I 
had to remind myself about procedures and took me more time to follow 
instructions, but that is improving now. I still struggle following instructions, but 
I compensate by keeping instructions I can follow.” Participant 8 
 
“During chemo I began noticing bad memory problems. I became unable to 
multitask and could only manage one thing at a time when I went shopping. I 
had to go back to the shop to buy another item when I got home. Before 
treatment, I was able to do a full shop list before chemo, post letters, get the 
stamps, and go to the recycling centre, all in one go, but I cannot do that 
anymore. Now I also have trouble remembering names, and that is unusual for 
me. I used to be a multitasking person, and now I only can deal with one thing at 
a time.” Participant 11 
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“Also I avoid to work too far away, because I have trouble driving because of 
the lack of concentration, and that makes me feel limited and has had a big 
impact on my social life and work. My work has also been affected because I 
struggle with emails and planning, and I feel it is falling behind.” Participant 14 
 
“Before treatment I was able to follow map direction by seeing the map once, 
now I have to refer to the map constantly to get to my destination.” Participant 3 
 
Participants were also asked about how their memory difficulties made them feel and 
how they were coping with these. With regard to mood, two general categories were 
identified: positive mood and negative mood. 
 
8.2.4 Negative mood, frustration and anxiety (Theme four) 
 
Words like frustration, cross, stupid, bewildered, worried were clustered into the 
category “feeling frustrated and anxious”. 
 
This theme explains the associated symptoms of the chemo brain phenomenon. Anxiety 
is very common during cancer treatment and can be associated with lack of attention 
and concentration. Patients are usually worried about the outcome of their treatment and 
how they would cope with all the demands that their treatment required, such as keeping 
up with appointments, handling the treatment’s side effects, surgery, relapse and all the 
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daily activities not related to their treatment, such as taking care of children, work, etc. 
To sum this up, they would need to cope with these new memory lapses, and they 
would worry about not being normal again, offend people around them or to cause harm 
as a result of their lack of attention. This new situation would sometimes make them 
feel frustrated, angry, stupid, or that they were not themselves anymore. 
 
8.2.4.1 Examples 
“I was quite concerned, but I realised that I had to accept that I was affected by 
the chemo, and now I am hoping that the memory will improve with time.” 
Participant 6 
 
“My family and friends noticed that I had memory problems because I said 
stupid things.” Participant 1 
“All these memory changes make me feel frustrated and angry.” Participant 1 
 
“Sometimes these changes make me feel irritated.” Participant 3 
“I feel embarrassed because I am unable to remember stories they had told me, 
and I keep asking questions about things they have already told me about. I feel 
frustrated, but I am getting used to these memory changes.” Participant 8 
 
“I feel frustrated and confused at times.” Participant 9 
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“My husband thinks I am not making a good effort to look after the household 
and family and gets cross when I do stupid things. I feel very stupid at times.” 
Participant 10 
 
“I avoid making plans in advance as I used to do, because I fear I will forget and 
I do not want to disappoint people, because that make me feel very bad. I need to 
ask them to remind me about our appointments.” Participant 11 
 
“I feel stupid and that I insult people by calling them with a different name.” 
“I have obsessive thoughts about the diagnosis and treatment, and its 
consequences.” Participant 14 
 
“In a way I feel less than I was before treatment. When talking to my friends, I 
feel embarrassed because I am unable to remember stories they had told me, and 
I keep asking questions about things they have already told me about. I feel 
frustrated, but I am getting used to these memory changes.” Participant 8 
 
8.2.5 Positive mood, acceptance, humour and resilience (Theme five) 
 
Words like laugh, accept, not let me bother, open about my forgetfulness were clustered 
in “acceptance and positive attitude”. 
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Some cancer patients showed that they were resilient in the face of adversity, even when 
they were facing life-threatening conditions. Sense of humour is a quality that could be 
observed in these patients who instead of letting themselves fall into a depressive state, 
laughed at those problems and accepted the fact that they were facing cancer. They also 
seemed to feel better by learning to cope instead of getting depressed about their cancer, 
thereby improving their quality of life.  
 
8.2.5.1 Examples 
“I was quite concerned, but I realised that I had to accept that I was affected by 
the chemo, and now I am hoping that the memory will improve with time.” 
Participant 6 
 
“I like to be a realist person, I think the human brain has imperfections, and I 
accept that. It is not possible to remember everything anyway.” Participant 7 
 
“The memory changes make me laugh rather than bother me.” Participant 13 
 
“My family and friends simply laugh about my memory lapses, but when I am 
trying to communicate with my teenage children about their social activities, it 
sometimes causes problems.” Participant 3 
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“My family laugh about these lapses, but still I get frustrated sometimes when I 
misplace things, although I do not let these things to bother me.” Participant 9  
 
8.2.6 Reminders dependency (Theme six) 
 
Participants were asked about how they were coping with their memory difficulties. The 
vast majority was relying on reminders of different sorts, such as asking people to 
remind them of their appointments, using dictionaries and by keeping diaries and lists. 
Only one participant mentioned about completely avoiding to drive because of her lack 
of attention, meaning that she was using avoidance as a coping strategy.  
 
8.2.6.1 Examples 
“All these memory changes make me feel frustrated and angry, but I am coping 
fine and I take my time to say things.” Participant 1 
 
“…but I am coping well by carrying a notepad with me to make list of the things 
I have to do.” Participant 3 
“I still have difficulty remembering words, and I have to describe the meaning 
so that someone reminds me the word. I still struggle following instructions, but 
I compensate by keep instructions I can follow. But I am getting used to these 
memory changes, and I use aids that help me cope, such as calendars and to do 
lists, and I use simpler words to describe things. Although it is frustrating, I am 
coping perfectly well. It has been a matter of making adjustments.” Participant 8 
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 “I am coping by making lists all the time as my reminders to do things.” 
Participant 10 
 
“I feel fine that I can do my job without any trouble, but I need to be more 
careful, and write things down so I can remember to do things.” Participant 11 
“My work has not been affected as much as I thought. I use aids to help me with 
my problems with words. I am coping fine, but I need to use reminders. I need to 
write everything down and then remember to look at it.” Participant 11 
 
Another coping strategy employed by participants was to work harder or take longer 
time to do or say things. Those who reported trouble following instructions or 
procedures tried to adhere to the procedures they were familiar with and used reminders 
or simply avoided new instructions. Some also avoided making plans in advance to 
circumvent embarrassment or situations they felt unable to cope with: 
“All these memory changes make me feel frustrated and angry, but I am coping 
fine and I take my time to say things.” Participant 1 
 
“At work, I have to write everything down, so I do not forget what I have to do. 
Before treatment I was able to follow map directions by seeing the map once, 
now I have to refer to the map constantly to get to my destination.” Participant 3 
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“My life at work became difficult because I couldn’t remember what I had 
previously done the day before, or it stated having difficulty following 
procedures that I was familiar with, and were easy to follow before… Since my 
memory problems began, after chemo, it takes me longer to work. I had to 
remind myself about procedures and took me more time to follow instructions, 
but that is improving now. I still struggle finding instructions, but I compensate 
by keeping instructions I can follow.” Participant 8 
 
“With all these, I feel anxious, but now I avoid making plans in advance as I 
used to do, because I fear I will forget and I do not want to disappoint people, 
because that makes me feel very bad. I need to ask them to remind me about our 
appointments.” Participant 11 
 
Not all participants in this study reported significant memory difficulties as a result of 
cancer treatment. Some reported that their memory was the same after treatment as 
before treatment. However, they did acknowledge memory difficulties, but attributed 
them to aging or menopause: 
“I cannot say for sure that my memory lapses are due to chemotherapy. Perhaps 
it is just due to aging. My family and friends do not notice anything, but they 
would think it is an age thing anyway. I like to be a realist person, I think the 
human brain has imperfections, and I accept that. It is not possible to remember 
everything anyway.” Participant 7 
 
260 
 
“I have always had memory problems, since childhood. Only my husband and 
children have noticed my memory problems during treatment, but they are not 
too significant, because my memory is the same than before treatment…” 
Participant 2 
 
“After treatment I have slight occasional memory loss, but my family and 
friends have not noticed them. I have occasional forgetfulness, but I cannot 
recall a cycle in particular when I noticed the forgetfulness. My memory now is 
the same as before treatment, and it has not affected my social activities.” 
Participant 5 
 
“…and think it’s an age thing anyway. Who remembers everything anyway? I 
like to think I’m a realist about the human brain and accept its imperfections. I 
assumed it is an age issue as has happened gradually since menopause.” 
Participant 7 
 
8.3 Summary of findings 
8.3.1 Emerging themes 
16. Words and names. The vast majority of participants in our sample reported having 
trouble remembering names of familiar people and with retrieving familiar words in 
conversations. 
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17. Attention. Patients reported changes in attention and inability to concentrate, 
leading to forgetfulness, affecting everyday tasks such as reading and attending 
appointments. 
18. Multitasking. Participants reported losing their ability to do several things at a time 
at work or at home. They felt they became slower and that some tasks became 
harder. 
19. Negative mood, frustration, anxiety. Chemo brain symptoms experienced by 
patients made them feel frustrated and anxious. They had the tendency to “feel less 
than before” and that created anxiety, affecting their social life, work and family life. 
20. Positive mood, acceptance, humour, resilience. Despite the frustration caused by 
chemo brain, some participants reported taking their forgetfulness with humour and 
becoming resilient, learning coping strategies to survive a life threatening illness. 
21. Use of reminders. The most common coping strategy used by participants was to 
become dependent on reminders to be able to remember their plans for the 
immediate future. 
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CHAPTER NINE 
9 CASE STUDIES: RESULTS AND DISCUSSION 
 
9.1 Case studies 
 
9.1.1 Case study one 
 
Participant one was agreeable, interested and compliant throughout the testing sessions. 
She communicated at ease with the researcher, and rapport was easily achieved. This 
participant had consistently reported cognitive decline since the beginning of the 
treatment and that her life had been affected significantly by these changes. 
Nevertheless, the support of her family and her own resilience had helped her to cope 
with the situation. Although her test results showed no significant impairment, her daily 
life was affected, and she clearly showed PM failure. In her report, she noted that her 
memory had not improved more than one year after the treatment and according to her 
partner, it had probably worsened. She worked as a driving instructor, but she reports 
that her work and social life had not been affected by her memory decline. 
 
9.1.1.1 Background information 
 
Participant one was a 44-year-old, Caucasian, British woman. She lived with her family 
and received strong family support from her two daughters and partner. She completed 
her secondary studies in the UK and was self-employed. 
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She underwent breast cancer surgery in September 2011, one month after being 
diagnosed. She began chemotherapy treatment one month after surgery and also 
received radiotherapy and hormonal treatment. She experienced chemotherapy-induced 
menopause. Her Full Scale IQ was 111 (30th percentile) on the NART. Her overall 
performance fell within the normal range and was equal to or higher than 30% of the 
women in this sample. The test was administered four times. 
 
EF scaled test scores for Participant one (Table 9.1) showed that her cognitive abilities 
fell within the normal range within the normal distribution when compared to women in 
this sample, showing a consistent pattern in responses over time. Her overall raw scores 
placed her on the 75th percentile on the Digit Symbol tests (where processing speed and 
intellectual abilities are measured), indicating that she could learn new tasks and had no 
problem making associations. The same was true for her attentional abilities, which 
showed not to be affected at the baseline measurement, even if her performance was 
poorer more than six months after treatment. Her Digit Span and Benton scores 
confirmed that her attention was unaffected and did not show any sign of memory 
problems. Her scores fell within the normal range and were fairly consistent throughout 
the sessions, falling into the 80th percentile rank.  
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Executive 
Function 
Test 1 Test 2 Test 3 Test 4 Overall 
%rank 
Digit Symbol 73 85 88 80 75 
Digit Span Total 18 20 20 19 80 
COWAT 34 36 39 45 50 
BENTON 
Correct 
10 9 10 10 90 
Table Error! No text of specified style in document..1. Test scores for Participant one. 
 
Despite these results, Participant one reported having attentional and concentration 
problems throughout the testing sessions, and the problems had persisted for several 
months after the treatment, with no sign of improvement. 
 
Her COWAT test scores indicated that she did not present difficulty retrieving words, 
but her anecdotal reports indicated the opposite. Despite the fact that she improved her 
test scores in the last session, six months after treatment, word retrieval was the most 
evident complication in her daily life, because as a driving instructor, her job depended 
on giving instructions and remembering what to say. 
 
For the PM measures, Participant one performed worse in the first test, before treatment, 
but after surgery, however, at post-treatment she performed worse than any of the 
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previous tests (Table 9.2). This suggested that her PM was more affected, possibly due 
to the anxiety experienced before commencing the treatment. Her performance was 
better for focal tasks than for nonfocal tasks, meaning that her self-initiating monitoring 
was affected even before treatment. Interestingly, her PM scores improved significantly 
during mid-treatment and immediately after treatment. The improved performance in 
the second test might have been due to familiarity with the test; however, the most 
significant improvement was for time-based tasks, which showed that there was a more 
conscious self-monitoring behaviour. Nevertheless, her performance declined in the 
third and fourth tests. Six months after treatment, her performance continued to 
deteriorate. These results are consistent with the findings that cognitive decline after 
chemotherapy is manifested in some patients several months after treatment. Her overall 
performance between time-based and event-based prompts demonstrated that her self-
monitoring behaviour was better than cue-dependent monitoring. 
 
CAMPROMPT Test 1 Test 2 Test 3 Test 4 
Time  12 18 16 16 
Event 14 16 16 12 
Total 26 34 32 28 
Classification B AA A P 
B=Borderline P=Poor A=Average AA=Above Average VG=Very Good 
Table Error! No text of specified style in document..2. CAMPROMPT scores for 
Participant one. 
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9.1.1.2 Sleep 
 
On measures of sleep, Participant one reported poor sleep patterns and that she felt 
sleepy during day time. The number of hours she slept were inconsistent with her self-
reports, which showed that she slept for more than 8 hrs a day, but she felt that she did 
not sleep enough and felt somewhat sleepy during the day (Table 9.3). This 
inconsistency might be because despite the fact that the SWA showed that she slept for 
more than the average hours of sleep, her sleep time was not efficient. There is evidence 
that hypersomnia affects sleep efficiency and may also interfere with PM. These sleep 
patterns might have been contributing to some of her memory difficulties and might 
have been caused by medication or anxiety. 
 
Sleep Test 1 Test 2 Test 3 Test 4 Overall 
%rank 
PSQI 15 14 16 11 95 
ESS 
 
7 5 4 5 50 
Sleep 
(hours) 
32.23 22.11 32.23 27.03 50 
Table Error! No text of specified style in document..3. Measures of sleep Participant 
one. 
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9.1.1.3 Online questionnaires and face-to-face interviews 
 
In the online questionnaires, Participant one reported that her memory became very bad 
during and after treatment. It was her family who first realised that she was having 
memory changes, and her partner said that it was worse at over 12 months after the 
treatment began. She reported that her work had been affected because she was a 
driving instructor and needed to give many verbal instructions to her students, but 
sometimes forgot what she needed to say. However, her social life had not been 
affected, as opposed to some patients who became isolated to avoid embarrassment with 
their friends. She reported feeling frustrated at times and bewildered as to why she 
could not remember simple words, but her family support had helped her to face the 
situation with humour, rather than with complaining: 
 
“During and since chemotherapy my memory has gotten really bad. I put things 
down and forget where I've put them. I forget my children’s name. I will start 
talking and stop mid-sentence because I either can't remember what I wanted to 
say or I have forgotten the next word.” 
“Oh, got bad! It hasn’t gotten any better either. Umm… I can start a sentence 
and get half way through and I forget totally what I wanted to say. Umm…I put 
things…away, umm…and then can’t remember where I put them.” 
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9.1.1.4 Prospective memory common failures 
PM self-reports were administered for screening and to observe if participants had an 
actual PM problem. In the PMQ and PRMQ, Participant one reported that quite often if 
she decided to do something in a few minutes’ time, she would then forget to do it. She 
would also forget things that she had been told a few minutes before. 
Participant one reported some of the most common PM deficits: She often found herself 
repeating the same story to someone on different occasions, but she did not realise until 
they told her that she had already told the story a few minutes before: 
 
“…Yeah, Andy will say, “you’ve told me this already”, I’ll go, “no I haven’t”… 
“yes, you have.”… And he’ll go, “but I just told you half an hour ago, I’ve just 
told you.”…and I say, “Really?” 
 
She also reported that she would quite often forget to buy something that she had 
planned to buy, even when she saw the shop. She frequently went to do her shopping 
and found herself inside the grocery shop, because she planned to buy something there, 
but would then not remember why she was there. Once she got home, she would 
remember what she wanted to buy and planned to do it the next day, but then the next 
day, the same thing would happen again: 
 
“…the other day in the high street I was like… ‘I know I wanted to go to 
Waitrose…what did I want to go to Waitrose for? Hmm…I can’t remember,’ 
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and I get home and then later in the evening I remember and I go, ‘Okay 
tomorrow I’ll walk into Winton and go to Waitrose,’ get there…can’t remember, 
I still haven’t got the stuff (laughs) cause every time I walk into the high street I 
forget what I want…I’ve got to write it down so that I remember what I want to 
get.” 
 
She reported that she often failed to recall things that had happened to her in the 
previous days, but she did not have problems with her LTM. She sometimes got 
confused about the things she had done, which she did not have recollection of doing. 
 
“Umm…but yeah, my memory is shot to pieces, but it’s not my long term 
memory really it is…more short term, on an everyday basis.” 
“umm but events…no…it’s more you know, umm…I don’t know I mean 
sometimes I think I’m just getting confused, umm…and my other half will say 
to me, ‘no, no, no, yes you…you did this,’ and I’m ‘no I didn’t… I didn’t do 
that,’ he’s like ‘yes…we did do that.’” 
 
When asked how often she mislaid things, she said that it was quite often, and that very 
often she would walk into a room and forgot why she went there. She also reported that 
very often, she would forget to take her medication. She mentioned that to be able to 
remember an appointment with the doctor, she had to use a reminder, otherwise she 
would forget it. She would also forget to mention a point during a conversation and 
would fail to complete a sentence without realising. 
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“…and I’ll stop and Andy will say…‘what you saying? Finish the sentence.’ I 
don’t know what I’m saying, I can’t remember. A lot of the times I don’t realise, 
I don’t realise that I’ve stopped… talking. Umm…I just stop and carry on doing 
something different and he’ll go, ‘what’s the rest of the conversation?’ 
‘Oh…umm, oh I can’t remember,’ but…my memory is shot (laughs).” 
 
9.1.1.5 Words and names: Tip-of-the-tongue phenomenon 
 
Consistent with chemo brain difficulties, Participant one reported having trouble with 
names, particularly her children’s and fiancé’s names. She had the tendency to mix their 
names and call her fiancé by the name of her ex-husband. 
 
“My children’s names, I...get them muddled up and there’s nine years between 
them (inaudible) so they’re not even close in age. One is 21 and one, you know 
12 nearly, and…can never remember which one is which. Umm…even to the 
point I’m getting married this year and my other half, I keep going to call him by 
my children’s fathers’ name, and…Yeah it’s, it’s…I think once I have called 
him it… umm, and the other times I’ve stopped myself and I’ve gone “no, that’s 
not right.”  
 
At work, she also struggled finding the right words when teaching her students. She 
worried about this situation because she was a driving instructor, and sometimes she 
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would know that she had to give the student an instruction, but was unable to remember 
the instruction or a particular word she needed to use.  
9.1.1.6 Attention 
 
Although Participant one reported that she rarely forgot to do her housework, it would 
often take her several hours because she would find herself doing several things at once, 
but not finishing any of them. She would start doing a task and would suddenly 
remember that she had to do something else, so she would stop what she was doing and 
would start on the second task. While she was doing the second task, she would 
remember a third one, she would switch, without finishing the second one, and so on. It 
seemed that she had lost the ability to focus her attention on one thing at a time: 
 
“…but when I’m doing the house work, I don’t seem to be able to concentrate 
on just doing one thing, let’s say the hoovering, start the hovering then finish it 
then go on to something else. I start and then go, ‘Oh! Okay, I’ll go and do this,’ 
I get very distracted very quickly. …then about an hour later I go, ‘oh! I haven’t 
finished the hoovering,’ so I go back… and It’ll take me, it took me three and a 
half hours the other week to do all my house work, and I don’t have a big 
house…I get distracted and do… other bits of housework, not that I go off and 
watch television or… you know, go and do… I… I just think of other things that 
I need to do in the house work, or I need to change that bed or I need to do this, 
and I need to do that. Umm… and then I forgot what I was doing before and 
then I realised… ‘Oh! I didn’t actually finish doing that,’ and sometimes I’ve 
made half a bed, gone off and done something else… and hour and a half later 
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realised that I didn’t actually finish what I had first started… uhh (laughs)… The 
hoover, I can leave that on… and not noticed that I’ve left it on, literary it’ll still 
be sucking air and I’ve gone downstairs and I’ve come back up half an hour later 
and go, ‘What’s that noise? Oh! The hoover is on.’ Yeah, that’s when I 
remember I haven’t finished hoovering.” 
 
Another PM failure that was present in Participant one was that when she was cooking, 
she would forget things heating on the hob, or she would be unable to remember some 
of the ingredients of a recipe that she had been cooking for years. Before treatment, she 
did not have these problems, but subsequently, she could not manage without following 
the recipe, otherwise she would forget ingredients adding and miss out parts of the 
recipe. A more serious consequence was that she frequently forgot to switch off the gas 
after cooking: 
 
“…but something as simple as…umm, Yorkshire pudding, every Sunday I have 
to get the recipe out to have a look, and every Sunday it’s the same recipe! But I 
can’t remember all parts of it, I can remember some of it but not all parts of it, 
and what order to put everything in, and it’s like… really frustrating, uhh…” 
“Umm… the one I do the most… is… and it happened the other day, is the 
stove, and leave the stove on… the hob, and I… it could be when I’m doing rice 
and stuff so it’s down really low but I forget it’s on and then I either burn the 
rice or… the other day umm… my older walked through the kitchen and she 
went, ‘oh god it stinks of gas in here!’ and I went, ‘why?’ and I hadn’t switched 
off the gas, I turned it down so it had gone out… but it hadn’t switched off…” 
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She also commented that when she would be cooking and remembered that she needed 
an ingredient from the fridge, by the time she approached the fridge, she would 
completely forget why she had opened it. 
 
Her attention span had also changed since treatment, in that she had found herself 
reading a book, and it was only near the end of the book that she would remember that 
she had already read it. The same thing happened with films or TV shows. Every night 
before going to bed, she struggled to remember the book she was reading. It would take 
her a few minutes of reading to remember the plot and characters of the book: 
 
“…most evenings when I go to bed, it takes me a good fifteen, twenty minutes 
before… I realise what book I’m reading. So like last night when I picked it up I 
was like, ‘I can’t remember any of these characters, who are they? And what are 
they doing? What is this book about?’ and then about fifteen twenty minutes 
later I go, ‘Ah okay, now I know what’s going on’… I couldn’t even tell you the 
name of the book. I can’t even tell you the characters names…” 
 
She also reported that she had trouble following maps and that she needed directions to 
go to even very familiar places. She had to rely on her Sat Nav to be able to go to the 
house of her best friend, which was located in another city, even when she had travelled 
there many times before: 
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“…I have to have a Sat Nav tell me… because… I wouldn’t be able to just look 
at a map and remember I have to, even like going to my best mates, she lives in 
Swindon way, and we go up there quite often but I still have to put the Sat Nav 
on otherwise I’ll not get there and it’s one straight road from Salisbury, it’s not 
like having to turn down all different roads and it’s all signposted but I still need 
the Sat Nav on… and when I get there I go, ‘I didn’t really need the Sat Nav,’ 
but if I tried to do without the Sat Nav I would not get there.” 
 
She would usually forget her purse with all her money and credit cards in it; however, 
she would not realise that she had left the purse until someone else reminded her or 
found it. 
 
9.1.1.7 Multitasking 
 
The ability of Participant one to multitask was also affected. She was used to handling 
several things at a time, such as having a conversation on the phone while she was 
doing some housework or other things. After the treatment, she was unable to pay 
attention to a phone conversation if she was trying to focus on something else: 
 
“….I’m not as good at multitasking as I used to be, I can’t concentrate… I can’t 
do two things at one time…” 
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9.1.1.8 Dependency on reminders 
 
As with many of chemo brain patients, Participant one had become dependent on 
reminders in order to execute her plans. She used her phone to remind her of 
appointments and had to write notes with to-do lists. Nevertheless, she would usually 
forget her reminders. For example, she would forget her phone or iPad at home and 
would not remember where she had left them: 
 
“…I have to write notes to remind me to do things… even like for today I had to 
put that in to remind us so this morning my phone came up to remind me…this 
morning I had to go to the doctor to have my implant in my stomach put in, and 
that’s every four weeks I go for that, and it’s the same time every four weeks, 
same day… I have to program it, so it tells me 15 minutes before I need to be at 
the doctor’s, that I need to be leaving to go to the doctor’s.” 
 
9.1.1.9 Negative mood, frustration and anxiety 
 
Participant one reported feeling frustrated and bewildered. She showed moderate levels 
of anxiety, particularly at testing session 4, and she was within the 75% percentile rank 
in scores of anxiety and depression (Table 9.4). This is consistent with many cancer 
patients who report being more anxious once they have finished the treatment due to the 
fact that they are no longer under the care of the medical team. However, EFs were not 
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significantly affected by this increased anxiety, except for PM and processing speed. 
Although only a slight increase, it could not be ruled out that this might explain why her 
PM had been more affected after finishing the treatment. 
 
HADS Test 1 Test 2 Test 3 Test 4 Overall 
%rank 
Anxiety 7 7 6 9 75 
Depression 1 3 2 1 75 
Table Error! No text of specified style in document..4. Anxiety and depression scores 
for Participant one. 
 
9.1.1.10 Positive mood acceptance, humour and resilience 
 
Despite facing an illness such as cancer, Participant one has learned how to cope with 
her memory difficulties as well as possible. She reported feeling frustrated at times, but 
she and her family learnt to laugh about her memory changes and did not allow these 
things to bother her. Her depression scores confirmed this may be true, since they show 
that there are no signs of concern. 
 
9.1.1.11 Summary of findings for Participant one 
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The findings for Participant one are summarised in Table 9.5 
Parameter Comment 
Neuropsychological tests Overall, neuropsychological tests showed that 
cognitive abilities were not affected by cancer 
treatment. 
Executive function Normal 
CAMPROMPT Average, above average 
Interviews and self-reports  
PM Failures 1. Misplacing things, problems with attention and 
concentration 
2. Problems with multitasking 
3. Needed to use reminders 
4. Forgot appointments, forgot to take medication 
5. Forgot to switch things off 
Other difficulties associated 
with chemo brain 
Problem with words and names 
Anxiety Mild 
Depression Low 
Sleep Poor 
Table 9.5. Summary of findings for Participant one. 
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9.1.2 Case study two 
 
Participant two showed a positive and interested attitude throughout the testing sessions. 
She communicated at ease with the researcher, and rapport was easily achieved. Her 
cognitive tests showed no sign of decline; however, she reported having significant 
memory difficulties on a daily basis, and these had not improved after more than one 
year of treatment. She used to be a person who would multitask, but now she thinks she 
had lost this ability since the beginning of the treatment. She had strong social support 
and worked full time, despite her illness. 
 
9.1.2.1 Background information 
 
Participant two was a 45-year-old, Caucasian, British woman. She had college level 
studies and worked full time. She underwent breast cancer surgery and began 
chemotherapy treatment one month after her second surgery, which was three months 
after being diagnosed. She also received radiotherapy and hormonal treatment. Her 
menopausal status was not affected by the treatment, because she had a full 
hysterectomy two years before being diagnosed with breast cancer.Her Full Scale IQ of 
121 (75th percentile rank) was on the NART. The test was administered four times.  
 
The EF abilities of Participant two were in the normal range compared with women in 
the same age group (Table 9.6). Her ability to learn unfamiliar tasks and process 
information on the Digit Symbol test showed an improvement during and immediately 
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after treatment, even though she had reported having trouble learning new tasks and 
following instructions. Assessment of anxiety, distractibility and sequencing problems 
on Digits Span measures also showed an improvement in sessions two and three; 
however, a slight decline was seen six months after treatment. Her visual memory and 
spatial orientation remained constant during sessions one and two, but a decline was 
observed in subsequent sessions. This might explain her failures in PM because of a 
lack of attention to visual cues in the environment that might prompt her to perform an 
intended action. Her verbal production abilities showed an improvement over time in 
the COWAT tests scores, but she struggled to retrieve words in her daily life. 
 
Executive 
Function 
Test 1 Test 2 Test 3 Test 4 Overall 
%rank 
Digit Symbol 66 81 82 80 75 
Digit Span Total 16 18 22 21 80 
COWAT 28 39 38 43 50 
BENTON 
Correct 
9 9 8 7 50 
Table Error! No text of specified style in document..6. Test scores for Participant 
two. 
 
In the CAMPROMPT test, Participant two showed that her PM was between average 
and very good range throughout the test sessions when compared with women in her 
age range (Table 9.7). On her first test, her scores were lower than in the following tests, 
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performing better in self-monitoring tasks than cue-dependent tasks. Her best 
performance was precisely in the middle of chemotherapy treatment and immediately 
after treatment. However, six months later, her performance deteriorated. The fact that 
she performed better in the second test might have been due to familiarity with the test, 
but her performance declined in the third and fourth tests; therefore, familiarity could be 
ruled out. Her performance in event tasks indicated that she had poorer PM for cues that 
were prompted in the environment than for time-based cues, and that her self-initiating 
PM was better. 
 
CAMPROMPT Test 1 Test 2 Test 3 Test 4 
TIME 18 18 18 18 
EVENT 12 18 16 14 
TOTAL 30 36 34 32 
Classification A VG AA A 
B=Borderline P=Poor A=Average AA=Above Average VG=Very Good  
Table Error! No text of specified style in document..7. CAMPROMPT scores for 
Participant two. 
 
9.1.2.2 Sleep 
 
Sleep self-reports for Participant two showed that her sleep habits were not severely 
affected, but she presented some degree of sleepiness during day time (Table 9.8). 
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However, her objective measure of sleep reported that she was sleeping for more than 
the average number of hours per day, which might explain her feeling of sleepiness 
(hypersomnia and PM). 
 
Sleep Test 1 Test 2 Test 3 Test 4 Overall 
%rank 
PSQI 6 9 4 6 75 
ESS 7 5 5 8 75 
Sleep 
(hours) 
33.21 35.24 31.31 34.37 90 
Table Error! No text of specified style in document..8. Sleep scores for Participant 
two. 
 
The anxiety self-report showed that her anxiety levels were in the low range for the first 
three tests. However, six months after treatment, she showed an increase in anxiety 
levels (Table 9.9). She did not present significant signs of depression. 
 
HADS Test 1 Test 2 Test 3 Test 4 Overall 
%rank 
Anxiety 3 4 2 7 25 
Depression 2 3 1 3 50 
282 
 
Table Error! No text of specified style in document..9. Anxiety and depression scores 
for Participant two. 
 
 
9.1.2.3 Online questionnaires and face-to-face interviews 
 
Despite the fact that the PM test results of Participant two showed that her PM was very 
good and had not been affected by cancer treatment, self-reports and interviews 
reflected the opposite. 
 
Participant two reported that her memory difficulties became obvious during 
chemotherapy, and that she struggled at work as she could not always remember what 
she had done the previous day, or follow procedures that she was familiar with before 
treatment. She started noticing a difference in her memory after the second treatment 
when she found it difficult to do some of her work as easily as before. She reported that 
more than a year later, she still found it hard to remember appointments, so she had to 
rely heavily on reminders, such as her diary and to-do-lists. 
 
Participant two reported that she did not have memory problems before treatment, and 
that she could remember processes at work, appointments and people more easily. She 
used to have a better recall of words, especially more descriptive and difficult words. 
For these reasons, her work had been negatively impacted, but she had learned how to 
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cope. On the other hand, in her social life, she sometimes felt embarrassed with her 
friends, when she asked questions about things that she has been told before.  
These memory changes made her feel frustrated, because she enjoyed using complicated 
language, but now she needed to use simple words and struggled to find the right words 
to describe things. However, she had learned to cope by using aids and by adjusting to 
the situation. 
 
9.1.2.4 Attention 
 
Participant two’s attention had suffered since she started treatment. Her attention before 
treatment was fine and she was able to focus on her job and duties quite well. Since 
treatment, she started to lose attention to things at work and found herself misplacing 
things in different drawers and files. She also struggled following instructions or 
procedures she was previously familiar with: 
 
“I usually misplace files at work. I put them in a different drawer, or the same 
drawer but in a different file. I also struggle following procedures and 
instructions, but I try to keep things simple. For example, filling a form can 
become difficult, so I try to fill forms always in the same way.” 
 
She also reported that her attention at work had been affected and that she often 
repeated actions, such as sending the same email twice. However, she had learnt to cope 
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with this situation by keeping a reminder or records of the activities she had already 
performed: 
 
“At work I have to be very careful with my emails and make notes that I have 
sent the email, so I do not send it twice…” 
 
When asked about finding herself repeating the same story to the same person on 
different occasions, she responded that she sometimes had been in that situation and felt 
embarrassed with her friends or colleagues, and that she sometimes forgot something 
she was told just a few minutes before: 
 
“I usually have to ask people if I have told a story before, because I cannot 
remember if I have told them, or if in a group of people I have said that story 
before” 
“When I drive to a new place, before treatment I just had to refer to a map once, 
but now I need to constantly look at like, sort of like, one step at a time, and not 
the complete sequence.” 
 
Her attention had also been affected at home, and she got easily distracted, especially 
after arriving home from shopping: 
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“I very often leave the iron on, and when my groceries arrive home, it’s a 
problem because I start unpacking and leave the groceries for a minute to go to 
another room, I get distracted and begin doing another thing, and then I stop 
doing that, to begin another thing, and I completely forget about the groceries, 
until I come back to the kitchen later. The problem is with the frozen food that 
needs to be kept in the freezer.” 
“I force myself to keep my attention on one thing until I finish it.” 
 
She also complained about having trouble with her concentration, especially when she 
tried to read a book or a magazine, and could not focus for long periods of time: 
“My concentration is not as good. When I read, I just can read like little chunks, 
and then I have to move to another thing, but I do not find myself reading and 
reading the same page several times.” 
 
Other abilities that showed poor PM were that she had problems remembering new 
places that she had visited (with her boyfriend having to remind her that they had 
already been in some place that she did not remember). When driving to a new place, 
she needed to constantly refer to a map, going one step at a time rather than in a 
complete sequence: 
“Now I forgot about places and events I have attended, such as concerts, and I 
only know I have been there because my boyfriend tells me we went, but I am 
completely blank about it.” 
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9.1.2.5 Multitasking 
 
Participant two also reported that her attention at work had been affected, and that she 
had lost her ability to multitask. Before treatment, she used to be able to handle several 
work-related activities at once, but now she could only cope with one or two tasks at the 
same time: 
 
“Also, I was able to do several things at a time, like checking emails, answering 
the phone, and filing stuff, but now I can only manage one or two things at a 
time.” 
 
9.1.2.6 Dependency on reminders 
 
Participant two reported that she had to rely heavily on reminders, otherwise it would be 
impossible to remember plans, and that she very often forgot appointments if they were 
not prompted by a reminder. She had opted for writing things on her hand to remind her 
not to forget her notes or diary, but she would forget to look at her hand. She would also 
miss appointments with her doctor: 
 
“I always have to keep a diary and write up everything I have panned ahead. It 
has become impossible to remember what I have to do next week, or even 
tomorrow, or in a few hours without looking at my diary.”  
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“The other day someone called me to ask if I have noticed that I had forgotten 
my appointment, and I said, no, because even at that moment I couldn’t 
remember.” 
 
She reported that she sometimes forgot to buy something that she had planned to before 
going to the shops, unless she had written it down, but then she would forget to look at 
the reminder: 
 
“When I go shopping I must write everything down on a list or in my hand to 
remember what I need to buy, but the trouble is that I forget to look at my hand, 
so I come back home without what I was supposed to buy.” 
“I think it would be impossible for me to remember to do things if I do not keep 
a dairy or use reminders.” 
 
Overall, neuropsychological tests showed that her cognitive abilities were not affected 
and that depression and anxiety as well as reported sleep and objective sleep measures 
were not abnormal. However, the qualitative analysis showed that her PM and other 
cognitive abilities associated with PM, such as attention and concentration, and her 
ability to multitask had been affected by the treatment. 
 
9.1.2.7 Words and names: Tip-of-the-tongue phenomenon 
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One of the things that made Participant two feel more frustrated was that she struggled 
to find the right word to say when constructing a sentence. She explained that she had 
been used to using complicated words, but after treatment, she could not even remember 
simple things. She felt like she had the word in the back of her mind, but she simply 
could not retrieve it, so she ended up describing what she was trying to say. She also 
had problems with names and she kept mixing up the names of people she had known 
for a long time, particularly at work: 
 
“I was very good with words, and like to use complicated words, but now I need 
to use simple words. I feel frustrated, but I am learning to get used to it. The 
feeling is that I know that I know the word, but I simply cannot recall it. I mix 
names of people, and I do realise that I have done it.” 
 
9.1.2.8 Positive mood acceptance, humour and resilience 
 
Participant two reported coping with these troubles perfectly well and although it was 
frustrating, she had learnt to adjust to the situation by using calendars, reminders and by 
being very open about her forgetfulness with her friends and colleagues. However, she 
also reported that she felt as if she was “less” than she was before. 
 
9.1.2.9 Summary of findings for Participant two 
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The findings for Participant two are summarised in Table 9.10. 
 
Parameter Comment 
Neuropsychological tests  
Executive function Normal 
CAMPROMPT Average, above average 
Interviews and self-reports  
PM Failures 1. Misplaced things 
2. Problems with attention and concentration 
3. Problems with multitasking 
4. Needed to use reminders  
5. Forgot important appointments 
6. Forgot to switch things off 
Other difficulties associated with chemo 
brain 
Problem with words and names 
Anxiety Mild 
Depression Low 
Sleep Good 
Table.10. Summary of findings for Participant two. 
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9.1.3 Case study three 
 
Participant three was agreeable, interested and compliant throughout the testing 
sessions. She communicated at ease with the researcher, and rapport was easily 
achieved. She reported having memory difficulties as a consequence of chemotherapy, 
but more than one year after treatment, her memory had improved. Participant three was 
in the middle range of the spectrum of chemo brain and PM for this study, meaning that 
her memory was not badly affected and she had slowly recovered her cognitive abilities. 
This particular case was interesting because although she presented very common 
attention and PM failures, she had the tendency to attribute them to other factors such as 
age, lack of confidence or miscommunication. 
 
9.1.3.1 Background information 
 
Participant three was a 49-year-old, Caucasian, British woman. She worked full time 
before treatment and received strong family support. She completed her college 
education in the UK and worked part time during treatment. She lived with her family 
and received strong social support. 
 
She underwent breast cancer surgery and began treatment one month after being 
diagnosed. She also received radiotherapy and hormonal treatment. Before treatment, 
she was pre-menopausal, but chemotherapy induced her menopause. Her Full Scale IQ 
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of 121 (75th percentile rank) was on the NART when compared with other women in the 
sample. The test was administered four times.  
 
In EF abilities, Participant three was in the normal range compared to women in her 
same age group, meaning that her cognitive performance had not been affected by 
treatment (Table 9.11). However, a decline was observed during session four for 
attention span, distractibility on the Digits Span test and on the Digit Symbol test, 
through which intellectual abilities are assessed. Improvement from baseline in 
subsequent sessions might have been due to practice effects.  
Executive 
Function 
Test 1 Test 2 Test 3 Test 4 Overall 
%rank 
Digit Symbol 58 66 82 68 50 
Digit Span Total 14 19 22 18 50 
COWAT 29 26 38 34 25 
BENTON 
Correct 
9 9 4 9 50 
Table Error! No text of specified style in document..11. Test scores for Participant 
three. 
 
In the CAMPROMPT test, Participant three performed better in the first test than the 
following two tests and improved again in the last test (Table 9.12). This suggested that 
her PM remained in a very good condition, although a slight decline was present during 
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treatment, particularly in event-based tasks. Overall, she showed better performance on 
self-initiating monitoring than on cue-dependent monitoring. 
CAMPROMPT Test 1 Test 2 Test 3 Test 4 
TIME 18 18 18 18 
EVENT 18 16 16 18 
TOTAL 36 34 34 36 
Classification VG AA AA VG 
B=Borderline P=Poor A=Average AA=Above Average VG=Very Good 
Table Error! No text of specified style in document..12. CAMPROMPT scores for 
Participant three. 
 
9.1.3.2 Sleep 
 
Sleep self-reports for Participant three showed that her sleep time during treatment was 
better than both before and after treatment (Table 9.13). In spite of this, objective 
measures showed that she was oversleeping and that she felt sleepy during the day. Her 
sleep self-reports showed that she felt her sleep quality was poor and she slept for 
slightly more hours than the average sleeping hours. 
 
Sleep Test 1 Test 2 Test 3 Test 4 Overall 
%rank 
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PSQI 12 7 4 10 75 
ESS 6 6 5 5 50 
Sleep 
(hours) 
38.58 32.13 34.00 32.48 90 
Table Error! No text of specified style in document..4. Sleep scores for participant 
three. 
 
9.1.3.3 Online questionnaires and face-to-face interviews 
 
Although Participant three obtained very good PM scores on the CAMPROMPT, she 
reported that her memory was affected by treatment on a daily basis. In the online 
questionnaires, she said that she was unable to concentrate for a long time, so she could 
not register things and therefore, could not remember them later. She reported that her 
memory before treatment was usually good and that she could not recall exactly when 
her memory problems began after starting treatment: 
 
“I think my memory is better now than what it was during treatment. But 
probably not as good as it was before treatment.” 
 
9.1.3.4 Dependency on reminders 
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Participant three became very dependent on reminders, so that she could remember 
what she had planned to do. She set reminders on her phone and carried a calendar, but 
she would often forget them at home: 
 
“Yeah, I always remember those, but I do use…. I’m quite heavily reliant on my 
phone to remind me... I... I put all my appointments on my phone and I have a 
calendar as well, so I do use that. I have to write lists now for shopping… but I 
forget my phone all the time, my girls are telling me off all the time I have 
forgotten my phone… but generally I do remember things umm… but as I say 
it’s unimportant things that I don’t tend to remember.” 
 
9.1.3.5 Attention 
Before treatment, Participant three was attending a college course and she reported that 
she was able to study for several hours; however, during treatment, she lost that ability 
and could not concentrate, so she could not remember the content of the lectures or her 
reading, and her studies were affected. By the end of this study, she had not returned to 
college, so she did not know if she had regained her ability to concentrate: 
 
“I could sit and study for two hours before…but during treatment there was no 
way I could have done it.” 
“…and I couldn’t remember what I had learnt… and to sit and study for two 
hours just…I just couldn’t do it…” 
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When driving to a new place, she needed to refer constantly to maps, but she thought 
that it was more of a confidence problem rather than attention or memory: 
 
“...I think that’s a confidence thing... umm… I… I could always pick up a map, 
see where I was, see where I needed to go, and work out the way. Whereas now, 
more or less at every junction I look… to make sure I’m going to right way.” 
 
She reported that sometimes she forgot to do something that she was going to do a few 
minutes later, and that she quite often forgot to buy things that she had planned to even 
when she saw the shop. She also reported that she would sometimes find herself 
repeating the same story to someone on different occasions and that she mislaid things 
and forgot to pass on messages. 
 
She often forgot something she had been told a few times before, but she attributed it to 
a communication failure rather than to memory problems, and that this probably 
happened to her once or twice a week: 
 
“...and then they say to me, ‘oh you promised to take me here!’ and I was like, ‘I 
don’t remember telling you that?’” 
“…somebody might have said…’I’m going to Poole tomorrow,’ and then the 
next day I would say to them, ‘what did you do today?’ ‘Well I told you I was 
going to Poole’, you know I’d forget things like that but they weren’t really 
important to me.” 
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Her lack of attention and a tendency to lose concentration was usually related to TV 
shows or unimportant things. She had trouble following the sequence of a programme, 
but she explained that her lack of attention was intentional, and that her failures were 
due to her lack of interest in unimportant details: 
 
“…television programs for example… I tend to get bored very quickly… and if 
there is, say a thriller or something like that, I’m not interested in, I just want to 
know who’s done it, I’m not interested in all… in all the bits in between… I tend 
to lose concentration and… very often I have to say to one of my daughters, 
‘what happened there? I missed that, what happened there?’” 
“It’s usually when I’m not interested (laughs)… I think it’s rude actually... I 
know, I know I do it, but I can’t help myself… My husband... my ex-husband 
often used to say to me, ‘you’ve gone blank again, I’ve lost you’… but that’s 
because I wasn’t interested in what he was talking about.” 
 
Despite the fact that her work had not been affected, she admitted that on occasions, she 
had forgotten to do something, but it did not cause much of a problem at work, and her 
omissions were related to unimportant issues: 
 
“...I don’t think I ever forgot anything that was major that would have caused a 
problem at work... umm… I did forget a few things that actually didn’t matter if 
they were done or not, but my boss thought they were important but actually at 
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the end of the day, you know, in the big scheme of things it didn’t matter at all. 
So I think subconsciously I was filtering out…. to try and prioritise and to try 
and fit everything in.” 
 
9.1.3.6 Words and names: Tip-of-the-tongue phenomenon 
 
Participant three also reported having trouble with words and names and that she felt 
frustrated because she was supposed to know the word. She mentioned she usually 
coped well with this, because she would quickly find another word: 
 
“…sometimes I do, even now have trouble thinking of the right word…I 
consider that I’ve got quite a good vocabulary.… but sometimes , I’m having a 
conversation and a word just won’t come to me. Even now, normally names. I 
could usually look at somebody and remember their names straight away, but 
not now…and this happens very often.” 
 
9.1.3.7 Positive mood acceptance, humour and resilience 
 
Participant three had coped well with her memory difficulties and had tried to keep up 
good spirits throughout. However, even if she did have PM deficits, she did not 
acknowledge those deficits as important or significant in her life. She preferred to focus 
her attention on more important things in life rather than to worry about minor 
problems. 
298 
 
 
9.1.3.8 Negative mood, frustration and anxiety 
 
Participant three experienced a moderate level of anxiety, particularly before and after 
treatment. She suffered from a very mild depression, which increased six months after 
treatment (Table 9.14). She reported a feeling of frustration when she could not find the 
correct word, but it did not affect her daily life, and she believed that her problems with 
following maps or driving to new places were due to a lack of confidence and a fear of 
getting lost. 
HADS Test 1 Test 2 Test 3 Test 4 Overall 
%rank 
Anxiety 9 6 2 7 60 
Depression 2 2 1 5 75 
Table Error! No text of specified style in document..14. Anxiety and depression 
scores for Participant three. 
 
9.1.3.9 Summary of findings for Participant three 
 
A summary of findings for Participant three are presented in Table 9.15. 
 
 
299 
 
Parameter Comment 
Neuropsychological tests Overall, test scores showed no sign of 
impairment, and her self-reports were also 
normal. However, according to her reports, 
she might be attributing PM failures to 
factors other than memory, but that would 
not mean that she had a PM problem. Her 
reports were consistent with those of PM 
failures. 
Executive function  Normal 
CAMPROMPT Average, above average 
Interviews and self-reports  
PM Failures 
 
1. Misplaced things, problems with attention 
and concentration. Needed to use reminders  
2. Forgot appointments, forgot to take 
medication, forgot to switch things off 
Other difficulties associated with chemo 
brain 
Problem with words and names 
Anxiety Mild 
Depression Low 
Sleep Good 
Table 9.15. Summary of findings for Participant three. 
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9.1.4 Case study four 
 
Participant four was agreeable, interested and compliant throughout the testing sessions. 
She communicated at ease with the researcher, and rapport was easily achieved. This 
participant suffered from mild PM impairment during chemotherapy treatment, but her 
memory had improved over time. Although her test results showed no significant 
impairment, her daily life was somewhat affected, and she clearly showed mild PM 
failure. Her social, family and work life had not been affected. She received strong 
family support throughout her treatment.  
 
9.1.4.1 Background information 
 
Participant four was a 52-year-old, Caucasian, British woman. She completed her 
secondary education in the UK and worked part time. She underwent breast cancer 
surgery and began chemotherapy treatment one week after being diagnosed. She also 
received radiotherapy and hormonal treatment. Her Full Scale IQ of 108 (25th percentile 
rank) was on the NART. Her overall performance was classified within the normal 
range and was equal to or higher than 25% of women in this sample. The test was 
administered four times. 
 
Measures of EF abilities for Participant four were in the normal range compared with 
other women in this sample (Table 9.16). Processing speed and intellectual abilities 
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obtained from Digit Symbol were unaffected by treatment. An improvement was 
observed after baseline, and no decline was observed in any of the tests after six 
months. For attention span, fairly consistent results were observed during sessions one, 
two and three, but a slight decline was observed immediately after treatment. Her word 
naming abilities showed a consistent improvement in sessions one, three and four, but in 
daily life situations, she reported having trouble retrieving words. A slight decline was 
observed in session two. Visual memory scores showed a very slight decline during 
sessions two and three, but improved in session four. 
Executive 
Function 
Test 1 Test two Test 3 Test 4 Overall 
%rank 
Digit Symbol 70 78 72 82 50 
Digit Span Total 17 18 11 17 50 
COWAT 37 35 38 39 40 
BENTON 
Correct 
8 7 7 8 30 
Table Error! No text of specified style in document..16. Test scores for Participant 
four. 
 
PM test scores showed that Participant four performed better in the first test than in the 
second (during treatment), but improved in the subsequent tests, particularly six months 
after treatment (Table 9.17). This suggests that the practice effect did not take place and 
that chemotherapy treatment might have been affecting her PM. A significant decline 
was observed for event-based task scores in sessions one and two, and time-based 
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scores declined from session two to session three. The observed improvement over time 
might have been due to practice effects, but since the fourth test took place six months 
later, there was only a very small chance that practice effects were playing a role, and it 
was more likely that her memory improved once she had finished treatment. 
 
 
 
CAMPROMPT Test 1 Test 2 Test 3 Test 4 
TIME 11 16 13 16 
EVENT 18 8 18 16 
TOTAL 29 24 31 32 
Classification A P A AA 
B=Borderline P=Poor A=Average AA=Above Average VG=Very Good 
Table Error! No text of specified style in document..17. CAMPROMPT scores for 
Participant four. 
 
9.1.4.2 Sleep 
Sleep self-reports indicated that her sleep time was normal, but she felt sleepy during 
the day, particularly during sessions two and four (Table 9.18). Despite the fact that her 
sleep time increased over time, her self-reports showed worse perceived sleep 
efficiency. 
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Sleep Test 1 Test 2 Test 3 Test 4 Overall 
%rank 
PSQI 6 7 8 9 75 
ESS 5 10 6 12 75 
Sleep 
(hours) 
28.31 25.20 31.30 31.28 75 
Table Error! No text of specified style in document..18. Sleep scores for Participant 
four. 
 
9.1.4.3 Online questionnaires and face-to-face interviews 
 
In the online questionnaires, Participant four reported that her memory problems began 
while she was undergoing chemotherapy treatment. She reported problems 
remembering words and making sentences, keeping up with conversations and 
remembering the names of the people she had known for years. Her memory difficulties 
were evident to her family, but her memory improved after finishing the treatment. She 
reported that she had not been able to go back to her normal job due to problems with 
her shoulder and not as a consequence of her memory decline. The memory difficulties 
made her feel frustrated and angry. 
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She reported that she very often forgot to do something a few minutes after she had 
decided to do it. She also reported that she would forget something that she had been 
told just a few minutes before. She also misplaced things, forgot appointments, forgot to 
pass on messages and to buy items while shopping. She occasionally forgot to take her 
medicine and why she had gone in to a particular room: 
 
“Sometimes I struggle to remember what I was doing half an hour 
ago…(laughs)…” 
 
 
9.1.4.4 Dependency on reminders 
Participant four reported that she had become reliant on reminders to help her remember 
her plans. She needed to carry a diary to remind her of appointments and to-do lists. She 
would refer to the diary first thing in the morning. This was a new habit for her, because 
before treatment, she did not need reminders. She also used her phone to set reminders: 
 
“Now I carry a little diary down with me to not forget things such as 
appointments and things to do and, I never used to do that… I would probably 
forget. It is not about the things this week, but things about two or three weeks’ 
time, I wouldn’t remember the day or the time…” 
 
9.1.4.5 Words and names: Tip-of-the-tongue phenomenon 
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As with many chemo brain patients, she also struggled with names and words. This 
caused her difficulties in a conversation when trying to construct a sentence; it would 
take a lot of time to find the words for what she wanted to say: 
 
“…I couldn’t remember the word for windshield, or windbreaker and I was 
telling something about down the beach, and I said, you know those things that 
you put in the sand and stop the wind, and he said, a wind breaker, and I went oh 
yeah! But it took me ages to describe it, so he knew what I was talking about…” 
 
She also mentioned how sometimes she could not follow conversations, especially when 
she was in a group of people: 
 
“…but I still struggle with conversations, I suppose if there is lots of people 
talking, I tend just to drift off sometimes, because I can’t follow it…” 
 
She also described frustration with spelling. She said she used to be a very good speller, 
but after treatment, her spelling had become very bad, even with simple, common 
English words: 
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“For example if I want to spell WHERE, you know, I want to write WERE and I 
spell WEAR and I look at it and think, oh no, that’s the wrong one…and even 
then, I say, that doesn’t look right, what have I done wrong?” 
 
This made her feel frustrated because she knew that she was familiar with the word, but 
she could not remember it. She also experienced the same feeling with the names of the 
people she knew. She was often unable to associate the name of a person whose face 
she recognised: 
 
“…It is just frustrating because it is on the back of your head, and you want to 
say it, but you just can’t remember it or can’t find the right word to say it. With 
names of people, I am useless, absolutely usless…I really, really struggle, 
especially if they are unusual names, I do struggle, there are loads of people at 
work, I couldn’t tell you their names, and it still happens…I can’t associate the 
name with someone…” 
 
9.1.4.6 Attention 
 
When referring to attention, she said it had improved with time, but had been affected 
by treatment. She was unable to concentrate on anything, and reading was hard work. 
During treatment, she would sit just staring out of the window for hours just watching 
what was going on. She found noise irritating, and she could not concentrate on the 
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television. She reported her brain “feeling fuzzy” and could not concentrate on 
anything: 
“Trying to read a book is hard work…my son gave me some of his books to 
read, oh, I ended reading the same page three or four times because couldn’t take 
in what they were saying. I am reading, and I am thinking I haven’t got that, so I 
have to start back at the thing again, and I think oh, I’ve read this page three 
times, why hasn’t sank it?” 
“…your brain feels very fuzzy…that is the only way to describe it, your 
brain…my husband was trying to explain something, and I just said, don’t 
bother, I just cannot concentrate, and can’t take what you are saying…” 
 
She also explained how she struggled following instructions, such as how to use her 
new phone, and had to wait several months until she felt able to go back again to try and 
understand: 
 
“You struggle reading instructions, you would really struggle…I got a new 
phone in December and I just couldn’t work it. I couldn’t read the instructions 
and follow what they were saying to do on the phone, so I just put the phone 
away for a couple of months, and my son came down and set it all up for me.” 
 
She reported that during treatment, she had visited places, but that she did not have any 
recollection of ever being at those places. She only knew she had been there because her 
husband confirmed that they had visited the place together. 
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“When someone is describing things that happened either last year or maybe the 
year before, while I was going through the treatment, we’ve been somewhere, or 
done something, and he would be explaining it to me…I have just complete 
blanks, that is the only way to describe it, you know as you’ve been describing 
stuff and I say I honestly could say I wasn’t there, but you are telling me I was, 
my husband a couple of times, he sort of describes stuff and I say I really can’t 
remember that, but he is the only one I told him that.” 
 
She mentioned that she used to forget appointments, not realising until she received a 
call from the hospital to remind her. She also found herself repeating the same story to 
someone several times: 
 
“…and he’d say you’ve already told me about, and I say, ‘have I?’ and couldn’t 
remember that I’ve already told you. That happens quite a lot 
recently…sometimes I say have I told you? And he says yes! And I say Ok, or if 
he says no, I say Ok I’ll tell you now…(laughs)…” 
 
She often forgot to eat meals or why she had entered a room. She reported that when she 
was doing her housework, she got very easily distracted, changing from one chore to 
another without finishing any of them: 
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“(laughs)…Before treatment I use to do it occasionally, but I suppose I tend to 
do it a lot more now…and I say what the hell I am doing here, I can’t remember 
but I go back and do something else. …I flip a lot, I can be in the middle of 
hovering, and then something distracts me, I don’t know, say my telly is dusty, 
so I go and get a duster, I do that, and then I go do something else, and the hover 
is still in the middle of the floor because I’ve forgotten I was in the 
middle…(laughs)…that is quite common…” 
 
When she cooked, she always realised that she had forgotten to put one of the main 
ingredients in the dish, as she found it later in the fridge or cupboard: 
 
“(laughs)…I quite often forgot using an ingredient…(laughs)…say I am doing a 
new recipe or something, I read it and I put all of the ingredients there, but may 
be one is left in the fridge and I…(laughs)…and then when we get to eat the 
dinner…(laughs)…the ingredient is still in the fridge. It’s quiet often…it has 
happened before treatment, but not as often…I am well known for doing that.” 
9.1.4.7 Positive mood acceptance, humour and resilience 
 
Participant four reported coping well, but she needed to take more time to figure out 
what she was going to say and even if she felt frustrated and angry at times, she faced 
her failures with humour and laughed about the situation. 
 
9.1.4.8 Negative mood, frustration and anxiety 
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Participant four initially reported mild levels of anxiety, but by the time her treatment 
ended, she showed higher levels of anxiety (Table 9.19). Her depression levels were 
mild throughout the sessions. 
 
HADS Test 1 Test 2 Test 3 Test 4 Overall 
%rank 
Anxiety 5 4 8 5 50 
Depression 0 5 3 5 60 
Table Error! No text of specified style in document..19. Anxiety and depression 
scores for Participant four. 
 
Overall, Participant four showed no signs of serious memory impairment, but she did 
report very common PM decline during her treatment. Her memory improved over time, 
but a very mild impairment was still present at the end of this study. 
 
9.1.4.9 Summary of findings for Participant four 
A summary of findings for Participant four are presented in Table 9.20. 
 
Neuropsychological tests  
Executive functions Normal 
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CAMPROMPT Average, above average 
Interviews and self-reports  
PM Failures 1. Misplaced things 
2. Problems with attention and concentration 
3. She did not mention problems with 
multitasking 
4. Needed to use reminders  
5. Forgot appointments 
6. Difficulty following instructions 
Other difficulties associated with chemo 
brain 
Problem with words and names 
Anxiety Mild 
Depression Mild 
Sleep Good 
Table 9.20. Summary of findings for Participant four. 
 
9.1.5 Case study five 
 
Participant five was agreeable, interested and compliant throughout the testing sessions. 
She communicated at ease with the researcher, and rapport was easily achieved. This 
participant reported not having noticed significant memory changes as a consequence of 
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cancer treatment. She reported that her memory had always been poor. However, her 
social and work life was severely affected by a lack of concentration and fuzziness. This 
was because she could not concentrate well while driving, which created social and 
work limitations. She received strong family and social support and continued working 
although her inability to drive and lack of concentration had limited her working hours. 
 
9.1.5.1 Background information 
 
Participant five was a 54-year-old, Caucasian, British woman. She underwent breast 
cancer surgery and began chemotherapy treatment a week after being diagnosed. She 
also received radiotherapy and hormonal treatment. She was married and completed her 
postgraduate studies in the UK and worked part time. She experienced chemotherapy-
induced menopause. Her Full Scale IQ of 117 (50th percentile rank) was on the NART. 
Her overall performance was classified as being within the normal range and was equal 
to or higher than 50% of women in her age group. The test was administered four times. 
 
The EF abilities of Participant five were in the normal range compared with the other 
women in this sample (Table 9.21). Her ability to learn new things and processing speed 
showed a decline from baseline to session two, but improved in the last two sessions. 
She improved on measures of attention span and distractibility from sessions one to 
two, declining in session three and improving again in session four. On word-producing 
abilities, she showed a decline in the second session, but improved over time. Her 
scores on visual abilities were excellent, which might have been because she was a 
graphic artist. Her visuo-spatial abilities were highly developed, but in situations such as 
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driving, she felt disoriented and could not cope well with driving since beginning the 
treatment. 
 
Executive 
Function 
Test 1 Test 2 Test 3 Test 4 Overall 
%rank 
Digit Symbol 70 66 69 76 50 
Digit Span Total 22 29 24 30 95 
COWAT 47 41 51 56 75 
BENTON 
Correct 
10 10 10 10 90 
Table Error! No text of specified style in document..21. Test scores for Participant 
five. 
 
In the CAMPROMPT test, Participant five showed that her PM was average in the first 
two sessions and improved to above average in her last two tests (Table 9.22). Her self-
monitoring abilities were poorer at baseline, before experiencing chemotherapy 
treatment, but significantly improved in the following sessions. These results might be 
due to familiarity of the tests, but an alternative explanation can be that poor sleep and 
anxiety at baseline might be interfering with her performance. However, for the second 
testing session, during mid-treatment, her cue-dependent performance was more 
affected, and self-initiating monitoring was improved. This can be explained as a more 
conscious effort of monitoring her time-checking behaviour. Her third and fourth tests 
scores showed that her performance on self-initiating monitoring remained unaffected, 
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and that she had poorer cue-dependent PM. Overall, her time-based scores showed a 
slightly better performance than event-based scores. Her overall PM was very good. 
 
CAMPROMPT Test 1 Test 2 Test 3 Test 4 
TIME 12 18 18 18 
EVENT 14 12 16 16 
TOTAL 26 30 34 34 
Classification A A AA AA 
B=Borderline P=Poor A=Average AA=Above Average VG=Very Good 
Table Error! No text of specified style in document..22. CAMPROMPT scores for 
Participant five. 
 
Sleep self-reports for Participant five indicated that she slept well at night, but she felt 
very sleepy during the day (Table 9.23). Objective measures indicated that she had a 
tendency to sleep less than the average number of hours, particularly at baseline, which 
could be associated with her feeling of fuzziness during the day and poorer PM scores. 
 
Sleep Test 1 Test two Test 3 Test 4 Overall 
%rank 
PSQI 6 4 4 4 25 
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ESS 13 10 13 17 95 
Sleep 
(hours) 
21.32 27.27 20.40 26.48 10 
Table Error! No text of specified style in document..23. Sleep scores for Participant 
five. 
 
The levels of anxiety of Participant five were higher before treatment and six months 
after treatment (Table 9.24). During the course of treatment and immediately after 
treatment, she experienced mild levels of anxiety. She did not experience abnormal 
levels of depression, but reported that she was unable to cope with stressful situations or 
stories. 
 
HADS Test 1 Test 2 Test 3 Test 4 Overall 
%rank 
Anxiety 12 7 6 10 80 
Depression 2 2 6 3 75 
Table Error! No text of specified style in document..24. Anxiety and depression 
scores for Participant five. 
 
 
9.1.5.2 Online questionnaires and face-to-face interviews 
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In the online questionnaires, Participant five reported that her memory had always been 
a bit of a problem, but what she had noticed more than anything else was fuzziness and 
lack of concentration. Since her memory had always been poor, she was used to relying 
on reminders and copying strategies all the time. Therefore, she could not tell whether 
memory problems were a consequence of her cancer treatment: 
 
“…I do feel like I’ve got a kind of gap in my memories. From about…probably 
when… it all started off whether it was the treatment or whether it was before 
that was just the shock of it. There is a gap somewhere there…which lasted for 
quite some time. There are things that people mention and I think I didn’t know 
about that... and there’s a lot of things that I’ve sort of…that seem to have 
dropped out. But…I also found my memory, my concentration… has been 
awful. Now…I’m not saying I was brilliant to start with, but my concentration 
has been so bad that I’ve really, really struggled, umm…to get my life back 
together.” 
 
9.1.5.3 Attention 
 
Participant five reported that when she decided to do something, she very often forgot to 
do it minutes later; she failed to recognise places she had been to before; she forgot 
things she had just been told; she forgot appointments; she forgot what she had planned 
to buy at the shop, even when she saw it; and she could not remember things that had 
happened to her in the previous few days. 
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She also said that she misplaced things, failed to pass on messages and that very often 
went into a room and would forget why she was there. She also reported that on 
occasions, she accidentally repeated tasks by mistake. 
She acknowledged that her lack of concentration had affected her driving capabilities, 
which affected her ability to work. She could not drive for more than 10 minutes 
without feeling confused and anxious. Therefore, she had to reject jobs outside her close 
surroundings. This had also affected her social life, and she found it very restricting: 
“…it’s like when you were trying to do something when you’re asleep if you see 
what I mean…and… my driving, now my driving was never…my best thing, I 
mean…I realised that…I should never drive for too long because it takes a lot of 
concentration…” 
“…I couldn’t cope with the focusing, so basically I was trying to restrict my 
driving to... night time and ten minutes” 
 
She also reported that very often she found herself repeating a story to the same person 
on different occasions: 
 
“Probably not the same day, I mean you know it’s…So I see…Mike one week 
and I see him another week and I tell him the same story and he very politely 
doesn’t say anything … but I would say I would’ve done that anyway…” 
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Despite having been a good reader, she started to prefer books for children, since she 
was not able to follow a more complex story. She also reported problems following a 
conversation: 
 
“Well… I started to get back on the adult books which was a great relief cause 
I’ve been reading children’s books all this time…I need something that would 
grab me quickly…I’ve found I couldn’t cope with reading a book that could 
distress me because… I will find it…hard to follow… If somebody is talking 
and I’m not joining in. At some extent I would’ve been like that anyway, but at 
the moment I’ve gotten worse. Yeah… umm…yeah.” 
“I was more able to cope with… all that sort of thing. So where that… I mean 
it’s not memory but it’s something. Concentration maybe? Because I know that I 
would not have that concentration that I need to do it for very long.” 
 
9.1.5.4 Words and names: Tip-of-the-tongue phenomenon 
 
Participant five also reported that she had trouble with names and words. She mixed up 
the names of family members, often forgetting the names of her brothers. She struggled 
with common words (such as marmite) and although she knew the word she wanted to 
use, she could not bring it to her mind to complete a sentence: 
 
“…I mean I’ve got a weird thing with names at the moment… I find myself 
mixing up the names of people I know very well, which could get me in quite a 
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lot of trouble you know. To call my daughter by the name of my sister, You 
know it’s... it is… really not a good thing to do… umm… to call my friends by 
each other names… that’s not a good thing to do.” 
“…this is just in the last couple of years…it’s words that I should know. They’re 
not difficult and I would be having a conversation and… that word is not there, 
it’s an easy word if you see what I mean, and it might come back to me 
eventually but it might take while some time (laughs). Well you got to say it… 
and (sigh)…(sigh)…it’s just going to come out and it just… doesn’t so… I know 
that I know the word. That’s it.” 
 
9.1.5.5 Dependency on reminders 
 
Participant five stated that she had always been very dependent on reminders to 
remember the things she planned to do. 
 
“I am very dependent on reminders…such as phones and a calendar that gives 
me reminders, which is on the computer now. I have…an alarm that would go 
off and just to say… ‘Have you had your walk?’ and sometimes it would go off 
with things like ‘You need to be leaving here in an hour,’ and it’s always done 
that.” 
 
Her social life had been affected because she could not go to places, and she was 
anxious about not being able to concentrate and follow a conversation: 
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“…being able to talk to people and actually feel that I don’t know how my 
conversations came across to you before whether you noticed any difference. It’s 
about being able to feel and make sense in a conversation. …umm…I’ve been a 
bit more inclined to say yes, a bit more inclined to go somewhere slightly new, a 
bit less afraid that it’s all going to fall apart, and that isn’t a confidence thing that 
is about… the concentration and the stress and all the sort of thing.” 
“I don’t cope with stress, I know people don’t cope with stress, but I have found 
that that’s been a big problem for me. Umm…so… stress, anxiety and 
concentration are first things have tired me very, very quickly.” 
 
9.1.5.6 Summary of findings for Participant five 
 
A summary of the findings for Participant five is presented in Table 9.25. 
Parameter Comment 
Neuropsychological tests  
Executive functions Normal 
CAMPROMPT Average, above average 
Interviews and self-reports  
PM Failures 1. Misplaced things 
2. Problems with attention and concentration 
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3. No evident problems with multitasking 
4. Needed to use reminders  
5. Forgot appointments 
6. Forgot to take medication 
Other difficulties associated with 
chemo brain 
Problem with words and names 
Anxiety Mild 
Depression Low 
Sleep Poor 
Table 9. 25. Summary of findings for Participant five. 
 
9.1.6 Case study six 
 
Participant six was agreeable, interested and compliant throughout the testing sessions. 
She communicated at ease with the researcher, and rapport was easily achieved. At her 
first testing session, she showed very high levels of anxiety, whereas in the following 
sessions, she was calmer. This participant was at the low end of the chemo brain and 
PM memory decline spectrum, meaning that she did not report significant memory 
changes after cancer treatment. She reported that her memory difficulties had 
disappeared at the time of the interview, and that she was more able to cope with her 
family and work life than during and immediately after treatment. Due to a lack of time, 
this participant only underwent three testing sessions, i.e. baseline, mid-treatment and 
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two months after treatment. However, she was able to complete the online 
questionnaires and face-to-face interviews 14 months after treatment.  
 
9.1.6.1 Background information 
 
Participant six was a 58-year-old, Caucasian, British woman. She was married and 
completed a bachelor’s degree in the UK and worked full time. She underwent breast 
cancer surgery one month after being diagnosed. She began chemotherapy treatment 
one month after surgery. She also received radiotherapy and hormonal treatments. She 
was postmenopausal at the beginning of her treatment. Her Full Scale IQ of 113 (40th 
percentile rank) was on the NART. 
 
The EF abilities for Participant six were within the normal range compared with other 
women in the sample (Table 9.26). Her processing speed abilities on the Digit Symbol 
tests improved slightly in the second test session, but declined on session three. On the 
other hand, her attention span and word-retrieving abilities were better at baseline and 
significantly declined in the middle of her treatment. 
 
Executive 
Function 
Test 1 Test 2 Test 3 Overall 
%rank 
Digit Symbol 49 50 42 10 
Digit Span Total 21 18 18 50 
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COWAT 41 28 35 25 
BENTON 
Correct 
8 8 7 50 
Table Error! No text of specified style in document..26. Test scores for Participant 
six. 
 
The PM of Participant six ranged from average to above average (Table 9.27). She 
performed worst at baseline in time-based tasks and showed an improvement in her last 
two tests. This might have been due to practice effects or because her anxiety levels 
were higher before commencing treatment, affecting her ability to self-initiate when 
completing an action.  
She expressed her nervousness before her first chemotherapy treatment. Her 
performance on time-based tasks was poorer than event-based tasks in session one, 
meaning that she was more reliant on cues in the environment than self-reminders. 
However, in the following sessions, her scores showed a balanced improvement and 
remained constant in the last test session. 
 
CAMPROMPT Test 1 Test 2 Test 3 
TIME 9 18 18 
EVENT 16 16 16 
TOTAL 25 34 34 
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Classification A AA AA 
B=Borderline P=Poor A=Average AA=Above Average VG=Very Good 
Table Error! No text of specified style in document..27. CAMPROMPT scores for 
Participant six. 
 
Sleep self-reports for Participant six showed that her self-perceived sleep was not 
affected significantly by the treatment, and that she slept for the average number of 
hours a day (Table 9.28). She did not report feeling sleepy during the day. 
 
Sleep Test 1 Test 2 Test 3 Overall 
%rank 
PSQI 2 6 6 50 
ESS 0 2 2 10 
Sleep 
(hours) 
27.32 28.06 28.10 50 
Table Error! No text of specified style in document..28. Sleep scores for Participant 
six. 
 
9.1.6.2 Online questionnaires and face-to-face interviews 
At the time of screening for PM failure, Participant six reported that she sometimes 
forgot to do something that she had decided to do a few minutes before. She also 
reported that she often failed to do things such as taking tablets or turn off the kettle 
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even when they were in front of her. She also reported that she quite often forgot her 
appointments if she was not prompted by a reminder. She sometimes forgot to pass on 
messages or would find herself in a room, but not remember why she was there. She 
also misplaced things. However, she reported not having extreme progression of 
memory difficulties, but sometimes struggled with words. The results showed some PM 
failures, which improved over time: 
 
“It is hard to remember how my memory was during treatment, but definitely a 
lot more vague!” 
“…I was doing funny things like starting the tap and walking away, and not 
coming back, or forgetting…I was doing things like that, yeah, leaving 
something and then going off, or forgetting what I was doing…” 
 
9.1.6.3 Words and names: Tip-of-the-tongue phenomenon 
 
A new thing that emerged a few months after treatment was that she started to have 
problems finishing her sentences during a conversation: 
 
“…I am saying something and I completely forgotten, completely forgotten 
rather than just hesitating, completely forgotten what I was on about, and then 
thinking oh well, I just cannot remember it again, there been certain things 
where I come, oh… I do not even know what I was going to say!…wow! I can’t 
even think what I was going to say!” 
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However, she did not associate this problem with words to problems with finishing 
sentences: 
 
“…slightly different from forgetting what I was going to say…but I do not think 
I have that now. It was as if I was going to say something to you and then I 
cannot quiet think the word to describe it may be, or the word I was going to use 
to explain so, I could not explain what I was going to say, but it is cleared 
now…I said things in a different way to say things to cope.” 
 
9.1.6.4 Dependency on reminders 
 
Participant six also became dependent on reminders to plan ahead, otherwise she would 
forget what she wanted to do: 
 
“I do remember my plans…I do write things down, and have to remember to 
look at it…I do try to remember…luckily I suppose, we have our diary at work 
so we are every day going in looking. I have habit for work…I think if I do not 
write it down, I probably would forget to do things…” 
 
9.1.6.5 Attention 
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Participant six reported she had not had problems with attention, but she was not able to 
concentrate during treatment: 
 
“I am very attentive, not so vague. My concentration is much better. During 
treatment I think I could not concentrate on things…” 
 
9.1.6.6 Multitasking 
 
Participant six described having more difficulties in her work life. During treatment, she 
found that tasks that were once easy were more difficult to accomplish. She also found 
that she could not manage to carry out several tasks at the same time: 
 
“I did find it very difficult at first, it is not that work is difficult but…something 
I have done for many years…I did find it more difficult… to know what I was 
doing…even making appointment with people, I was frail and could not know 
how to do it, and they are very simple things to do.” 
“Now I just can get on with things… I have just noticed now that I can cope 
with all these things, the family and all those things…and the transition was 
quite difficult… from when treatment stopped…and then you think ok I am 
fine...simple things seemed difficult…and that took a while to get to this 
stage…it is like you are learning to do things again…” 
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9.1.6.7 Negative mood, frustration and anxiety  
 
For her first screening, Participant six had very high (near to abnormal) anxiety levels, 
which might explain her poor performance on CAMPROMPT at baseline (Table 9.29). 
However, in the following sessions, anxiety decreased significantly. She showed more 
signs of depression during her second screening, but this declined in her third screening.  
 
HADS Test 1 Test 2 Test 3 
Anxiety 13 7 7 
Depression 2 9 4 
Table Error! No text of specified style in document..29. Anxiety and depression 
scores for Participant six. 
 
Overall, Participant six showed mild PM impairment during and after treatment, but 
also reported that her daily life was not impacted significantly by memory difficulties 
despite the fact that some decline was present in her reports. By the end of this study, 
they had improved. 
 
 
9.1.6.8 Summary of findings for Participant six 
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A summary of findings for Participant six is shown in Table 9.30. 
 
Parameter Comment 
Neuropsychological tests  
Executive functions Normal 
CAMPROMPT Average, above average 
Interviews and self-reports  
PM Failures During treatment only: 
1. Misplaced things 
2. Problems with attention and concentration 
3. Problems with multitasking 
4. Needed to use reminders  
5. Forgot appointments, forgot to take 
medication, forgot to switch things off 
Other difficulties associated with chemo 
brain 
Problem with words and names 
Anxiety Mild 
Depression Low 
Sleep Good 
Table 9.30. Summary of findings for Participant six. 
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CHAPTER TEN 
10 GENERAL DISCUSSION 
 
10.1 Overview of key findings 
 
The primary aim of this thesis was to examine PM within the context of chemo brain 
using qualitative and quantitative methodologies as well as objective and subjective 
measures of memory and sleep. The need for this type of research emerged firstly from 
the fact that until recently, in the literature, very little emphasis had been placed on PM 
as a cognitive deficit in patients experiencing chemo brain. Nevertheless, evidence 
exists that chemo brain patients present PM deficits (Paquet et al., 2013; Cheng et al., 
2013). On the other hand, evidence that neuropsychological assessment has failed to 
adequately measure cognitive deficits in breast cancer patients, to the point that some 
authors even deny the existence of the phenomenon (Mehlsen, 2007), led this study to 
qualitatively investigate the everyday cognitive deficit experiences that patients report 
as a result of cancer treatment, and how these failures relate to PM decline.  
 
The need to measure sleep and sleepiness emerged from studies confirming the 
relationship between sleep, memory decline and breast cancer (Lockerfeer et al., 2012; 
Savard et al., 2009; Meerlo et al., 2009), in order to analyse its effects within the 
context of chemo brain and PM decline.  
To date, the majority of studies in the area of chemo brain have failed to use measures 
with reliable ecological validity (Schagen et al., 1998); therefore, a vast majority of 
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studies found inconsistencies between patients’ anecdotal reports and 
neuropsychological tests (Ahles, 2007); they used a wide variety of measures and 
statistical analyses, contributing to contradictory results that led to disagreement about 
whether there is significant impairment on cognition after experiencing chemotherapy 
treatment (Shilling et al., 2005); they used actigraphy to measure sleep objectively, 
rather than the SWA (Ancoli-Israel et al., 2001; Savard et al., 2009; Kuo et al., 2006); 
they assessed cognitive domain in general, leading to more inconsistencies (Mehelsen 
et al., 2009; Ganz, 2013), with only a handful having focused on a single aspect of 
cognition, such as PM (Paquet et al., 2013; Cheng et al., 2013) and attention (Weis et 
al., 2009; Adams-Price et al., 2009; Ball et al., 1990) in particular; and they focused on 
the neuropsychological assessment of chemo brain, neglecting the qualitative aspect of 
chemo brain as a PM deficit, with only a handful of studies considering the importance 
of patients’ interviews and case studies (Downie et al., 2006; Shilling et al., 2007; 
Mitchell et al., 2011). To our knowledge, none of the studies included a 
comprehensive analysis that includes neuropsychological assessment along with in-
depth qualitative analysis and case studies interviews with the inclusion of biological 
markers to observe comorbidity among symptoms. 
 
To our knowledge, this study is the first one to use CAMPROMPT to investigate if this 
is a more sensitive tool for the assessment of PM in breast cancer patients, and the first 
one to combine mixed methodologies, including statistical analyses, thematic analysis 
and case studies in the same study for the investigation of PM within the context of 
chemo brain as well as including measures of sleep. 
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10.1 Key Findings 
 
10.1.1 Neuropsychological assessment 
 
Consistent with previous research, our results did not show significant impairment on 
neuropsychological measures, but the study added to the limited literature analysing 
PM in the context of chemo brain, finding that breast cancer patients showed 
significantly lower scores than healthy controls in measures of PM time-based tasks 
during treatment on the CAMPROMPT test  (Time-based tasks F(1,54)=7.959, 
p=0.007, and for CAMPROMPT total score F(1,54)=5.905, p=0.018 ). 
  
The hypothesis that PM would be poorer for the PT group for the second time in the 
middle of the treatment was not confirmed by these tests. The results indicated that 
CAMPROMPT might be a sensitive measure of PM, reflecting situations presented in 
real life situations; however, using this measure for retesting is controversial, because 
of practice effects. Alternate versions A and B of the battery should be revised by the 
authors. 
 
In the current sample, both the groups showed improvement in most of the tests. 
Healthy controls performed better in the tests than cancer patients, but cancer patients 
showed no indication of memory decline as previously predicted. However, this might 
be due to practice effects. Poorer performance in the tests of the patients when means 
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were compared with the healthy controls’ (patient mean 13.46, healthy controls 16.39) 
suggest that self-initiating monitoring was better for the healthy controls at both the 
testing sessions. 
 
Overall, our results confirmed the hypothesis that breast cancer patients have poorer 
PM, particularly in time-based tasks, than healthy controls, and that the effects are 
stronger in the middle of treatment. The hypothesis that PM will be poorer for the 
patient group for the second time in the middle of treatment was not confirmed by 
these tests. However, the fact that the improvement was greater for the healthy controls 
might suggest that despite the influence of practice effects in both the groups, the 
healthy control group has increased cognitive abilities to develop better strategies 
when PM is tested. Despite the fact that patients did not show a decline in PM 
performance, the hypothesis that healthy controls will perform better in PM test was 
confirmed. 
 
One criticism of the last time-based task of CAMPROMPT the author of this thesis has 
is that in version A, participants are required to stop what they are doing and switch to 
another task, e.g. while participants are working on the quiz questions, they are asked 
to change the task and continue with the puzzles. It was found that the participant often 
finished the quiz questions exactly at the end of the seven minute interval, and it was 
difficult for the tester to know whether they were changing the task because the 
participant had remembered the instruction or merely because they had just finished 
that section. In this case, the examiner had to make a judgement as to whether it was 
actual remembering or coincidence, which might have had a negative effect on scoring. 
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Furthermore, results from Heffernan et al. (2012) were consistent with these results in 
which significant differences were found for the time-based tasks, but not for the 
event-based tasks, and this could be explained by the fact that self-initiating 
monitoring is more difficult or more demanding than cue-dependent tasks. 
 
Although this test was a good attempt to assess PM—because it includes time-based 
and event-based tasks and resembles real life situations (having to remember to do 
things at a certain time or when reminded by a particular cue in the environment)—it 
could not be recommended for re-testing due to a high familiarity effect. Although the 
test–re-test reliability was 0.98 (Wilson et al., 2005), it was suspected that in this 
sample, familiarity for both the groups was very high for the second assessment, 
although the effect was lower for the PT group, which might suggest that cancer 
treatment was having a detrimental effect on the PM of breast cancer patients. 
 
Processing speed and intellectual abilities were not affected by treatments, and 
despite the fact that both the groups showed better performance at testing time 2  in 
abilities to learn more information and accuracy of visual-motor coordination and 
attentional skills assessed by this test, the healthy control group showed significantly 
better rates of performance. These results could suggest that breast cancer patients’ 
attention skills, although not technically considered impaired, are not as good as 
those in healthy controls. This could mean that cancer treatment or illness affect the 
attention, learning, motivation and intellectual abilities of patients. 
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Our results for executive control measures indicate that the scores of Digits Span 
tests for the cancer patient group were not affected by their treatments. However, 
attention span, anxiety, distractibility and rote memory (skills assessed by these 
tests) were less affected by the control group. 
 
BVRT test results assess attentional difficulties, visual perception and visual 
memory. Our results indicate that patients’ group performed poorer than the healthy 
controls in these abilities, although both the groups showed improved performance 
from baseline to testing session 1. 
 
COWAT test results indicate that the patient group showed a better performance in 
both testing sessions when compared to healthy controls in word naming tests. 
Interestingly enough, word retrieval is one of the most common complaint in chemo 
brain patients (Mitchell et al. 201; Downie et al., 2006; Mulrooney, 2007; Silverman 
& Davidson, 2009), and our qualitative analysis also confirmed this fact. However, 
these results might be associated with a lack of motivation in our healthy control 
group and the fact that IQ scores were higher in the patient group. 
 
Even when practice effects might have taken place, strategies developed by healthy 
controls led them to perform better, meaning that perhaps the effects of treatment 
were influencing results in cancer patients. 
The hypothesis that the cancer group was expected to perform worse than the 
healthy group was met, but an improvement was seen in most of the tests in both 
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the groups. According to Lezak (1983), it is not uncommon that cognitively 
impaired patients show improved performance on neuropsychological measures, 
even in robust tests, due to practice effects, and this can be seen even when the tests 
increase in difficulty. 
 
These results are consistent with previous studies in this area of research, in which 
cancer patients show improvement on neuropsychological tests (Shagen et al., 2002; 
Jenkins et al., 2006; Hermelink et al., 2007). However, these results should not 
imply that there is no cognitive impairment on cancer patients after experiencing 
chemotherapy. As Burgess (2001) explained, PM deficits are not usually well 
represented on neuropsychological batteries, but patients do show significant 
impairment in daily life performance. 
 
Consistent with the fact that participants from the cancer group sleep for more hours 
than the healthy group are the sleepiness during the day scores from ESS. Mean 
results exposed that healthy controls are more sleepy during the day than the cancer 
group, and this might be a result of significantly decreased sleep hours (patient 
baseline mean 4.96 time 2 mean = 5.79; healthy controls baseline mean = 6.39 time 
2 mean = 6.68. Higher scores indicate sleepiness. 
 
In our sample, breast cancer patients showed in our objective measure of ME that 
they have a tendency of oversleeping; however, their perceived sleep is poorer than 
healthy controls. This might be due to several reasons, one being that at the time of 
testing, patients were recovering from the chemotherapy cycle, and no assessment 
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was conducted precisely at the time of treatment. Anecdotal reports of participants 
suggested that their sleep patterns were completely different immediately after the 
treatments, when the worst of the physiological side effects were taking place. On 
the other hand, studies of sleep and PM indicate that long sleep might be also 
associated with impairments to PM. Scullin and colleagues (2014) found that 
hypersomnia patients (9> hrs/night) performed significantly worse than healthy 
controls (p < .05). Contrary to these results, these same authors found that short 
sleep is also associated with nonfocal PM decline. In a sample of college students, 
those who slept for <7 hrs per night showed poorer performance than normal 
sleepers (7–9 hrs per night) (p < .001). 
 
Our hypothesis that patient group will show poorer sleep patterns, which in turn will 
affect PM, has not been confirmed by ME; however, these results might be affected 
by the fact that sleep was not measured objectively exactly during treatment. On the 
other hand, PSQI results confirm our hypothesis, and the patient group showed 
impaired levels of sleep (>5 on PSQI scoring,), when compared to controls. These 
contradictory results between objective and subjective results might be due to the 
fact that it is not uncommon that participants have the tendency to overemphasize 
their symptoms, and the results should be considered with caution. 
 
The relevance of this study is that to the best knowledge of the author of this work, no 
study has previously been conducted using the CAMPROMPT test within the context 
of chemo brain, and it is only the second time that PM testing has been used in the 
study of participants in the area of chemo brain. 
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To date, the literature on chemo brain has demonstrated that there is subtle cognitive 
impairment in some breast cancer patients. It remains unknown which are the 
mechanisms underlying this phenomenon, but fMRI has provided deeper insight into 
the phenomenon, suggesting that some brain structures might be affected (Deprez et 
al., 2012). 
 
It is suggested that more sensitive memory measures are needed to better understand 
the MCI as a by-product of chemotherapy. 
 
A deeper study focusing on PM is suggested using PM self-reports, a combination of 
PM batteries (suitable for re-testing), along with PM experimental tasks and fMRI 
analyses in longitudinal studies with larger sample sizes. 
 
The DSM-5 (American Psychiatric Association, 2013), states that due to the fact that 
major and mild neurocognitive disorder ( MND)  states that due to the fact that major 
and MND exist in a continuum, precise thresholds are difficult to determine, and 
perhaps that is one reason that neuropsychological batteries have failed to detect 
cognitive impairment in some studies on chemo brain. They suggest that careful 
history taking, observation, and integration of other findings are required for 
diagnosis. For this reason, the PI would like to stress on the importance of qualitative 
studies along with quantitative measures to better understand the phenomenon of 
chemo brain. 
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10.1.2 Qualitative: Emerging themes 
 
Contrary to the quantitative findings, patients’ interview results showed that cognitive 
failures are present in their everyday life, and that at times they could be debilitating. 
Patients’ responses confirmed the research question that chemo brain failures are in 
fact PM failures in everyday life functioning. Emerging themes from thematic 
analysis involved attention deficits, inability to multitask and over-reliance on 
reminders as coping strategies, all pertaining to PM deficits (Mulrooney, 2007; 
Silverman et al., 2009; Cohen et al., 2008). An interesting theme that emerged, is 
related to breast cancer patients having trouble retrieving common words and names, 
which could be associated with the TOT phenomenon, because patients described the 
problem as “having the word in the back of your head” and “you know that you know 
the word”, which have been associated with TOT (Kykyio et al., 2001).  
 
Scientific evidence suggests that this memory problem might be due to the TOT 
phenomenon (Kikyio et al., 2001). The TOT phenomenon has been described as “a 
situation that occurs when a person cannot remember a specific piece of information but 
can provide information about that item and can accurately predict whether the answer 
will be recognised” (Neath et al., 2003). This is also one of the forms of metamemory 
(self-knowledge of how the memory of an individual works) (Neath et al., 2003; Oh-
Lee et al., 2012). Oh-Lee et al. (2012) explained that the TOT experience reflects a state 
of mind in which people are unable to think of target words, but feel that retrieval is 
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imminent. The experience results in frustration because of the inability to retrieve the 
word, but the patients have the strong feeling that the information will pop into their 
minds at any moment. Kikyo et al. (2012) argued that the retrieval effort and the 
successful retrieval are temporarily dissociated. 
 
Of special interest is that neural correlates associated with TOT are anterior cingulate 
cortex (ACC), right dorsolateral PFC and right inferior cortex (Oh-Lee et al., 2012). 
The relevance of this to this study is that these same areas appear to be involved in PM 
and chemo brain (Burgess et al., 2012; Sherling et al., 2013). Therefore, the author 
suggests that TOT should be analysed further within the context of PM and chemo brain 
to fully understand the problems that cancer patients report with word and name 
retrieval. Supporting this statement, research on metacognition and brain imaging 
suggests that EF and metacognitive regulation (processes that coordinate and monitor 
goal-directed behaviour, i.e. PM) are based on similar cognitive and neural mechanisms 
related to prefrontally mediated executive control processes, and that impairment of 
metamemory judgments is related to frontal-lobe lesions (Mantyla et al., 2010; Kikyo et 
al., 2012). 
 
Furthermore, Mantyla et al. (2010) suggested that self-reports on PM and metacognitive 
regulation play an important role in self-belief of efficacy, meaning that individuals 
with effective control functions, such as multitasking and metamemory capabilities, 
have a stronger assurance of their cognitive capabilities. This might explain why some 
cancer patients report feeling like a lesser person than they used to be when faced with 
PM difficulties. 
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The fact that our participants reported forgetfulness may be due to divided attention, 
which interferes with monitoring processes (Parasuraman et al., 1977) and disrupts 
spontaneous retrieval due to highly demanding tasks (Harrison et al., 2013). Those 
highly demanding tasks may include their treatment and its implications and that, all in 
all, life and work become more difficult due to impaired PM or side effects, not to 
mention emotional processes such as anxiety and depression. All of these combined 
might be preventing the participants from noticing PM cues in their environment.  
 
The use of reminders also indicated that PM was involved, because it showed that 
patients were lacking monitoring strategies, so they needed to rely on reminders to be 
able to remember their intentions.  
 
Feeling anxious and frustrated were also the themes that emerged; however, those 
feelings were frequently counterbalanced through resilience and acceptance.  
 
10.1.3 Case studies: Integration of results 
 
The case studies showed how patients who undergo cancer treatment experience 
memory difficulties regardless of their neuropsychological tests results. PM is one of 
the cognitive domains affected and patients also face problems with words, which 
might be a problem of the TOT phenomenon, associated with LTM. This finding also 
gives insight to explore a new theory in the context of chemo brain, which is the TOT 
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phenomenon, and which, to our knowledge, has not been addressed as such in the 
chemo brain literature. 
 
Our findings derived from the six case studies presented here provide clear evidence 
that chemo brain is a real phenomenon, despite the fact that our quantitative study 
showed the opposite. Our qualitative analysis explains the struggles cancer patients 
face with PM deficits after undergoing chemotherapy. 
 
10.1.4 Implications of the current findings 
 
Our results show that there is evidence that PM failure might be one of the underlying 
causes of chemo brain. The patients’ reports relate to those of PM lapses. The 
examples provided by this sample showed that these PM failures, such as the ability to 
multitask or divided attention affect patients’ lives significantly and at times, these 
failures might be stressful and even life threatening (e.g. difficulties with driving 
instructions, forgetting to take the medication or taking it twice). 
 
Although participants showed a tendency to accept their situation, which helped them 
cope with these problems, feelings of frustration and anxiety were present most of the 
times, which could lead to feelings of inadequacy. Another detrimental effect of PM 
failures in chemo brain patients was that their self-esteem was in jeopardy. They 
tended to feel “stupid” or “less than”, and they had to reduce or limit their span of 
activities or perform them more slowly. However, most of the participants reported 
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not being significantly affected in their social lives or at work, and that they only 
needed to learn or develop strategies of how to cope. 
 
On a positive note, some of the cancer patients with memory difficulties approached 
the issue with a sense of humour and became very resilient when facing adversity. 
Almost intuitively, they developed coping strategies to help with PM failures, such as 
keeping reminders and lists at home and at work. 
 
Due to the nature of this phenomenon, and because of the inconsistencies in 
neuropsychological test results, the author recommends that more mixed methods 
studies in the area of chemo brain should be conducted to better understand the 
phenomenon and to counterbalance the fact that MCI might be overlooked by 
neuropsychological tests. The use of more studies integrating patients’ lived 
experiences, laboratory assessments and imaging techniques as well as the use of new 
technologies are suggested. This research was partly conducted online, and it was 
demonstrated to be highly effective and non-intrusive for participants, who could 
respond to the questionnaires at their own pace (Das 2012; Procter et al., 2013). 
 
The lack of ecological validity when trying to assess cognitive deficits in breast cancer 
patients is of extreme importance for this type of study, mainly because in order to be 
able to better help patients to cope with their memory problems, it is important to 
consider how patients experience cognitive difficulties in their everyday life 
situations, and not only under laboratory conditions. It is very important that 
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neuropsychological assessment reflects the reality of these experiences, which would 
lead to more conclusive and valid results.  
 
According to Schagen et al. (1998), the ecological validity of most 
neuropsychological tests is low due to the fact that the cognitive domains assessed by 
traditional tests of cognitive function have little overlap with everyday experiences on 
which patients base their self-reports, and hence the lack of correlation between self-
reports and standardised assessment as opposed to neuropsychological tests, which are 
highly artificial because of the way the material is presented to the patients and show 
little resemblance to everyday memory performance. 
 
On the other hand, interviews are more focused on problems in daily life. The 
problem with self-reports is that they depend on patients’ reports and if a patient has 
memory problems, he/she will forget to report it and will compromise the objectivity 
of the assessment. Moreover, personal beliefs and personality traits may compromise 
objectivity, influencing the responses on self-reports. It is believed that patients have a 
strong tendency to overemphasize their memory problems, but this could be overcome 
by the opinion of relatives or a person close to the patient (Schagen et al., 1998; Cull 
et al., 1996). 
 
In the current study, it was decided to contrast neuropsychological assessment with 
interviews to get a deeper understanding of this controversial finding between 
neuropsychological tests and self-reports. It was decided to conduct online and face-
to-face interviews rather than standardised self-reports, in order to gain a deeper 
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insight into patients’ everyday life situations. Our findings suggest a significant 
discrepancy between tests and interviews (Downie et al.2006; Shilling et al., 2007). 
 
10.2 Strengths and limitations 
 
10.2.1 Strengths 
 
One of the strengths of this study was the use of multiple sources of data collection by 
examining test results, questionnaires and interviews as well as analysis of the 
literature on the various areas of study (PM, chemo brain, TOT, sleep time). This 
allowed the issue of chemo brain to be addressed in a broader manner by presenting 
objective and subjective evidence together. Data triangulation was achieved by using 
multiple sources, which helped to corroborate that PM failures and chemo brain 
present the same cognitive disadvantages to sufferers, that chemo brain patients show 
the TOT phenomenon and that neuropsychological tests might not be sensitive enough 
to detect MCI (Patton, 1987; Yin, 1994; Burgess et al., 2004). Issues regarding 
construct validity were also addressed with data triangulation, because multiple 
sources of evidence provided multiple measures of the same phenomenon, enhancing 
the quality of the case studies presentation (Yin, 2004). 
 
The strength of this type of study was the ability to analyse in depth the PM aspect of 
chemo brain using a mixed methods design, which was aimed at addressing the whole 
spectrum of the problem, by studying the patients’ experiences in their daily lives as 
well as self-reports and neuropsychological batteries. 
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10.2.2 Limitations 
 
Recruitment and assessment of patients after being diagnosed with cancer may be 
challenging. For the patients, this is a very traumatic time and they often do not want 
to participate in studies. A more convenient time for recruitment is after surgery, 
because they have already accepted the fact that they have cancer. However, 
assessment after surgery also has its drawbacks. Recent experience of general 
anaesthetic and the shock of diagnosis may alter cognitive status, thereby affecting 
test scores, but the use of a control group helped resolve this as well as the possibility 
of practice effects (Mar Fan et al., 2005). For the reasons stated above, the qualitative 
study conducted for this work was limited by a relatively small sample size. When 
breast cancer patients were approached before surgery, they refused to take part; 
therefore, the study was limited to patients who had already undergone breast surgery, 
and together with NHS ethics procedures, recruitment became a very slow process. 
Our results might have also been influenced by the effects of surgery, in which breast 
cancer patients showed significantly poorer scores than the controls at baseline. 
 
10.2.2.1 Methodological issues 
 
Due to the challenges with recruitment of our patient population and time constraints 
regarding PhD studentship along with patients’ duration of chemotherapy treatment, 
neuropsychological assessment was only possible during patients’ cancer treatment 
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and not after it. Our study was limited by a small sample size, but in the study of 
chemo brain, there are many comparable studies with relatively small samples sizes 
(Wefel et al., 2004; Bender et al., 2006; Downie et al., 2006; Menheret et al., 2006; 
Hurria et al., 2006; Mehelsen et al., 2009; Tager et al., 2009). However, this study 
stands out from the others in that it longitudinally assesses participants’ PM and sleep 
changes in the middle of the treatment cycle in an attempt to explore when changes in 
cognition begin. However, further studies are needed with larger sample sizes that 
include assessment of neuropsychological measures of PM before, during and after 
treatment within different populations and that consider cultural and ethnic variability. 
 
On the other hand, despite the fact that CAMPROMPT test’s ecological validity 
seems to accurately reflect situations similar to those experienced in real life 
situations, it is not a good measure for retesting due to high familiarity effect. This 
could be because versions A and B of the tests are almost identical rather than 
alternate and equivalent. Furthermore, distractor tasks do not seem to be very reliable 
due to the fact that test instructions require participants to choose which distractor task 
to work on, lacking standardisation of the ongoing activity for all participants. In 
addition, the cost of the ongoing activity could be one of lesser value than other 
activities, meaning that while working on an ongoing activity, some participant could 
have chosen to work on a very demanding task, whereas others might have chosen to 
work on a much less attention demanding task. Moreover, participants are provided by 
a clock and timers to constantly monitor the time; therefore, it is difficult to conclude 
whether automatic monitoring is in place or if it is prompted by cues provided by 
clock or timer observations. 
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As an example, and contrary to our results, in a study conducted to assess PM decline 
in patients with Parkinson’s disease, Foster et al.’s (2009) results showed that event-
based tasks required more attentional monitoring (nonfocal tasks). Their results also 
suggested that patients in their sample showed worse performance than controls in 
such tasks. Foster and colleagues (2009) argued that although time-based task are 
thought to require more attentional control than event-based tasks, the presence of an 
external cue such as the clock in such tasks could reduce the “need for internally-
guided monitoring”.  
 
However, the author of this thesis argues that in CAMPROMPT tests, the time-based 
tasks are nonfocal and require self-initiating monitoring despite the fact that the clock 
is present during the testing session. When participants are working on the ongoing 
tasks, they need to remember to monitor the clock while their attention is focused on 
the ongoing task. In the literature, it has been very well stablished that self-initiating 
monitoring is a strong predictor of time-based PM performance (Einstein et al., 1995; 
Phillips et al., 2004; Mioni et al., 2013). The TWTE (Harris et al., 1982) is based on 
the assumption that participants synchronise their internal clock with an external 
clock, and that test takers rely more on their internal clock during testing, and when 
the time to give a response approaches, they start to rely more on the external clock; 
this can be observed by the rate of clock checking observations (Mioni et al., 2013). 
In our sample, participants were more engaged in working on the ongoing activity 
rather than on checking the clock; however, it is suggested that CAMPROMPT test 
developers should add a clock checking recording to address this situation. 
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In order to investigate how attentional and WM resources are allocated in time 
monitoring strategies, it is suggested that studies on chemo brain patients focus on 
time perception, attention shifting and differences in monitoring. In our sample, the 
fact that patients showed lower performance than healthy controls in time-based tasks 
could indicate that patients have trouble inhibiting the ongoing activity to shift their 
attention to check the clock in order to perform the PM task (Mioni et al., 2013). 
 
A more reliable neuropsychological measure of PM could be the MIST, which has 
shown promising results for breast cancer patients (Paquet, 2013). This test controls 
better for the ongoing tasks by using word search puzzles and also assesses time-
based and event-based PM. However, there is no evidence of its efficacy for retesting 
on breast cancer patients. The author of this thesis suggests that assessment of PM 
should be carried out by using PM neuropsychological assessment together with well 
validated PM paradigms that assess attention and EFs and try to replicate real life 
situations. One of the PM tools that might be useful for the study of PM and chemo 
brain along with neuroimaging techniques is the Virtual Reality-based Prospective 
Memory Test (VRPMT-CV), which has shown promising results with the 
rehabilitation of cancer survivors (Alana et al., 2013), schizophrenic patients (Man et 
al., 2014) and TBI patients (Yip et al., 2013). Man et al. (2014) suggested that 
VRPMT is a reliable and sensitive tool for the assessment of PM, and that its 
concurrent validity was established by computing scores with that of the 
CAMPROMPT, with a significant correlation found between both the tests (r = 0.90, 
p < 0.001). The VRPMT consists of a computer-based test in which participants go 
shopping in a convenience store, providing an everyday PM scenario, where event-
based and time-based PM tasks can be assessed. The author of this thesis suggests that 
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VRPMT, along with neuroimaging tools, should be used in further studies of chemo 
brain and PM as a more sensitive measure of chemo brain.  
Other limitations of the current study were that breast cancer patients were not 
assessed at exactly the same time as the treatment, but a few weeks after having 
chemotherapy, when the recovery phase was taking place. Anecdotal reports in our 
laboratory indicated that patients’ sleep and cognition were worst exactly during 
treatment, when the common side effects of chemotherapy were taking place. 
However, for ethics purposes, it was decided not to intrude in the patients’ lives while 
they were experiencing such discomfort. It is worth noting that in the literature on 
chemo brain, it is not possible to ascertain when exactly in the treatment cycle the 
patients are being assessed. The patients may be assessed a few hours before their 
chemotherapy begins, a few hours after the treatment, one, two or three weeks after 
treatment, or immediately before the next cycle. It is imperative to be clearer in 
identifying at which stage of the treatment patients are being assessed to gain further 
understanding about the effects that chemotherapy-related side effects such as nausea 
and lack of sleep have on cognition. 
 
Our thematic analysis comprised a convenience sample of 12 participants who 
provided insight into their memory difficulties after experiencing cancer treatment. 
However, some limitations were observed. Firstly, the study was conducted several 
months after treatment only; therefore, no baseline assessment with interviews was 
provided, and secondly, we do not know how participants rated their memory before 
treatment, although they did mention that their memories were better before 
commencing treatment. 
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One of the advantages of this study was the possibility of carrying out online 
questionnaires; however, this technique also had its limitations. A lot of relevant 
information might have been lost through conducting research online, because the 
possibility of deriving information from facial expressions and non-verbal behaviour 
was not available. Furthermore, it was not possible to ask the participants if they could 
expand on their answers if they gave short responses. However, despite these 
limitations, it is recommended that online resources are more commonly used, as they 
tend to be cost effective and convenient for participants, especially when they are 
dealing with an illness. Another disadvantage might be that some participants might 
not have access to a computer or they might not be computer literate. In our sample, 
all the participants who were invited from the previous study had access to a 
computer, but were invited to go to their local library in case they needed access to a 
computer and assistance in using it. 
 
Another limitation was that we did not use PM self-reports for analysis but only for 
screening participants for the case studies. We wanted to keep our study as objective 
as possible and did not want to influence the qualitative study responses while taking 
part in the neuropsychological assessment. Self-reports were used in the qualitative 
study as screening measures and to direct the conversation of the interviews to be able 
to ask questions related to PM in open-ended, semi-structured interviews and to give a 
sense to the topic of the case studies. The author suggests that future assessment of 
PM and chemo brain would be based on a self-report questionnaire that is developed 
and validated to aid chemo brain research, and for an accurate assessment of patients 
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to receive proper healthcare when they come to the clinics and report memory 
complaints. 
 
10.3 Future directions and further research 
 
Although this study was the first of its kind to use the CAMPROMPT test to 
investigate PM in chemo brain patients in a mixed methods methodology, including a 
biological marker to observe if sleep was an intervening factor leading to PM 
complaints, further studies that increase power using these measures are needed once 
CAMPROMPT is revised by its developers. The author of this thesis believes that 
CAMPROMPT is in fact a sensitive measure, but alternative forms should be more 
reliable. 
 
10.3.1 APOE, dopamine and neural correlates 
 
Similar lines of research in the areas of chemo brain and PM had been separately 
analysed in the literature in both the areas: the study of their relationship with APOE 
allele e4, the role of dopamine in PM and the analysis of neural correlates (Ahles et al. 
(2014; Foster et al.,2009;  Keser et al., 2011; Inagaki et al., 2007) . An examination 
combining these areas in future studies is suggested by the author of this thesis. 
 
10.3.1.1 Neural correlates 
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In the past few years, there has been an increase in studies looking for structural brain 
changes associated with cancer treatment. A comparison of those studies with the 
ones conducted in relationship to PM would be useful to observe if there is an overlap 
between both the areas of study.  
 
Among cancer patients, Inagaki et al. (2007) reported decreased PFC volume and/or 
tissue and white matter bilateral middle frontal gyri. McDonald et al. (2010) found 
decreased bilateral middle frontal gyri, while McDonald et al. (2012) found left 
middle frontal gyrus (Sherling et al., 2013). Using PET and fMRI studies, Silverman 
et al. (2007) found increased activity in the left inferior frontal gyrus (near Brodmann 
areas 44 & 45) and right superior frontal gyrus; Ferguson et al. (2007) found 
widespread increased activity on bilateral PFC; Ruiter et al. (2010) found decreased 
activity in the dorsolateral PFC; and Keser et al., 2011) found decreased caudal lateral 
PFC (Sherling et al., 2013). Based on this evidence and the evidence provided above 
with regard to PM neural correlates, it can be concluded that there is a structural 
correlation between PM and chemo brain activity. 
 
Burgess et al. (2001) argued that delayed intentions are supported by brain structures 
located in the frontal lobes and related structures such as frontal pole (Brodmann area 
10), where they found increased blood flow bilaterally in the right lateral prefrontal 
and inferior parietal regions and the precuneus (Brodmann area 7), with all of these 
involved in the maintenance of the intention. Activation in the thalamus and PFC have 
been found to be involved in the realisation of the intention and reported a decrease in 
activation in the right lateral PFC (Burgess et al., 2012). Other regions of the brain 
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involved in PM are the anterior PFC during transient clock-related activity (before 
clock monitoring activity takes place) (Oksanen et al., 2014) and the medial temporal 
lobes and hippocampus (McDaniel et al., 2007; Gordon et al., 2011). The parietal 
lobes (Brodmann area 40) and the anterior cingulate (Brodmann area 32) were found 
to be activated during PM paradigms by Burgess et al. (2011). 
Studies of PM involving breast cancer patients are suggested to further analyse the 
structures of the brain involved during PM paradigms and to observe in further detail 
the regions of the brain that might be affected while executing PM tasks. These kinds 
of studies might provide a more ecologically valid assessment of neuroimaging and 
PM assessment of patients suffering from chemo brain. While neuroimaging 
techniques provide a clear observation of the regions of the brain involved during 
psychological assessment, they might still lack ecological validity. That is, 
psychological assessment is still being conducted under laboratory conditions, and 
therefore, no accurate analysis of patients’ daily activities is taking place. According 
to our findings that PM decline is implicated in chemo brain, the author of this thesis 
suggests that involvement of neuroimaging studies using more ecologically valid 
psychological measures are combined for more accurate results. 
 
10.3.1.2 Neural correlates for name and word finding failures or tip-of-the-tongue 
states 
 
Our thematic analysis and interview results showed that one of the most common 
difficulties reported by patients was the problem of remembering words and names of 
familiar people. Interestingly, this area of research has been neglected in the study of 
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chemo brain, and to our knowledge, this is the first study considering its analysis as a 
result of our case studies interviews. 
 
A word finding problem, TOT is the inability to produce a well-known word, despite 
the strong feeling that recall of the word is imminent, and occurs when a familiar 
word temporarily fails to come to mind (Shafto et al., 2009; James, 2006); it is most 
noticeable with aging (James, 2006). This age-related word retrieval has been 
associated with neural atrophy in the left anterior insula (Shafto et al., 2007) and with 
reduction and atrophy of grey matter (Resnick et al., 2003). Furthermore, substantial 
grey matter atrophy across the brain has been related to age-related cognitive decline 
in EF and verbal memory, and the neural correlates involved are mostly prefrontal and 
medial-temporal regions (Shafto et al., 2009; Resnick et al., 2003; Raz et al., 1998). 
On the other hand, face naming has been associated with the posterior temporal 
region, the insula, lateral and medial prefrontal areas and the medial temporal lobe in 
successful retrieval of information about a person’s name, and TOT has been a 
valuable tool for studying these processes (Galdo-Alvarez et al., 2011). Galdo-
Alvarez et al. (2011) reported that successful name retrieval and naming are 
associated with interaction of a brain network involving occipital areas, occipital 
parietal areas, the anterior cingulate, the PFC and the insula. 
 
Taken together, some areas of the brain associated with TOT and face naming have 
been considered in chemo brain studies; however, they have not been associated with 
TOT and chemo brain. The author of this thesis suggests that more emphasis is placed 
on the study of TOT and chemo brain neural correlates to better understand the 
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aetiology of the most commonly reported complaint from breast cancer patients, 
which is face and word naming failure. 
 
10.3.1.3 The presence of the e4 allele of the apolipoprotein E (APOE e4) and 
dopamine  
 
Another line of research that should be analysed is the relationship between chemo 
brain, PM and APOE e4, which is a genetic risk factor for developing Alzheimer’s 
disease (McDaniel et al., 2005). According to Ahles et al. (2003), only a percentage 
of cancer patients who receive chemotherapy present the phenomenon of chemo brain, 
and they suggested that this might be due to the presence of the APOE e4 gene in 
some patients, which might be a potential risk factor. They explained that 
chemotherapy is considered as a type of insult to the brain, and patients with APOE e4 
will be more vulnerable to cognitive decline associated with chemotherapy. On the 
other hand, they argued that patients with MCI, who are APOE e4 carriers, had 
smaller baseline brain volumes. Furthermore, Archer et al. (2006) found that MCI had 
an increased prevalence in healthy APOE e4 carriers. On the other hand, McDaniel et 
al. (2005) found a significant deficit in PM for APOE e4 carriers failing to perform an 
intended action at the appropriate moment. Further research in this area is suggested 
by the author of this thesis, inviting APOE e4 carriers who have undergone 
chemotherapy assisted by PM tools to further analyse the involvement of APOE e4 
genotype on chemo brain as a PM failure. 
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In a study conducted by Ahles et al. (2014) to assess whether breast cancer treatment 
and nicotine interact with APOE e4 carriers, thereby decreasing neuropsychological 
tests performance, they suggested that dopaminergic activity could be one mechanism 
that can explain post-treatment cognitive decline in breast cancer patients. Their 
conclusions are in agreement with previous studies that suggest that low dopamine 
levels in the PFC negatively affect cognitive performance in breast cancer patients 
undergoing chemotherapy treatment (Small et al., 1995; McDonald et al., 2012. Ahles 
et al., 2014). 
 
Research suggests that the PFC plays an important role in cognitive functions, such as 
PM, inhibition and goal maintenance (Cabeza et al., 2013; Beck et al., 2016). 
Furthermore, there are indications that dopamine in the PFC modulates cognitive 
control, influencing attention, inhibition, PM and cognitive flexibility (Foster et 
al.,2009, Costa et al., 2008; Beck et al., 2016).  
 
Foster et al. (2009) found that Parkinson’s disease participants fail to efficiently 
perform monitoring strategies in PM tasks, and they suggested that this might be due 
to the fact that patients were unable to retrieve the intention on nonfocal cues, 
reflecting difficulty in shifting their attention. They also suggested that this 
impairment in cognitive flexibility has been associated with dopamine depletion in the 
PFC. 
 
On the other hand, Costa et al. (2008) also investigated impaired executive control 
abilities involved in PM in Parkinson’s disease participants and found that dopamine 
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alterations play a critical role in cognitive deficits in PM. However, when they 
administered the medication Levadopa, patient’s PM performance was significantly 
improved; in fact, previous PM deficits were restored. 
 
In lieu of these results, the author of this thesis suggests that in future studies, the 
assessment of dopamine levels should be included along with measures of PM that 
focus on nonfocal cues related to attentional monitoring, cognitive flexibility and 
attention shifting. 
 
10.4 Conclusion 
 
To date, the literature on chemo brain has demonstrated that there is a subtle cognitive 
impairment in some breast cancer patients. Our findings suggest that the problem is 
real and affects breast cancer patients’ quality of life. Although the underlying 
mechanisms in this phenomenon remain unknown, there is evidence about which 
areas of the brain get affected. Our findings suggest that the type of memory that is 
affected in chemo brain patients is PM. A vast majority of the research has focused on 
general cognitive dysfunction, although some studies have started adding 
neuroimaging technologies to their assessments. More specific and comprehensive 
studies that include experimental PM tools and PM neuropsychological assessment, 
along with neuroimaging techniques, are necessary to deeply analyse the relationship 
between PM and chemo brain. More sensitive memory measures are also needed to 
better understand the phenomenon. It is recommended that more focus on the study of 
PM and chemo brain be placed in future longitudinal and imaging studies in order to 
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replicate current findings and to include the analysis of TOT and face and word 
naming failures. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
360 
 
 
11 REFERENCES 
Abraham, J., Haut, M. W., Moran, M. T., Filburn, S., Lemiuex, S., & Kuwabara, H. 
(2008). Adjuvant chemotherapy for breast cancer: Effects on cerebral white matter seen 
in diffusion tensor imaging. Clinical breast cancer, 8(1), 88–91. 
 
 
Adams-Price, C., Morse, L., Cross, G., Williams, M., & Wells-Parker, E. (2009). The 
effects of chemotherapy on useful field of view (UFOV) in younger and older breast 
cancer patients. Experimental Aging Research, 35, 220–234. 
 
 
Ahles, T. A., & Saykin, A. (2001). Cognitive effects of standard-dose chemotherapy in 
patients with cancer. Cancer Investigation, 19(8), 812–820. 
 
 
Ahles, T., Saykin, A., Furstenberg, C., Cole, B., Mott, L., Skalla, K., & Silberfarb, P. 
(2002). Neuropsychologic impact of standard-dose systemic chemotherapy in long-term 
survivors of breast cancer and lymphoma. Journal of Clinical Oncology, 20(2), 485–
493. 
 
 
Ahles, T. A., Li, Y., McDonald, B. C., Schwartz, G. N., Kaufman, P. A., Tsongalis, G. 
J., & Saykin, A. J. (2014). Longitudinal assessment of cognitive changes associated 
with adjuvant treatment for breast cancer: The impact of APOE and smoking. 
Psycho‐Oncology, 23(12), 1382–1390. 
 
 
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental 
disorders (5th ed.) Washington, D.C.: American Psychiatric Association. 
 
 
Anderson-Hanley, C., Sherman, M. L., Riggs. R., Agocha, V. B., & Compas, B. E. 
(2003). Neuropsychological effects of treatments for adults with cancer: A meta-
361 
 
analysis and review of the literature. Journal of the International Neuropsychological 
Society, 9, 967–982. 
 
 
Tim A. A., Andrew J. S., Walter W. N., Charlotte T. F., Stephen, G., Bernard, C., & 
Leila A. M. (2003). The relationship of APOE genotype to neuropsychological 
performance in long-term cancer survivors treated with standard dose chemotherapy. 
Psycho-Oncology, 12(6), 612. 
 
 
Ahles, T., & Saykin, A. (2007). Candidate mechanisms for chemotherapy-induced 
cognitive changes. Nature Reviews Cancer, 7(3), 192–201. 
 
 
Ahles, T. A., Saykin, A. J., & McDonald, B. C. (2010). Longitudinal assessment of 
cognitive changes associated with adjuvant treatment for breast cancer: The impact of 
age and cognitive reserve. Journal of Clinical Oncology, 28, 4434–4440. 
 
Ahles, T. A., Saykin A. J., Furstenberg, C. T., Cole, B., Mott, L. A., Skalla, K., & 
Silberfarb, P. M. (2002). Neuropsychologic impact of standard-dose systemic 
chemotherapy in long-term survivors of breast cancer and lymphoma. Journal of 
Clinical Oncology, 20, 485–493. http://dx.doi.org/10.1200/JCO.20.2.485 
 
 
Alberoni, M., Baddeley, A., Della Sala, S., Logie, R. H., & Spinnler, H. (1992). 
Keeping track of a conversation: Impairments in Alzheimer’s disease. International 
Journal of Geriatric Psychiatry, 7, 639–646. 
 
 
Allport, D. A., Styles, E. A., & Hsieh, S. (1994). Shifting intentional set: Exploring the 
dynamic control of tasks. In Umilta, C., & Moscovitch, M. (Eds.), Attention and 
performance XV. Conscious and nonconscious information processing (pp. 421–452). 
Cambridge, MA: MIT Press. 
 
 
362 
 
Aluise, C., Miriyala, S., Noel, T., Sultana, R., Jungsuwadee, P., Taylor, T., & 
Butterfield, D. (2011). 2-Mercaptoethane sulfonate prevents doxorubicin-induced 
plasma protein oxidation and TNF-α release: Implications for the reactive oxygen 
species-mediated mechanisms of chemobrain. Free Radical Biology & Medicine, 
50(11), 1630–1638. 
 
Ancoli-Israel, S., Moore, P., & Jones, V. (2001). The relationship between fatigue and 
sleep in cancer patients: A review. European Journal of Cancer Care, 10(4), 245. 
 
 
Argyriou, A. A., Assimakopoulos, K., Iconomou, G., Giannakopoulou, F., & 
Kalofonos, H. P. (2011). Either called “chemobrain” or “chemofog,” the long-term 
chemotherapy-induced cognitive decline in cancer survivors is real. Journal of Pain & 
Symptom Management, 41(1), 126–139. 
 
 
Arsel, Z., & Bean, J. (2013). Taste regimes and market-mediated practice. Journal of 
Consumer Research, 39(5), 899–917. 
 
 
Atkinson, R. C., & Shiffrin, R. M. (1968). Human memory: A proposed system and its 
control processes. In Spence, K. W. & Spence, J. T. (Eds.), The psychology of learning 
and motivation, Vol. 2 (pp. 89–195). New York: Academic Press. 
 
 
Baddeley, A. (1990). Human memory: Theory and practice. Lawrence Erlbaum 
Associates. 
 
 
Baddeley, A. (1996). Exploring the central executive. The Quarterly Journal of  
Experimental Psychology, 49(a), 5–28. 
 
 
Baddeley A. D. (2000). The episodic buffer: A new component of working memory? 
Trends Cognitive Science, 4(11), 417–423. 
 
363 
 
 
Baddeley, A. D. (2003). Working memory: Looking back and looking forward. Nature 
Reviews Neuroscience, 4, 829–839. 
 
 
Baddeley, A. D. (2009). Foreword what’s it for? Why ask? Applied Cognitive 
Psychology, 23, 1045–1049. 
 
 
Baddeley, A. D. (2006). Working memory: An overview. In Pickering S., Working 
Memory and Education (pp. 1–31). New York: Academic Press. 
 
 
Baddeley, A. D. (2007). Working memory: Multiple models, multiple mechanisms. In 
H. L. Roediger, Y. Dudai, & S. M. Fitzpatrick (Eds.), Science of memory: Concepts (pp. 
151–153). Oxford: Oxford University Press. 
 
 
Baddeley, A. D. & Andrade, J. (2000). Working memory and the vividness of imagery. 
Journal of Experimental Psychology: General, 129(1), 126–145. 
 
 
Baddeley, A. D., Bressi, S., Della Sala, S., Logie, R. H. & Spinnler, H. (1991). The 
decline in working memory in Alzheimer’s disease: A longitudinal study. Brain, 114, 
2521–2542. 
 
 
Baddeley, A. D., Chincotta, D. M., & Adlam, A. (2001) Working memory and the 
control of action: Evidence from task switching. Journal of Experimental Psychology: 
General, 130, 641–657. 
 
 
Baddeley, A. D., Eysenck, M., & Anderson, M. C. (2009). Memory. Hove: Psychology 
Press. 
 
364 
 
 
Baddeley, A. D., & Hitch, G. J. (1974). Working memory. In G. H. Bower (Ed.), The 
psychology of learning and motivation: Advances in research and theory, Vol. 8 (pp. 
47–89). New York: Academic Press. 
 
 
Baddeley, A. D., & Larsen, J. D. (2007). The phonological loop: Some answers and 
some questions. Quarterly Journal of Experimental Psychology, 60 (4), 512–518.  
 
 
Baddeley, A. D., & Larsen, J. D. (2007). The phonological loop unmasked? A comment 
on the evidence for a “perceptual-gestural” alternative. Quarterly Journal of 
Experimental Psychology, 60, 497–504. 
 
 
Baddeley, A., Lewis, V., Eldridge, M., & Thomson, N. (1984). Attention and retrieval 
from long-term memory. Journal of Experimental Psychology: General, 113, 518–540. 
doi:10.1037/0096-3445.113.4.518 
 
 
Balbontín, & Alvarado, R. P. (2012). Exploring effective secondary schools in 
challenging contexts: A study in two Chilean regions. Doctoral dissertation. University 
of Nottingham. England. 
 
 
Ball, K. K., Roenker, D. L., & Bruni, J. R. (1990). Developmental changes in attention 
and visual search throughout adulthood. Advances in psychology, 69, 489–508.  
 
Bampton, R., & Cowton, C. J. (2002, May). The e-interview. In Forum Qualitative 
Sozialforschung/Forum: Qualitative Social Research (Vol. 3, No. 2). 
 
 
Banks, S., & Dinges, D. F. (2007a). Behavioral and physiological consequences of sleep 
restriction. Journal of  Clinical Sleep Medicine., 3(5), 519–528. 
 
365 
 
 
Bargh, J. A., & Chartrand, T. L. (1999). The unbearable automaticity of being. 
American psychologist, 54(7), 462. 
 
 
Barton, D., & Loprinizi, C. (2002). Novel approaches to preventing chemotherapy-
induced cognitive dysfunction in breast cancer: The art of the possible. Clinics in Breast 
Cancer, 3(Suppl.), S121–S127. 
 
 
Beck, S. M., Ruge, H., Schindler, C., Burkart, M., Miller, R., Kirschbaum, C., & 
Goschke, T. (2016). Effects of Ginkgo biloba extract EGb 761® on cognitive control 
functions, mental activity of the prefrontal cortex and stress reactivity in elderly adults 
with subjective memory impairment–a randomized double‐blind placebo‐controlled 
trial. Human Psychopharmacology: Clinical and Experimental, 31(3), 227–242. 
 
 
Bender, C., Sereika, S., Berga, S., Vogel, V., Brufsky, A., & Paraska, K. (2006). 
Cognitive impairment associated with adjuvant therapy in breast cancer. Psycho-
Oncology, 15(5), 422–430. 
 
 
Benton, A. L., & Hamsher, K. (1983). Multilingual aphasia examination. Iowa City: 
AJA Associates. 
 
 
Benton, A. L., Sivan, A. B., & Spreen, O. 1996. Der Benton Test (7th ed.). Bern, 
Switzerland: Huber.  
 
 
Boyatzis, R. E. (1998). Transforming qualitative information: Thematic analysis and 
code development. Thousand Oaks, CA: Sage. 
 
 
366 
 
Boykoff, N., Moieni, M., & Subramanian, S. (2009). Confronting chemobrain: An in-
depth look at survivors’ reports of impact on work, social networks, and health care 
response. Journal of Cancer Survivorship, 3(4), 223-232 
 
 
Braver, T. S., Cohen, J. D., Nystrom, L. E., Jonides, J., Smith, E. E., & Noll, D. C. 
(1997). A parametric study of prefrontal cortex involvement in human working 
memory. Neuroimage, 5(1), 49–62.  
 
 
Brezden, C., Phillips, K., Abdolell, M., Bunston, T., & Tannock, I. (2000). Cognitive 
function in breast cancer patients receiving adjuvant chemotherapy. Journal of Clinical 
Oncology, 18(14), 2695–2701. Retrieved from EBSCOhost. 
 
Breast Cancer Care. Primary Breast Cancer. March 2016, BCC4. 10th Ed. 
 
 
Bryman, A. (1988). Quantity and quality in social research, London, Routledge. 
 
 
Burgess, P. W. (2000). Strategy application disorder: The role of the frontal lobes in 
human multitasking. Psychological Research, 63(3/4), 279. 
 
 
Burgess, P. W., & McNeil, J. E. (1999). Content-specific confabulation. Cortex, 35, 
163–182. 
 
 
Burgess, P. W., Quayle, A., & Frith, C. (2001). Brain regions involved in prospective 
memory as determined by positron emission tomography. Neuropsychologia, 39(6), 
545–555. doi:10.1016/S0028-3932(00)00149-4 
 
 
367 
 
Burgess, C., Ramirez, A., Cornelius, V., Love, S., Graham, J., & Richards, M. (2005). 
Depression and anxiety in women with early breast cancer: Five year observational 
cohort study. British Medical Journal, 330, 702–705. 
 
 
Burgess, P. W., Alderman, N., Volle, E., Benoit, R. G., & Gilbert, S. J. (2009). 
Mesulam’s frontal lobe mystery re-examined. Restorative Neurology And Neuroscience, 
27(5), 493–506. 
 
 
Burgess, P. W., Gonen-Yaacovi, G., & Volle, E. (2011). Functional neuroimaging 
studies of prospective memory: What have we learnt so far? Neuropsychologia, 49(8), 
2246–2257. doi:10.1016/j.neuropsychologia.2011.02.014 
 
 
Burgess, P. W., Gonen-Yaacovi, G., & Volle, E. (2012). Rostral prefrontal cortex: What 
neuroimaging can learn from human neuropsychology. In B. Levine & F. I. M. Craik 
(Eds.), Mind and the frontal lobes: Cognition, behaviour, and brain imaging (pp. 47–
92). New York: Oxford University Press. 
 
 
Buysse, D. J., Reynolds, C. F., Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989). The 
Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. 
Psychiatry Research., 28, 193–213. 
 
 
Cabeza, R., & Dennis, N. A. (2012). Frontal lobes and aging. Principles of frontal lobes 
function, pp.628–652. 
 
Castaños, C., & Piercy, F. P. (2010). The wiki as a virtual space for qualitative data 
collection. The Qualitative Report, 15(4), 948. 
Chicago  
 
 
Castellon, S., & Ganz, P. (2009). Neuropsychological studies in breast cancer: In search 
of chemobrain. Breast Cancer Research and Treatment, 116(1), 125–127. 
368 
 
 
 
Chartrand, T. L., & Bargh, J. A. (1999). The chameleon effect: The perception-behavior 
link and social interaction. Journal of Personality and Social Psychology, 76, 893–910. 
 
 
Cheng, H., Yang, Z., Dong, B., Chen, C., Zhang, M., Huang, Z., & Wang, K. (2013). 
Chemotherapy-induced prospective memory impairment in patients with breast cancer. 
Psycho-Oncology, 22(10), 2391–2395. doi:10.1002/pon.3291 
 
 
Cleeland, C. S., Bennett, G. J., Dantzer, R., Dougherty, P. M., Dunn, A. J., Meyers, C. 
A., & Lee, B. N. (2003). Are the symptoms of cancer and cancer treatment due to a 
shared biologic mechanism? Cancer, 97(11), 2919–2925. 
 
 
Clifasefi, S., Garry. M., Harper, D., Sharman, S. J., & Sutherland, R. (2007). 
Psychotropic placebos create resistance to the misinformation effect. Psychonomic 
Bulletin & Review, 12, 112–117. 
 
 
Cohen, G., & Conway, M. (2008). Memory in the real world (3rd ed.). New York, NY: 
Psychology Press. Retrieved from PsycINFO database. 
 
 
Collins, B., Mackenzie, J., Stewart A., Bielajew, C., & Verma, S. (2009). Cognitive 
effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment. 
Psycho-Oncology, 18, 134–143. 
 
 
Collins, B., MacKenzie, J., Tasca, G. A., Scherling, C., & Smith, A. (2013). Cognitive 
effects of chemotherapy in breast cancer patients: A dose-response study. Psycho-
Oncology, 22(7), 1517–1527. 
 
 
369 
 
Cona, G., Arcara, G., Tarantino, V., & Bisiacchi, P. S. (2012). Age-related differences 
in the neural correlates of remembering time-based intentions. Neuropsychologia, 
50(11), 2692–2704. 
 
 
Coren, S., Ward, L. M., & Enns, J. T. (1994). Sensation and Perception (4th ed.). New 
York: Harcourt Brace. 
 
 
Costa, A., Peppe, A., Brusa, L., Caltagirone, C., Gatto, I., & Carlesimo, G. A. (2008). 
Dopaminergic modulation of prospective memory in Parkinson’s disease. Behavioural 
neurology, 19(1-2), 45–48. 
 
 
Costa, A., Carlesimo, G., & Caltagirone, C. (2012). Prospective memory functioning: A 
new area of investigation in the clinical neuropsychology and rehabilitation of 
Parkinson’s disease and mild cognitive impairment. Review of evidence. Neurological 
Sciences, 33(5), 965-972. 
 
 
Cowan, N. (1995). Attention and memory: An integrated framework. Oxford, 
Oxfordshire: Oxford University Press. ISBN 0-19-506760-6. OCLC 30475237 
 
 
Craik, F. I. M., & Lockhart, R. S. (1972). Levels of processing: A framework for 
memory research. Journal of Verbal Learning & Verbal Behavior, 11(6), 671–684. 
doi:10.1016/S0022-5371(72)80001-X 
 
 
Crawford, J. R., Smith, G., Maylor, E. A. M., Della Sala, S., & Logie, R. H. (2003). The 
prospective and retrospective memory questionnaire (PRMQ): Normative data and 
latent structure in a large non-clinical sample. Memory, 11(3), 261–275. 
 
 
Creswell, J. W. (2009). Research design: Qualitative, quantitative, and mixed methods 
approaches (3rd ed.). Thousand Oaks, CA: Sage. 
370 
 
 
 
Cull, A., Hay, C., Love, S. B., Mackie, M., Smets, E., & Stewart, M. (1996). What do 
patients mean when they complain of concentration and memory problems? British 
Journal of Cancer, 74, 1674–1679. 
 
 
Curcio, G., Casagrande, M., & Bertini, M. (2001). Sleepiness: Evaluating and 
quantifying methods. International Journal of psychophysiology, 41(3), 251–263. 
 
 
van Dam, F. S., Schagen, S. B., & Muller, M. J. (1998). Impairment of cognitive 
function in women receiving adjuvant treatment for high-risk breast cancer: High-dose 
versus standard-dose chemotherapy. Journal of the National Cancer Institute, 90, 210–
218. 
 
Das, M. (2012). Innovation in online data collection for scientific research: The Dutch 
MESS project. Methodological Innovations Online, 7(1), 7-24. 
Chicago  
 
 
 
Davidson, J. R., MacLean, A. W., Brundage, M. D., & Schulze, K. (2002). Sleep 
disturbance in cancer patients. Social Science & Medicine, 54(9), 1309–1321. 
 
 
Della Sala, S., MacPherson, S. E., Phillips, L. H., Sacco, L., & Spinnler, H. (2004). The 
role of semantic knowledge on the cognitive estimation task: Evidence from 
Alzheimer’s disease and healthy adult aging. Journal of Neurology, 251(2), 156–164. 
 
 
Denzin, N. K., & Lincoln, Y. S. (2003). Handbook of Qualitative Research. Thousand 
Oaks, CA: Sage. 
 
 
371 
 
Deprez, S., Amant, F. & Yigit, R. (2011). Chemotherapy-induced structural changes in 
cerebral white matter and its correlation with impaired functioning in breast cancer 
patients. Human Brain Mapp. 32, 480–493. 
 
 
Deprez, S., Amant, F., Smeets, A., Peeters, R., Leemans, A., Van Hecke, W., 
Verhoeven, J. S., Christiaens, M. R., Vandenbulke, M., & Sunaert, S. (2012). 
Longitudinal assessment of chemotherapy-induced structural changes in cerebral white 
matter and its correlation with impaired cognitive functioning. Journal of Clinical 
Oncology, 30(3), 274–281. doi: 10.1200/JCO.2011.36.8571  
 
 
Deprez, S., Vandenbulcke, M., Peeters, R., Emsell, L., Amant, F., & Sunaert, S. (2013). 
Neuropsychologia, 51(11), 2251–2260. 10p. 
DOI:10.1016/j.neuropsychologia.2013.07.024. 
 
 
Divesta, F. I., Ingersoll G., & Sunshine, P. (1971). A factor analysis of imagery tests. 
Journal of Verbal Learning and Verbal Behavior, 10, 471–479. 
 
 
Doyle, K. L., Loft, S., Morgan, E. E., Weber, E., Cushman, C., Johnston, E., & HIV 
Neurobehavioral Research Program (HNRP) Group. (2013). Prospective memory in 
HIV-associated neurocognitive disorders (HAND): The neuropsychological dynamics 
of time monitoring. Journal of clinical and experimental neuropsychology, 35(4), 359–
372.  
 
 
Downie, F., Mar Fan, H., Houede-Tchen, N., Yi, Q., & Tannock, I. (2006). Cognitive 
function, fatigue, and menopausal symptoms in breast cancer patients receiving 
adjuvant chemotherapy: Evaluation with patient interview after formal assessment. 
Psycho-Oncology, 15(10), 921–930.  
 
 
Dowling, S. (2012). Online asynchronous and face-to-face interviewing: Comparing 
methods for exploring women’s experiences of breastfeeding long-term. New Delhi: 
Sage Publications, pp. 277–296. 
372 
 
 
El Beltagy, M., Mustafa, S., Umka, J., Lyons, L., Salman, A., Gloria Tu, C. Y., & 
Wigmore, P. M. (2010). Fluoxetine improves the memory deficits caused by the 
chemotherapy agent 5-fluorouracil. Behavioural brain research, 208(1), 112–117.  
 
 
Einstein, G. O., & McDaniel, M. A. (1990). Normal aging and prospective memory. 
Journal of Experimental Psychology: Learning, Memory, and Cognition, 16, 717–726. 
 
 
Einstein, G. O., Holland, L. J., McDaniel, M. A., & Guynn, M. J. (1992). Age-related 
deficits in prospective memory: The influence of task complexity. Psychology and 
aging, 7(3), 471. 
 
 
Einstein, G. O., McDaniel, M. A., Richardson, S. L., Guynn, M. J., & Cunfer, A. R. 
(1995). Aging and prospective memory: Examining the influences of self-initiated 
retrieval processes. Journal of Experimental Psychology: Learning, Memory and 
Cognition, 21, 996–1007. 
 
 
Einstein, G. O., & McDaniel, M. A. (1996). Retrieval processes in prospective memory: 
Theoretical approaches and some new empirical findings. In M. Brandimonte, G. O. 
Einstein, & M. A. McDaniel (Eds.), Prospective memory: Theory and applications (pp. 
115–141). Mahwah, NJ: Erlbaum. 
 
 
Einstein, G. O., Smith, R. E., McDaniel, M. A., & Shaw, P. (1997). Aging and 
prospective memory: The influence of increased task demands at encoding and retrieval. 
Psychology and Aging, 12, 479–488. 
 
 
Einstein, G. O., & McDaniel, M. A. (2005) Prospective memory: Multiple retrieval 
processes. Current Directions in Psychological Science, 14, 286–290. 
 
 
373 
 
Ellis, J. A. (1996). Prospective memory or the realisation of delayed intentions: A 
conceptual framework for research. In M. Brandimonte, G. O. Einstein, & M. A. 
McDaniel (Eds.), Prospective memory: Theory and applications (pp. 1–22). Hillsdale, 
NJ: Erlbaum. 
 
 
Ericsson, K. A., & Kintsch, W. (2000). Shortcomings of generic retrieval structures 
with slots of the type that Gobet (1993) proposed and modeled. British Journal of 
Psychology, 91, 571–588. 
 
 
Eslinger, P. J., & Damasio, A. R. (1985). Severe disturbance of higher cognition after 
bilateral frontal lobe ablation Patient EVR. Neurology, 35(12), 1731–1731. 
 
 
Feng, W., Jiajia, L., Liyuan, L., Fei, W., Zhongbing, M., Dezong, G., & Zhigang, Y. 
(2014). The status and correlates of depression and anxiety among breast-cancer 
survivors in Eastern China: A population-based, cross-sectional case-control study. 
BMC Public Health, 14(1), 1–14. 
 
 
Ferguson, R. J., McDonald, B. C., Saykin, A. J., and Ahles, T. A. (2007). Brain 
structure and function differences in monozygotic twins: Possible effects of breast 
cancer chemotherapy. Journal of Clinical Oncology, 25, 3866–3870. 
 
 
Finke, R. A., & Slayton, K. (1988). Explorations of creative visual synthesis in mental 
imagery. Memory & Cognition, 16, 252–257. 
 
 
Fitch, M., Armstrong, J., & Tsang, S. (2008). Patients’ experiences with cognitive 
changes after chemotherapy. Canadian Oncology Nursing Journal, 18(4), 180–185. 
 
Foster, E. R., McDaniel, M. A., Repovš, G., & Hershey, T. (2009). Prospective memory 
in Parkinson disease across laboratory and self-reported everyday performance. 
Neuropsychology, 23(3), 347. 
374 
 
 
 
Friedman, N. P., Miyake, A., Young, S. E., DeFries, J. C., Corley, R. P., & Hewitt, J. K. 
(2008). Individual differences in executive functions are almost entirely genetic in 
origin. Journal of Experimental Psychology: General, 137(2), 201. 
 
 
Ganz, P. A. (2012). Cognitive changes & breast cancer treatments. Cancer Research, 
72(24 Supplement). ES4-2 
 
 
Gianico-Relyea, J. L., & Altarriba, J. (2012). Word concreteness as a moderator of the 
tip-of-the-tongue effect. Psychological Record, 62(4), 763–776. 
 
 
Gilbert, S. J., & Burgess, P. W. (2008). Executive function. Current Biology, 18(3), 
R110–R114. doi:10.1016/j.cub.2007.12.014 
 
 
Gilbert, S. J., Bird, G., Frith, C. D., & Burgess, P. W. (2012). Does “task difficulty” 
explain “task-induced deactivation”? Frontiers in Psychology, 3, 125. 
doi:10/3389/fpsyg.2012.00125 
 
 
Gilbert, S. J., Armbruster, D. J. N., & Panagiotidi, M. (2012). Similarity between brain 
activity at encoding and retrieval predicts successful realization of delayed intentions. 
Journal of Cognitive Neuroscience, 24, 93–105. 
 
 
Cohen, G., & Conway, M. A. (Eds.). (2007). Memory in the real world. Psychology 
Press. 
 
 
375 
 
Gioia, G. A., Isquith, P. K., & Kenealy, L. E. (2008). Assessment of behavioral aspects 
of executive function. Executive functions and the frontal lobes: A lifespan perspective, 
179–202. 
 
 
Glisky, E. L. (1996). Prospective memory and the frontal lobes. Prospective memory: 
Theory and applications, 249–266. 
 
 
Gonen-Yaacovi, G., & Burgess, P. W. (2012). Prospective memory: The future for 
future intentions. Psychologica Belgica, 52(2), 173. 
 
 
Goschke, T., & Kuhl J. (1993). Representation of intentions: Persisting activation in 
memory. Journal of Experimental Psychology: Learning, Memory and  
Cognition, 19, 1211–1226. 
 
 
Gregg, M. E., Andrykowski, M. A., Schmitt, F. A., Brady, M. J., & Henselee-Downey, 
P. J. (1991). Long-term cognitive impairment in adult cancer patients. Presented at 
American Psychological Association meeting, San Francisco, CA. 
 
 
International Cognition and Cancer Task Force Conference, 2011, abstract. 
 
 
Guynn, M. J. (2003). A two-process model of strategic monitoring in event-based 
prospective memory: Activation/retrieval mode and checking. International Journal of 
Psychology, 38(4), 245–256. 
 
 
Habota, T., Cameron, J., McLennan, S. N., Ski, C. F., Thompson, D. R., & Rendell, P. 
G. (2013). Prospective memory and chronic heart failure. BMC cardiovascular 
disorders, 13(1), 1–9. 
 
376 
 
 
Hadjiefthyvoulou, F., Fisk, J., Montgomery, C., & Bridges, N. (2011). Prospective 
memory functioning among ecstasy/polydrug users: Evidence from the Cambridge 
Prospective Memory Test (CAMPROMPT). Psychopharmacology, 215(4), 761–774. 
 
 
Harris, J. E. (1980). Memory aids people use: Two interview studies. Memory & 
Cognition, 8(1), 31–38. 
 
 
Harris, J. E., Wilkins, A. J. (1982). Remembering to do things: A theoretical framework 
and an illustrative experiment. Human Learning, 1, 123–136. 
 
 
Harris, J. E. (1984). Remembering to do things: A forgotten topic. In Harris J. E., & 
Morris, P. E. (Eds.), Everyday memory: Actions and absentmindedness (pp. 71–92). 
London: Academic Press. 
 
 
Harris, L. M. (1999). Mood and prospective memory. Memory, 7(1), 117–127. 
 
 
Harris, L. M., & Cumming, S. R. (2003). An examination of the relationship between 
anxiety and performance on prospective and retrospective memory tasks. Australian 
Journal of Psychology, 55(1), 51–55. 
 
 
Harris, J. E., & Wilkins, A. J. (1982). Remembering to do things: A theoretical 
framework and an illustrative experiment. Human Learning, 1, 123–136. 
 
 
Harrison, T. L., & Einstein, G. O. (2010). Prospective memory: Are preparatory 
attentional processes necessary for a single focal cue? Memory & Cognition, 38(7), 
860–867. doi:10.3758/MC.38.7.860 
 
377 
 
 
Heffernan, T. T., & O'Neill, T. T. (2012). Time based prospective memory deficits 
associated with binge drinking: Evidence from the Cambridge Prospective Memory Test 
(CAMPROMPT). Drug And Alcohol Dependence, 123(1–3), 207–212. 
doi:10.1016/j.drugalcdep.2011.11.014 
 
 
Henry, J. D., MacLeod, M. S., Phillips, L. H., & Crawford, J. R. (2004). A meta-
analytic review of prospective memory and aging. Psychology and aging, 19(1), 27. 
 
 
Henry, J. D., Terrett, G., Altgassen, M., Raponi-Saunders, S., Ballhausen, N., 
Schnitzspahn, K. M., & Rendell, P. G. (2014). A virtual week study of prospective 
memory function in autism spectrum disorders. Journal of experimental child 
psychology, 127, 110–125. 
 
 
Henson, R. N. A., Norris, D. G., Page, M. P. A., & Baddeley, A. D. (1996). Unchained 
memory: Error patterns rule out chaining models in immediate serial recall. Quarterly 
Journal of Experimental Psychology, 49A, 80–115. 
 
 
Hermelink, K., Untch, M., Lux, M. P., Kreienberg, R., Beck, T., Bauerfeind, I., & 
Münzel, K. (2007). Cognitive function during neoadjuvant chemotherapy for breast 
cancer. Cancer, 109(9), 1905–1913. 
 
 
Hermelink, K., Küchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Bühner, M., & 
Münzel, K. (2010). Two different sides of ‘chemobrain’: determinants and 
nondeterminants of self‐perceived cognitive dysfunction in a prospective, randomized, 
multicenter study. Psycho‐Oncology, 19(12), 1321–1328. 
 
 
Hermelink, K., Henschel, V., Untch, M., Bauerfeind, I., Lux, M. P., & Munzel, K. 
(2008). Short‐term effects of treatment‐induced hormonal changes on cognitive function 
in breast cancer patients. Cancer, 113(9), 2431–2439. 
378 
 
 
 
Herriott, R. E., & Firestone, W. A. (1983). Multisite qualitative policy research: 
Optimizing description and generalizability. Educational researcher, 12(2), 14–19. 
 
 
Hersen, M., & Barlow, D. H. (1976). Single case experimental designs: Strategies for 
studying behavior change. New York, NY: Pergamon. 
 
 
Hesse-Biber, S. N., & Johnson, R. B. (Eds.). (2015). The Oxford handbook of 
multimethod and mixed methods research inquiry. Chicago: Oxford University Press. 
 
  
Hine, C. (2015). Mixed methods and multimodal research and internet technologies. 
The Oxford handbook of multimethod and mixed methods research inquiry. Oxford 
University Press. 
 
 
Hodgson, K. D., Hutchinson, A. D., Wilson, C. J., & Nettelbeck, T. (2013). A meta-
analysis of the effects of chemotherapy on cognition in patients with cancer. Cancer 
treatment reviews, 39(3), 297–304. 
 
 
Hurria, A., Rosen, C., Hudis, C., Zuckerman, E., Panageas, K. S., Lachs, M. S., & 
Holland, J. (2006). Cognitive function of older patients receiving adjuvant 
chemotherapy for breast cancer: A pilot prospective longitudinal study. Journal of the 
American Geriatrics Society, 54(6), 925–931. 
 
 
Hussain, M. M. (2012). Journalism’s digital disconnect: The growth of campaign 
content and entertainment gatekeepers in viral political information. Journalism, 13(8), 
1024–1040. 
 
 
379 
 
Inagaki, M., Yoshikawa, E., Matsuoka, Y., Sugawara, Y., Nakano, T., Akechi, T., & 
Uchitomi, Y. (2007). Smaller regional volumes of brain gray and white matter 
demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer, 
109(1), 146–156. 
 
 
Jacobs, E., & D'Esposito, M. (2011). Estrogen shapes dopamine-dependent cognitive 
processes: Implications for women's health. The Journal of Neuroscience, 31(14), 5286-
5293. 
 
 
Jacoby, L. L., & Dallas, M. (1981). On the relationship between autobiographical 
memory and perceptual learning. Journal of Experimental Psychology: General, 110(3), 
306–340. 
 
 
Janelsins, M. C., Mustian, K. M., Palesh, O. G., Mohile, S. G., Peppone, L. J., Sprod, L. 
K., & Morrow, G. R. (2012). Differential expression of cytokines in breast cancer 
patients receiving different chemotherapies: Implications for cognitive impairment 
research. Supportive Care in Cancer, 20(4), 831–839. 
 
 
Jansen, C. E., Miaskowski, C., Dodd, M., Dowling, G., & Kramer, J. (2005). A 
metaanalysis of studies of the effects of cancer chemotherapy on various domains of 
cognitive function. Cancer, 104(10), 2222–2233. 
 
 
Jansen, C. E. (2007). Cognitive function in breast cancer patients undergoing 
chemotherapy. Doctoral dissertation. University of California, San Francisco. 
 
 
Jansen, C., Miaskowski, A., Dodd, M., & Dowling, G. A. (2007). Meta-analysis of the 
sensitivity of various neuropsychological tests used to detect chemotherapy-induced 
cognitive impairment in patients with breast cancer. Oncology Nursing Forum, 34, 5. 
 
 
380 
 
Jansen, C., Dodd, M., Miaskowski, C., Dowling, G., & Kramer, J. (2008). Preliminary 
results of a longitudinal study of changes in cognitive function in breast cancer patients 
undergoing chemotherapy with doxorubicin and cyclophosphamide. Psycho-Oncology, 
17(12), 1189–1195. 
 
 
Jenkins, V., Shilling, V., Deutsch, G., Bloomfield, D., Morris, R., Allan, S., & 
Winstanley, J. (2006). A 3-year prospective study of the effects of adjuvant treatments 
on cognition in women with early stage breast cancer. British Journal of Cancer, 94(6), 
828–834. 
 
 
Jenkins, V., Shilling, V., Fallowfield, L., Howell, A., & Hutton, S. (2004). Does 
hormone therapy for the treatment of breast cancer have a detrimental effect on memory 
and cognition? A pilot study. Psycho‐Oncology, 13(1), 61–66. 
 
 
Jenkins, V., Shilling, V., Deutsch, G., Bloomﬁeld, D., Morris, R., Allan, S., Bishop, H., 
Hodson, N., Mitra, S., Sadler, G., Shah, E., Whitehead, S., & Winstanley, J. (2006). A 
3-year prospective study of the effects of adjuvant treatments on cognition in women 
with early stage breast cancer. British Journal of Cancer, 94, 828–834. 
 
 
Jim, H. L., Donovan, K. A., Small, B. J., Andrykowski, M. A., Munster, P. N., & 
Jacobsen, P. B. (2009). Cognitive functioning in breast cancer survivors: A controlled 
comparison. Cancer, 115(8), 1776–1783. 
 
 
Johns, M.W. (1993). Daytime sleepiness, snoring and obstructive sleep apnea: The 
Epworth Sleepiness Scale. Chest, 103(1), 30–36. 
 
 
Johns, M. W. (2002). Sleep propensity varies with behaviour and the situation in which 
it is measured: the concept of somnificity. Journal of sleep research, 11(1), 61–67. 
 
 
381 
 
Johns, M. W. (2003). The amplitude-velocity ratio of blinks: A new method for 
monitoring drowsiness. Sleep, 26, A51. 
 
 
Jones, D. M, Hughes, R. W., & Macken, W. J. (2007). The phonological store 
abandoned. The Quarterly Journal of Experimental Psychology, 60(4), 505–5011. Doi: 
10.1080/17470210601147598 
 
 
Jones, S. L., Hadjistavropoulos, H. D., & Sherry, S. B. (2012). Health anxiety in women 
with early-stage breast cancer: What is the relationship to social support? Canadian 
Journal of Behavioural Science/Revue canadienne des sciences du comportement, 
44(2), 108. 
 
 
Kant, N., van den Berg, E., van Zandvoort, M. J., Frijns, C. J., Jaap Kappelle, L., & 
Postma, A. (2014). Functional correlates of prospective memory in stroke. 
Neuropsychologia, 60, 77-83. 
 
 
Kvavilashvili, L., & Ellis, J. A. (1996). Varieties of intention: Some distinctions and 
classifications. In M. Brandimonte, G. O. Einstein, & M. A. McDaniel (Eds.), 
Prospective memory: Theory and applications (pp. 23–51). Mahwah, NJ: Erlbaum. 
 
 
Kesler, S. R., Bennett, F. C., Mahaffey, M. L., & Spiegel, D. (2009). Regional brain 
activation during verbal declarative memory in metastatic breast cancer. Clinical 
Cancer Research, 15(21), 6665–6673. 
 
 
Kesler, S. R., Kent, J. S., & O’Hara, R. (2011). Prefrontal cortex and executive function 
impairments in primary breast cancer. Archives of neurology, 68(11), 1447–1453. 
 
 
382 
 
Kidd, L. (2007). An exploration of patients’ perceived control, self-efficacy and 
involvement in self-care during chemotherapy for colorectal cancer. University of 
Stirling, UK. 
 
 
Kliegel, M., Jäger, T., & Phillips, L. H. (2008). Adult age differences in event-based 
prospective memory: A meta-analysis on the role of focal versus nonfocal cues. 
Psychology and aging, 23(1), 203. 
 
 
Kikyo, H., Ohki, K., & Sekihara, K. (2001). Temporal characterization of memory 
retrieval processes: An fMRI study of the ‘tip of the tongue’ phenomenon. European 
Journal of Neuroscience, 14(5), 887–892. 
 
 
Kikyo, H., Ohki, K., & Miyashita, Y. (2002). Neural correlates for feeling-of-knowing: 
An fMRI parametric analysis. Neuron, 36(1), 177–186. 
 
 
Kissane, D. W., Grabsch, B., Love, A., Clarke, D. M., & Bloch, S. (2004). Psychiatric 
disorder in women with early stage and advanced breast cancer: A comparative 
analysis. Australian and New Zealand Journal of Psychiatry, 38(5), 320–326. 
 
 
Kvavilashvili, L., & Ellis, J. A. (1996). Varieties of intention: Some distinctions and 
classifications. In M. Brandimonte, G. O. Einstein, & M. A. McDaniel (Eds.), 
Prospective memory: Theory and applications (pp. 23–51). Mahwah, NJ: Erlbaum.  
 
 
Kvavilashvili, L. (1987). Remembering intention as a distinct form of memory. British 
Journal of Psychology, 78, 507–518. 
 
 
Kliegel, M., Jäger, T., & Phillips, L. H. (2008). Adult age differences in event-based 
prospective memory: A meta-analysis on the role of focal versus nonfocal cues. 
Psychology And Aging, 23(1), 203–208. doi:10.1037/0882-7974.23.1.203 
383 
 
 
 
Kliegel, M., Martin, M., McDaniel, M. A. & Einstein, G. O. (2004). Importance effects 
on performance in event-based prospective memory tasks. Memory, 12, 553–561. 
 
 
Kliegel, M., Altgassen, M., Hering, A., & Rose, N. S. (2011). A process-model based 
approach to prospective memory impairment in Parkinson's disease. Neuropsychologia, 
49(8), 2166–2177. 
 
 
Koppelmans, V., Breteler, M., Boogerd, W., Seynaeve, C., Gundy, C. & Schagen, S. B. 
(2011). Neuropsychological performance in survivors of breast cancer more than 20 
years after adjuvant chemotherapy. Journal of Clinical Oncology, 30(10), 1080-1086. 
 
 
Koppelmans, V., de Ruiter, M.B., van der Lijn, F., Boogerd, W., Seynaeve, C., van Der 
Lugt, A., & Schagen, S. B. (2012). Global and focal brain volume in long-term breast 
cancer survivors exposed to adjuvant chemotherapy. Breast cancer research and 
treatment, 132(3), 1099–1106. 
 
 
Kuo, H. H., Chiu, M. J., Liao, W. C., & Hwang, S. L. (2006a). Quality of sleep and 
related factors during chemotherapy in patients with stage I/II breast cancer. Journal of 
the Formosan Medical Association, 105(1), 64–69. 
 
 
Lockefeer, J. P. M., & De Vries, J. (2013). What is the relationship between trait 
anxiety and depressive symptoms, fatigue, and low sleep quality following breast cancer 
surgery? Psycho‐Oncology, 22(5), 1127–1133. 
 
 
Lezak, M. D. (1983) Neuropsychological assessment. New York, USA: Oxford 
University Press. 
 
384 
 
 
Liu, L. L., & Park, D. C. (2004). Aging and medical adherence: The use of automatic 
processes to achieve effortful things. Psychology and Aging, 19, 318–325. 
 
 
Mann, C., & Stewart, F. (2000). Internet communication and qualitative research: A 
handbook for researching online. Sage, London,UK. 
 
 
Mäntylä, T., Missier, F. D., & Nilsson, L. G. (2009). Age differences in multiple 
outcome measures of time-based prospective memory. Aging, Neuropsychology and 
Cognition, 16(6), 708–720. 
 
 
Mäntylä, T., Rönnlund, M., & Kliegel, M. (2010). Components of executive functioning 
in metamemory. Applied neuropsychology, 17(4), 289–298. 
 
 
Mar Fan, H.G., Houédé-Tchen, N., Yi, Q. L., Chemerynsky, I., Downie, F. P., Sabate, 
K., & Tannock, I. F. (2005). Fatigue, menopausal symptoms, and cognitive function in 
women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a 
prospective controlled study. Journal of Clinical Oncology , 31, 8025–8032.  
 
 
Marsh, R. L., & Hicks, J. L. (1998). Event-based prospective memory and executive 
control of working memory. Journal of Experimental Psychology: Learning, Memory 
and Cognition, 24, 336–349. 
 
 
Marsh, R. L., Hicks, J. L., Cook, G. I., Hansen, J. S., & Pallos, A. L. (2003). 
Interference to ongoing activities covaries with the characteristics of an event-based 
intention. Journal of Experimental Psychology: Learning, Memory and Cognition, 29, 
861–870. 
 
 
385 
 
Marsh, R. L., Cook, G. I., & Hicks, J. L. (2006). Task interference from event-based 
intentions can be material specific. Memory & Cognition, 34, 1636–1643. 
 
 
May, T. (1993). Social research: Issues, methods and research. McGrawHill 
International. NY, USA. 
 
 
McDaniel, M. A., Robinson-Riegler, B., & Einstein, G. O. (1998). Prospective 
remembering: Perceptually driven or conceptually driven processes? Memory & 
Cognition, 26(1), 121–134. 
 
 
McDaniel, M. A. (1995). Prospective memory: Progress and processes. In D. L. Medin 
(Ed.). The psychology of learning and motivation, Vol. 33 (pp. 191–222). San Diego, 
CA: Academic Press. 
 
 
McDaniel, M. A., & Donnelly, C. M. (1996). Learning with analogy and elaborative 
interrogation. Journal of Educational Psychology, 88, 508–519. 
 
 
McDaniel, M., Glisky, E., Guynn, M., & Routhieaux, B. (1999). Prospective memory: 
A neuropsychological study. Neuropsychology, 13(1), 103–110. 
 
 
McDaniel, M. A., & Einstein, G. O. (2000). Strategic and automatic processes in 
prospective memory retrieval: A multiprocess framework. Applied Cognitive 
Psychology, 14, S127–S144. 
 
 
McDaniel, M. A., Guynn, M. J., Einstein, G. O., & Breneiser, J. (2004). Cue-focused 
and reflexive associative processes in prospective memory retrieval. Journal of 
Experimental Psychology: Learning, Memory, and Cognition, 30, 605–614. 
 
386 
 
 
McDaniel, M. A., & Einstein, G. O. (2007). Prospective memory: An overview and 
synthesis of an emerging field. Thousand Oaks, CA: Sage. 
 
 
McDaniel, M. A., & Einstein, G. O. (2011). The neuropsychology of prospective 
memory in normal aging: A componential approach. Neuropsychologia, 49, 2147–2155. 
 
 
McDaniel, M. A., LaMontagne, P., Beck, S. M., Scullin, M. K., & Braver, T. S. (2013). 
Dissociable neural routes to successful prospective memory. Psychological Science, 
24(9), 1791–1800. doi:10.1177/0956797613481233 
 
 
McDermott, E., & Roen, K. (2012). Youth on the virtual edge researching marginalized 
sexualities and genders online. Qualitative Health Research, 22(4), 560–570. 
 
 
McDonald, B. C., Conroy, S. K., Ahles, T. A., West, J. D., & Saykin, A. J. (2010). Gray 
matter reduction associated with systemic chemotherapy for breast cancer: A 
prospective MRI study. Breast cancer research and treatment, 123(3), 819–828. 
 
 
McDonald, B. C., Conroy, S. K., Ahles, T. A., West, J. D., & Saykin, A. J. (2012). 
Alterations in brain activation during working memory processing associated with 
breast cancer and treatment: A prospective functional magnetic resonance imaging 
study. Journal of Clinical Oncology: Official Journal of the American Society of 
Clinical Oncology, 30(20), 2500–2508. 
 
McGuirk, P. M., & O'Neill, P. (2005). Using questionnaires in qualitative human 
geography. (pp. 147-162). South Melbourne, Australia: Oxford University Press. 
 
 
 
 
387 
 
MacLeod, J. E., DeLeo, J. A., Hickey, W. F., Ahles, T. A., Saykin, A. J., & Bucci, D. J. 
(2007). Cancer chemotherapy impairs contextual but not cue-specific fear memory. 
Behavioural brain research, 181(1), 168–172.  
 
 
 
Macmillan Cancer Support. Undesrtandin Breast Cancer. October 2013. MAC11616, 
10th Ed. 
 
Meerlo, P., Mistiberger, R. E., Jacobs, B. L., Heller, H. C., & McGinty, D. (2009). New 
neurons in the adult brain: The role of sleep and consequences of sleep loss. Sleep 
Medicine Reviews, 13(3), 187–194. 
 
 
Mehnert, A., Scherwath, A., Schirmer, L., Schleimer, B., Petersen, C., Schulz-
Kindermann, F., & Koch, U. (2007). The association between neuropsychological 
impairment, self-perceived cognitive deficits, fatigue and health related quality of life in 
breast cancer survivors following standard adjuvant versus high-dose chemotherapy. 
Patient Education and Counseling, 66(1), 108–118. 
 
 
Mehlsen, M., Pedersen, A., Jensen, A., & Zachariae, R. (2009). No indications of 
cognitive side-effects in a prospective study of breast cancer patients receiving adjuvant 
chemotherapy. Psycho-Oncology, 18, 248–257. 
 
 
Merton, R. K. (1990). Focused interview. Simon and Schuster. 
 
 
Meyers, C. A. (2000). Neurocognitive dysfunction in cancer patients. Oncology, 14(1), 
75–79. 
 
 
Miller, G. A., Galanter, E., & Pribram, K. H. (1960). Plans and the Structure of 
Behavior. New York: Holt, Rinehart & Winston. 
388 
 
 
 
Milner, B. (1966). Amnesia following operation on the temporal lobes. In Whitty, C. W. 
M. and Zangwill, O. L. (Eds.), Amnesia (pp. 109–133). London: Butterworths. 
 
 
Mioni, G., Stablum, F., McClintock, S. M., & Cantagallo, A. (2012). Time-based 
prospective memory in severe traumatic brain injury patients: The involvement of 
executive functions and time perception. Journal of the International 
Neuropsychological Society, 18(04), 697–705. 
 
 
Mioni, G., & Stablum, F. (2014). Monitoring behaviour in a time-based prospective 
memory task: The involvement of executive functions and time perception. Memory, 
22(5), 536–552. 
 
 
Mitchell, T., & Turton, P. (2011). ‘Chemobrain’: Concentration and memory effects in 
people receiving chemotherapy–a descriptive phenomenological study. European 
Journal of Cancer Care, 20(4), 539–548. 
 
 
Mihuta, M. E., Green, H. J., Man, D. W. K., & Shum, D. (2012). Improving the 
ecological validity of cancer-related cognitive assessment: Virtual reality testing of 
prospective memory following chemotherapy treatments for breast cancer. In COSA 
39th Annual Scientific Meeting and IPOS 14th World Congress of Psycho-Oncology. 
 
 
Miyake, A., & Shah, P. (Eds.). (1999). Models of working memory: Mechanisms of 
active maintenance and executive control. New York: Cambridge University Press 
 
 
Morris, C. D., Bransford, J. D., & Franks, J. J. (1977). Levels of processing versus 
transfer appropriate processing. Journal of Verbal Learning and Verbal Behavior, 16, 
519–533. 
 
389 
 
 
Moscovitch, M. (1994). Memory and working with memory: Evaluation of a 
component process model and comparisons with other models. In D. L. Schacter & E. 
Tulving (Eds.), Memory systems (pp. 269–310). Cambridge, MA: MIT Press. 
 
 
Mulrooney, T. (2007). The lived experience of cognitive impairment in women treated 
with chemotherapy for breast cancer. Unpublished doctoral dissertation. University of 
Utah, Salt Lake City, UT. 
 
 
Neath, I., & Suprenant, A. (2002). Human Memory (2nd ed.). Wadsworth Publishing 
Company. 
 
 
Neisser, U. (1967). Cognitive Psychology. New York: Appleton-Century-Crofts. 
 
 
Nelson, H. E., & Willison, J. (1991). National Adult Reading Test (NART) Manual (2nd 
ed.). Windsor, UK: NFER-Nelson. 
 
 
Norman, D. A., & Shallice, T. (1986). Attention to action: Willed and automatic control 
of behaviour. In Davidson, R. J., Schwartz, G. E., & Shapiro, D. (Eds.), Consciousness 
and self-regulation, Vol. 4 (pp. 1–18). New York: Plenum. Reprinted as: Norman, D. 
A., & Shallice, T. (2000). Attention to action: Willed and automatic control of behavior. 
In M. S. Gazzaniga (Ed.), Cognitive neuroscience: A reader. Malden, MA: Blackwell. 
 
 
O'Cathain, A., Murphy, E., & Nicholl, J. (2008). The quality of mixed methods studies 
in health services research. Journal of Health Services Research & Policy, 13(2), 92–98. 
 
 
390 
 
Oh-Lee, J. D., Szymkowicz, S. M., Smith, S. L., & Otani, H. (2012). Metacognitive 
performance, the tip-of-tongue experience, is not disrupted in Parkinsonian patients. 
Parkinson’s Disease, 2012, 1704079, 12. 
 
 
Paquet, L., Collins, B., Song, X., Chinneck, A., Bedard, M., & Verma, S. (2013). A 
pilot study of prospective memory functioning in early breast cancer survivors. The 
Breast, 22(4), 455–461. 
 
 
Paraska, K. K., & Bender, C. C. (2003). Cognitive dysfunction following adjuvant 
chemotherapy for breast cancer: Two case studies. Oncology Nursing Forum, 30(3), 
473–478. 
 
 
Parasuraman, R., & Davies, D. R. (1977). A taxonomic analysis of vigilance 
performance. In R. R. Mackie (Ed.), Vigilance: Theory, operational performance, and 
physiological correlates (pp. 559–574). New York, NY: Plenum Press. 
 
 
Parker, S., Garry, M., Einstein, G. O., & McDaniel, M. A. (2011). A sham drug 
improves a demanding prospective memory task. Memory, 19(6), 606–612. 
doi:10.1080/09658211.2011.592500 
 
 
Parker, S. K., Williams, H. M., & Turner, N. (2006). Modeling the antecedents of 
proactive behavior at work. Journal of Applied Psychology, 636–652. 
 
 
Parker, S., Garry, M., Einstein, G. O., & McDaniel, M. A. (2011). A sham drug 
improves a demanding prospective memory task. Memory, 19(6), 606–612. 
 
Patterson, P., & Rangganadhan, A. (2010). Losing a parent to cancer: A preliminary 
investigation into the needs of adolescents and young adults. Palliative and Supportive 
Care, 8(03), 255-265. 
 
391 
 
 
Patton, M. Q. (1987). How to use qualitative methods in evaluation (No. 4). Sage. 
 
 
Patton, M. Q. (2002). Two decades of developments in qualitative inquiry a personal, 
experiential perspective. Qualitative Social Work, 1(3), 261–283. 
 
 
Paulesu, E., Frith, C. D., & Frackowiak, R. S. (1993). The neural correlates of the verbal 
component of working memory. Nature, 362(6418), 342–345. 
 
 
Phillips, K. A., & Bernhard, J. (2003). Adjuvant breast cancer treatment and cognitive 
function: Current knowledge and research directions. Journal of the National Cancer 
Institute, 95(3), 190–197. 
 
 
Pigeon, W. R., Sateia, M. J., & Ferguson, R. J. (2003). Distinguishing between 
excessive daytime sleepiness and fatigue: Toward improved detection and treatment. 
Journal of psychosomatic research, 54(1), 61–69. 
 
 
Pires, C., Silva, D., Maroco, J., Ginó, S., Mendes, T., Schmand, B. A., & De Mendonça, 
A. (2012). Memory complaints associated with seeking clinical care. International 
Journal of Alzheimer's Disease, 2012. 
 
 
Player, L., Mackenzie, L., Willis, K., & Loh, S. Y. (2014). Women’s experiences of 
cognitive changes or ‘chemobrain’ following treatment for breast cancer: A role for 
occupational therapy? Australian occupational therapy journal, 61(4), 230-240. 
 
 
Preston, F. A., & Wilfinger, C. (1997). Memory Bank for Chemotherapy (3rd ed.). 
Massachusetts: Jones & Bartlett Publishers. 
 
392 
 
 
Procter, R., Vis, F., & Voss, A. (2013). Reading the riots on Twitter: Methodological 
innovation for the analysis of big data. International journal of social research 
methodology, 16(3), 197–214. 
 
Sattler, J. M. (2001). Assessment of Children: Cognitive Applications (4th ed.). San 
Diego: Jerome M. Sattler Publisher, Inc. 
 
 
Raffa, R. B., Duong, P. V., & Finney, J. (2006). Is ‘chemo-fog’⁄‘chemo-brain’ caused 
by cancer chemotherapy? Journal of Clinical Pharmacy and Therapeutics, 31, 129–138.  
 
 
Raffa, R. B., & Tallarida, R. J. (Eds.). 2010. Chemo-fog: Cancer chemotherapy-related 
cognitive impairment. Austin, TX: Springer⁄Landes Publishers. 
 
 
Raffa, R. B. (2011). A proposed mechanism for chemotherapy-related cognitive 
impairment (‘chemo-fog’). R. B. Raffa, PhD Thesis. Temple University School of 
Pharmacy, Philadelphia, PA, USA. 
 
 
Rasch, B., & Born, J. (2008). Reactivation and consolidation of memory during sleep. 
Current Directions in Psychological Science, 17(3), 188–192. 
 
 
Ray, C., & Baum, M. (1985). Psychological aspects of early breast cancer. New York: 
Springer-Verlag.  
 
 
Repovš, G., & Baddeley, A. (2006). The multi-component model of working memory: 
Explorations in experimental cognitive psychology. Neuroscience, 139(1), 5–21. 
 
 
393 
 
de Ruiter, M. D., Reneman, L., & Boogerd, W. (2011). Cerebral hyporesponsiveness 
and cognitive impairment 10 years after chemotherapy for breast cancer. Human Brain 
Mapp., 38, 1206–1219. 
 
 
Rich, E. L., & Shapiro, M. L. (2007). Prelimbic/infralimbic inactivation impairs 
memory for multiple task switches, but not flexible selection of familiar tasks. The 
Journal of neuroscience, 27(17), 4747–4755. 
 
 
de Ruiter, M. B., Reneman, L., Boogerd, W., Veltman, D. J., Caan, M., Douaud, G., & 
Schagen, S. B. (2012). Late effects of high-dose adjuvant chemotherapy on white and 
gray matter in breast cancer survivors: Converging results from multimodal magnetic 
resonance imaging. Human Brain Mapping, 33(12), 2971–2983. 
 
 
Salmon, G. (2000). Computer mediated conferencing for management learning at the 
Open University. Management Learning, 31(4), 491–502. 
 
 
Salmons, J. E. (2014). Qualitative online interviews: Strategies, design, and skills. Sage 
Publications, Inc. 
 
 
Santangelo, V., & Macaluso, E. (2013). The contribution of working memory to divided 
attention. Human brain mapping, 34(1), 158–175. 
 
 
Savard, J., Liu, L., Natarajan, L., Rissling, M., Neikrug, A., & He, F. (2009). Breast 
cancer patients have progressively impaired sleep-wake activity rhythms during 
chemotherapy. Sleep: Journal of Sleep and Sleep Disorders Research, 32(9), 1155–
1160. 
 
 
394 
 
Schagen, S. B., Hamburger, H. L., Muller, M. J., Boogerd, W., & van Dam, F. S. 
(2001). Neurophysiological evaluation of late effects of adjuvant high-dose 
chemotherapy on cognitive function. Journal of neuro-oncology, 51(2), 159–165. 
 
 
Schagen, S. B., Muller, M. J., Boogerd, W. W., Rosenbrand, R. M., Rhijn, D., 
Rodenhuis, S. S., & Dam, F. (2002). Late effects of adjuvant chemotherapy on cognitive 
function: a follow-up study in breast cancer patients. Annals of Oncology, 13(9), 1387–
1397. Retrieved from EBSCOhost. 
 
 
Schacter, D. L., & Tulving, E. (Eds.). (1994). Memory systems 1994. MIT Press. 
 
 
Schilder, C. M., Eggens, P. C., Seynaeve, C., Linn, S. C., Boogerd, W., Gundy, C. M., 
Beex, L. V., van Dam, F. S., & Schagen, S. B. (2009). Neuropsychological functioning 
in postmenopausal breast cancer patients treated with tamoxifen or exemestane after 
AC-chemotherapy: Cross-sectional ﬁndings from the neuropsychological TEAM-side 
study. Acta Oncologica., 48, 76–85. 
 
 
Schilder, C., Seynaeve, C., & Beex, L. V. (2010). Effects of Tamoxifen and Exemestane 
on cognitive function of postmenopausal patients with breast cancer: Results from the 
neuropsychological side study of the Tamoxifen and Exemestane Adjuvant 
Multinational Trial. Journal of Clinical. Oncology, 28, 1294–1300. 
 
 
Scherling, C., Collins, B., MacKenzie, J., Bielajew, C., & Smith, A. (2012). 
Prechemotherapy differences in response inhibition in breast cancer patients compared 
to controls: a functional magnetic resonance imaging study. Journal of clinical and 
experimental neuropsychology, 34(5), 543–560. 
 
 
Scherling, C. S., & Smith, A. (2013). Opening up the window into “chemobrain”: A 
neuroimaging review. Sensors (14248220), 13(3), 3169–3203. doi:10.3390/s130303169 
 
395 
 
 
Scullin, M. K., McDaniel, M. A., & Einstein G. O. (2010). Control of cost in 
prospective memory: Evidence for spontaneous retrieval processes. Journal of 
Experimental Psychology: Learning, Memory and Cognition, 36(1), 190. 
 
 
Scullin, M. K., McDaniel, M.A., Shelton, J. T., & Lee, J. H. (2010). Focal/nonfocal cue 
effects in prospective memory: Monitoring difficulty or different retrieval processes? 
Journal of Experimental Psychology: Learning, Memory and Cognition, 36(3), 736. 
 
 
Scullin, M. K., Bugg, J. M., & McDaniel, M. A. (2012). Whoops, I did it again: 
Commission errors in prospective memory. Psychology and aging, 27(1), 46. 
 
 
Scullin, M. K., McDaniel, M. A., & Shelton, J. (2013). The dynamic multiprocess 
framework: Evidence from prospective memory with contextual variability. Cognitive 
Psychology, 67(1/2), 55–71. doi:10.1016/j.cogpsych.2013.07.001 
 
 
Scullin, M. K., Harrison, T. L., Factor, S. A., & Bliwise, D. L. (2014). A 
neurodegenerative disease sleep questionnaire: Principal component analysis in 
Parkinson’s disease. Journal of the neurological sciences, 336(1), 243–246. 
 
 
Schagen, S. B., Hamburger, H. L., Muller, M. J., Boogerd, W., & van Dam, F. S. 
(2001). Neurophysiological evaluation of late effects of adjuvant high-dose 
chemotherapy on cognitive function. Journal of neuro-oncology, 51(2), 159–165. 
 
 
Schagen, S. B, Muller, M. J., Boogerd, W., Rosenbrand, R. M., van Rhijn, D., 
Rodenhuis, S., & van Dam, F. S. (2002). Late effects of adjuvant chemotherapy on 
cognitive function: A follow-up study in breast cancer patients. Annals of Oncology, 13, 
1387–1397. 
 
 
396 
 
Shallice, T., & Burgess, P. (1991). Deficits in strategy application following frontal lobe 
damage in man. Brain: A Journal Of Neurology, 114 (Pt 2), 727–741.  
 
 
Shallice, T., & Warrington, E. K. (1970). Independent functioning of verbal memory 
stores: A neuropsychological study. Quarterly Journal of Experimental Psychology, 22, 
261–273. 
 
 
Shen, J., Barbera, J., & Shapiro, C. M. (2006). Distinguishing sleepiness and fatigue: 
Focus on definition and measurement. Sleep medicine reviews, 10(1), 63–76. 
 
 
Shilling, V. V., Jenkins, V. V., Fallowfield, L. L., & Howell, A. A. (2001). The effects 
of oestrogens and anti-oestrogens on cognition. The Breast, 10(6), 484–491. Retrieved 
from EBSCOhost. 
 
 
Shilling, V., & Jenkins, V. (2007). Self-reported cognitive problems in women 
receiving adjuvant therapy for breast cancer. European Journal of Oncology Nursing, 
11(1), 6–15. 
 
 
Shilling, V., Jenkins, V., Morris, R., Deutsch, G., & Bloomfield, D. (2005). The effects 
of adjuvant chemotherapy on cognition in women with breast cancer-preliminary results 
of an observational longitudinal study. The Breast, 14, 142–150.  
 
 
Shilling, V., Jenkins, V., & Trapala, I. S. (2006). The (mis)classification of chemo-fog-
methodological inconsistencies in the investigation of cognitive impairment after 
chemotherapy. Breast Cancer Research and Treatment, 95, 125–129.  
 
 
Shimamura, A. P., Janowsky, J. S., & Squire, L. R. (1991). What is the role of frontal 
lobe damage in amnesic disorders? In H. S. Levin, H. M. Eisenberg, & A. L. Benton 
(Eds.), Frontal lobe functioning and dysfunction. Oxford: Oxford University Press. 
397 
 
 
 
Silberfarb, P. M., Philibert, D., & Levine, P. M. (1980). Psychosocial aspects of 
neoplastic disease: II. Affective and cognitive effects of chemotherapy in cancer 
patients. The American journal of psychiatry, 137(5), 597-601. . 
 
 
Silverman, D. H., Dy, C. J., Castellon, S. A., Lai, J., Pio, B. S., Abraham, L., & Ganz, 
P. A. (2007). Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-
treated breast cancer survivors 5–10 years after chemotherapy. Breast cancer research 
and treatment, 103(3), 303–311. 
 
 
Silverman, D., & Davidson, I. (2009). Your brain after chemo: A practical guide to 
lifting the fog and getting back your focus. Da Capo Lifelong Books. 
 
 
Simons, J. S., Schölvinck, M. L., Gilbert, S. J., Frith, C. D., & Burgess, P. W. (2006). 
Differential components of prospective memory: Evidence from fMRI. 
Neuropsychologia, 44(8), 1388–1397. doi:10.1016/j.neuropsychologia.2006.01.005 
 
 
Small, B. J., Rawson, K. S., Walsh, E., Jim, H. S., Hughes, T. F., Iser, L., ... & 
Jacobsen, P. B. (2011). Catechol‐O‐methyltransferase genotype modulates cancer 
treatment‐related cognitive deficits in breast cancer survivors. Cancer, 117(7), 1369–
1376. 
 
 
Smith R. (2008). Connecting the past and the future: Attention, memory, and delayed 
intentions. In Prospective memory: Cognitive, neuroscience, developmental, and 
applied perspectives [e-book] (pp. 29–52). New York, NY: Taylor & Francis 
Group/Lawrence Erlbaum Associates. 
 
 
Smith, E. E., Jonides, J., & Koeppe, R. A. (1996). Dissociating verbal and spatial 
working memory using PET. Cerebral Cortex., 6(1), 11–20. 
 
 
398 
 
Smith, E. E., & Jonides, J. (1997). Working memory: A view from neuroimaging. 
Cognitive Psychology, 33(1), 5–42. 
 
 
Smith, G., Della Sala, S., Logie, R., & Maylor, E. (2000). Prospective and retrospective 
memory in normal ageing and dementia: A questionnaire study. Memory, 8, 311–321. 
doi:http://dx.doi.org/10.1080/ 096582100406801 
 
 
Smith, R. E. (2003). The cost of remembering to remember in event-based prospective 
memory: Investigating the capacity demands of delayed intention performance. Journal 
of Experimental Psychology: Learning, Memory, and Cognition, 29, 347–361. 
 
 
Smith, R. E., & Bayen, U. J. (2004). A multinomial model of event-based prospective 
memory. Journal of Experimental Psychology: Learning, Memory & Cognition, 30, 
756–777. 
 
 
Sperling, G. (1960). The information available in brief visual presentations. 
Psychological Monographs, 74(11, Whole No. 498), 1–29. 
 
 
Stewart, K., & Williams, M. (2005). Researching online populations: The use of online 
focus groups for social research. Qualitative Research, 5(4), 395–416. 
 
 
Stewart, A., Bielajew, C., Collins, B., Parkinson, M., & Tomiak, E. (2006). A meta-
analysis of the neuropsychological effects of adjuvant chemotherapy treatment in 
women treated for breast cancer. The Clinical Neuropsychologist, 20(1), 76–89. 
 
 
Stewart, A. (2009). An examination of chemo fog: Cognitive decline in early-stage 
breast cancer patients treated with adjuvant chemotherapy. Dissertation Abstracts 
International, 69. 
399 
 
 
Suler, J. (2005). The online disinhibition effect. International Journal of Applied 
Psychoanalytic Studies, 2(2), 184-188. 
 
 
Tager , F., McKinley, P., Schnabel, F., El-Tamer ,M., Cheung, Y., Fang, Y., Golden, C., 
Frosch, M., Habif, U., Mulligan, M., Chen, I., & Hershman, D. (2009). The cognitive 
effects of chemotherapy in post-menopausal breast cancer patients: A controlled 
longitudinal study. Breast Cancer Research and Treatmant, 123 ( 1), 25-34. 
 
 
Tannock, I. F., Ahles, T. A., Ganz, P. A., & van Dam, F. S. (2004). Cognitive 
impairment associated with chemotherapy for cancer: Report of a workshop. Journal of 
Clinical Oncology, 22, 2233–2239. 
 
 
Tashakkori, A., & Teddlie, C. (Eds.). (2010). Sage handbook of mixed methods in social 
& behavioral research. Sage. 
 
 
Tashakkori, A., & Teddlie, C. (1998). Mixed methodology: Combining qualitative and 
quantitative approaches, Vol. 46. Sage.  
 
 
Temkin, N. R., Heaton, R. K., Grant, I., & Dikmen, S. S. (1999). Detecting significant 
change in neuropsychological test performance: a comparison of four models. Journal 
of the International Neuropsychological Society, 5(04), 357–369. 
 
 
Thelen, J. M., Lynch, S. G., Bruce, A. S., Hancock, L. M., & Bruce, J. M. (2014). 
Polypharmacy in multiple sclerosis: Relationship with fatigue, perceived cognition, and 
objective cognitive performance. Journal of psychosomatic research, 76(5), 400–404. 
 
 
Thöne-Otto, A. I., & Walther, K. (2008). Assessment and treatment of prospective 
memory disorders in clinical practice. In M. Kliegel, M. A. McDaniel, & G. O. Einstein 
400 
 
(Eds.), Prospective memory: Cognitive, neuroscience, developmental, and applied 
perspectives. (pp. 321–345). Mahwah: Erlbaum. 
 
 
Titov, N., & Knight, R. G. (2001). A video‐based procedure for the assessment of 
prospective memory. Applied Cognitive Psychology, 15(1), 61–83. 
 
 
Trochim, W. M. (1989). An introduction to concept mapping for planning and 
evaluation. Evaluation and program planning, 12(1), 1–16. 
 
 
Turkington, C., & Krag, K. (2005). The encyclopaedia of breast cancer. New York: 
Facts On File, Inc. 
 
 
Uttl, B. (2008). Transparent meta-analysis of prospective memory and aging. Plos ONE, 
3(2), 1–31. doi:10.1371/journal.pone.0001568 
 
 
Vallar, G., Papagno, C., & Baddeley, A. D. (1991). Long-term recency effects and 
phonological short-term memory. A neuropsychological case study. Cortex, 27, 323–
326. 
 
 
van den Berg, E., Kant, N., & Postma, A. (2012). Remember to buy milk on the way 
home! A meta-analytic review of prospective memory in mild cognitive impairment and 
dementia. Journal of the International Neuropsychological Society, 18(04), 706–716. 
 
 
Vardy, J., Booth, C., Pond, G. R., Zhang, H., Galica, J., Dhillon, H., Clarke, S. J., & 
Tannock, I. F. (2007). Cytokine levels in patients with colorectal cancer and breast 
cancer and their relationship to fatigue and cognitive function. In abstract presented at 
the American Society of Clinical Oncology – Poster, Patient and Survivor Care, 
Chicago, IL. 
401 
 
 
 
Vardy, J., Wefel, J., Ahles, T., Tannock, I., & Schagen, S. (2008). Cancer and cancer-
therapy related cognitive dysfunction: An international perspective from the Venice 
cognitive workshop. Annals Of Oncology: Official Journal Of The European Society 
For Medical Oncology/ESMO, 19(4), 623–629. 
 
 
Volle, E., Gonen-Yaacovi, G., de Lacy Costello, A., Gilbert, S. J., & Burgess, P. W. 
(2011). The role of rostral prefrontal cortex in prospective memory: A voxel-based 
lesion study. Neuropsychologia, 49(8), 2185–2198. 
 
 
von Zglinicki, T., & Martin-Ruiz, C. M. (2005). Telomeres as biomarkers for ageing 
and age-related diseases. Current Molecular Medicine, 5, 197–203. 
 
 
Wade, T. D., Nehmy, T., & Koczwara, B. (2005). Predicting worries about health after 
breast cancer surgery. Psycho‐Oncology, 14(6), 503–509. 
 
 
Waldron, J. (2013). YouTube, fanvids, forums, vlogs and blogs: Informal music 
learning in a convergent on-and offline music community. International Journal of 
Music Education, 2012. 
 
 
Walker, M., & Stickgold, R. (2006). Sleep, memory, and plasticity. Annual Review of 
Psychology, 57(1), 139-C-2. Retrieved from Academic Search Complete database. 
 
 
Wechsler, D. (1997). Wechsler Adult Intelligence Scale—Third Edition (WAIS-3®). San 
Antonio, TX, USA: Harcourt Assessment. 
 
 
402 
 
Wechsler, D. (2008). Wechsler adult intelligence scale–Fourth Edition (WAIS–IV). San 
Antonio, TX: NCS Pearson. 
 
 
Wefel, J. S., Lenzi, R., Theriault, R. L., Davis, R. N., & Meyers, C. A. (2004). The 
cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast 
carcinoma: Results of prospective, randomized, longitudinal trial. Cancer, 100, 2292–
2229. 
 
 
Wefel, J. S., & Schagen, S. B. (2012). Chemotherapy-related cognitive dysfunction. 
Current Neurology and Neuroscience Reports, 12(3), 267–275. doi:10.1007/s11910-
012-0264-9 
 
 
Weinberg, J., Diller, L., Gerstman, L., & Schulman, P. (1972). Digit span in right and 
left hemiplegics. Journal of Clinical Psychology, 28, 361. 
 
 
Weis, J., Poppelreuter, M., & Bartsch, H. (2009). Cognitive deficits as long-term side-
effects of adjuvant therapy in breast cancer patients: ‘Subjective’ complaints and 
‘objectiver’ neuropsychological test results. Psycho-Oncology, 18(7), 775–782. 
Retrieved from E-Journals database. 
 
 
Wieneke, M., & Dienst, E. (1995). Neuropsychological assessment of cognitive 
functioning following chemotherapy for breast cancer. Psycho-Oncology, 4(1), 61–66. 
 
 
Williams, S., Clausen, M. G., Robertson, A., Peacock, S., & McPherson, K. (2012). 
Methodological reflections on the use of asynchronous online focus groups in health 
research. International Journal of Qualitative Methods, 11(4), 368–383. 
 
 
Williams, D. M., Jarrold, C., Grainger, C., & Lind, S. E. (2014). Diminished time-
based, but undiminished event-based, prospective memory among intellectually high-
403 
 
functioning adults with autism spectrum disorder: Relation to working memory ability. 
Neuropsychology, 28(1), 30–42. doi:10.1037/neu0000008 
 
 
Wilson, B. A., Alderman, N., Burgess, P. W., Emslie, H., & Evans, J. J. (1996). The 
behavioural assessment of the dysexecutive syndrome. Bury St Edmunds: Thames 
Valley Company. 
 
 
Wilson, B. A., Cockburn, J., & Baddeley, A. D. (1985). The Rivermead Behavioural 
Memory Test. London: Pearson Assessment. 
 
 
Wilson, C. J., Finch, C. E., & Cohen, H. J. (2002). Cytokines and cognition: The case 
for head-to-toe inflammatory paradigm. Journal of the American Geriatric. Society, 50, 
2041–2056.  
 
 
Wilson, B. A., Emslie, H., Foley, J., Shiel, A., Watson, P., Hawkins, K., Groot, Y. & 
Evans, J. J. (2005). The Cambridge Prospective Memory Test (CAMPROMPT). 
London: Harcourt Assessment. 
 
 
Witkowska, M. A. (2011). Selected aspects of prospective memory impairment in 
chronic pulmonary diseases. Clinical Neuropsychologist, 25(4), 575–576. 
 
 
Woods, S. P., Iudicello, J. E., Moran, L. M., Carey, C. L., Dawson, M. S., & Grant, I. 
(2008). HIV-associated prospective memory impairment increases risk of dependence in 
everyday functioning. Neuropsychology, 22(1), 110. 
 
 
Yang, M., Kim, J. S., Song, M. S., Kim, S. H., Kang, S. S., Bae, C. S., & Moon, C. 
(2010). Cyclophosphamide impairs hippocampus-dependent learning and memory in 
adult mice: Possible involvement of hippocampal neurogenesis in chemotherapy-
induced memory deficits. Neurobiology of learning and memory, 93(4), 487–494. 
404 
 
 
Yin, R. K. (2010). Qualitative research from start to finish. Guilford Press. 
 
 
Zacks, R. T., & Hasher, L. (Eds.). (1994). Inhibitory processes in attention, memory, 
and language. In D. Dagenbach & T. H. Carr (Eds.), Directed ignoring (pp. 241–264). 
San Diego, CA: Academic Press. 
 
 
Zunini, R. A. L., Scherling, C., Wallis, N., Collins, B., MacKenzie, J., Bielajew, C., & 
Smith, A. M. (2013). Differences in verbal memory retrieval in breast cancer 
chemotherapy patients compared to healthy controls: a prospective fMRI study. Brain 
imaging and behavior, 7(4), 460–477.  
 
405 
 
APPENDIX I   Recruitment Materials 
 
I-1 Invitation to participate in the study 
 
 
 
 
 
STUDY TITLE: THE EFFECTS OF CANCER TREATMENT ON MEMORY 
 
INVITATION 
 
We would like to invite you to take part in the above-named research study, as you have 
recently been diagnosed with breast cancer. 
 
The purpose of the study is to observe if cancer treatment has an effect on memory 
processes. We will be using a series of tests and questionnaires to help us understand 
this better with the aim of trying to improve care/treatment for this group of patients. 
 
The duration of the study will be 9 months. During this time, you will be required to 
attend on four occasions to complete the study procedures.  
 
Your participation is entirely voluntary; no payment will be given for participation. 
 
All screening and tests will take place at this hospital, and we will arrange schedules at 
your convenience and availability. 
 
If you decide you would like to participate, you will be given an information sheet to 
keep and asked to sign a consent form. 
 
We hope that this study will help cancer patients understand how to improve their 
quality of life. 
 
If you think you would like to take part, please contact Liliana Moyers at 
 
lmoyers@bournemouth.ac.uk 
 
 
Phone 01202514903  Mobile 07427869252 
 
 
 
Chief investigator: Dr Tamas Hickish 
Principal researcher: Liliana Moyers 
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I-2 Invitation to participate in online questionnaires 
 
 
Dear Mrs_______________ 
 
We are inviting you to take part in the second part of the memory study on the effects of 
chemotherapy on memory. You have been invited because you have already completed 
your treatment, and completed the first part of the study, in which you took a series of 
psychology test. 
 
Your participation in this second part is entirely optional, and consists of an online 
interview and questionnaires. 
 
This study will be used as a follow up for the first one, and both complement each other. 
The principal investigator will be comparing results from each study as case studies. 
 
If you do not have access to a computer or Internet, you can go to your local library 
where you can use computers with free Internet access. 
 
In order to access the online interview, please follow this link______________ and 
write the following access code_____________ 
 
Please email lmoyers@bournemouth.ac.uk or ring 07427869254 as soon as you have 
completed the interview, or in case you find any difficulty, or have any further 
questions. 
 
 
Your information will be confidential and only the principal investigator and advisors 
from Bournemouth University will have access to it. 
 
 
 
 
 
 
 
 
 
 
Invitation 
Version 2 
Date   08/04/13 
REC Ref: 10/H0502/92 
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I-3 Invitation to participate in face-to-face interview 
 Invitation to participate in face-to-face interview 
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I-4 Consent form 
      
 
Patient Identification Number:  
 
CONSENT FORM 
 
STUDY TITLE:  INVESTIGATION OF PROSPECTIVE AND WORKING 
MEMORY AND THE IMPACT OF IMPAIRED SLEEP 
AND/OR IMPAIRED GLUCOSE METABOLISM IN 
RECENTLY DIAGNOSED BREAST CANCER PATIENTS 
UNDERGOING CHEMOTHERAPY: A LONGITUDINAL 
STUDY 
 
Chief Investigator: Dr Tamas Hickish 
 
Name of Researcher: Liliana Moyers-Ruiz 
 
Please initial box 
1. I confirm that I have read and understood the information sheet 
dated........................for the above study. I have had the opportunity to 
consider the information, ask questions and have had these answered 
satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason, without my medical care or 
legal rights being affected.  
 
3. I understand that relevant sections of my medical notes and data collected 
during the study may be looked at by individuals from Bournemouth 
University, Bournemouth and Poole hospital, from regulatory authorities or 
from the NHS Trust, where it is relevant to my taking part in this research. I 
give permission for these individuals to have access to my records.  
 
4. I agree to my GP being informed of my participation in the study. 
 
5. I agree to take part in the above study.  
 
 
 
_______________   ________________  _______________  
Name of Participant            Date                              Signature  
 
 
_________________  ________________ ___________________  
Name of Person taking       Date                  Signature  
consent 
 
When completed, 1 for patient; 1 for researcher site file; 1 (original) to be kept in 
medical notes 
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I-5 Participant information sheet 
 
 
 
PARTICIPANT INFORMATION SHEET 
 
STUDY TITLE: INVESTIGATION OF PROSPECTIVE AND WORKING 
MEMORY AND THE IMPACT OF IMPAIRED SLEEP 
AND/OR IMPAIRED GLUCOSE METABOLISM IN 
RECENTLY DIAGNOSED BREAST CANCER PATIENTS 
UNDERGOING CHEMOTHERAPY: A LONGITUDINAL 
STUDY 
 
Chief investigator: Prof. Tamas Hickish 
 
Principal researcher: Liliana Moyers-Ruiz, PhD student 
 
INVITATION  
We would like to invite you to consider taking part in the above research study. Before 
you decide whether or not you would like to take part, we would like to explain what 
the research is about, why it is important and what is involved.  
 
A member of the research team will go through the information sheet with you in case 
you have any questions; this will take approximately 10 minutes. You can talk about the 
study with others if you wish and please ask any questions. You can contact the 
principal researcher and/or the chief investigator with any queries. If you decide not to 
participate, your care will not be affected in any way.  
 
 
PART 1 
What is the purpose of the study?  
Sleep and glucose regulation are frequently altered in breast cancer patients who receive 
chemotherapy. The purpose of this project is to observe the effects of chemotherapy on 
sleep and glucose regulation, and observe whether or not these have an effect on 
memory processes in breast cancer patients during and after chemotherapy treatment. 
 
Why have I been invited?  
 
You have been invited as you have been diagnosed with breast cancer and are scheduled 
to begin treatment soon. If you were invited to take part but do not have breast cancer is 
because your participation will help us to compare your results with cancer patients. 
Participants in this project will include individuals who have been diagnosed with breast 
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cancer and are receiving chemotherapy treatment, individuals who have been diagnosed 
with breast cancer who are receiving treatment other than chemotherapy, and a group of 
individuals who do not have cancer.  
 
 
Do I have to take part?  
 
No. Your participation in this project is entirely voluntarily. If you agree to participate, 
you can withdraw at any time without affecting your medical treatment, or your chance 
to participate in another study. If you decide to participate and later do not want to 
continue, you have the right to withdraw without giving any further explanation. This 
decision will not affect your medical treatment. 
We will describe the study in this information sheet, and if you decide you would like to 
take part, we will ask you to sign a consent form. 
 
What will happen to me if I take part?  
 
Your participation in this project will not represent any greater risk than in those 
encountered under normal daily activities. We will give you two copies of a consent 
form to sign: one or your own records and one for our file. You will be required to 
attend on four occasions to complete the study procedures, which include 
1. Filling out 7 questionnaires  
2. Performing some psychology tests  
3. Wear a SenseWear® armband  
4. Measurements taken of your pupils 
5. Blood tests to measure your glucose levels 
 
These four visits will take place over approximately a 9-month period. 
 
What will I have to do? 
 
The questionnaires will take approximately 10 minutes to complete, and you need to 
complete these before we go on to the following tests.   
 
For the psychology tests, the researcher will need to ask you questions following a 
certain format to make sure that all participants are treated in the same way. Each of 
these sessions will take approximately one hour to complete and will take place at the 
hospital. You will also be asked to perform some tasks at this time. 
 
You will be required to wear an apparatus called SenseWear®, which resembles an 
armband for a 7-day period before you attend the above session. This piece of 
equipment will not cause you any discomfort or harm, and it is easy to wear. 
Measurements of your pupil will be taken; this assessment takes about 15 minutes to 
complete and will take place in a dark room at the hospital. You will have to wear a 
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goggle-like mask with web cams attached to it. You will need to stay awake during this 
assessment while measurements of your pupil dilation are taken by the web cams on the 
mask. 
 
We will also take some blood samples at each visit to measure your glucose levels. 
 
Duration of participation 
 
The four visits will take place as follows: one before chemotherapy, one after the 
second or 3rd cycle, one immediately after your last cycle, and the last one six months 
after completing your treatment. 
 
Time 1 
Baseline Testing 
(10 days prior to 1st 
cycle) 
 Time 2 
Mid-term 
Testing 
(11 days before 4th 
cycle) 
 
 Time 3 
Post-treatment 
testing 
(11 days after 6th 
cycle)  
 
 Time 4 
6 months follow-
up 
(6 months after 6th 
cycle)  
2 Screening 
Questionnaires  
(10 min) At any time 
before testing 
 
  
1 Screening 
questionnaire 
  
1 Screening 
questionnaire 
  
1 Screening 
questionnaire 
Psychology tests 
 (1 hr) 
 
 Psychology tests 
 (1hr) 
 
 Psychology tests 
 (1 hr) 
 
 Psychology tests 
(1hr) 
 
Questionnaires: 
2 Sleep scales 
(5 min. Day of 
testing) 
 
 Questionnaires: 
2 Sleep scales 
(5 min. Day of 
testing) 
 
 Questionnaires: 
2 Sleep scales 
(5 min. Day of 
testing) 
 
 Questionnaires: 
2 Sleep scales 
(5 min. Day of 
testing) 
 
Sensewear 
(7 days before 
testing) 
Pupil measurement 
(15 min. Day of 
testing) 
Blood test 
 
 Sensewear 
(7 days before 
testing) 
Pupil 
measurement 
(15 min. Day of 
testing) 
Blood test 
 
 Sensewear 
(7 days before 
testing) 
Pupil 
measurement  
(15 min. Day of 
testing) 
Blood test 
 
 Sensewear 
 (7 days before 
testing) 
Pupil 
measurement  
(15 min. Day of 
testing)  
Blood test 
 
 
What are the possible disadvantages and risks of taking part? 
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You may find that some of the questionnaires ask for sensitive information, and it is 
possible that you might feel overwhelmed by answering a scientific test battery (what’s 
this!). You may also experience some inconvenience whilst wearing the SenseWear® 
for 7 days and you might feel uncomfortable and sleepy being in a dark room for 15 
minutes during the pupil measurement. You may experience some slight bruising or 
discomfort from the blood samples. To reduce the risks for you, only experienced and 
qualified members of the research team will perform these procedures. Please discuss 
any concerns with a member of the research team who will do their best to help you. 
 
What are the possible benefits of taking part? 
 
We hope that the information we obtain from this study will help us understand more 
about memory processes in patients who are undergoing chemotherapy. You will gain 
understanding on how psychological tests and experiments are used to gain knowledge 
in psychology research. There may not be any direct benefit to you, but we hope that 
this study will help us improve care for patients in the future.  
 
What if there is a problem? 
If you have any complaint about the way you have been dealt during your participation 
in the study or any possible harm you might suffer, it will be addressed (detailed 
information on this is given in Part 2). 
 
Will my taking part in the study be kept confidential? 
Yes. All information will be kept strictly confidential. Your name will not be used, as a 
unique code number will be used to identify your data. We will adhere to ethical and 
legal practice to keep your information confidential. 
 
 
If the information in Part 1 has interested you and you are considering participation, 
please read the additional information in Part 2 before making any decision. 
 
 
PART 2 
 
What will happen if I don’t want to carry on with the study? 
If, for any reason, or at any time, you decide that you no longer wish to be involved in 
this study, you are free to withdraw without giving a reason. Deciding to withdraw from 
the trial will not affect your care. If you do decide to withdraw from the study, we will 
ask for your consent to allow us to use the data collected up to your withdrawal with 
your permission. 
 
What if there is a problem?  
If you have a concern about any aspect of this study, you should ask to speak with the 
researchers, who will do their best to answer your questions: 
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Liliana Moyers (Principal investigator): 01202 514903. 
If you remain unhappy and wish to complain formally, you can do this through the NHS 
Complaints Procedure (or Private Institution). Details can be obtained from  
Professor Tamas Hickish (Chief investigator): 01202 704789. 
In the event that something does go wrong and you are harmed during the research and 
this is due to someone’s negligence, then you may have grounds for compensation, but 
you may have to pay your legal cost. The normal National Health Service complaints 
mechanisms will still be available to you (if appropriate).  
 
Will my taking part in this study be kept confidential?  
If you join the study, some parts of your medical records and the data collected for the 
study will be looked at by authorised persons from Bournemouth University and 
Bournemouth and Poole hospitals. They may also be looked at by authorised staff 
employed by the regulatory authorities to check that the study is being carried out 
correctly. All will have a duty of confidentiality towards you as a research participant, 
and we will do our best to meet this duty. 
All completed questionnaires, tests and other collected data will be stored at 
Bournemouth University in a secure locked cabinet for a period of 5 years after the end 
of the trial and then destroyed. 
 
All electronic data will be kept on a secure computer, and access to the data will be 
secured by use of specific passwords known only to authorised persons within the 
research team. We will ensure that you are not named in any publications that may 
result from this research. 
 
Involvement of the General Practitioner/Family doctor. 
If you agree to participate, we will write to your GP to let him/her know that you are 
taking part in this study.   
 
What will happen to any samples I give? 
 
The blood samples that you will provide for routine tests will be analysed locally at the 
hospital laboratory. Tests will be conducted to analyse your glucose levels, to see if 
there have been any changes that may be affecting memory. After the tests have been 
completed, these samples will be destroyed. 
 
What will happen to the results of the research study? 
The results of this research will be used as a part of a PhD dissertation and might be 
published in relevant scientific journals. They may also be presented at scientific 
conferences. You will not be named in this or any study results. When available, a 
summary of the results of the study may be obtained from the principal researcher. 
 
Who is organising and funding the research? 
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This research is organised by Bournemouth University as a part of a PhD grant and 
sponsored by The Royal Bournemouth Hospital. 
 
Who has reviewed the study?  
All research in the NHS is looked at by independent group of people, called a Research 
Ethics Committee, to protect your interests. This study has been reviewed and given 
favorable opinion by Southampton REC A Research Ethics Committee. 
 
Physical Exercise 
Evidence indicates that exercising 3 times a week helps maintain cognitive health, and 
we would encourage you to do so. We also will be collecting information regarding 
your exercise levels by asking about your exercise habits in some of your diaries. 
 
Further information and contact details  
You can contact the principal investigator for more information about this study. 
 
Thank you for taking the time to read this information sheet. If you decide to take 
part in the study, you will be given a copy of this information sheet and the signed 
consent form to keep for your own records. 
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I-6 Letter to patient’s doctor 
 
 
 
Dr  
 
Dear Dr __________________________________ 
 
We would like to inform you that your patient _____________________________ will 
be taking part in a research study at Poole Hospital looking at the effects of 
chemotherapy on memory. This is a 9-month longitudinal study where participants will 
be asked to undergo the following:  
 
1. a series of neuropsychological tests 
2. complete sleep and sleepiness questionnaires and diaries 
3. complete screening questionnaires.  
4. provide blood samples. 
 
We will also record sleep wake/activity and take measurements of pupil aperture. 
 
Your patient has been invited to participate in this project, as she has been recently 
scheduled to begin breast cancer treatment with chemotherapy. 
 
If you have any questions or require any further information, please do not hesitate to 
contact me. 
 
Yours sincerely, 
 
Liliana Moyers Ruiz 
Principal Investigator 
 
Email: lmoyers@bournemouth.ac.uk 
Tel:     01202 514903 
 
Chief Investigator: Professor Tamas Hichkish 
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I-7 Patient background information request 
 
 
 
 
 
BACKGROUND INFORMATION 
 
Participant ID number_________                     DOB__________ 
Weight______Height______Contact No.___                        Hospital No.        _ 
 
In order to be able to have a better understanding of your participation on this study, we 
require this basic background information. Please circle the response that best describes 
you. 
 
1) What is your age? 
a. 18–30 
b. 31–40 
c. 41–50 
d. 50–60 
e. 60+ 
 
2) What is your gender? 
 
     a. Female 
     b. Male 
 
3) What is your current marital status? 
 
     a. Married 
     b. Single 
     c. Divorced 
     d. Widow 
     e. Patternship 
     f. Separated 
 
4) What is your highest level of education? 
 
     a. Less than upper school 
     b. Upper school 
     d. College 
     e. Bachelors 
     f.  Masters  
     g. Postgraduate 
     f.  Other                       Explain_____________________ 
 
5) Have you been previously diagnosed with? 
1. Cancer 
2. Diabetes 
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3. Mental or psychiatry disorder  
4. Mood disorder (i.e. depression, anxiety) 
5. Any other medical condition            Explain____________________ 
 
6) Do you have a significant other supporting you while you receive your cancer 
treatment? 
 
       a. Yes 
       b. No 
 
7) Do you consider yourself a multitasking person? 
 
1. Yes 
2. No 
 
8) What is your current employment status? 
     a. Full time 
     b. Part time 
     c. Self-employed 
     d. Unemployed 
     e. Volunteer 
     f.  Care taker 
     g. Do not work 
 
9) Do you smoke?  
     a. Yes 
     b. No 
 
10) If yes, how much?  
 
 
11) Do you drink alcohol? 
      a. Yes 
      b. No 
 
12) If yes, how much? 
 
 
13) Do you exercise regularly? 
      a. Yes 
      b. No   
 
14) If yes, how often? And how much? 
 
 
 
15) Are you currently taking any medication?  
 
1. Yes 
2. No 
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16) If yes, explain 
 
 
17) What is your current menopausal status? 
 
 
18) Have you previously had breast surgery? 
 
19) If yes, when?_______________ 
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APPENDIX II Ethics Submissions 
 
II-1 Reply from National Research Ethics Service 
  
420 
 
 
421 
 
 
422 
 
 
423 
 
II-2 Reply to amendment from National Research Ethics Service 
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II-3 Notice of substantial amendment 
 
NOTICE OF SUBSTANTIAL AMENDMENT 
 
For use in the case of all research other than clinical trials of investigational medicinal 
products (CTIMPs).  For substantial amendments to CTIMPs, please use the EU-
approved notice of amendment form (Annex 2 to ENTR/CT1) at 
http://eudract.emea.eu.int/document.html#guidance. 
To be completed in typescript by the Chief Investigator in language comprehensible to a 
lay person and submitted to the Research Ethics Committee that gave a favourable 
opinion of the research (“the main REC”). In the case of multi-site studies, there is no 
need to send copies to other RECs unless specifically required by the main REC. 
 
Further guidance is available at 
http://www.nres.npsa.nhs.uk/applicants/review/after/amendments.htm. 
 
Details of Chief Investigator:  
1. Name: Dr Tamas Hickish 
Address: 
 
 
 
 
 
 
 
Telephone:  
Email:  
Fax:  
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Full title of study: 
 
Previous version:  
THE INFLUENCE OF IMPAIRED SLEEP 
AND/OR IMPAIRED GLUCOSE 
METABOLISM ON PROSPECTIVE AND 
WORKING MEMORY IN BREAST 
CANCER PATIENTS UNDERGOING 
CHEMOTHERAPY TREATMENT: A 
LONGITUDINAL STUDY 
 
Revised version:  
PROSPECTIVE AND WORKING MEMORY 
DECLINE AND IMPAIRED SLEEP AND/OR 
IMPAIRED GLUCOSE METABOLISM IN 
BREAST CANCER PATIENTS 
UNDERGOING CHEMOTHERAPY 
TREATMENT: A LONGITUDINAL STUDY 
 
Name of main REC: 
 
 
Southampton & South West Hampshire REC 
(A) 
REC reference number: 
 
 
10/H0502/92 
Date study commenced: 
 
 
Not yet started 
Protocol reference (if applicable), 
current version and date: 
 
10/H0502/92 
Amendment number and date:  
 
 
Type of amendment (indicate all that apply in bold) 
 
(a) Amendment to information previously given on the NRES Application Form 
 
Yes                No            
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If yes, please refer to relevant sections of the REC application in the 
“summary of changes” below. 
 
(b) Amendment to the protocol 
 
Yes                No             
 
If yes, please submit either the revised protocol with a new version 
number and date, highlighting changes in bold, or a document listing 
the changes and giving both the previous and revised text. 
 
(c) Amendment to the information sheet(s) and consent form(s) for participants, or to 
any other supporting documentation for the study 
 
Yes                No             
 
If yes, please submit all revised documents with new version numbers 
and dates, highlighting new text in bold.  
 
Is this a modified version of an amendment previously notified to the REC and 
given an unfavourable opinion? 
                                Yes                      No 
 
Summary of changes 
Briefly summarise the main changes proposed in this amendment using language 
comprehensible to a lay person. Explain the purpose of the changes and their 
significance for the study. In the case of a modified amendment, highlight the 
modifications that have been made. 
 
If the amendment significantly alters the research design or methodology, or could 
otherwise affect the scientific value of the study, supporting scientific information 
should be given (or enclosed separately). Indicate whether or not additional scientific 
critique has been obtained. 
 
 
REC Form 
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1. The sponsor information provided on the initial application form was incorrect. This 
should have indicated Dr Robert Chapman, Head of Research, Royal Bournemouth 
Hospital as the sponsor representative and should have been signed accordingly.  
 
2. The R&D Lead has been corrected from Dr Tamas Hickish to Dr Robert Chapman. 
 
3. The filter question form was completed incorrectly. 
 
Question 2 – tick should have been entered in ‘other study’ instead of ‘Study 
administering questionnaires/interviews for quantitative analysis, or using mixed 
quantitative/qualitative methodology’. 
 
Question 2a(c) – this should have been ‘no’. By making this change, some questions 
were added to the form. Copies of the original forms and the amended form have been 
included. Changes have been highlighted in both forms. 
 
Protocol 
 
1. We have amended the title slightly to accurately emphasize the study. 
 
Previous version:  
THE INFLUENCE OF IMPAIRED SLEEP AND/OR IMPAIRED GLUCOSE 
METABOLISM ON PROSPECTIVE AND WORKING MEMORY IN BREAST 
CANCER PATIENTS UNDERGOING CHEMOTHERAPY TREATMENT: A 
LONGITUDINAL STUDY 
 
Revised version:  
PROSPECTIVE AND WORKING MEMORY DECLINE AND IMPAIRED SLEEP 
AND/OR IMPAIRED GLUCOSE METABOLISM IN BREAST CANCER PATIENTS 
UNDERGOING CHEMOTHERAPY TREATMENT: A LONGITUDINAL STUDY 
 
Participant Information Sheet and Consent Form (dated 24/03/11 version 3) in which 
the title was changed are included with this submission. Only study title was changed. 
 
Demographics Questionnaire: 
2. Further questions have been added to the background information. We have 
included a copy of the original submission (dated 18/11/10) and the amended 
submission (dated 24/03/11 version 2), in which additional questions are 
highlighted. 
3. All information regarding actiwatch has been changed to Sensewear. 
4. All information regarding sleep diaries (KSS and KSD) has been removed. 
5. After proofreading, some typographical changes had been made. Original 
submission (dated 18/11/10) and the amendment version (dated 24/03/11 v. 2) have 
been submitted. The original submission highlights the changes and omissions; the 
amendment submission underlies the changes. 
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Equipment 
1. It has been decided to use the “SenseWear®” device instead of the “actiwatch” to 
observe sleep/wake activity. The SenseWear® is worn on the arm of the patient, 
being more reliable and comfortable. 
 
Methodology 
2. Sleep diaries will be taken out of the study (they were going to be used to support 
actiwatch data). 
3. Days of using SenseWear® will change from 10 days to 7 days. 
4. Research Assistant James Le couteur will not be taking part in the study. 
 
 
Any other relevant information 
Applicants may indicate any specific ethical issues relating to the amendment, on 
which the opinion of the REC is sought. 
 
 
 
 
 
 
 
List of enclosed documents 
 
Document Version Date 
   
   
   
 
Declaration 
1. I confirm that the information in this form is accurate to the best of my knowledge 
and I take full responsibility for it. 
 
2. I consider that it would be reasonable for the proposed amendment to be 
implemented. 
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Signature of Chief Investigator:      …….……………………………… 
 
Print name:                                     …….……………………………… 
 
Date of submission:                        ……………………………………. 
 
 
 
431 
 
II-4 Data controller register 
 
 
 
 
DATA PROTECTION ACT 1998 
DATA CONTROLLER REGISTER 
Use this form to summarise details about each collection of (or system containing) 
person-identifiable data. Include details of all manually held and computerised 
personal data involved.  Use a new form for each collection/system. 
 
For help in completing this form, please contact: 
Bournemouth & Christchurch Hospitals: Mike Riding, 01202 704461 
Poole Hospital: Richard Hatton, 01202 448689/442866 
 
Department Oncology Location        Poole Hospital 
Name of person completing 
form 
 
Liliana Moyers-Ruiz 
Project title  
INVESTIGATION OF PROSPECTIVE AND WORKING 
MEMORY DECLINE AND THE IMPACT OF IMPAIRED SLEEP 
AND/OR GLUCOSE METABOLISM IN RECENTLY 
DIAGNOSED BREAST CANCER PATIENTS UNDERGOING 
CHEMOTHERAPY: A LONGITUDINAL STUDY 
 
 
 
REC Approval                       X YES           NO                    N/A 
 
If YES, REC Reference No. 
  10/H0502/92 
 
REC Reference Number:  10/H0502/92 
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1.  Details of the system and ownership 
1.  Who is collecting the data?   Principal Investigator: Liliana 
Moyers-Ruiz 
 
2.  Where is the data being held? In Locked cabinets at Bournemouth 
hospital 
 
3.  Details of the data processing 
1.  Is the data held on a computer, manually 
or both? 
Both  
2.  If computerised, which IT systems will be 
used to the capture the data e.g. Excel, 
Access, Electronic CRF or other database? 
SPSS (Statistical Program for the 
Social Sciences) latest version, excel 
3.  Is any of the data processed externally? 
i.e. does an outside bureau or agency or 
other NHS organisation do some or all of 
the data processing? 
Yes 
 
Pupillometry analyses at Poole 
Hospital 
4.  If the data is processed externally, please 
give the name of the company, university or 
other NHS organisation that processes it. 
 
Poole Hospital 
5.  Does a written contract or an agreement 
exist with the company or NHS 
organisation? 
Yes 
 
 
6.  Information recorded and disclosed 
  Recorded Disclosed 
 Patients’ name  YES NO     X YES NO    X 
 Initials YES NO     X YES NO    X 
 
Address 
 
YES NO     X YES NO    X 
 Hospital number  YES NO     X YES NO    X 
 Date of birth YES NO     X YES NO    X 
 Post Code YES NO     X YES NO    X 
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 Telephone number YES NO     X YES NO    X 
 Age YES    X NO      YES NO    X    
 Sex YES   X NO     YES NO    X 
 
7.  
Source of Data 
Please indicate which of the following you will be using 
1.  Paper records YES   X NO 
2.  Hospital computer not attached to the network YES     NO   X 
3.  Hospital computer attached to the network YES    X           NO    
4.  
Home or other personal computer not attached to the 
network 
YES NO     X 
5.  Home or personal computer attached to the network YES NO     X 
6.  Laptop, palmtop or hand held computer YES     NO     X 
7.  University computer YES    X NO 
8.  Computer disk, CD or memory stick YES    X NO 
9.  Audio tapes YES NO    X 
10.  Digital camera   (Pupillometry’s webcam) YES   X NO      
11.  Images including x-ray YES NO      X 
 
12.  Details required for the organisation to register with the Information 
Commissioner 
1.  For what purpose is the data collected and 
held?  E.g. health administration, personnel, 
employment, contractors, health research, 
accounts, crime prevention, etc. (e.g. is the 
data collected for the purpose of treating the 
patient?) 
Health Research 
2.  About whom is the data collected and 
processed? E.g. patients, complainants, 
relatives, staff, contractors, suppliers, etc. 
Breast cancer patients receiving 
chemotherapy treatment, breast 
cancer patients receiving treatment 
other than chemotherapy, healthy 
women 
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3.  What sort of data is collected and held? E.g. 
health details, employment details, finance 
details, personal views, trade union 
membership, other personal details. 
Patient’s background information, 
psychological tests and 
questionnaires, sleep/wake activity, 
sleepiness, blood samples 
4.  To whom may the data be disclosed?  E.g. 
other NHS depts or sites, social services, 
government, voluntary agencies, relatives, 
legal representatives, survey/research 
organisations.  
Pupillometry to Poole hospital staff  
5.  How often will the data be shared or 
disclosed.  
Every time we collect this kind of 
data (4 times for each patient) 
6.  Can you confirm that you keep a record of disclosures and 
associated reasons? 
YES    X NO 
7.  If you are collecting data directly from the patient, will you 
obtain written consent from the patient for the information 
stored and processed? 
YES    X NO 
8.  If you are collecting data directly from the patient, will you 
ensure the data is not used by anyone else for other 
purposes? 
YES     X NO 
 
9.  Data Quality and Security 
1.  If you are collecting data directly from the patient, will you 
have a method of checking data accuracy? 
YES   X NO 
2.  If the data is to be published, state where and if it will be 
completely anonymised 
In PhD dissertation, 
scientific journals. It 
will be completely 
anonymised 
3.  How will the data be held? – personal laptop not attached to 
a network, laptop attached to network or other? 
University’s and 
Hospital’s 
computers, CD 
4.  How is personal and sensitive data destroyed? Files will be 
shredded, and blood 
samples will be 
destroyed according 
to NHS policies 
5.  When sending sensitive and bulk personal data by post, is it 
sent via Royal Mail Special Delivery or a Courier service? 
YES   X NO 
6.  Are staff aware of the security guidelines regarding e-mail 
i.e. sensitive and confidential data must be send via 
encrypted e-mail e.g. NHS.net? 
YES   X NO 
7.  Are staff aware of the Safe Haven policy? 
YES    X NO 
8.  What contingency arrangements are there to 
cover loss of records? 
CD’s and computers will have a 
password to access the information. 
Information will be also held in 
University and hospital’s computers 
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9.  If data is being submitted electronically, is it being done 
using secure send or the N3 network? 
YES NO 
 
10.   Compliance with Data Protection (DP) principles 
1.  If you are collecting data directly from the patient or member 
of staff, have they been informed that it is being used? 
YES   X NO 
2.  Have the patients or members of staff given their consent to 
all processing and disclosure? 
YES    X NO 
3.  Have measures been taken to ensure that those to whom the 
data is disclosed will process it appropriately? 
YES    X NO 
4.  Are there routine audits of how the data is managed? 
YES     X NO 
5.  How is the data kept accurate and up to date? 
 
Standardised measures will be used 
for accuracy and direct contact with 
Chief Investigator (patient’s 
oncologist) to update treatment 
course. 
6.  Is the data archived in line with NHS guidelines? 
YES   X NO 
7.  Can patients or staff access their personal data within the 40 
day limit set by the DP Act? 
YES    X NO 
8.  Is it possible to prevent processing that can cause damage or 
distress? i.e. If a person does not want to have their data 
processed, can their request be met without detriment to the 
service provided? 
YES     X NO 
9.  Are their procedures in place within the department to 
control security and access to personal and sensitive data? 
YES     X NO 
10.  Are departmental staff aware of their responsibilities under 
the DP Act? 
YES     X NO 
11.  Is data to be transferred outside the 
European Economic Area? If so, to which 
country? 
No 
 
 
Completed by the Data Protection Officer    Initials: 
……………………………………… 
 
Name of Data Protection Officer  
……………………………………………………………… 
 
Signed: 
……………………………………………………………………………………………. 
 
436 
 
Register Reference Number: 
..………………………………………………………………... 
 
Date: 
………………………………………………………………………………………………. 
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APPENDIX III  Open ended questions and PM questionnaire 
 
11.1. Online questionnaire 
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APENDIX IV Example how themes emerged 
 
1. Identified categories for each question, per participant using a colour code: 
Green: Problems with words 
Blue: When memory problems began 
Red: Problems with memory 
Purple: More difficulty, multitasking, slowness 
 
Example Question 1(Each question has its own colour code), Participant 1 
 
Q1 Please explain whether your memory has been affected during or after your 
chemotherapy/radiotherapy treatment and how 
Raw data analysis: 
  “Definitely during, I had real trouble remembering words, making a sentence was 
really hard work, and remembering people's names that I had known for years.” 
Identified categories  
Purple: Inability to do things, more difficult, slowness (takes more time to do 
things), harder, cannot multitask (Multitasking) 
Green: Problems with words and names, sentences (semantic) 
Blue: During treatment (beginning of memory problems) 
Red: Problems with memory and remembering, forgetfulness, concentration 
(Attention) 
Words, names, sentences = semantic category  
Remembering/forgetting = memory category 
  
2. Example question 1 raw data analysis:  
 
1. Initial identification of key words 
2. Paraphrases  
Participant  1   
  “Definitely during, I had real trouble remembering words making a sentence was 
really hard work, and remembering people's names that I had known for years.” 
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During treatment, it became harder to make sentences and recalling the names of 
people I know well. I struggled retrieving words. 
 
Memory problems started during treatment. I have trouble remembering words 
and names. I work harder to make a sentence.  
 
3. Summarize responses  
Example Participant 1 all responses from question 1 to question 7: 
 
During treatment, it became harder to make sentences and recalling the names of 
people I know well. I struggled retrieving words. 
Memory problems started during treatment. I have trouble remembering words and 
names. I work harder to make a sentence 
My family and friends are aware of how my memory got bad, I feel stupid for the things 
I say. 
My family notices. I feel stupid. 
When I finished treatment, my memory started getting better, but I cannot say when it 
started to deteriorate. 
I cannot recall when it started, and it is better now. 
Before treatment and illness my memory was ok, but sometimes I forget what I was 
doing and started doing other things. 
My memory was better before treatment. 
 
4. Re-read–Re-write and making sense from summaries 
Example Participant 1 
It was very apparent that my memory problems began during treatment. Making 
sentences became a very difficult thing to do, as well as remembering names. My 
family and friends noticed that I had memory problems because I said stupid 
things. 
Memory is getting better now, but I cannot recall exactly when the problems began 
after commencing treatment. Before treatment, I did not have bad memory, 
although sometimes I started some jobs but forgot about another one. 
Problems with my shoulder due to treatment are preventing me to return to work, 
but not related to memory, although they affect my social life, and I find it difficult 
to keep up with conversations. All these memory changes make me feel frustrated 
and angry, but I am coping fine and I take my time to say things. 
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5. Identification of key words and cluster into similar topics for data reduction.  
All participants’ responses were analysed. Each and every raw response and 
participants’ summaries were compared to identify key words for each question. Key 
words were identified according to the frequency of usage. 
Examples of key words that emerged from summaries: 
Key words: Remembering, forgetfulness        
Clustered in memory construct 
Key words: Attention, concentration              
       Clustered in PM construct 
Key words: Problems with words and names, trouble making sentence 
Clustered in semantic construct 
Key words: Reminders, lists, write down  
Clustered in dependency construct 
Key words: Frustrated, angry, laugh 
Clustered in mood 
Key words: Difficulty, harder than before, slowness 
Clustered multitasking constructs 
 
Final Clusters: Mood, ability to multitask, semantic problems, use of reminders, 
attention, memory. 
 
6. Comparison of theme’s clusters and reduction into small packets 
 
i.e.  Semantic: problems with words and name 
Semantic problems = Tip-of-the-tongue 
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7. Code creation (themes): 
ATTENTION: FORGETFULNESS, LACK OF ATTENTION, CONCENTRATION 
TIP OF THE TONGUE: DIFFICULTY FOLLOWING CONVERSATIONS AND 
COMPLETING SENTENCES, TROUBLE REMEBERING WORDS AND NAMES 
MULTITASKING: DIFFICULTY DOING MY JOB, DIFFICULT TO MULTITASK, 
HARDER TO DO MY JOB, SLOWNESS 
NEGATIVE MOOD, FRUSTRATION, ANXIETY: FRUSTRATION, CROSS, 
STUPID, BEWILDERED, WORRIED 
POSITIVE MOOD, ACCEPTANCE: LAUGH, ACCEPT, NOT BOTHER, OPEN 
REMIDER DEPENDENCY: WRITE IT DOWN, USE AIDS, CALENDAR 
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Glossary 
ANOVA- Analysis of  Variance 
APOE -Apolipoprotein 
BVRT -Benton Visual retention Test 
CAMPROMPT -Cambridge Prospective Memory Test 
CAPM-Comprehensive Assessment of Prospective Memory 
COWAT -Controlled Oral Word Association Test 
EF- Executive function 
EEG- Electroencephalography 
ESS-Epworth Sleepiness Scale  
FIQ- Full IQ 
HADS- Hospital Anxiety and depression Scale 
HC-Healthy controls 
ICT Information and Communication Technologies 
IQ- Intelligence Coefficient 
LTM- Long term memory 
MCI- Mild cognitive impairment 
MIST- Memory for Intention Screening test 
ME- Measured sleep 
NART- National Adult Reading test 
NHS- National Health Service 
PAM- Preparatory Attentional and Memory Processes 
PFC- Prefrontal cortex 
PM- Prospective memory 
PIQ- Performance IQ 
PRMQ- Prospective and Retrospective Memory Questionnaire 
PSQI- Pittsburgh Sleep Quality Index 
PT-Patient 
QUAL- Qualitative 
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QUANT- Quantitative 
RM- Retrospective memory 
SAS- Supervisor attention system 
SD- Standard Deviation 
SPSS- Statistical Program for the Social Sciences 
STM- Short term memory 
TOT- Tip-of-the-tongue 
VIQ- Verbal IQ 
WAIS- Wechsler Adult Intelligence Scale 
WM- Working memory  
 
 
 
